Pharmacotherapy by unknown
Pharmacotherapy
Edited by Farid Badria
Edited by Farid Badria
The intent of this book is to provide an overview of current conceptualizations of 
Pharmacotherapy. The book focuses on three major areas; diagnosis, treatment, 
and prevention for a wide array of diseases; Cognitive and Psychological disorders 
(Schizophrenia and Nicotine addiction), Inflammatory disorders (New Chemical 
anti-inflammatory and Immunotherapy), updated antihypertensive therapy and 
healing of ulcers with venous origin.  A separate chapter is dedicated to the rationality 
of drug use in earthquake injuries. The last chapter deals with Imaging of potential 
therapeutic or diagnostic agents in animal models in the early stage of research. We 
hope this book is useful to a wide range of people, from students first learning about 
Pharmacotherapy, to advanced clinicians and researchers.
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Though Pharmacotherapy continues  to be complex,  it never ceases  to be  interesting. 
Pharmacotherapy  is  frequently  combined  with  other  treatment  methods,  such  as 
physical therapy and dietotherapy. Drugs are often used in various combinations.  
We have two major objectives in writing this book; firstly, to strike a balance between 
developments  in  Pharmacotherapy  research  and  the  facts  that  researchers  must 





The  intent  of  this  book  is  to  provide  an  overview  of  current  conceptualizations  of 
Pharmacotherapy. The book  focuses on  three major areas; diagnosis,  treatment, and 





or  diagnostic  agents  in  animal  models  in  the  early  stage  of  research.  This  is  an 
important step towards pre‐clinical and clinical trials in human.  
We hope  this book  is useful  to a wide  range of people,  from  students  first  learning 
about Pharmacotherapy, to advanced clinicians and researchers who are looking for a 
review of  current  treatments and  conceptualizations of  the  condition.  It  is our hope 










In Vivo Imaging – New Diagnostic  
and Therapeutic Approach 
Section 1 
In Vivo Imaging – New Diagnostic  
and Therapeutic Approach 
 1 
Small Animal Imaging in Development of New 
Generation Diagnostic and Therapeutic Agents 
Tuulia Huhtala and Ale Närvänen* 
Biomedical Imaging Unit, A. I. Virtanen Institute for Molecular Sciences  
and Department of Biosciences, University of Eastern, 
Finland 
1. Introduction 
Imaging technologies form an inseparable part of molecular medicine and is a major 
research focus globally. Imaging of potential therapeutic or diagnostic agents in animal 
models in the early stage of research is an important step towards pre-clinical and clinical 
trials in humans. The resent achievements in molecular biology, virology and 
nanotechnology provide a totally new approaches to deliver therapeutic agents to the 
patient starting from conventional small molecules to virus based gene therapy. This creates 
a need for better tools for the pharmaceutical research. Small animal imaging provides 
excellent method for development of new generation diagnostic and therapeutic agents. 
Modern transient medicine provides completely new approaches to the diagnosis and 
therapy of diseases. Aim of the research is to develop more specific and efficient agents with 
minimum side effects. Furthermore, early diagnosis of diseases and accurate follow-up is an 
important part of the therapy. These requirements have lead to the more complicated 
bioactive molecules and their carriers. Development and refinement of new bioactive agents 
like peptides, proteins, nanoparticles, cells or viruses to human drugs is challenged by the 
perplexities and instability of the complexes in vivo.  
Due to the complexity of new diagnostic and therapeutic agents, their biodistribution and 
pharmacokinetic profiles in vivo is difficult to predict. Besides toxicity which is one of the 
main concerns to conventional small pharmaceutical compounds, new agents have to face 
defense mechanisms like reticuloendothelial system (RES), immunological response and 
liver as well. Larger size may also affect to the bioavailability of the agent. To overcome 
these problems comparative biodistribution studies in vivo with potential candidates should 
be started in early phase of the development. 
Non-invasive imaging has become important part of the basic and applied research. It 
allows biodistribution studies within same animal in different time points and phases of the 
disease. This is important for accurate monitoring since variations between individuals 
should be minimized. In other words, using imaging applications more equal results may be 
achieved than with using traditional methods based on post mortem or dosing studies. 
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Imaging is done with fewer animals which is cost-effective and also in accordance to 3R 
principle (Russell & Burch 1959). Appropriate dose is also easier to evaluate since behavior 
of the studied compound is immediately seen and changes can be done in relative short time 
interval compared to dosing studies which may last several months before any effects or 
results are obtained. 
In pharmacological aspect several in vivo modalities for small animal imaging exist today. 
Magnetic resonance imaging (MRI) and resonance (MRS), single photon emission computed 
tomography (SPECT), positron emission tomography (PET) and optical imaging (OI) are 
widely used and several reviews (King et al. 2002, Gröhn & Pitkänen, 2007, Kagadis et al. 
2010, Snoeks et al. 2011) have been published about these techniques, their strengths and 
faults. Choosing the most suitable imaging application for a certain study depends of the 
prioritization of features. 
Our laboratory has experience to use wide range of targeting and carrier moieties in 
experimental animal imaging. In this review we discuss applications in different imaging 
moieties in development of novel diagnostic and therapeutic agents. 
2. Small animal imaging 
Small animal imaging provides a non-invasive method to study biodistribution and 
pharmacokinetics of novel bioactive agents in physiologically relevant environment. 
Dedicated imaging equipments for laboratory animals, mostly for rodents and rabbits, are 
available. Different imaging modalities produce information about anatomical structures 
and physiological processes. Using different modalities together and combining the 
information, the most accurate information of the function of studied agents with good 
anatomical reference is achieved. 
2.1 SPECT 
Single photon emission computed tomography (SPECT) is based on detection of gamma 
radiation from the studied object. Scanning of different projections from several angles enable 
three dimensional (3D) reconstruction and further analysis of the patient or animal from 
various planes and directions. Furthermore, using 2D planar imaging pharmacokinetics of the 
radiolabelled agents can be followed over the time in the same animal.  
There are several radiotracers which can be used in SPECT imaging. The most used are 
Technetium, Indium and Iodine. Since different tracers have different physicochemical 
properties, labeling of the molecules or living particles for imaging purposes requires 
knowledge in biochemistry, traditional chemistry and radiochemistry. 
Historically iodine radiolabels are the most used in biochemistry and cell biology. Over 30 
isotopes of iodine have been reported of which around ten has been evaluated for biomedical 
applications (Welch & Redvanly 2002). Choose of the isotope depends on the purpose of the 
study. 123Iodine decays with practical energy for imaging studies (159 and 127 keV), but its 
relative short half-life (13 hours) limits its usage to the transient biodistribution studies. The 
half life of 125I is 60 days but emission energy is only 36 keV, which makes it impractical for 
human studies but adequate for animal experiments, especially in mice. Its long half-life 
enables imaging studies for several weeks with single administration of the studied agent.  
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For the labeling Iodine is oxidated. The target molecule typically contains benzene ring with 
ortho-substitution which in the most cases is OH-group, like tyrosine in the peptides or 
proteins. Oxidated iodine reacts to the positions 3 or 5 or both of the benzene ring. Iodine is 
oxidated by chloramine-T, Iodogen or lactoperoxidase in direct chemical methods (Hunter 
& Greenwood 1962, Fraker & Speck 1978, Marchalonis 1969). The most convenient method 
for iodination of biologically active molecules is commercially available Iodo-Gen tubes, 
which are coated with an oxidative agent 1,3,4,6-tetrachloro-3-6-diphenylglycouril. Due to 
the high hydrophobicity, this toxic oxidative compound is insoluble to water based buffers 
and remains in the walls of test tubes enabling solid phase oxidation of Sodium Iodine 
(NaI). Biomolecules are Iodinated in aquatic environment. The method is optimal for 
sensitive molecules and the toxic compound remains on the solid phase.  
If the target molecule lacks a benzene ring, an additional radioiodinating reagent may be 
used. The most common and commercially available reagent is Bolton-Hunter reagent. This 
reagent is succinimidyl derivatized ortho-substituted benzene ring (N-succinimidyl-3-[4-
hydroxyphenyl]propionate) (Bolton & Hunter 1973, Zalutsky & Narula 1987, Vaidyanathan 
et al. 1997, Gabel & Shapiro 1978). It reacts with primary amines, which are common in 
bioactive peptides, proteins, viruses and cells enabling iodination position to the target 
molecule.  
Alternative methods for iodine tracers are 99mTechnetium (99mTc)and 111Indium (111In), which 
are the most used isotopes in nuclear medicine. However, these metals have to form 
complexes with donor ligands or chelates prior administration. If the molecule itself lacks 
chemical structures, which react with the metal as a ligand like sulphur fingers (Maret, 
2004), the molecule has to be chelated. Diethylenetriaminepentaacetic acid (DTPA) and 
1,4,7,10-tetraazacyclododecane-N,N',N,N'-tetraacetic acid (DOTA) are the most commonly 
used chelates in imaging. As with Bolton-Hunter reagent, these chelates are also available as 
bifunctional chelating agents (BCA) (Figure 1.) (Chakraborty & Liu 2010, Liu & Edwards 
2001).  
 
Fig. 1. Commonly used bifunctional chelating agents (BCA) in imaging. Isothiocyanate 
(S=CH=N-) reacts with primary amines in physiogical conditions allowing labeling of 
unstable peptides and proteins. A) Isothiocyanate DTPA and B) isothiocyanate DOTA.  
Chelates increase the molecular weight of the target molecule and may also change the 
overall charge. Due to the molecular weight they may cause steric hindrances and change in 
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of chelates is more common. In some cases the use of the linker between chelating part and 
reactive part may have effect to the pharmacokinetic properties (Garrison et al. 2008, Qu et 
al. 2001). 
2.2 PET 
In positron emission tomography (PET) imaging positron emitters and the following 
annihilation, is used to measure radioactive accumulation or consumption in the object. 
Annihilation produces two gamma quanta of 511 electron volts, which are emitted to the 
opposite directions (180o). The gamma quanta are easily located by using a serie of stable 
gamma cameras around the animal. The advantage of the PET radiotracers is that 
radionuclides are incorporated in the molecule with minimal inference to the function of the 
pharmaceuticals. Also sensitivity in PET is superior to SPECT. One important limitation for 
PET resolution is that the localisation of positron emission is not the same that the place of 
annihilation. The distance between emission and annihilation depends of the energy of the 
particle and also the density of tissue, for example average range for 18F in water is 0.064 cm 
(Cherry 2003). 
Labeling of PET radiopharmaceuticals is complicated and requires on-site cyclotron and 
highly educated personnel. Due to the short half-lives of tracers the cyclotron facilities should 
be near the research laboratory. Only 18F has adequate long half-life that the delivery time can 
be hours not minutes. It’s also notable that even the half-lives of PET nuclides are shorter than 
SPECT nuclides the dose effect may be larger with PET nuclides since their emission energy of 
511 electron volts is much higher than those of conventional SPECT nuclides.  
In clinical PET studies 18F in deoxyglucose (FDG) is the most commonly used diagnostic 
molecule for the functional studies in tissues. Others, such as sodium 18fluoride, 
18fluorothymidine, 18fluoromisonidazole, and 64Cu-labeled diacetyl-bis N4-
methylthiosemicarbazone are under evaluation for clinical use (Vallabhajosula et al. 2011). 
2.3 CT 
The oldest imaging modality is based on X-rays describe first by Wilhelm Röntgen already 
on 1895 (Röntgen, 1896). Ever since x-rays has been used to produce two dimensional 
images. Today X-rays are used in 3D topographic imaging. In principle, CT unit consist of 
high-voltage x-ray tube and oppositely located detector. Both x-ray source and detector 
rotate around the animal and a 3D reconstruction of the target can be made. Contrast is 
based on the ratio of the radiation which is passed through and absorbed in the patient. In 
contrast to SPECT and PET where radiation comes from the patient, in CT radiation is 
produced in the imaging equipment and the fraction of radiation passing through the target 
is measured. Since differences in linear attenuation coefficients for soft tissues are small 
(water = 0.21 cm-1; lean tissue = 0.20 cm-1; fat = 0.18 cm-1; bone 0.38 cm-1), contrast in the soft 
tissues is limited with x-ray based CT technique. Also increased resolution in CT raise 
significantly the radiation dose. 
Although x-ray based CT is not optimal for small animal imaging this method facilitates the 
localization of labeleld molecules in biodistribution studies. Today there are few 
manufacturers, which provide combined SPECT/CT and PET/CT equipments for clinical 
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use but also dedicated animal devices are on the market (Picler et al. 2008, Golestani et al. 
2010). The advantage of these multimodality systems is the ease of imaging with different 
modalities without moving the object and hence the co-localization of images can be 
performed easily (Figure 2). 
 
Fig. 2. Combined SPECT/CT images of mouse. A) 99mTc labeled commercially available 
bisphosphonate, Etidronate. Biodistribution profile studied in healthy mouse 30 min after 
i.v. injection. Etidronate accumulates mainly to the spine and joints of the hind limb. The 
image also visualizes the elimination of Etindronate through the kidneys and further 
excretion to the bladder (red accumulation). B) 111In labeled monoclonal antibody mF4-31C1 
against vascular endothelial growth factor receptor 3 (VEGFR-3) in ovarian carcinoma 
mouse model. Biodistribution profile studied 48 h after the single intra venous (i.v.) 
injection. Most of the antibodies are excreted through the liver. Signal in the lower part of 
the body indicates antibody’s accumulation in the tumor area and the upper signal 
represents remote activation of VEGFR-3 in metastatic lymph nodes (Huhtala et al. 2010). 
2.4 MRI/MRS 
The best modality for high contrast soft tissue anatomical imaging is magnetic resonance 
imaging (MRI). It is based on nuclear magnetic resonance (NMR) and the nature of proton 
nucleus. Isotopes that contain an odd number of protons and/or neutrons and have an 
intrinsic magnetic moment and angular momentum, like 13C, 2D, 15N and 31P can be used for 
MRI. When an isotope with magnetic properties (usually a proton) is in a strong magnetic 
field, the nucleus of the isotope is aligned with the magnetic field. When using a short 
radiofrequency (RF) pulse, the nucleus will align itself with the magnetic field. After the 
pulse, the nucleus will return on its natural state at certain rate called relaxation time, 
emitting an RF signal which is recorded. The RF signal is analyzed and used to produce MR 
image. Since the environment of the proton affects strongly to the relaxation time, contrast is 
achieved between tissues. Furthermore, using Magnetic Resonance Spectroscopy (MRS) 
analyses the relative concentrations of molecules in the target tissue can be estimated 
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use but also dedicated animal devices are on the market (Picler et al. 2008, Golestani et al. 
2010). The advantage of these multimodality systems is the ease of imaging with different 
modalities without moving the object and hence the co-localization of images can be 
performed easily (Figure 2). 
 
Fig. 2. Combined SPECT/CT images of mouse. A) 99mTc labeled commercially available 
bisphosphonate, Etidronate. Biodistribution profile studied in healthy mouse 30 min after 
i.v. injection. Etidronate accumulates mainly to the spine and joints of the hind limb. The 
image also visualizes the elimination of Etindronate through the kidneys and further 
excretion to the bladder (red accumulation). B) 111In labeled monoclonal antibody mF4-31C1 
against vascular endothelial growth factor receptor 3 (VEGFR-3) in ovarian carcinoma 
mouse model. Biodistribution profile studied 48 h after the single intra venous (i.v.) 
injection. Most of the antibodies are excreted through the liver. Signal in the lower part of 
the body indicates antibody’s accumulation in the tumor area and the upper signal 
represents remote activation of VEGFR-3 in metastatic lymph nodes (Huhtala et al. 2010). 
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intrinsic magnetic moment and angular momentum, like 13C, 2D, 15N and 31P can be used for 
MRI. When an isotope with magnetic properties (usually a proton) is in a strong magnetic 
field, the nucleus of the isotope is aligned with the magnetic field. When using a short 
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achieved between tissues. Furthermore, using Magnetic Resonance Spectroscopy (MRS) 
analyses the relative concentrations of molecules in the target tissue can be estimated 





In MRI fine structure investigation and spectroscopy of the tissues is performed without any 
tracers but biodistribution studies of active compounds are followed using contrast agents. 
It’s notable that in small animal imaging, MRI is typically suitable to image certain part of 
the body and only local biodistribution e.g. the brain areas are imaged. Ferric, gadolinium or 
manganese are common contrast agents Ultra small superparamagnetic iron oxide (USPIO) 
particles, size range of 10 – 50 nm, are widely used for various applications like vascularity 
and macrophage content in atherosclerotic carotid plaques (Metz et al. 2011), lymph node 
metastasis (Lei et al. 2010), tumor vascular morphology and blood hemodynamics 
(Gambarota et al. 2010), diffusion in the brain disorders (Chin et al. 2009, Vellinga et al. 
2009), cell number quantification (Cheung et al. 2006) and oncological studies (Gambarota et 
al. 2006, Baghi et al. 2005, Keller et al. 2004).  
For the labeling several surface activated USPIO particles are available. The surface may 
contain chemically active groups like carboxylic acid, primary amines, aldehydes or 
isothiocyanates. Also biotinylated or avidin/streptavidin coated particles are available. 
Since biotin-avidin complex is one of the strongest found in nature, this phenomena can be 
used widely for various targeted applications or as a conjugation techniques. It should be 
noted that USPIO nanoparticles are several magnitudes larger than bioactive molecules and 
may cause sterical hindrances.  
For MRI studies gadolinium and mangansese based contrast agents have also been used. 
They require, like Technetium and Indium, chelates for labelling. Gadolinium ion as a water 
soluble salt is also quite toxic to animals and chelating reduces significantly its toxicity. 
However, the sensitivity of these contrast agents in MRI or MRS is significantly lower than 
corresponding radioactive metals in SPECT or PET techniques. In MRI millimolar 
concentrations are needed whereas nano and even picomolar concentration of radionuclides 
gives reliable SPECT or PET imaging results.  
Combination of PET/MRI is relatively new and rare hybrid scanning technique but very 
fascinating (Pichler et al. 2008, Bisdas et al. 2010, Antoch & Bockisch 2009). Especially in brain 
imaging combination of PET and MRI seems advantageous and promising (Heiss 2009). With 
combined PET and MRI imaging gives valuable information about function of the heart (PET) 
and also information about ventricular structure of the heart (MRI) (Nekolla et al. 2009). 
Combination of SPECT and MRI is available only for animal studies (Goetz et al. 2008). 
2.5 Optical imaging 
Compared to previously described methods advantaged of optical imaging (OI) include 
relatively ease usability, inexpensiveness and no need of radioactive tracers. In OI the 
detection is based on produced light from the tissues and monitored by common CCD 
camera. This method has been used for pharmacokinetic studies, angiogenesis, cancer, 
evaluating biodistribution or biological activity of potential therapeutic agents but also 
visualization of living embryos (Baker 2010, Dufort et al. 2010b, Penet et al. 2010, 
Eisenblatter et al. 2010, Canaria & Lansford 2010).  
The OI modality uses either fluorescence of bioluminence as a tracer. The molecules are 
typically labelled with fluorescent molecules and their biodistribution is followed like in 
SPECT or PET modalities (Weissleder & Ntziachristos 2003, Napp et al. 2011). The labelling 
chemistry is similar as with chelates. Several fluorescence molecules like fluorescein or 
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cyanine based molecules (Cy3, Cy5 etc.) may contain either amino or carboxylic acid groups 
or are pre-activated with succinimides, maleimimides or isothiocynanates for the 
conjugation. Another fluorescence method is based on green fluorescence protein (GFP). 
Using cells transfected with GFP gene, the function of the cells can be studied (Chudakov et 
al. 2005). However using fluorescence the depth of imaging target, surface reflectance, 
absorption, scattering and autofluorescence limit the sensitivity in true 3D imaging (Dufort 
et al. 2010a, Welsh & Kay 2005, Bremer et al. 2003).  
The light emission in bioluminescence is more sensitive, mainly because it is not interfered 
by autofluorescence since it is based on or oxygenation of Luciferin by Luciferase enzyme. 
During the oxygenation Luciferin substrate produces a photon, which is measured. As with 
GFP the function i.e. proliferation or cell death can be studied by using transfection with 
Luciferase gene. Transfected cells are inoculated to the experimental animal and followed 
over the time with Luficerin injections. After systemic injection, luciferin circulates and 
internalizes in to the cells. In Luciferase expressing cells the light is lit and can be imaged. 
This method has successfully use i.e. in imaging of the therapeutic effect of the viruses in 
cancer (Heikkilä et al. 2010). 
Another fascinated optical imaging application is splice correction method developed by 
Kole and his colleagues in 1998 (Kang et al. 1998). This method is based on transfection of a 
plasmid containing mutated Luciferase gene. This mutation causes an aberrant splicing of 
the pre-mRNA resulting non-functional mRNA. Upon the treatment with slice correcting 
oligonucleotide , which has complementary structure to the mutation site, the aberrant 
splicing is corrected and active Luciferase enzyme is expressed. This method has 
successfully used in cell cultures to study oligonucleotide internalisation in to the nucleus 
using cell penetrating peptides (CPP) (Mäe et al. 2009), but in the future it may have several 
applications in in vivo optical imaging. 
3. Therapeutic and diagnostic agents in imaging 
Although most of the pharmaceutical compounds are small and relatively simple structures, 
there are a growing number of other types of molecules for therapy and diagnostics. Exactly 
speaking it’s inaccurate to speak novel therapeutic molecules, since there are also other 
solutions to deliver the therapeutic agents and affect the target tissue or cells. In recent years 
nanoparticles (NP), viruses and stem cells has been in focus. 
What is common aim in developing novel therapeutic or diagnostic agents? The first aim is 
to develop specific targeting to the pathological alterations in tissues or cells. Secondly, they 
should be multifunctional containing several biological or chemical structures like targeting, 
drug, carrier and tracer moieties. Thirdly, the side effects should be minimized. Gene 
technology provides totally new approach to therapeutic field by delivering genes to the 
host cell, which transcription and translation machinery is used as "drug factory". 
Small animal imaging methods are ideal to study biodistribution of various types of 
molecules or even viruses and cells. Since nano- and picomolar concentration of radiolabel 
gives adequate signal, small amounts of label is needed to preliminary results of the 
biodistribution, accumulation, pharmacokinetics and metabolic routes of the studied 
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pharmacological studies since whole body results can be achieved over the time in vivo 
without sacrificing the animals.  
3.1 Conventional pharmaceutical and imaging compounds 
Most of the commercially available pharmaceutical compounds are small molecules below 500 
Da and they typically lack homing properties but the effect is based on specific binding as an 
agonist or antagonist in the target tissue or cell. If small pharmaceutical compounds are used 
in imaging studies, in the most cases the tracer should be directly incorporated to the molecule 
structure like chemical labelling of Iodine for SPECT, with cyclotrone for PET or the molecule 
should have chelating properties, like bisphosphonates, if a radioactive metal is used.  
There are several small molecules used in diagnostic imaging. One widely used imaging 
agent is (-)-2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT or RTI-55). In SPECT and 
PET imaging it has been used as 123I labeled or 18F (FP-CIT) labeled to map distribution of 
dopamine transporters and serotonin transporters in the brain e.g. in Parkinson’s disease 
and supranuclear palsy (Zubal et al. 2007, Shaya et al. 1992, Shang et al. 2007, Staffen et al. 
2000, Seppi et al. 2006). 
For PET the small organic imaging agent 18FGD, a glucose derivate, which accumulation 
through the body is related to tissue glucose consumption. This phenomenon is utilized in 
several applications of brain, tumor and myocardial metabolism (Berti et al. 2010, Miletich 
2009, Chen & Chen 2011, Kopka et al. 2008). 18FGD is widely used especially in 
neurosciences including drug research and development. With 18FDG it’s possible to 
determine activation of certain brain areas and hence applications are numerous, e.g. the 
sensitivity of brain areas to drugs as well as behavioral and therapeutic effects of the drug 
(Welch & Redvanly 2002).  
99mTc is the most commonly used isotope in nuclear medicine. When it is conjugated with 
DTPA, it is used to measure functionality of the kidneys (Eckelman & Richards 1970), as a 
pyrophosphate or bisphosphonate for skeletal imaging (Thrall 1976) and with 
hexamethylpropyleneamine oxine (HMPAO, Ceretec™) for brain perfusion (Leonard et al. 
1986a). 111Indium, chelated to oxine is used in clinics to label white blood cells or platelets to 
study sites of acute inflammation and infection but also thrombocytopenia in vivo (Leonard 
et al. 1986b, Thakur et al. 1977, Thakur 1977, Rodrigues et al. 1999, Louwes et al. 1999). 
3.2 Peptides 
Although peptides and polypeptides have been used for therapeutic purposes already for 
over 80 years when insulin was taken in clinical use, only few novel peptide based drugs 
have been approved by FDA or EMEA. Most of the drugs are direct copies from nature like 
follitropin beta, which is a synthetic copy of follicle stimulating hormone (FSH) (Fares et al. 
1992, Shome et al. 1988). Second generation peptide drugs are modified from the original 
molecule or are part of the larger proteins. Octreotide is a long-acting octapeptide with 
pharmacologic properties mimicking those of the natural hormone somatostatin (Bornschein 
et al. 2009, Anthony & Freda 2009, Stajich & Ashworth 2006). Fuzeon (Enfuvirtide) is a 36 
residue synthetic peptide that inhibits HIV-1 fusion with CD4 cells. Enfuvirtide binds to the 
first heptad-repeat (HR1) in the gp41 subunit of viral envelope glycoprotein and prevents 
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the conformational changes required for the fusion of viral and cellular membranes. It 
interferes the HIV-1 molecular machinery at the final stage of fusion with the target cell. 
Enfuvirtide is a biomimetic peptide that was rationally designed to mimic components of 
the HIV-1 fusion machinery and displace them, preventing normal fusion. (Joly et al. 2010, 
McKinnell & Saag 2009, Makinson & Reynes 2009)  
The number of bioactive peptides , with potential therapeutic or diagnostic properties, will 
be increased due to new screening methods for novel peptides. Epitope scanning (Reece et 
al. 1994, Frank, 2002) and phage display libraries produce novel biologically active peptides 
with specific binding properties to target proteins such as receptors and proteases (Nilsson 
et al. 2000). Some of the identified peptides are highly specific to the receptors of the 
specialized tissues providing a possibility to use peptides for targeting (Laakkonen et al. 
2002). These peptides serve as lead molecules for development of molecules for tumour 
imaging and therapy.  
Both natural peptides and peptides characterized by phage display are sensitive to 
metabolic processes like protease activity. This limits their usefulness as diagnostic and 
therapeutic agents. Rationale design of chemical modifications to maximize enzymatic 
bioavailability while preserving the potency and specificity of the peptide is needed (Adessi 
& Soto 2002). Typically peptides are cyclised or the amino acid side chains or bridge 
structures are modulated by using unnatural structures called peptidomimetics (Pakkala et 
al. 2007, Pakkala et al. 2010). 
Peptides and their modifications are typically produced by using solid phase peptide 
synthesis method (SPPS). Today synthesis is made with automated synthesiser and the time 
to produce a peptide is relatively short and several companies provide synthesis services for 
reasonable price. For labelling an additional reactive amino acid like tyrosine or cysteine are 
easy to add to the sequence for further labelling or conjugation purposes.  
3.3 Proteins 
Unlike peptides proteins are large and contain secondary, tertiary and some cases even 
quaternary structures on which the biological activity is based. Due to their defined tertiary 
structure and size, they may be sensitive to the labelling and purification methods. 
Furthermore, the administration route, which is mainly the systemic injection, and 
immunological response limits the usefulness of the proteins as drug candidates.  
For the biodistribution studies the surface of the proteins contains several different 
chemically active amino acid side chains or polysaccharides, which can be used for labelling 
purposes. Typically proteins are labelled via the ortho-hydroxy benzene ring of tyrosine or 
via primary amino groups of either the amino terminus or the side chain of lysine. For the 
imaging purposes proteins are labelled with iodine or conjugated with chelates as 
previously described. After the conjugation proteins can be purified with conventional size-
exclusion chromatography, dialysis or ultrafiltration using physiological conditions. In 
addition, chelate conjugated proteins can be labelled with 99mTc or 111In without further 
purification steps (Helppolainen et al. 2007). 
One of the most used group of proteins for diagnostic and therapeutic purposes are 
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way from the primary finding to the licensed drug (Biopharma, 2011). The limiting factors of 
antibodies are large size (150 000 Da) which may interfere penetration of the molecule to the 
target tissue and possible squeamishness. Large size can be bypassed with Fab1 or Fab2 
fragments of the antibodies or as in human therapy using humanized monoclonal 
antibodies. The advantage of antibodies is high affinity compared to other protein-ligand 
interactions but also relatively easiness and diversity of modification chemistry without 
losing the binding activity.  
Antibodies have been successfully used in cancer therapy. Cetuximab (Erbitux) is a 
humanized monoclonal antibody against epidermal growth factor receptor (EGFR) which is 
over-expressed in various cancers (Vincenzi et al. 2008, Rivera et al. 2008). It has been 
successfully used in the treatment of colon carcinoma in humans. Same antibody has been 
studied as versatile SPECT and PET imaging agent in several cancer models, e.g. malignant 
mesothelioma, prostate cancer, head-and-neck squamous cell carcinoma, ovarian carcinoma 
(Figure 2.), colon cancer and universally EGFR positive tumors (Nayak et al. 2011, 
Malmberg et al. 2011, Hoeben et al. 2011, Huhtala et al. 2010, Cho et al. 2010, Ping Li et al. 
2008). 
3.4 Viruses 
This very exiting approach is based on natures own gene delivery method. After delivery, 
modified virus in target cell begins to use cell’s natural amplification techniques to produce 
therapeutic molecules. Today there are both transient (Adenoviruses) and stable 
(Lentiviruses) viral delivery systems (Rissanen & Yla-Herttuala 2007, Mahonen et al. 2010, 
Lesch et al. 2009). 
Biodistribution studies using non-invasive imaging is an important part of the development 
of virus based therapeutic agents. Viruses for the therapy are modified, they are unable to 
multiply and additional therapeutic and/or reporter genes are added to the viral genome. 
Expressed reporter genes can be imaged by using radiolabelled ligands. Using 
sodiumiodine symporter (hNIS) gene together with cancer-specific human telomerase 
promoter, human colocarcinoma xengraft has been imaged using radiolabelled iodine with 
SPECT/CT in animal model (Merron et al. 2007). 
Fusion proteins composed of avidin and either macrophage scavenger or low-density 
lipoprotein receptors (LDLR) have been constructed in order to target biotinylated 
molecules to cells of desired tissues. Using adenovirus mediated gene transfer transient 
expression of the fusion protein on cell membrane was achieved (Lehtolainen et al. 2002, 
Lehtolainen et al. 2003). When biotinylated molecule binds to the fusion receptor, it is 
internalized into the cell. Local gene transfer to target tissues could be used as a universal 
tool to deliver therapeutic agents at systemic low concentrations. Using biotinylated tracers 
like biotin-DTPA or biotin-DOTA compelexes these cells can be imaged in vivo (Turhanen et 
al. 2011). 
An alternative method to study the biodistribution of the viruses is avidin expression on the 
surface of the viral particle. Their homing properties to the target tissue may be enhanced 
using biotinylated moieties like antibodies or peptides. For imaging purposes biotinylated 
radiotracer is conjugated on the virus surface and biodistribution of the labelled virus is 
followed by SPECT (Raty et al. 2007, Raty et al. 2006, Kaikkonen et al. 2009).  
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Homing properties of viruses can be modified with biochemical methods using hybrid 
peptide with poly-lysine spacer together with cyclic peptide HWGF (His-Tyr-Gly-Phe) 
which binds to membrane metalloprotein receptors, MMP-2 and MMP-9 (Koivunen et al. 
1999). This peptide has been conjugated with trasnglutaminase enzyme on the surface of 
Adenovirus. The use of enzyme for conjugation is gentle and do not decrease the infectivity 
of the virus. Conjugated receptor specific peptide enhanced the tropism of the virus in vivo 
in rabbits (Turunen et al. 2002). 
3.5 Living cells 
Nuclear medicine has been used to image leucocytes in infectious or inflammatory processes 
in vivo already over four decades. The techniques detect inflammatory processes to which 
leukocytes migrate, such as those associated with abscesses or other infection. During 1970’s 
a new cell membrane tropic radioactive compound was developed. 111In-oxine is a lipophilic 
complex and penetrates through cell membrane without interference of the membrane 
bound molecules like receptors. Penetration is unspecific and all cell types can be labelled 
(Thakur et al. 1977, Becker & Meller 2001). 
Stem cells are immature cells, which have regenerative potential in various diseases. 
Especially neurodegradative disorders have been in the focus due to the poor regenerative 
properties on neuronal cells. The regenerative properties of the stems cells have been 
studied in Parkinson disease (PS), amyotrophic lateral sclerosis (ALS), Huntington's disease 
and stroke (Lindvall et al. 2004). For in vivo biodistribution studies stem cells have been 
labelled either with paramagnetic nanoparticles and followed with MRI (Arbab et al. 2003, 
Frank et al. 2003) or with 111In-oxine (Figure 3.) for SPECT imaging (Lappalainen et al. 2008, 









Fig. 3. 111Indium oxine i.e. Indium 111 oxyquinoline. Indium is coordinating three 
oxyquinoline molecules. Due to the relative high hydrophobicity Indium oxine penetrates 
directly but unspecifically into the cytoplasm of the target cells and do not bind to the 
surface proteins. 
Radiolabeling of living cells is probably the most challenging labeling process since several 
issues has to be considered. Firstly, labeling conditions have to be effective, mild, temperate, 
fast and without complicated purification steps. Secondly, aseptic techniques have to be 
followed and last, appropriate dose for the cell batch has to be evaluated avoiding too high 
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different cell type according their usual cultivation techniques. If longer (i.e. over 24 h) 
biodistribution studies are measured, effect of the labeling to the viability of the cells in vitro 
during timescale is worth to analyze. This is important since only the nuclide is seen in in vivo 
imaging but no information is achieved about the absolute condition of the cells viability. 
3.6 Nanoparticles 
There have been invasion of basic nanoparticle research in biomedicine. Many therapeutic 
agents like small organic compounds, nucleic acids, peptides and proteins are unstable in 
vivo and novel delivery technologies should be developed to improve their pharmacokinetic 
properties. Development of nanoparticle based delivery could enable sustained and hence 
regular release of drug. If NPs are also targeted, in the ideal case they would concentrate to 
the desired area and allow sustained release of the drug to the circulation or locally if 
needed. This would be beneficial for the patient as fewer drug intakes, steadier effect of the 
drug and hence milder side-effects but maybe also economically cost-effective. 
The size range of nanoparticles is comparable to the viruses. Conventionally nanosized 
materials like polymeric nanoparticles, liposomes and micelles are prepared from organic 
materials although they have limited chemical and mechanical stability and inadequate 
control over the drug release rate (Arruebo et al. 2006). Today there are NPs made of 
inorganic materials like silica or silicon (Haley & Frenkel 2008, Salonen et al. 2008). 
Inorganic material allows the production of porous or mesoporous nanoparticles with 
particle size in range of 50 – 300 nm and the pore diameter in the range 5 – 50 nm. The 
porous structure allows high loading capacity for the therapeutic agents and/or tracers, like 
fluorescein, radioactive compounds or paramagnetic iron (Wiekhorst et al. 2006, Alexiou et 
al. 2006a, Alexiou et al. 2006b).  
Furthrmore, the transportation and release of the molecules can be controlled. Mesoporous 
silicon nanoparticles have also shown to be non-toxic and stable (Salonen et al. 2008, Brigger 
et al. 2002, Limnell et al. 2007, Salonen et al. 2004). The surface of the nanoparticles can be 
derivatized with chemically active groups like primary amines or carboxylic acids and 
conjugated with several biologically and chemically active molecules (Figure 4). Large 
surface area allows conjugation of several different molecules on the same particle. Using 
targeting moieties the tropism of NPs can be modulated (Kukowska-Latallo et al. 2005, 
Costantino et al. 2005). 
 
Fig. 4. Chemically modified surfcaes of the silicon based mesoporous nanoparticles for the 
conjugation of bioactive molecules. A) carboxylic acid derivatized nanoparticles and B) 
primary amino derivatized nanoparticles with alkane spacers. 
 




Several imaging modalities for small animal pre-clinical studies have been developed. 
Various modalities provide different information about biodistribution, pharmacokinetics 
and effect of potential therapeutic agents to the target tissues and cells. Using SPECT or PET, 
biodistribution of the labelled agents can be easily followed over the time in animals with 
high sensitivity. Due to high spatial resolution, chances in fine structure and furthermore 
chemical chances of the target tissue can be studied using MRI and MRS. Contrast of CT is 
not optimal for soft tissue studies in small animals in vivo but using combined images with 
SPECT and PET it facilitates the localisation of the labelled bioactive agents. Optical imaging 
provides an excellent tool for the viability studies of cells and tissues. Luciferase expression 
based on transfected cells or whole transgenic animal gives direct information of the gene 
activation, growth and the death of the cells in vivo. 
Today several new therapeutic and diagnostic agents are large and/or complexed structures 
especially viruses, stem cells and nanoparticles. Due to high variety of the structures in new 
agents, requirement of interdiscipline skills and collaboration starting from basic organic 
chemistry to virology and cell biology is required. Accurate information of the 
biodistribution and pharmacokinetics before clinical trials is needed. Using different 
imaging modalities and combining the information, excessive preliminary knowledge of 
behaviour and effect of the studied complexes in vivo can be achieved. 
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1. Introduction  
Earthquake can be defined as the shaking of earth caused by waves moving on and below 
the earth's surface and causing: surface faulting, tremors vibration, liquefaction, landslides, 
aftershocks and/or tsunamis (World Health Organization [WHO], 2011). 118 earthquakes of 
magnitude 7 or over occurred since 21st century all over the world, and caused millions of 
casualties (National Geophysical Data Centre [NGDC], 2011). In 2004，the Indian Ocean 
earthquake with a magnitude of 9.1 triggered a series of devastating tsunamis along the 
coasts, killing 230,000 people in 14 countries, which was one of the deadliest natural 
disasters in recorded history. In 2011, the 9.0 magnitude East Japan earthquake, which 
caused tsunami and nuclear crisis, killed 15,365 people.  
Earthquakes cause high mortality resulting from trauma, asphyxia, dust inhalation (acute 
respiratory distress), or exposure to the environment (i.e. hypothermia) (WHO, 2011). Recent 
studies suggest that primary prevention is the most effective means of reducing earthquake 
casualties (Durkin & Thiel, 1992). Therefore, priority should be given to considering seismic 
safety in land-use planning and in building design (Coburn & Spence 1992). After an 
earthquake occurs, however a well-planned medical response is a key strategy for reducing 
mortality and disability (Schultz et al, 1996). During a medical response, drug use is an 
important issue in the management of the injured, especially for ones have known or 
suspected infections, internal injuries and crush syndrome requiring intensive drug treatment 
besides surgery. Therefore, the rationality of drug use in earthquake injured needs to be 
discussed to find whether irrationality exists and how to get improved in future medical 
response. In addition, there is no doubt that the pharmacists as medical professionals play an 
important role in promoting rational drug use in our medical service, however, what can 
pharmacists do to promote rational drug use in earthquake medical response? Based on these 
facts and questions, in this chapter we reviewed drug use and practice experience of 
pharmacists in management of injured in previous earthquakes, to provide evidence for better 
pharmacy practice in earthquake medical response in the future. 
2. Death and diseases caused by earthquakes 
In most earthquakes, people are injured and killed by mechanical energy as direct result of 
being crushed by falling building materials. Deaths caused by earthquakes can be 
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instantaneous, rapid or delayed (Naghii, 2005). Instantaneous death can result from sever 
crushing injuries to the head or chest, severe external or internal bleeding, or get drowned in 
the tsunamis caused by the earthquake. Rapid death occurs within minutes or hours and can 
result from asphyxia caused by inhalation or chest compression, hypovolemic shock, or 
environmental exposure. Delayed death occurs within days and can result from 
dehydration, electrolyte disturbance, crush syndrome, or infections (Pretto et al, 1994).  
Within 1 week after an earthquake occurs, the dominated disease is traumas. In the first day 
after Sichuan earthquake in 2008, trauma accounted for 96.8% of all the patients (Liu et al, 
2011). 1 week later, number of traumas patients decreases and more patients are admitted to 
internal medicine, pediatrics and dermatology department for infectious diseases, in which 
respiratory infection, diarrhea and skin rash are more common (Ma et al, 2011). Trauma is 
mostly caused by the collapse of building and leads the majority of deaths and injuries in most 
earthquakes (Coburn & Spence 1992). Major injury requiring hospitalization includes skull 
fractures with intracranial hemorrhage, spine injuries, and damage to intrathorcic, intra-
abdominal, and intrapelvic organs, including pneumothorax, liver lacerations, and ruptured 
spleen. Most seriously injured people have combination injuries, such as pneumothorax in 
addition to an extremity fracture (Naghii, 2005). A study based on the Spitak-88 earthquake in 
1988 found that combination injuries accounted for 39.7% of the cases. Superficial trauma such 
as lacerations and contusions were the injuries most frequently observed (24.9%), followed by 
head injuries (22%), lower extremity injuries (19%), crush syndrome (11%), and upper 
extremity trauma (10%) (Noji, 1992). Appropriate medical and surgical treatment of these 
injuries is vital to improving survival, minimizing future functional impairment and disability. 
3. Drug use in earthquake injured patients  
There was scarcely any study investigating drug use in the earthquake injured until several 
studies based on data from Sichuan Earthquake in 2008 had addressed this topic. To our 
knowledge, there is no data on this subject from other earthquakes, we discussed drug use 
in earthquake injured patients based on available data from Sichuan earthquake. 
3.1 Characteristics of drug use  
3.1.1 Types of drugs 
The study conducted by Yuan analyzed types of drugs used in injured patients in a hospital 
which is the nearest large general hospital to epicenter in Sichuan earthquake. This study 
was based on medical record of 325 patients who were admitted within 1 week after the 
disaster. Most patients had trauma, including bone fractures, soft tissue trauma, brain injury 
and other kinds of contusion/laceration. The results showed that 21 types and 433 drugs 
were used. The top 10 types in number of individual drugs used were listed in table 1. 
Among all drugs used, anti-infective drugs had the most individual drugs, in which 84 
drugs were used, accounting for 19.39% of all the 433 individual drugs. 65 drugs acting on 
central nervous system were used, including analgetics sedatives and antianxietics. 59 
cardiovascular drugs were used, most of which were calcium channel blockers, drugs for 
chronic cardiac insufficiency, drugs for angina, hypotensive agents, and anti-shock drugs. 36 
gastrointestinal drugs were used, and most of them were drugs for peptic ulcer, prokinetic 
agents, antiemetic agents, catarrhectics, anti-diarrheal agent and drugs for liver and gall 
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diseases. 34 drugs were used in respiratory disease, including expectorants, antitussives and 
antasthmatics. Drugs affecting blood included blood coagulants, anticoagulant drugs, blood 
plasma and its substitutes. Externally applied drugs included disinfectants, antiseptics and 
dermatological drugs. Hormones included adrenal cortex hormone and trypsin. Antiallergic 
agents are mainly anti-histamine drugs. These drugs are mainly administered by injection or 
external application (Yuan & Zhang, 2009).  
 
Types of drugs Number of individual drugs Percentage (%) 
Anti-infective drugs 84 19.39 
Drugs acting on central nervous 
system 65 15.01 
Cardiovascular drugs 59 13.63 
Gastrointestinal drugs 36 8.31 
Drugs acting on respiratory 
system 34 7.85 
Drugs affecting the blood 26 6.00 
Externally applied and 
ophthalmological preparations 18 4.16 
Hormones 17 3.93 
Antiallergic drugs 9 2.08 
Drugs correcting water, electrolyte 
and acid-base disturbances 9 2.08 
Table 1. The top 10 types in number of individual drugs used in Sichuan earthquake injured 
patients 
Another study analyzed drug use in 329 women and children injured after Sichuan 
earthquake, and found that 26 types involving 398 individual drugs were used (Han et al, 
2008). Anti-infective, involving 77drugs, had the most number of individual drugs, which 
was consistent with results found by Yuan in the general hospital (Yuan & Zhang, 2009).  
These results suggest that many types involving hundreds of individual drugs might be 
used during the treatment of earthquake injured patients, and thus actions should be taken 
to ensure those essential drugs accessible in medical response. Decision makers in hospitals 
and local governments especially in areas where earthquakes occur frequently should make 
related polices, such as an essential drug list to ensure those essential drugs are well 
prepared when an earthquake breaks out.  
3.1.2 Frequently used drugs 
2 studies conducted in different hospitals analyzed the consumption of drugs in injured 
patients after Sichuan earthquake. The top 20 frequently used drugs in injured patients 
admitted in 2 hospitals were listed in table 2. Both results suggested that water and 
electrolyte supplements were most frequently used drugs, including glucose, sodium 
chloride, potassium chloride, sodium lactate Ringer's and sodium bicarbonate. Antibiotics 
were second frequently used, but different antibiotics were used in the 2 hospitals. 
Ciprofloxacin was the most frequently used antibiotic in Mian Yang Central Hospital. 
Metronidazole, cefazolin and ofloxacin were other frequently used antibiotics (Yuan & 
Zhang, 2009). Benzylpenicillin was most frequently used in West China Hospital, 
cefuroxime, ciprofloxacin, and clindamycin were other frequently used antibiotics (Li et al, 
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and other kinds of contusion/laceration. The results showed that 21 types and 433 drugs 
were used. The top 10 types in number of individual drugs used were listed in table 1. 
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gastrointestinal drugs were used, and most of them were drugs for peptic ulcer, prokinetic 
agents, antiemetic agents, catarrhectics, anti-diarrheal agent and drugs for liver and gall 
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diseases. 34 drugs were used in respiratory disease, including expectorants, antitussives and 
antasthmatics. Drugs affecting blood included blood coagulants, anticoagulant drugs, blood 
plasma and its substitutes. Externally applied drugs included disinfectants, antiseptics and 
dermatological drugs. Hormones included adrenal cortex hormone and trypsin. Antiallergic 
agents are mainly anti-histamine drugs. These drugs are mainly administered by injection or 
external application (Yuan & Zhang, 2009).  
 
Types of drugs Number of individual drugs Percentage (%) 
Anti-infective drugs 84 19.39 
Drugs acting on central nervous 
system 65 15.01 
Cardiovascular drugs 59 13.63 
Gastrointestinal drugs 36 8.31 
Drugs acting on respiratory 
system 34 7.85 
Drugs affecting the blood 26 6.00 
Externally applied and 
ophthalmological preparations 18 4.16 
Hormones 17 3.93 
Antiallergic drugs 9 2.08 
Drugs correcting water, electrolyte 
and acid-base disturbances 9 2.08 
Table 1. The top 10 types in number of individual drugs used in Sichuan earthquake injured 
patients 
Another study analyzed drug use in 329 women and children injured after Sichuan 
earthquake, and found that 26 types involving 398 individual drugs were used (Han et al, 
2008). Anti-infective, involving 77drugs, had the most number of individual drugs, which 
was consistent with results found by Yuan in the general hospital (Yuan & Zhang, 2009).  
These results suggest that many types involving hundreds of individual drugs might be 
used during the treatment of earthquake injured patients, and thus actions should be taken 
to ensure those essential drugs accessible in medical response. Decision makers in hospitals 
and local governments especially in areas where earthquakes occur frequently should make 
related polices, such as an essential drug list to ensure those essential drugs are well 
prepared when an earthquake breaks out.  
3.1.2 Frequently used drugs 
2 studies conducted in different hospitals analyzed the consumption of drugs in injured 
patients after Sichuan earthquake. The top 20 frequently used drugs in injured patients 
admitted in 2 hospitals were listed in table 2. Both results suggested that water and 
electrolyte supplements were most frequently used drugs, including glucose, sodium 
chloride, potassium chloride, sodium lactate Ringer's and sodium bicarbonate. Antibiotics 
were second frequently used, but different antibiotics were used in the 2 hospitals. 
Ciprofloxacin was the most frequently used antibiotic in Mian Yang Central Hospital. 
Metronidazole, cefazolin and ofloxacin were other frequently used antibiotics (Yuan & 
Zhang, 2009). Benzylpenicillin was most frequently used in West China Hospital, 
cefuroxime, ciprofloxacin, and clindamycin were other frequently used antibiotics (Li et al, 
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2009). Other frequently used drugs included hemostatic drugs（etamsylate and 
aminomethylbenzoic acid), dexamethasone, vitamin C, atropine, dopamine, tetanus 
antitoxin, ambroxol, inosine injection, lidocaine hydrochloride, and disinfectants (hydrogen 
peroxide solution and betagen solution) . 
 
Rank 
Drug name （specification） 
Mian Yang Central Hospital West China Hospital 
1 Glucose injection 
（5% 500ml） Benzylpenicillin （80 U） 
2 Etamsylate injection 
（2ml 0.5g） Sodium chloride injection (0.9% 500ml) 
3 
Glucose and sodium chloride injection（
5% 500ml） Sodium chloride injection (0.9% 100ml) 
4 Dexamethasone sodium phosphate injection（1ml 5mg） Vitamin C injection*  
5 Potassium chloride injection 
（10ml 1 g） 
Tetanus antitoxin 
(250 U) 
6 Ciprofloxacin lactate injection 
（100ml 0.2g） Sodium chloride injection (0.9% 250ml) 
7 Vitamin C injection  
（2ml 0.5g） Potassium chloride Injection (10ml) 
8 Sodium chloride injection 
（0.9% 500ml） Etamsylate injection* 
9 Sodium lactate Ringer's injection 
（500ml） Glucose injection（5% 500ml） 
10 Atropine sulfate injection 2ml 1mg Cefuroxime* 
11 Metronidazole injection 
（100ml 0.5g） Dexamethasone (5 ml) 
12 Cefazolin injection 
（0.5g） Ciprofloxacin injection* 
13 Ofloxacin and glucose injection 
（100ml 0.2g） 
Sodium lactate Ringer's injection 
(500ml) 
14 Dopamine hydrochloride injection 
（2ml 20mg） Aminomethylbenzoic acid injection*  
15 Glucose injection 
（10% 500ml） 
Glucose and sodium chloride injection（5% 
500ml） 
16 Hydrogen peroxide solution 
（3% 100ml） Glucose injection（5% 250ml） 
17 Sodium bicarbonate injection 
（10ml 0.5g） Clindamycin injection* 
18 Tetanus antitoxin 
（1500U） Ambroxol injection*  
19 Lidocaine hydrochloride injection 
（5ml 0.1g） Inosine injection* 
20 Betagen solution 
（5% 200ml） Dopamine injection* 
* Drug specifications were not given in primary studies 
Table 2. Top 20 frequently used drugs in Sichuan earthquake injured patients admitted in 2 
hospitals 
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These results provided information on drugs that frequently used and thus urgently needed 
by injured people, which can be important evidence for drug donation and pharmaceutical 
management in the earthquake disaster. Priority should be given to those drugs when 
purchasing and donating drugs after an earthquake, and actions should be taken in hospitals 
to ensure that those drugs were or can be supplied in sufficient quantity immediately. 
3.1.3 Antibiotic use  
Open injuries are common in trauma caused by an earthquake, and have a potential for 
bacterial wound infections. These in turn may lead to long term disabilities, chronic wound 
or bone infection, and death. As the delay between injury and treatment after an earthquake, 
most injury presented with infected wounds, and necessitated empirical antimicrobial 
treatment urgently （Miskin et al, 2010）. Appropriate management with antibiotics to 
prevent and control infections is criticality important to the injured.  
 
Fig. 1. Proportion of each type of antibiotics in prescriptions for injured patients in Sichuan 
earthquake 
World Health Organization and The Centers for Disease Control and Prevention have 
proposed guidelines for management of wound infectious. Considering that most wound 
infections are due to staphylococci streptococci and anaerobe, WHO recommends penicillin 
G and metronidazole for empirical prophylaxis and treatment of infection (WHO, 2010). 
CDC recommended beta-lactam antibiotics and clindamycin for management of wound 
infections (Centers for Disease Control and Prevention [CDC], 2010). However, a study on 
Haiti earthquake injured patients found that 77% of the wound infections were poly-
microbial, with 89% involving gram-negative pathogens, and these pathogens were 
generally resistant to the antibiotics suggested by CDC and WHO. This result exactly 
demonstrated the types of pathogens around injured patients in the earthquake stricken 
place, as the patients had not been exposed to any other health care environment since the 
earthquake occurred, and could not be infected by nosocomial pathogens (Miskin et al, 
2010). Results of several previous studies based on data from earthquakes happened in 
Turkey (Keven et al, 2003), Pakistan (Kiani et al, 2009), China (Wang et al, 2008; Ran et al, 
2010) and Haiti (Miskin et al, 2010) in 1999~2010 also found that most bacterial isolates that 
caused infection in the injured were gram-negative. The emergency-relief medical teams 
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These results provided information on drugs that frequently used and thus urgently needed 
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and hospitals should be equipped with antimicrobial drugs for treatment of gram-negative 
infections as well as drugs for gram-positive currently recommended.  
A study analyzed the antibiotic use based on 2953 prescriptions of injured patients in 
Sichuan earthquake in 2008. The results showed that 2830 prescriptions included antibiotics, 
accounting for 98.5% of all studied prescriptions. The frequency of each type of antibiotics 
presented in the 2830 prescriptions is listed in Fig 1. Cephalosporin was the most frequently 
used antibiotic, about 2/3 prescriptions included this types of drugs, followed by 
Benzylpenicillins, nitroimidazoles and quinolones (Li et al, 2008). This result may suggest 
that the use of antibiotics for injured patients in Sichuan earthquake was consistent with the 
recommendation by WHO and CDC, and large quantities of beta-lactam antibiotics, 
nitroimidazoles and quinolones are needed for earthquake injured patients. 
3.2 Irrational drug use in earthquake injured patients 
Rational use of drugs requires that patients receive medications appropriate to their clinical 
needs, in doses that meet their own individual requirements, for an adequate period of time, 
and at the lowest cost to them and their community (WHO, May 2010).  
The drug utilization study in 329 injured women and children in Sichuan earthquake found 
that over-use and under-use of drugs were very common especially in children. In women 
patients, over-used drugs included vitamin C, magnesium sulfate, estradiol valerate, and 
dexamethasone. They were prescribed in an average daily dose 7~12 times larger than the 
defined daily dose (DDD) which is the assumed average maintenance daily dose for its main 
indication (WHO,2009). Drug over-use was more serious in earthquake injured children and 
mostly occurred when antibiotics and hormone were used. Benzylpenicillin and oxacillin 
were prescribed in an average daily dose more than 6 times larger than their DDD, and 
prednisolone was prescribed with over-dose 40-80 times than DDD. However, drug under-
use was also found, as amoxicillin and valaciclovir were far less than recommended dose, 
which were 0.03-0.13 times of DDD (Han et al, 2008).  
Over-use of drugs increases risk of adverse effect that can be harmful and causes trouble to 
the treatment of injured patients. In contrast, drug under-use caused failing to achieve the 
intended treatment outcome. Over-use and under-use both induce waste of drugs, which 
can make the lack of drug resources even worse in the earthquake-stricken area. Under 
these circumstances, prescription during the medical care of earthquake injured patients 
should be monitored and regulated to improve rational drug use.  
4. The role of clinical pharmacists in medical relief 
Clinical pharmacists can make a difference in drug supply and use in emergency. The job of 
clinical pharmacists includes ensuring adequate drug supply and promoting rational drug use. 
4.1 Ensuring adequate drug supply 
4.1.1 Participating in making earthquake relief drug list 
According to past experience and Hospital Formulary, hospitals could make an Earthquake 
Relief Drug List, which would act as a guide of drug supply and use during medical relief 
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(Rao et al 2009). The List based on the major diseases after earthquake, includes detail 
information of drugs, such as indication, usage, dosage, pharmacology, the main adverse 
reactions and precautions and warnings. Clinical pharmacists should participate in the 
development of the list, because they have rich pharmaceutical knowledge, basic medical 
knowledge and are familiar with clinical use of drugs. Furthermore, clinical pharmacists 
could specify first-line agents for each type of drugs in the list, which would be helpful for 
doctors choosing drugs rationally (Rao et al 2009).  
4.1.2 Choosing suitable drugs for medical team 
Choosing suitable drugs is part of the clinical pharmacists’ job. Medical team could bring 
only limited drugs with them. In case of that, it is necessary to choose the most suitable 
types and formulations of drugs for easy to use in the stricken area. Additionally, the drug 
packaging should be considered as well. It should be convenient to transport and not be 
frangible. Ciprofloxacin injection was listed on the Earthquake Relief Drug List in a hospital, 
which was packaged by glass bottle (Zhang et al 2010). Levofloxacin has similar 
antimicrobial spectrum and anti-bacterial effect with ciprofloxacin. It needs no allergy test 
before use as well. What’s more, Levofloxacin injection was packaged by plastic bags. 
Considering about the characteristics of levofloxacin, their pharmacists replaced 
Ciprofloxacin injection with Levofloxacin injection. 
4.1.3 Choosing alternative drugs for saving the short one 
After Sichuan earthquake, so many roads were blocked. It was difficult to send materials to 
the stricken area. In addition, there was a huge consumption of drugs. Therefore drug 
supply was relatively short. In this case, clinical pharmacists play a crucial role in 
guaranteeing drug supply by choosing alternative drugs. It is reported that in order to save 
injectable antibiotics during Haiti earthquake relief, pharmacists were asked to participate in 
rounds with doctors, and choose appropriate alternative oral antibiotics to replace injectable 
ones (Ferris 2010). In our hospital, albumin was once short during earthquake relief. Our 
pharmacists advised doctors to use Dextran and Amino acid injection for adding colloidal 
solution instead of albumin, and successfully saved several lives with serious crush 
syndrome (Chen et al 2010).  
4.2 Promoting rational drug use 
4.2.1 Suggesting better treatment plans 
Clinical pharmacists, who are familiar with pharmacokinetics, pharmacology and 
pharmacy, could choose suitable drugs, adjust drug dosage and suggest better treatment 
plans, especially for special patients. Crush syndrome was common after earthquake, which 
is a serious medical condition characterized by major shock and renal failure after a 
crushing injury of skeletal muscle. Individualized treatment plans should be considered for 
those patients who had renal insufficiency. In our hospital during Sichuan earthquake relief, 
there was a patient who was suspected to be infected with gram-negative bacterium (Chen 
et al 2010). Considering about his crush syndrome, our pharmacists advised doctor to use 
drugs which have little effect on kidney function or failing to excrete in urine via the 
kidneys (e.g. cefoperazone and ceftriaxone). Apart from renal insufficiency, patients who 
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(Rao et al 2009). The List based on the major diseases after earthquake, includes detail 
information of drugs, such as indication, usage, dosage, pharmacology, the main adverse 
reactions and precautions and warnings. Clinical pharmacists should participate in the 
development of the list, because they have rich pharmaceutical knowledge, basic medical 
knowledge and are familiar with clinical use of drugs. Furthermore, clinical pharmacists 
could specify first-line agents for each type of drugs in the list, which would be helpful for 
doctors choosing drugs rationally (Rao et al 2009).  
4.1.2 Choosing suitable drugs for medical team 
Choosing suitable drugs is part of the clinical pharmacists’ job. Medical team could bring 
only limited drugs with them. In case of that, it is necessary to choose the most suitable 
types and formulations of drugs for easy to use in the stricken area. Additionally, the drug 
packaging should be considered as well. It should be convenient to transport and not be 
frangible. Ciprofloxacin injection was listed on the Earthquake Relief Drug List in a hospital, 
which was packaged by glass bottle (Zhang et al 2010). Levofloxacin has similar 
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Considering about the characteristics of levofloxacin, their pharmacists replaced 
Ciprofloxacin injection with Levofloxacin injection. 
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After Sichuan earthquake, so many roads were blocked. It was difficult to send materials to 
the stricken area. In addition, there was a huge consumption of drugs. Therefore drug 
supply was relatively short. In this case, clinical pharmacists play a crucial role in 
guaranteeing drug supply by choosing alternative drugs. It is reported that in order to save 
injectable antibiotics during Haiti earthquake relief, pharmacists were asked to participate in 
rounds with doctors, and choose appropriate alternative oral antibiotics to replace injectable 
ones (Ferris 2010). In our hospital, albumin was once short during earthquake relief. Our 
pharmacists advised doctors to use Dextran and Amino acid injection for adding colloidal 
solution instead of albumin, and successfully saved several lives with serious crush 
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4.2 Promoting rational drug use 
4.2.1 Suggesting better treatment plans 
Clinical pharmacists, who are familiar with pharmacokinetics, pharmacology and 
pharmacy, could choose suitable drugs, adjust drug dosage and suggest better treatment 
plans, especially for special patients. Crush syndrome was common after earthquake, which 
is a serious medical condition characterized by major shock and renal failure after a 
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et al 2010). Considering about his crush syndrome, our pharmacists advised doctor to use 
drugs which have little effect on kidney function or failing to excrete in urine via the 
kidneys (e.g. cefoperazone and ceftriaxone). Apart from renal insufficiency, patients who 
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have hepatic insufficiency or chronic disease that need long-term medications require 
special attention to their drug use. Additionally, clinical pharmacists should also pay 
attention to treatment of children, pregnant women and the elderly.  
4.2.2 Prescription audit 
Clinical pharmacists are responsible for drug safety monitoring. Apart from reporting 
adverse drug reaction (ADR), they could contribute to reducing the incidence of ADR (Chen 
et al 2010). Incidence of ADR is particularly higher in patients with multi diseases, because it 
is positively correlated with the number of administered drugs. It is difficult to make a 
rational treatment plan alone for multi diseases patients. In addition, in an emergency like 
earthquake, the efficacy of drugs is usually considered at first. And there is no time to think 
much about the adverse drug reaction. In order to reducing ADR, Clinical pharmacists 
could conduct prescription audit to prevent irrational drug use, such as over-dose drug use 
and negative drug interactions. 
4.2.3 Providing information and guidance of drugs 
Compliance of patients affects the outcome of therapy. However, there are too many 
factors that cause patients taking drugs not as drug therapies. In order to improve 
compliance of patients, clinical pharmacists could instruct patients to take drugs 
rationally (Chen et al 2010; Zhang et al 2010). They could provide information about the 
effects, proper dosage and usage, and potential adverse effect of drugs for patients. In 
addition, clinical pharmacists could provide information and guidance for local residents 
and relief workers.  
Improving use of donated drugs could avoid wasting resources. But doctors are not 
familiar with donated drugs. Clinical pharmacists could introduce donated drugs to 
doctors, provide them with information on indication, efficacy, dosage, adverse effect, 
precautions and warnings of those drugs, and change their prescribing habits. In our 
hospital, the utilization rate of donated drugs was significantly improved in the effort of 
our clinical pharmacists (Zhang et al 2008). 
4.3 Making therapeutic decisions alone 
Clinical pharmacists have the ability to make and implement therapeutic decisions alone 
when a clear diagnosis is made by doctors (Chen et al 2010). Earthquake can cause a large 
number of injured. Facing too many patients after earthquake, it is crucial to distribute 
limited medical personnel reasonably. Optimizing the diagnosis and treatment procedures 
could greatly improve the efficiency of treating patients. Clinical pharmacists are familiar 
with clinical use of drugs and have the ability to make therapeutic decisions alone for the 
patients with common diseases such as diarrhea, upper respiratory tract infection and soft 
tissue or superficial infection, when a clear diagnosis is made. In addition, clinical 
pharmacists are responsible for making the Detailed Rules of the Reasonable Application of 
Antimicrobial Agents in many hospitals. They are vital in treating infective diseases which are 
common after earthquake. Therefore for part of medical disease, they also have the ability to 
make therapeutic decisions alone. 
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Clinical pharmacists can play an important role in medical response after an earthquake and 
thus should be included in the medical relief team. Hospitals especially those undertake 
medical relief should routinely employ clinical pharmacists. In addition, experienced clinical 
pharmacists can be sent to the earthquake-stricken place for the benefit of the injured to 
achieve a better treatment outcome.  
5. Pharmaceutical administration in medical response to an earthquake  
Multi-sectoral collaboration is vital in a relief operation. A survey in 2006 showed that 84% 
of pharmacy in the investigated hospitals had participated in emergency exercise (Hsu et al 
2006). Pharmaceutical administration is a key link to keep the medical response work in an 
orderly way. As different influencing factors exist in earthquake stricken areas distributed 
all over the world and decision makers may face new problems in each disaster, there can 
hardly a guideline for the administration work. The past experience can be important 
evidence for making decisions. 
5.1 Devising an emergency plan 
Earthquake could occur in a sudden, and in a flash. It is difficult to take an emergency 
evacuation or fight against earthquake. It can cause a large number of life and material 
losses. Pharmacy should be prepared for disasters such as earthquake. It is necessary to 
devise a well-developed emergency plans for earthquake (Rao et al 2009; Tong & Xiao 2008). 
Once the disaster happened, pharmacy could supply drugs rapidly and timely. Firstly, an 
Earthquake Relief Drug List should be made, which is the directory for drug supply in 
emergency. Secondly, there should be an emergency team, which can make a response to 
earthquake quickly. Five parts comprise the emergency team, which is respectively 
responsible for clinical pharmaceutical care, controlled drug management, drug purchase, 
transportation and dispensing (Rao 2009). All members of emergency team must be on call 
at any time (Tong & Xiao 2008). 
5.2 Management of drug supply 
5.2.1 Core principle of drug supply 
Drug supply should be based on the major diseases in different periods of earthquakes 
(Xing et al 2008; Xu et al 2008; Cui et al 2010). After Sichuan earthquake, drug supply 
respectively focused on emergency drugs for trauma, antimicrobial agents and 
antipsychotics in different periods. In 1995, Kobe Earthquake caused several fires. Drug 
supply included emergency drugs for burn (Tong & Xiao 2008). In addition, disinfectant and 
vaccine are necessary in earthquake relief. 
5.2.2 Emergency drug purchase 
Our hospital, a women and children specialized hospital, is about 100 kilometers away from 
the epicenter of Sichuan earthquake and closed to the affected area. A large number of the 
injured were accepted in our hospital. But the area of drug warehouse in our hospital is very 
small so that the stock of emergency drugs is serious low. In the night of the day earthquake 
happened, pharmacy made an emergency purchase plan based on drug use of the injured in 
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have hepatic insufficiency or chronic disease that need long-term medications require 
special attention to their drug use. Additionally, clinical pharmacists should also pay 
attention to treatment of children, pregnant women and the elderly.  
4.2.2 Prescription audit 
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adverse drug reaction (ADR), they could contribute to reducing the incidence of ADR (Chen 
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is positively correlated with the number of administered drugs. It is difficult to make a 
rational treatment plan alone for multi diseases patients. In addition, in an emergency like 
earthquake, the efficacy of drugs is usually considered at first. And there is no time to think 
much about the adverse drug reaction. In order to reducing ADR, Clinical pharmacists 
could conduct prescription audit to prevent irrational drug use, such as over-dose drug use 
and negative drug interactions. 
4.2.3 Providing information and guidance of drugs 
Compliance of patients affects the outcome of therapy. However, there are too many 
factors that cause patients taking drugs not as drug therapies. In order to improve 
compliance of patients, clinical pharmacists could instruct patients to take drugs 
rationally (Chen et al 2010; Zhang et al 2010). They could provide information about the 
effects, proper dosage and usage, and potential adverse effect of drugs for patients. In 
addition, clinical pharmacists could provide information and guidance for local residents 
and relief workers.  
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doctors, provide them with information on indication, efficacy, dosage, adverse effect, 
precautions and warnings of those drugs, and change their prescribing habits. In our 
hospital, the utilization rate of donated drugs was significantly improved in the effort of 
our clinical pharmacists (Zhang et al 2008). 
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when a clear diagnosis is made by doctors (Chen et al 2010). Earthquake can cause a large 
number of injured. Facing too many patients after earthquake, it is crucial to distribute 
limited medical personnel reasonably. Optimizing the diagnosis and treatment procedures 
could greatly improve the efficiency of treating patients. Clinical pharmacists are familiar 
with clinical use of drugs and have the ability to make therapeutic decisions alone for the 
patients with common diseases such as diarrhea, upper respiratory tract infection and soft 
tissue or superficial infection, when a clear diagnosis is made. In addition, clinical 
pharmacists are responsible for making the Detailed Rules of the Reasonable Application of 
Antimicrobial Agents in many hospitals. They are vital in treating infective diseases which are 
common after earthquake. Therefore for part of medical disease, they also have the ability to 
make therapeutic decisions alone. 
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Clinical pharmacists can play an important role in medical response after an earthquake and 
thus should be included in the medical relief team. Hospitals especially those undertake 
medical relief should routinely employ clinical pharmacists. In addition, experienced clinical 
pharmacists can be sent to the earthquake-stricken place for the benefit of the injured to 
achieve a better treatment outcome.  
5. Pharmaceutical administration in medical response to an earthquake  
Multi-sectoral collaboration is vital in a relief operation. A survey in 2006 showed that 84% 
of pharmacy in the investigated hospitals had participated in emergency exercise (Hsu et al 
2006). Pharmaceutical administration is a key link to keep the medical response work in an 
orderly way. As different influencing factors exist in earthquake stricken areas distributed 
all over the world and decision makers may face new problems in each disaster, there can 
hardly a guideline for the administration work. The past experience can be important 
evidence for making decisions. 
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Earthquake could occur in a sudden, and in a flash. It is difficult to take an emergency 
evacuation or fight against earthquake. It can cause a large number of life and material 
losses. Pharmacy should be prepared for disasters such as earthquake. It is necessary to 
devise a well-developed emergency plans for earthquake (Rao et al 2009; Tong & Xiao 2008). 
Once the disaster happened, pharmacy could supply drugs rapidly and timely. Firstly, an 
Earthquake Relief Drug List should be made, which is the directory for drug supply in 
emergency. Secondly, there should be an emergency team, which can make a response to 
earthquake quickly. Five parts comprise the emergency team, which is respectively 
responsible for clinical pharmaceutical care, controlled drug management, drug purchase, 
transportation and dispensing (Rao 2009). All members of emergency team must be on call 
at any time (Tong & Xiao 2008). 
5.2 Management of drug supply 
5.2.1 Core principle of drug supply 
Drug supply should be based on the major diseases in different periods of earthquakes 
(Xing et al 2008; Xu et al 2008; Cui et al 2010). After Sichuan earthquake, drug supply 
respectively focused on emergency drugs for trauma, antimicrobial agents and 
antipsychotics in different periods. In 1995, Kobe Earthquake caused several fires. Drug 
supply included emergency drugs for burn (Tong & Xiao 2008). In addition, disinfectant and 
vaccine are necessary in earthquake relief. 
5.2.2 Emergency drug purchase 
Our hospital, a women and children specialized hospital, is about 100 kilometers away from 
the epicenter of Sichuan earthquake and closed to the affected area. A large number of the 
injured were accepted in our hospital. But the area of drug warehouse in our hospital is very 
small so that the stock of emergency drugs is serious low. In the night of the day earthquake 
happened, pharmacy made an emergency purchase plan based on drug use of the injured in 
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earthquake and stock of drugs, and informed the supply companies immediately. The day 
after earthquake, we revised the purchase plan and decided to store 3 to 10 times of the 
monthly average amount for emergency drugs, and 2 times for common drugs (Xu et al 
2009), considering about the major diseases after earthquake, and the characteristics of our 
hospital and drugs. What’s more, we kept in contact with each of the supply companies 
during earthquake relief.  
5.2.3 The way to obtaining drugs in the stricken area 
There are still many situations beyond our expected, although we prepared well for 
medical relief. Therefore, it is an important way to obtain drugs from other organizations 
and help each others. It is reported that in an international relief for Haiti Earthquake, 
there was no pediatric formulations and some special drugs in a mobile hospital, for 
example, oxytocin, which is necessary for a pregnant in labor and a woman with 
continuous vaginal bleeding after incomplete abortion (Yang et al 2006). Fortunately, they 
borrowed that from local Spanish Red Cross. What’s more, the hospital was seriously lack 
of drugs after a few days of relief operation (Yang et al 2006). But with the help of local 
army, non-governmental organization and international counterparts, the hospital 
obtained drugs for 1500 patients.  
5.3 Management of donated drugs 
It was estimated that about 2500 tons of drugs and medical supplies had been sent directly 
to Armenian by the end of 1989 after the earthquake in 1988 (Autier et al 1990). But 8% of 
those donations had already expired on arrival, 11% was proved to be useless, 21% was not 
for emergency situation, and 20% had been destroyed. Only 30% could be immediately 
regarded as usable drugs. These proportions were striking. In Sichuan Earthquake, there 
were a big difference between types of donated drugs and the actual demands in our 
hospital (Lin et al 2010). 
Although it was recognized that the management of donated medicines is important many 
years ago, there are still many problems need to be pay attention. According to the reviewed 
papers and our own experience, we provided some suggestions for management of donated 
drugs in order to avoid wasting resources.  
 Management of the received donated drugs, including repository, records of receiving 
and dispensing and the statistical data, should be separated from the common drugs in 
a hospital (Tong & Xiao 2008). 
 Providing information of clinical drug use to the organizations or individuals who are 
interested in donating . 
 Promoting the clinical use of the donated drugs (Zhang et al 2008). 
 Selling the remainder of the donated drugs in hospitals after the permission of donors 
has been obtained (Lin et al 2008).  
Decision makers can conduct pharmaceutical administration work based on evidence 
from those good experiences. In case that the disaster occurs in a sudden, an emergency 
plan should be made by local government and hospitals; An earthquake relief drug list 
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can be made to ensure essential relief drugs are well prepared; The drug purchase plan 
can be flexible, as the types and quantity of drugs used after an earthquake may be 
different from routine treatment; The obtaining of drugs can vary a lot depending on 
different situation; The management of donated medicines should be effective to avoid 
waste and ensure good quality. 
6. Conclusion  
After an earthquake occurred, trauma is the dominated disease within the first week, during 
the medical response, hundreds of drugs can be involved in the treatment of injured 
patients, but antibiotics and drugs correcting water, electrolyte and acid-base disturbances 
were most frequently used. Antibiotics for gram-positive bacterium and anaerobe are 
recommended by WHO and CDC for prophylaxis and treatment of wound infections, but 
antibiotics for gram-negtive bacterium should also be equipped by medical relief teams and 
hospitals.  
The pharmacist can play an important role in supply and rational use of drugs in an 
earthquake medical response, by providing drug information and participating in the 
decision-making. Past experience from earthquake medical relief had provided evidence for 
management of drug supply and donated drugs in pharmaceutical administration after an 
earthquake. 
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regarded as usable drugs. These proportions were striking. In Sichuan Earthquake, there 
were a big difference between types of donated drugs and the actual demands in our 
hospital (Lin et al 2010). 
Although it was recognized that the management of donated medicines is important many 
years ago, there are still many problems need to be pay attention. According to the reviewed 
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1. Introduction 
For decades, schizophrenia was considered exclusively as a biological disorder. As a result, 
pharmacotherapy has been considered as the predominant mode of treatment. 
Antipsychotic medication is indicated for first episode, acute, chronic as well as for 
refractory patients. So much research has been conducted to evaluate the efficacy of 
antipsychotics through clinical studies, randomized controlled trials and meta-analyses. 
Scientific journals are full of research on pharmacotherapy. According to the American 
Psychiatric Association [APA] (2004), a treatment plan for patients with schizophrenia 
should include: 1.- The reduction or elimination of symptoms, 2.- Improving quality of life 
and adaptive functioning, and 3.- Promote and maintain recovery. In the last decades, 
research in the social sciences and psychiatric rehabilitation has produced a considerable 
body of knowledge with respect to psychosocial factors that influence the curse of this 
illness. As a result psychosocial treatments have also been designed and implemented. With 
the beginning of the new century and after more than 60 years of research, there is a 
consensus that biological, psychological and social factors play a very important role in 
understanding and treating schizophrenia. Hence, the biopsychosocial model has been 
considered as the most comprehensive treatment approach for this illness. The treatment of 
schizophrenia has been the focus of changes since the introduction of neuroleptics in the 
1950´s which initiated the transition from mental hospitals to the community, with long-stay 
patients confined in mental institutions going through the deinstitutionalization process, to 
the new millennium where the majority of them are actually living in the community. A 
considerable effort has been carried out in recent years to articulate the scientific basis of the 
treatment for people with schizophrenia. As a result evidence based treatment for 
schizophrenia has recommended that all persons with schizophrenia should receive the 
combination of: 1) optimal dose of antipsychotic medication, 2) psychosocial interventions, 
3) psychoeducation for patients and carers as well as family therapy, and, 4) assertive home-
based management to help prevent and resolve various issues such as: crises, relapse, 
medication adherence, etc, (Drake et al., 2009; Falloon et al., 2004; Fenton & Schooler, 2000; 
Lehman & Steinwachs, 2003; Shean, 2009; Thornicroft & Susser, 2001). In summary, scientific 
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research indicates that the management of schizophrenia should include the following: 1) 
pharmacotherapy, 2) psychosocial interventions, and 3) the integration of these two 
approaches. The aim of this chapter is to describe a research area that integrates 
pharmacological and psychosocial treatment for patients with schizophrenia carried out at 
the National Institute of Psychiatry, in Mexico City. Based upon scientific research, the 
second aim consists on presenting a proposal of this integration on a comprehensive 
treatment approach for schizophrenia patients of a developing country as Mexico.  
2. Pharmacological treatment 
Schizophrenia represents a chronic and debilitating mental disorder that affects about 0.7% of 
general population all over the world (McGrath, 2008), which means approximately 24 million 
people worldwide (World Health Organization [WHO], 2011). In the case of Mexico, with a 
population of 112 million inhabitants, the population at risk between 15-65 years of developing 
schizophrenia is 63.6 millions, a one percent estimate would indicate that approximately 
630,000 individuals suffer schizophrenia as to 2011. Treatment is complex and should always 
be initiated with pharmacological interventions. Antipsychotics are the drugs of choice 
(Freedman, 2005; Geddes, 2000; Kane & Marder, 1993; Kane & McGlashan, 1995; Marder, 2002) 
as they control most of the symptom clusters that characterize this disorder. More than 60 
years ago, Jean Delay and colleagues discovered chlorpromazine (López-Muñoz et al., 2002), a 
then novel sedative compound, and almost at the same time Paul Janssen discovered 
haloperidol (Granger, 1999), a potent neuroleptic compound. Both drugs were shown to be 
useful to relieve psychotic symptoms, and so began a new era in the treatment of psychotic 
disorders, with schizophrenia as the prototype. Emergence of this 2 kind of drugs, 
phenothiazines and butyrophenones, placed the so called conventional antipsychotics as the 
first line treatment for schizophrenia for many decades (Geddes, 2000; Kane & Marder, 1993; 
Kane & McGlashan, 1995; Marder, 2002). Beginning with clozapine some decades ago, but 
mostly for the last 15 to 20 years, new antipsychotic medications have been developed 
(Geddes, 2000; Lehman et al., 2004). The now named atypical antipsychotics (more correctly 
second generation antipsychotics) represent a better said heterogeneus group of drugs (Davis 
et al., 2003; Geddes, 2000; Haddad & Sharma, 2007). These new agents are quite different in 
that, at least most of them, do not generate neuroleptization quite so much as some of the 
conventional medications and in that, most of them are effective antipsychotics with minimal 
or negligible EPS and hiperprolactinemia (García-Anaya et al., 2001, Geddes, 2000; Rosenheck, 
2003). One important issue that distinguishes this group of drugs from conventional 
antipsychotics is the separation of their clinical efficacy from their neurotoxic effects (Posligua, 
1995). Beside this advantages they also appear to have greater effectiveness than conventional 
antipsychotics in treating the so-called negative symptoms of schizophrenia (García-Anaya et 
al., 2001; Leucht, 1999; Posligua, 1995), in controlling other symptom clusters like behavioral 
disturbances, in having an apparent positive impact on neurocognitive functioning (Keefe, 
1999, 2003; Rosenheck, 2003) and on psychosocial functioning (Swartz, 2003; Swartz et al., 
2007), in lowering relapse and rehospitalisation rates (Csernansky & Schuchart, 2002) and in 
promoting a better quality of life for patients (Chung, 2004; Jones, 2006). This relative 
superiority could result from the reduction in side effects, especially EPS, but also maybe from 
a direct pharmacologic effect, that can explain why this group of drugs are now considered 
first line treatment choice and, as so, could have a relevant impact in improving social and 
vocational outcomes of patients with psychotic disorders like schizophrenia.  
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Antipsychotic Chemical Group Usual dose Available since 
Haloperidol* Butyrophenone 5-20 mg/day 70’s 
Chlorpromazine Phenothiazine 25-500 mg/day 70’s 
Sulpiride Benzamide 50-600 mg/day 70’s 
Perphenazine* Phenothiazine 4-60 mg/day 70’s 
Trifluoperazine Phenothiazine 5-50 mg/day 70’s 
Levomepromazine Phenothiazine 25-200 mg/day 70’s 
Clozapine Thienobenzo-diazepine 25-600 mg/day 80’s 
Flupenthixol Thioxanthene 5-20 mg/day 90’s 
Zuclopenthixol Thioxanthene 20-60 mg/day 90’s 
Olanzapine* Thienobenzo-diazepine 5-20 mg/day 90’s 
Risperidone* Benzisoxazole 1-6 mg/day 90’s 
Quetiapine Dibenzothiazepine 300-800 mg/day 90’s 
Ziprasidone* Benzisothiazol 80-160 mg/day 90’s 
Amisulpiride Benzamide 50-400 mg/day 2000’s 
Aripiprazole Dichlorophenyl-piperazine 10-30 mg/day 2000’s 
Sertindole Phenylindole 12-20 mg/day 2000’s 
Paliperidone Benzisoxazole 3-9 mg/day 2000’s 
(*) Available in the Mexican public health system 
Table 1. Oral antipsychotic drugs available in Mexico  
2.1 Introduction and use of antipsychotic drugs in Mexico 
History of Latin American countries use of antipsychotics parallels some socio-cultural and 
economic issues; Some cases like Cuba and some central American countries are 
characterized by having only available some conventional antipsychotics like haloperidol 
and chlorpromazine (González et al., 2004), and, in most Latin American countries, even 
though having second generation antipsychotics available, economic issues have limited 
their use. In Mexico we have had available conventional antipsychotics from the 70’s, 
initiating with the prototypes of the first two classes of this group of drugs: the 
butyrophenone haloperidol and the phenothiazine chlorpromazine, and then some other 
phenothiazine compounds and first generation atypical drugs (Table 1). Some first 
generation antipsychotic drugs like fluphenazine, thioridazine and penfluridol were 
available in Mexico in the past but now they are not available anymore. Some of this 
conventional antipsychotic drugs are frequently used in most public psychiatric hospitals 
and institutions and even some of them are still included in the “Cuadro básico” (Basic 
Table of Medications) of the Mexican public health system (Secretaría de Salud, 1999). 
Second generation antipsychotics were introduced in Mexico in the 80’s with their first 
representative drug, clozapine and then in the 90’s, drugs like olanzapine, risperidone, 
quetiapine and ziprasidone were available. Finally, in the 21th century, four more second 
generation antipsychotic drugs are now available: amysulpiride, aripiprazole, sertindole 
and paliperidone. Some of this second generation antipsychotic drugs, like risperidone and 
olanzapine, are being introduced in the Mexican public health system, so they now are at 
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2.2 Clinical considerations for prescribing antipsychotics 
Once a diagnosis of schizophrenia is established, patient should be started on antipsychotic 
treatment as soon as possible, meanwhile other therapeutic measures are initiated. Election 
of antipsychotic drug by a physician most take into account some issues like illness related 
characteristics, drug efficacy, side effects and cost (Kane & McGlashan, 1995; Leuch, Corves 
et al., 2009), patient characteristics including age, gender, health status, other drugs being 
taken by the patient, history of previous use of any antipsychotic drug and some other 
socio-cultural aspects. In a prospective naturalistic study (Edlinger, 2009), the factors 
influencing physicians' choice of antipsychotic drug therapy in the treatment of patients 
with schizophrenia were investigated; it was concluded that antipsychotic drug side effects 
have a larger influence on the choice of antipsychotic than other factors like demographic or 
illness-related variables, with the exception of the severity of positive symptoms, which did 
influenced decision. As it was mentioned above, in developing countries like most Latin 
American countries, including Mexico, aspects like antipsychotic drug availability and drug 
cost should always be considered when making a choice for any antipsychotic. Some 
general important issues concerning the adequate use of antipsychotic drugs that should 
always be considered every time pharmacological treatment is started on a patient with 
schizophrenia include: 
1. Type of antipsychotic drug: At this time, second generation drugs are usually 
considered as first line treatment for individuals with newly diagnosed schizophrenia 
(Leucht, 1999; Leucht, 2003; Leuch, Corves et al., 2009), even though their heterogeneity 
has brought some concerns about their superiority over conventional drugs (Geddes, 
2000; Leucht, 1999; Leuch, Corves et al., 2009; Marder, 2002), and in between them 
(Leuch, Kommossa et al., 2009). In Mexico and some other developing countries, is not 
rare that some patients could still be started on conventional antipsychotics mostly 
regarding availability and cost-effectiveness issues. The choice for oral, parenteral or 
depot formulations will be considered later. 
2. Recommended dosage of antipsychotic drug: Any antipsychotic drug given to treat a 
schizophrenic patient should be started at the lowest effective level of the 
recommended therapeutic range (Davis & Chen, 2004). Dosage outside of this range 
should be justified and documented always; “rapid neuroleptisation” is not 
recommended, and in case of using rapid loading doses, this manoeuvre should be 
made with extreme caution. Subsequent titration of antipsychotic drug on follow up 
should be made according to clinical response and tolerability, sometimes using blood 
levels as a useful manoeuvre (Citrome & Volavka, 2002).  
3. Antipsychotic drug treatment duration: Treatment should be continued for at least 12 
months, then, just in the eventual situation of the disease remitting fully, drug 
treatment may be ceased gradually over at least 1-2 months. In most cases, however, 
antipsychotic drug treatment should be continued indefinitely, as this stance represents 
the best option for the long standing control of symptoms.  
4. Definition and management of antipsychotic treatment resistance: If a patient with 
schizophrenia has been unresponsive to at least two adequate trials (that is using 
therapeutic doses of the drugs, for enough time to get a response) of two different 
antipsychotic medications, then it can be established the diagnosis of antipsychotic 
treatment resistance. If so, a trial of clozapine should be offered to patients, as this 
second generation antipsychotic has been recognized as the drug of choice for treatment 
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resistant schizophrenic patients (Chakos, 2001; Lehman et al., 2004; Marder, 2002; 
Wahlbeck, 1999).  
5. Switching of antipsychotic drug treatment: Reasons for switching antipsychotic drug 
treatment include lack of clinical response and important side effects (Essock, 2002; 
Lehman et al., 2004; Stroup, 2011) Treatment trial with a first prescribed antipsychotic 
drug should be kept for at least 4-8 weeks before considering the use of another 
antipsychotic medication, and only after optimizing first drug dosage, which could 
mean dose titrating until the maximum recommended (Essock, 2002). Two 
antipsychotic medications at a time, whatever second generation or conventional, 
should not be prescribed together, although this aspect is still controverted (Barnes & 
Paton, 2011; Lehman et al., 2004; Miller & Craig, 2002), with the exception of short 
periods to cover changeover when switching to another antipsychotic. Switching 
strategies of antipsychotic medications include 3 options (Weiden, 2006):  
 Discontinuation: This option consists in abruptly discontinuing the first drug before 
starting the second medication. This method of switching minimizes risk of dosing 
errors and allows closer monitoring for signs of relapse and can be an appropriate 
choice when switching from a conventional antipsychotic to a second generation one or 
from a depot medication to any oral formulation. This method has the inconvenience of 
potentially favoring symptom exacerbation and withdrawal reactions derived from 
discontinuation of the previous antipsychotic.  
 Cross-tapering: This option consists in gradual tapering of the first medication while 
starting and titrating the second antipsychotic drug, with temporal simultaneous 
administration of both the original and the new drug. This method of switching is 
suitable when stable patients are experiencing significant side effects from their 
previous medication. The time elapsed for the cross-titration usually goes between 1 
and 4 weeks (De Nayer et al., 2003) although a slower withdrawal period is convenient 
when switching particular antipsychotics. This option has the inconvenience of 
exposing patients to subtherapeutic dosages of both medications, with risk of relapse.  
 Delayed withdrawal: This option consists in starting a second antipsychotic drug, 
which is titraded to a therapeutic dose, before tapering of the first drug. Keeping the 
patient on a therapeutic dose of the new medication before reducing previous 
medication avoids exposure to subtherapeutic dosages, and may represent the safest 
switching method. This method may be suitable for patients who have not 
accomplished a complete stabilization following a recent relapse and for patients who 
are not having a good adherence to treatment. Using this method should require 
physicians to ensure the crossover is complete, without allowing patients to continue 
with both medications indefinitely. This method has the inconvenience of having 
patients exposed to the side effects of two antipsychotic drugs (Lehman et al., 2004).  
6. Follow-up of patients receiving antipsychotic medication: Routine laboratory and 
clinical monitoring should occur before starting an antipsychotic drug and during 
treatment follow up as well (Marder, 2002; Lehman et al., 2004). According to 
toxicology and potential side effects of the drug of choice, laboratory parameters to 
evaluate may include Complete Blood Count (CBC), Liver Function Tests (LFT), Blood 
Glucose (BG), Cholesterol (Total, HDL and LDL), Triglycerides, Prolactine Blood Level 
(PBL) and Electrocardiogram (EKG). Clinical parameters to evaluate include Blood 
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Sharma, 2007). Hyperprolactinemia is associated again with potent conventional drugs 
and some second generation drugs like risperidone and amysulpiride (García-Anaya et 
al., 2001; Haddad & Sharma, 2007). Metabolic side effects were originally described 
with some low potency conventional drugs but they were later evidently associated 
with some of the second generation drugs: Weight gain (Allison, 1999; Haddad & 
Sharma, 2007; Newcomer, 2005; Rosenheck, 2003); Hyperlipidemia (Haddad & Sharma, 
2007; Koro, 2002; Newcomer, 2005); Glucose metabolism disturbances (Haddad & 
Sharma, 2007; Henderson, 2005; Newcomer, 2005), and even Diabetes Mellitus (Leslie & 
Rosenheck, 2004; Newcomer, 2005) have been highly associated with clozapine and 
olanzapine, fairly associated with quetiapine and risperidone and lightly associated 
with haloperidol, ziprasidone, aripiprazole, amysulpiride and paliperidone. Sedation is 
usually expected with Chloropromazine, Thioridazine, Clozapine, Olanzapine and 
Quetiapine (Haddad & Sharma, 2007; Lehman et al., 2004; Ortega-Soto & Valencia, 
2001). Prolongation of QT interval (QTc) is at highest risk with thioridazine, ziprasidone 
and sertindole (Haddad & Sharma, 2007; Lehman et al., 2004). Other side effects 
reported in patients receiving antipsychotic drugs include sexual dysfunction, 
anticholinergic symptoms, postural hypotension, agranulocytosis, seizures and 
neuroleptic malignant syndrome (Haddad & Sharma, 2007; Lehman et al., 2004; 
Marder, 2002). Finally, cerebrovascular events have recently been associated with 
second generation antipsychotics (Haddad & Sharma., 2007).  
Antipsychotic Chemical Group Usual dose Available since 
Haloperidol* Butyrophenone 5-60 mg a day 70´s 
Zuclopenthixol Acetate Thioxanthene 50-100 mg q/2-3 d. 90´s 
Olanzapine* Thienobenzo-diazepine 10-30 mg a day 90¨s 
Ziprasidone* Benzisothiazol 10-40 mg a day 90¨s 
(*) Available in Mexican Public Health System 
Table 2. Parenteral antipsychotic drugs for acute states available in Mexico 
Management of acute episodes: Acute states of patients with schizophrenia require 
initiating or adjusting antipsychotic treatment to control new and/or exacervated 
symptoms (Kane & McGlashan, 1995). This episodes are sometimes managed in the 
psychiatric hospital setting (Lehman et al., 2004) A frequent problem found in these acute 
descompensated patients is the lack of conciousness about the need for an acute treatment 
intervention and a lack of disposition for receiving pharmacological treatment as well. So 
patient relatives are often confronted with difficult decisions like taking the patient into a 
closed institution where pharmacologic and other treatment strategies could be initiated 
even without patient cooperation. Under these circumstances, parenteral antipsychotic 
drugs -usually trough intramuscular administration- are very frequently used, as they are 
easier to administrate to patients not accepting treatment, with lower harm risks for them. 
Most of these drugs should be administrated once or more times during a day, as they 
usually have half lives no longer than 24 hours, with the exception of Zuclopenthixol 
(Clopixol Aquphase), which can be administrated every 48 to 72 hrs. These drugs are 
useful for getting a faster control of symptoms and for facilitating treatment continuation. 
Table 2 shows parenteral antipsychotic drugs available in Mexico, used in acute episodes 






Fig. 1. Therapeutic algorithm for the use of antipsychotic drugs in the treatment of 
schizophrenia 
7. Tolerability and toxicologic aspects of antipsychotics: Beyond the clear differences in 
side effects and toxicologic risks between antipsychotics, either conventional drugs or 
second generation drugs, there are common potential consequences that should be kept 
in mind every time an antipsychotic is prescribed to a schizophrenic patient (Haddad & 
Sharma, 2007; Lehman et al., 2004; Marder, 2002). Parkinsonism and other 
extrapyramidal side effects are common with potent conventional drugs like 
haloperidol and fluphenazine (Ortega-Soto et al., 1998; Ortega-Soto & Valencia, 2001), 
but also with some second generation antipychotics like risperidone (Haddad & 
Diagnostic confirmation
Start/Switch treatment with/to 





or significant side 
effects
Switch treatment to 
another second generation 
antipsychotic
Inadequate response 
or significant side 
effects
Switch treatment to Clozapine
and other non pharmacological 
treatments
Positive antipsychotic 
drug treatment history 
Good response and no 
significant side effects






Adequate response and 





Integration of Pharmacological and Psychosocial Treatment for  
Schizophrenia in Mexico: The Case of a Developing Country Proposal 
 
47 
Sharma, 2007). Hyperprolactinemia is associated again with potent conventional drugs 
and some second generation drugs like risperidone and amysulpiride (García-Anaya et 
al., 2001; Haddad & Sharma, 2007). Metabolic side effects were originally described 
with some low potency conventional drugs but they were later evidently associated 
with some of the second generation drugs: Weight gain (Allison, 1999; Haddad & 
Sharma, 2007; Newcomer, 2005; Rosenheck, 2003); Hyperlipidemia (Haddad & Sharma, 
2007; Koro, 2002; Newcomer, 2005); Glucose metabolism disturbances (Haddad & 
Sharma, 2007; Henderson, 2005; Newcomer, 2005), and even Diabetes Mellitus (Leslie & 
Rosenheck, 2004; Newcomer, 2005) have been highly associated with clozapine and 
olanzapine, fairly associated with quetiapine and risperidone and lightly associated 
with haloperidol, ziprasidone, aripiprazole, amysulpiride and paliperidone. Sedation is 
usually expected with Chloropromazine, Thioridazine, Clozapine, Olanzapine and 
Quetiapine (Haddad & Sharma, 2007; Lehman et al., 2004; Ortega-Soto & Valencia, 
2001). Prolongation of QT interval (QTc) is at highest risk with thioridazine, ziprasidone 
and sertindole (Haddad & Sharma, 2007; Lehman et al., 2004). Other side effects 
reported in patients receiving antipsychotic drugs include sexual dysfunction, 
anticholinergic symptoms, postural hypotension, agranulocytosis, seizures and 
neuroleptic malignant syndrome (Haddad & Sharma, 2007; Lehman et al., 2004; 
Marder, 2002). Finally, cerebrovascular events have recently been associated with 
second generation antipsychotics (Haddad & Sharma., 2007).  
Antipsychotic Chemical Group Usual dose Available since 
Haloperidol* Butyrophenone 5-60 mg a day 70´s 
Zuclopenthixol Acetate Thioxanthene 50-100 mg q/2-3 d. 90´s 
Olanzapine* Thienobenzo-diazepine 10-30 mg a day 90¨s 
Ziprasidone* Benzisothiazol 10-40 mg a day 90¨s 
(*) Available in Mexican Public Health System 
Table 2. Parenteral antipsychotic drugs for acute states available in Mexico 
Management of acute episodes: Acute states of patients with schizophrenia require 
initiating or adjusting antipsychotic treatment to control new and/or exacervated 
symptoms (Kane & McGlashan, 1995). This episodes are sometimes managed in the 
psychiatric hospital setting (Lehman et al., 2004) A frequent problem found in these acute 
descompensated patients is the lack of conciousness about the need for an acute treatment 
intervention and a lack of disposition for receiving pharmacological treatment as well. So 
patient relatives are often confronted with difficult decisions like taking the patient into a 
closed institution where pharmacologic and other treatment strategies could be initiated 
even without patient cooperation. Under these circumstances, parenteral antipsychotic 
drugs -usually trough intramuscular administration- are very frequently used, as they are 
easier to administrate to patients not accepting treatment, with lower harm risks for them. 
Most of these drugs should be administrated once or more times during a day, as they 
usually have half lives no longer than 24 hours, with the exception of Zuclopenthixol 
(Clopixol Aquphase), which can be administrated every 48 to 72 hrs. These drugs are 
useful for getting a faster control of symptoms and for facilitating treatment continuation. 
Table 2 shows parenteral antipsychotic drugs available in Mexico, used in acute episodes 





Issues regarding treatment adherence: As we all know now, schizophrenic patients 
should keep pharmacologic treatment in the long term, as far as it has been repeatedly 
demonstrated that a good treatment adherence means a more complete and a more rapid 
control of their symptoms, a low chance for future decompensations, and, in general, a 
more frequent reintegration to society and a better quality of life for them. CATIE and 
other international studies (Lieberman et al., 2005) have shown that about 75% of 
schizophrenic patients stop treatment because of different reasons, including lack of 
clinical response and presence of side effects like sedation, EPS, weight gain, and other 
metabolic disturbances. This so high non-adherence rate to pharmacologic treatment 
means for schizophrenic patients more numerous acute decompensation states, more 
hospitalizations and some other negative consequences. Having said this, one important 
issue on pharmacologic treatment of schizophrenic patients is promoting treatment 
adherence. To reach the goal of keeping schizophrenic patients on treatment, depot 
formulations of antipsychotic drugs are becoming a very useful alternative that favors this 
purpose. This long acting group of antipsychotic drugs allow patients, their families and 
other people taking care of them, to administrate drugs at intervals of 2 to 4 weeks, 
instead of taking them once or even more times a day, thus facilitating and assuring 
adherence to treatment, First depot antipsychotic drug available in Mexico were 
Pipothiazine and Haloperidol Decanoate, then other depot formulations have been 
introduced like the two thioxanthenes Zuclopenthixol Decanoate and Flupenthixol 
Decanoate and more recently Risperidone and Paliperidone Palmitate. 
Antipsychotic Chemical Group Usual dose Available 
since 
Pipothiazine Phenothiazine 25-200 mg/ every 2-4 weeks 70’s 
Haloperidol* Decanoate Butyrophenone 50-150 mg/ every 30 days 80’s 
Zuclopenthixol Decanoate Thioxanthene 200 mg/ every 30 days 90´s 
Flupenthixol Decanoate Thioxanthene 20-100 mg/ every 2-4 weeks 90´s 
Risperidone* Benzisoxazole 25-50 mg/ every 2 weeks 2000´s 
Paliperidone* palmitate Benzisoxazole 39-234 mg/ every 30 days 2000´s 
Table 3. Shows depot antipsychotics now available in Mexico 
Psychothropic drugs other than antipsychotic drugs used in the pharmacologic treatment 
of schizophrenia in Mexico: Beside any antipsychotic drug, and mostly used as adjuvant 
treatment, correcting and complementary pharmacologic treatments for patients with 
schizophrenia, some other classes of drugs are used in the Mexican psychiatric scenarium. 
Litheum and some anticonvulsive drugs like carbamazepine and valproate are frequently 
added to antipsychotic treatment as potentiators of response, especially in patients with 
partial response to antipsychotic drugs alone. Anticholinergic drugs like biperiden and 
trihexifenidile are usually prescribed to correct EPS like parkinsonism as well as beta 
blockers like propranolol, mostly in the presence of acathisia. Sedative-ansiolitic drugs like 
clonazepam, alprazolam and bromazepam are sometimes indicated in cases of anxious 
states accompanying classic symptoms of schizophrenia. Finally, antidepressant drugs are 
used when comorbidity with depressive symptoms is detected. 
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3. Psychosocial treatment 
3.1 Historical perspective of psychosocial treatment 
The introduction of psychosocial treatment for schizophrenia is very much related to the fact 
that psychotic disorders produce dysfunctions, disabilities, and deficits in various domains of 
everyday functioning. Poor psychosocial functioning is a defining characteristic of 
schizophrenia. Social dysfunction is one of the most relevant factors associated with the 
disability of the illness (APA, 1995). Disabilities include difficulties in social and independent 
living skills that act as an impediment for a more normal functioning, (Kopelowicz & 
Liberman, 2003). From all illnesses of mankind, schizophrenia is ranked as the seventh illness 
that causes disability (WHO, 2001). Since schizophrenia patients are often functionally 
impaired, impairments in social functioning could be understood as the inability to take care 
for his/her self, to maintain interpersonal relationships, or the inability to work. These are 
important reasons for considering psychosocial functioning as an important dimension of 
schizophrenia, Deficits in social functioning are a core feature of schizophrenia (Burns & 
Patrick, 2007). Lauriello, Lenroot & Bustillo (2003), state that: “Patients with schizophrenia 
have limitations in their social competence and vocational functioning for a significant period. 
To some extent, these limitations are a consequence of the multiple symptoms and cognitive 
impairments of the disorder”. Role functioning indicates the individual´s abilities to 
demonstrate role performance according to his/hers demands at work, school, social, and 
family situations. Even when psychotic symptoms are in remission with antipsychotic 
medication, approximately two-thirds of schizophrenia patients are unable to accomplish basic 
social roles, such as parenthood, friendship, worker, or being a spouse (Bellack et al., 2007). 
Schizophrenia is characterized by a deterioration, or failure to achieve adequate levels of social 
functioning. Because of the early illness onset many individuals with schizophrenia never 
learned the necessary skills required for adult functioning. The psychosocial environment that 
comprises family factors is another relevant component as demonstrated with a great amount 
of research in the area of Family Expressed Emotion (Leff et al., 1987), and family care of 
schizophrenia (Falloon et al., 1984; Kuipers et al., 2002). One of the most complicated 
challenges in schizophrenia treatment has been to restore impaired psychosocial functioning 
(Swartz et al., 2007), considering that current management has a strong emphasis on living in 
the community (Leucht & Van Os, 2009). The integration of pharmacological and psychosocial 
approaches has been recommended as a means of improving the outcome of patients with 
schizophrenia (Marder, 2000). In addition schizophrenia patients face several problems: 
relapse rates have been reported as high as 70% (McCann et al., 2008; Muller, 2004); even with 
the use of second generation antipsychotics, negatives symptoms still persist (Leucht, Corves 
et al., 2009; Stahl & Buckley, 2007;); approximately 50% meet criteria for substance or drug 
dependence (Bellack et al., 2007); cognitive deficits (Sharma & Harvey, 2000) and poor quality 
of life (Lehman, 1983) should also be considered. Some of these issues remain unresolved.  
Psychosocial treatment aims to improve the management of schizophrenia with the use of 
various techniques such as coping with symptoms, medication adherence, relapse 
prevention, and acquisition of psychosocial skills to improve functioning in certain areas 
such as social relations, work, school, home, recreation, use of mental health facilities, or 
independent living in the community. In the last fifty years a great array of psychosocial 
interventions have been designed such as: social skills training (Bellack et al., 2004; Glynn et 
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Tsang, 2001), teaching illness management skills (Atkinson et al., 1996; Birchwood et al., 
1989; Mueser et al., 2002), integrated psychological therapy (Briand et al., 2006; Roder et al., 
2006), assertive community treatment (Bond et al., 2001; Burns et al., 1999; Thornicroft et al., 
1998), cognitive rehabilitation (Bell et al., 2009; Velligan et al., 2006; Vesterager et al., 2011), 
integrated treatment for comorbid substance abuse (Bellack et al., 2006; Ridgely et al., 1990; 
Shaner et al., 2003), family psycho-education (Bauml et al, 2006; Murray & Dixon, 2004; Xia 
et al., 2011), and housing (McCrone & Strathdee, 1994; Harvard Medical School, 2001; 
Trainor et al., 1993). A large body of research supports the efficacy of psychosocial 
treatments, with Reviews (Bellack & Mueser,1993; Benton & Schroeder, 1990; Heinssen et al., 
2000; Huxley et al., 2000; Kopelowicz et al., 2006; Penn et al., 2005); Randomized control 
trials (Glyn et al., 2002; Granholm et al., 2005; Guo et al 2010; Hogarty et al, 2004; Liberman, 
1998); Meta-analysis (Kurtz & Mueser, 2008; Mojtabai et al., 1998; Pilling et al., 2002; Roder 
et al,. 2006) and Treatment recommendations (APA, 2004; Dixon et al., 2010; Kreyenbuhl et 
al., 2009; Lehman & Steinwaschs, 1998, 2003). 
3.2 Introduction of psychosocial treatment in Mexico 
The introduction, application and research in Mexico of psychosocial treatment can be 
divided in two stages: 1) Interventions with acute psychotic hospitalized patients, and 2) 
Interventions with chronic out-patients with schizophrenia.  
3.2.1 Psychosocial treatment for acute psychotic hospitalized patients 
In 1980, a study was conducted to assess the delivery of services of a Psychiatric Hospital for 
acute mentally ill patients, in Mexico City. It was found that the only treatment that patients 
were receiving was antipsychotic medication. As a result a proposal was made that 
considered the convenience to integrate pharmacological and psychosocial rehabilitation 
approaches, as a consequence a pilot study that was carried out between 1980 and 1984. 
Psychosocial treatment was included as a new component, in addition to pharmacological 
treatment, in a clinical trial that integrated a treatment and rehabilitation program for acute 
hospitalized psychotic patients. After patients were clinically stabilized with antipsychotic 
medication, (allowing a two week stabilization period), they participated in daily sessions 
during 4 weeks of the hospitalization period. Patients learned a variety of skills in various 
domains: 1.-Taking care of personal hygiene, appearance and clothing, 2.-Management of 
symptoms and medication, 3.-Occupational skills, 4.-Social skills, 5.-Communication and 
problem solving skills with the family, and 6.-Leisure and sports activities. Verification of 
the skills learned was recorded with the use of a check list. Using a quasi- experimental 
design, an experimental group (n=35) treated with pharmacological and psychosocial 
treatment was compared with a control group (n=35) that was treated with pharmacological 
treatment alone. Psychopathology and global functioning were assessed before and after 
treatment, using the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962) and 
the Global Assessment Scale (GAF) (Spitzer et al., 1976). Patients from the experimental 
group demonstrated significant improvements in symptoms such as: anxiety, tension, 
depression, unusual thought content and blunted affect. No improvements were found in 
psychopathology in the control group. These patients experienced more anxiety and tension 
than that reported when they started treatment. Similar results were found in global 
functioning since experimental patients improved their functioning: mean =52 before 
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treatment to a mean=72 at the end of treatment. Control patients showed no improvements 
since they remained at the same level of functioning (51-60) with a mean=59 and a mean=58, 
before and after treatment. It was concluded that an integrated program that combined 
pharmacological and psychosocial treatment was more effective for acute hospitalized 
psychotic patients than pharmacological treatment alone (Valencia, 1988; Valencia, 1991). 
Considering the outcome of this treatment program, it was recommended that the 
combination of pharmacological and psychosocial treatments should be used as the best 
delivery approach for treating these patients. Unfortunately, the rehabilitation work could 
not continue due to the fact of the lack of financial funds and changes in health politics that 
were oriented to alcohol and drugs research at that time. 
3.2.2 Psychosocial treatment for chronic outpatients 
Prior to the initiation of the intervention, we consider a necessity to take into account all 
persons that should be involved in a treatment process. Therefore, we included patients, 
relatives and mental health professionals as relevant participants of this process. Patients 
and relatives were considered as healthy allies and collaborators of the treatment team. 
Relative´s participation was considered as a key element since approximately 90% of our 
patients live with family members (Valencia et al., 2003). Their opinions and ideas served as 
the background for considering the content of a psychosocial treatment program that would 
be offered as an add-on to pharmacotherapy. Hence, we developed a methodology for the 
design of integrated psychosocial and pharmacological interventions, for a developing 
country, as Mexico. The information came from three important sources: a) clinically 
stabilized chronic patients with schizophrenia, b) caregivers living with their ill relatives 
and aware of the patient´s, daily activities, and c) mental health professionals with 
experience in the treatment of schizophrenia patients and their relatives. Information was 
collected considering the clinical needs and psychosocial problems of our patients, as well as 
the caregiver´s needs and demands. The design process included seven stages: 1) 
Identifying clinical and psychosocial problems through two sources: a) an exploratory study 
including patients as participants, so, they would give their opinions about their clinical and 
psychosocial needs, and, b) Using focus groups with patients, relatives and mental health 
professionals (psychiatrists, clinical psychologists, psychiatric social workers, and 
psychiatric nurses), to collect information from these three sources; 2) Establishing a 
consensus about clinical and psychosocial problems from all sources; 3) Designing the 
content of the intervention, and, in addition, with the advice of clinical and social science 
researchers, consider the corresponding methodological issues (experimental design, study 
groups, instruments); 4) Implementation of the treatment program; 5) Determining its 
effectiveness; 6) Follow-up, and 7) Dissemination. All patients were receiving exclusively 
pharmacological treatment. Psychosocial and clinical problems were identified as when 
patients: do not have friends (60-70%); do not have a loving relationship (90-96%); 
unemployed (50-80%); lack of financial sources (80-90%); economically dependent upon 
his/her family (80-90%); do not have good family relations (70-80%); do not know the 
characteristics of the illness (90-95%); do not know his/her diagnosis (55-65%); consider that 
they do not need medication (70-80%); and, consider that they do not need psychotherapy 
(80-90%). In addition, the consensus indicated the presence and persistence of deficits in 
various skills areas that were interfering in the patient´s community functioning. It was 
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treatment to a mean=72 at the end of treatment. Control patients showed no improvements 
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patient and his/her 
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6 months or 1 year 6 months or 1 year 8 sessions or  
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4 sessions or 5 sessions 
Table 4. Proposal of the integration of pharmacological and psychosocial treatment for 
Mexican out-patients with schizophrenia 
communication with the treating psychiatrists, the need to be informed about medication 
benefits, learning medication side effects, learning skills to cope with persistent symptoms, 
planning a long term pharmacological treatment, be willing to collaborate in making 
decision concerning medication, learning skills for avoiding alcohol and drug abuse, 
learning skills to improve adherence to antipsychotic medication, identifying warning signs 
of relapse and developing a relapse preventive plan, developing skills to improve social 
relations, and learning problem-solving skills for improving family relations (Valencia et al., 
2010). The consensus also recommended the inclusion of various therapeutic modalities 
integrated in a comprehensive biopsychosocial service delivery system including: 
pharmacotherapy, psychosocial therapy, psychoeducation, and family therapy. The content 
of these modalities are shown on table 4. After the study protocol was approved by the 
Scientific Research Committee, and for the Ethics Committee of the National Institute of 
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Psychiatry, stages 4) Implementation, and 5) Determining treatment effectiveness were 
tested. A research area was developed where various experimental trials were conducted 
comparing experimental and control groups, or four treatment groups: psychosocial 
treatment, musictherapy, multimodal therapies, and a control group, including 4, 5 or 7 
psychosocial treatment areas, either during a one year or during six months of treatment. In 
all trials pharmacological treatment was delivered once a month, psychosocial treatment 
included one or two sessions per week, 8 or 12 sessions were conducted for 
psychoeducation, 4 or 5 sessions for family therapy, in the last trials, the assessment of the 
level of expressed emotion was also included as an important variable to determine the 
emotional environment in the home as expressed by relatives. (Valencia et al., 2004a, 2004b, 
2006, 2007, 2010) 
In this chapter we describe the results of a research program that integrated 
pharmacological and psychosocial treatments that was carried out at the National Institute 
of Psychiatry in Mexico City. Out-patients diagnosed with schizophrenia according to the 
DSM-IV (APA, 1995) that was corroborated with the CIDI (Robins et al., 1988) participated 
in the study according to the following inclusion criteria: women or men, between 16 to 50 
years, with at least six years of education, living with their relatives in Mexico City or the 
metropolitan area. Patients had to be under pharmacological treatment and therefore 
demonstrate to be clinically stable as regards to their psychotic symptoms according to the 
PANSS within a range of 60-90 before the initiation of treatment. One hundred and fifty six 
out-patients attending the Schizophrenia Clinic were randomly assigned, in an alternate 
order, to two treatment conditions: a study group (n=78), or to a comparison group (n=78). 
Of the 156 patients initially included in the study, 10 from the study group (12.8%) and 17 
from the comparison group (21.7%) corresponding to a total of 17 patients (17.3%) of the 
sample, failed to complete the study, leaving a final sample of 129 patients: n=68, in the 
study group and n=61, in the comparison group. Patients of the study group received 
psychosocial treatment, specifically, psychosocial skills training and psychoeducation for 
their relatives, while the comparison group received the standard pharmacological 
treatment alone. Both groups completed one year of treatments. Pharmacological treatment 
for the two groups under study was provided at the Schizophrenia Clinic of the Institute, 
once a month, during twenty minutes, by two psychiatrists, who prescribed antipsychotics, 
verified medication compliance, keep a record of the attendance to appointments, and 
registered relapse and rehospitalizations. The treating psychiatrists were blind to the two 
treatment conditions. Psychosocial treatment included seven treatment areas as specified in 
Table 4. The aims of the intervention were: 1) facilitate patients’ acquisition of psychosocial 
skills; 2) improve psychosocial and global functioning, 3) prevent relapse and 
rehospitalizations, 4) promote compliance with medication and treatment adherence. A 
team of two therapists trained in psychosocial skills training held weekly group sessions 
during 90 minutes. To carry out the therapeutic work with the patients, therapists had to 
follow the therapist´s manual that describes the training strategies for all sessions (Valencia 
et al., 2001). For acquisition of the skills, a technique known as the “learning activities” was 
utilized and modified for our patients (Valencia et al., 2007). This technique was developed 
and empirically validated for schizophrenia patients (Liberman, 2007; Wallace et al., 1992), 
as well as for Latinos with schizophrenia in the United States (Kopelowicz et al., 2003). A 
check list was also available to verify that patients learned the corresponding skills for each 
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treatment alone. Both groups completed one year of treatments. Pharmacological treatment 
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Table 4. The aims of the intervention were: 1) facilitate patients’ acquisition of psychosocial 
skills; 2) improve psychosocial and global functioning, 3) prevent relapse and 
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check list was also available to verify that patients learned the corresponding skills for each 





assure that each learning activity included in the training manual was taught competently 
during treatment. Psychoeducation provided information for relatives about the 
management of schizophrenia, coping with the illness, antipsychotic medications and its 
side effects, compliance with medication, and with psychiatric consultations, and 
understanding and management of signs of relapse. This intervention was held during ten 
sessions in a group format. The two groups under study were evaluated before and after 
treatment. The Positive and Negative Syndrome Scale [PANSS], Spanish adaptation, (Kay et 
al., 1990), and the Global Assessment of Functioning Scale [GAF] (APA, 1995), were used to 
assess psychopathology and psychosocial functioning. Relapse, and rehospitalization rates, 
compliance with antipsychotic medication and adherence to treatment were also assessed.  
 Study 
Group 
n = 68 
Comparison 
Groupl 
n = 61 
Gender, n (%)     
 Male 50 (73.5) 47 (77.0) 
 Female 18 (26.5) 14 (23.0) 
Marital status, n (%)     
 Single 65 (95.6) 55 (90.2) 
 Married 2 (2.9) 3 (4.9) 
 Speratated/divorced 1 (1.5) 3 (4.9) 
Occupation, n (%)     
 Employed 9 (13.2) 16 (26.2) 
 Housewife 2 (2.9) 4 (6.6) 
 Student 2 (2.9) 8 (13.1) 
 Unemployed 55 (80.9) 33 (54.1) 
Age, years,  (s) 29.6 (6.9) 29.5 (7.1) 
Education, years,  (s) 11.2 (2.1) 11.1 (2.1) 
Age at onset  (s) 21.6 (6.5) 21.2 (4.6) 
Table 5. Participants demographic and clinical data at baseline 
All participants expressed in a written informed consent their desire to participate in the 
research project. Data analysis included the following: Descriptive and Chi square analysis 
to compare percentages, Student t tests to verify that there were no significant differences 
between the two groups under study in their initial levels of psychopatology, and 
psychosocial functioning, Analysis of variance for repeated measures (ANOVA) to detect 
pre-post differences within and between the two study groups. For the assessment of effect 
size, three levels were considered: small= .25, medium= .50 and large= 1.00 irrespective of 
the sign (+ or -) of the number (Kazdin & Bass, 1999). Standardized estimate of effect sizes 
were calculated using Cohen´s (1977) d formula defined as: d= 1x - 2x / s. Where 1x  and 2x
are the means at baseline and at the end of treatment of the two groups under study, and s is 
the pooled within-group standard deviation (SD). At baseline, no statistically significant 
differences were found between the two groups under study in psychopathology, (PANSS) 
or psychosocial functioning (GAF), or in their doses of antipsychotic medication as 
determined by calculation of chlorpromazine equivalents. Participant´s demographic and 
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clinical data at baseline is shown in table 5. Patients in both treatment conditions were 
similar with no differences on any of these variables, except for the occupational status with 
a minor percentage of unemployed patients in the comparison group.  
   Statistics b 
 Study Group 
n = 68 
Comparison 
Group 










PANSSa overall score,  (s)      
Baseline 92.6 (41.6) 83.5 (33.9) p < .001 -- p < .001 
Post 43.4 (13.0) 55.7 (16.4)    
Effect size -1.2 -.80    
PANSS positivea,  (s)      
Baseline 21.1 (11.5) 18.3 (9.8) p < .001 -- p < .01 
Post 9.1 (2.8) 11.6 (4.5)    
Effect size -1.0 -.70    
PANSS negativea,  (s)      
Baseline 24.4 (11.2) 22.4 (9.4) p < .001 -- p < .001 
Post 11.6 (5.2) 15.0 (6.3)    
Effect size -1.1 -.80    
PANSS GPSa, c,  (s)      
Baseline 47.1 (20.5) 42.8 (16.4) p < .001 -- p < .001 
Post 22.7 (6.0) 29.1 (8.3)    
Effect size -1.2 -.80    
Level of global functionigd 
(GAF) ,  (s) 
     
Baseline 43.1 (6.4) 43.1 (6.8) p < .001 p < .001 p < .001 
Post 67.0 (9.2) 43.7 (9.2)    
Effect size 3.8 .10    
 a Higher scores indicate more severe symptoms. b Analysis of variance for repeated measures.c GPS, 
General Psychopathology Scale. d Higher scores indicate better global functioning. Effect size levels: 
small=0.25; medium=0.50; large=1.00 
Table 6. Psychopatology and Psychosocial Functioning of the Study and Comparison Group  
When considering the mean change scores, over one year of treatment, the results indicated 
that statistically significant improvements in psychopatology, as rated by the PANSS, were 
observed in positive and negative symptoms, general psychopathology and in total PANSS 
score for both groups under study. Group-by-time analysis demonstrated significantly 
greater improvement in psychopatology in patients of the study group when compared 
with patients receiving standard pharmacological treatment. Comparison of the effect sizes 
were large for the study group on the total PANSS score, positive scale, negative scale, and 
in the general psychopathology scale. Effect sizes were medium for all score scales of the 
comparison group. Significant improvement in psychosocial functioning was also found for 
patients of the study group but not for patients under standard pharmacological care since 
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clinical data at baseline is shown in table 5. Patients in both treatment conditions were 
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assessment. Patients of the study group improved two levels of functioning from 41-50 at 
baseline to 61-70 at the end of treatment. Effect size was large for the study group and small 
for the comparison group (Table 6). 
   Statistics b 
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dose, a  (s) 
     
Baseline 300.8 (286.4) 328.1 (265.4) p < .05   
Post 367.0 (167.5) 408.8 (336.6)    
Dose Range,  
lower – higher 
     
Baseline 14 - 1600 25 – 1200    
Post 29 - 1000 50 – 2400    
a Chlorpromazine equivalents in mg per day. b Analysis of variance for repeated measures. 
Table 7. Antipsychotic dosage of the Study and comparison Group a 
Table 7, illustrates that patients in the two treatment conditions had significant increases in 
the dosage of antipsychotic medication from baseline to post-treatment. At the end of 
treatment, the variability on medication dosage was much higher in patients who received 
standard care. Of the total sample, 65.8% were taking first-generation and 34.2% second-
generation antipsychotics. The three most prescribed medications were: First generation: 
Haloperidol (21.4%), Trifluoperazine (18.8%), and Sulpiride (9.4%). Second generation: 
Risperidone (21.4%), Clozapine (14.3%), and Olanzapine (3.6%). 
 





Variable n % n % X2 
Relapse 8 11.8 17 33.3 p < .01 
Rehospitalizations 3 4.4 7 13.7 -- 
Compliance with medication 62 91.2 40 78.4 -- 
Table 8. Relapse, rehospitalizations and adherence  
Lower relapse (11.8%) and rehospitalization rates (4.4%) were found in the study group 
compared to 33.3% and 13.7% respectively for the group that received medication alone. 
Compliance with antipsychotic medication was higher in the study group (91.2% versus 
78.4%) of the comparison group, (Table 8) 
3.2.3 Integrating pharmacological and psychosocial treatment  
We conclude that a therapeutic approach that included the integration of pharmacological 
and psychosocial treatments for schizophrenia patients can be effective in a developing 
country as Mexico. Patients that received this integrated approach demonstrated significant 
improvements in psychopathology, psychosocial functioning, lower relapse and 
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rehospitalisation rates, and higher compliance with antipsychotic medication, as compared 
with their counterparts that received pharmacotherapy alone. The proposal of integrating 
pharmacological and psychosocial approaches has been described throughout this chapter 
and illustrated in table 4. Of the seven stages developed for designing the interventions, five 
stages were accomplished that ended up with their implementation. We had certain 
limitations with stage 6 since we could not carry out the patient´s “follow-up” due to the 
lack of financial funds. We still have a long way to go since stage 7 ”dissemination” is also a 
pendant task for all schizophrenia patients of our Institute as well for all schizophrenia 
patients in Mexico that would be willing to participate in integrated treatment approaches. 
To accomplish “dissemination”, we could face some complications”, if we consider that only 
0.36% of the Gross Internal Product (GIP) in Mexico is allocated to scientific research, 
compared to 0.49 % in Argentina, 1.11% in Brazil, 2.61% in the United States, 3.22% in Japan, 
and 3.32% in South Korea. It seems that scientific research is not considered a priority in 
Mexico, as a result schizophrenia research neither. However, we have high hopes as being 
optimistic. We expect the necessary support to continue our efforts. When connecting 
clinical practice with scientific research through research protocols, we were able to carry 
out this type of research at the National Institute of Psychiatry whose main goals are to 
conduct research, provide treatment for mental disorders, and training for mental health 
professionals. The Institute belongs to the Coordination of National Research Institutes of 
Mexico that includes 13 Institutes dedicated to treatment and scientific research. Financial 
support for this project was possible with funds from the Institute and a grant from the 
National Council on Science and Technology of Mexico. It was interesting to find out that 
the areas where Mexican patients had psychosocial problem skills were similar to those 
utilized in psychosocial treatment programs in first world countries (Liberman, 2007, Roder 
et al., 2006; Thornicroft & Susser, 2001). It seems that schizophrenia patients share similar 
problems all over the world. Above all, evidence indicates that psychosocial approaches 
when combined with pharmacotherapy results in better outcomes, than either antipsychotic 
medication alone or psychosocial treatment alone. For example, when these two approaches 
are integrated, relapse rates can be reduces as less than 20% (Hogarty, 1993). Understanding 
what bio psychosocial approaches can do for persons with schizophrenia could help us to 
face a new reality that indicates that although there is not a “total cure” for this disease 
research indicates that substantial advances have been made for improving the life of people 
with schizophrenia in the community with the integration of pharmacological and 
psychosocial approaches. 
4. Pharmacological and psychosocial treatment in Latin America 
Research on integrated pharmacological and psychosocial treatment for schizophrenia has 
been carried out mostly in developed countries. We wondered what would be the situation 
in Latin America as to find out what treatments are actually available in this region of the 
world. In order to get a complete picture we searched the following electronic bibliographic 
databases: Medline, Psychiatry, EBM Reviews, PsychINFO-APA, Psychology & Behavioral 
Sciences, Base Salud en Español, CC Clinical Medicine, CC Social and Behabioral Sciences, 
Medic Latina, Elsevier Science Direct, LILACS, SciELO, MEDCaribe, ISI Current Contents, 
PAHO Catalog, The Cochrane Library, Biblioteca Cochrane Plus, Ciencias de la Salud-





assessment. Patients of the study group improved two levels of functioning from 41-50 at 
baseline to 61-70 at the end of treatment. Effect size was large for the study group and small 
for the comparison group (Table 6). 
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with schizophrenia in the community with the integration of pharmacological and 
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Line. We used the following key words: schizophrenia, pharmacological treatment, 
antipsychotic medication, psychosocial treatment, psychological therapy, psychosocial 
intervention, psychosocial rehabilitation, psychoeducation, and family therapy. We 
searched the literature with publications in Spanish, Portuguese and English from January 
1970 to July 2011. We found that in addition to Mexico, integrated approaches have been 
carried out in two countries: Brazil (Zimmer et al., 2003, 2006, 2007), and Peru (Sotillo, et al., 
1998). It is worth mentioning that since the early 1950´s, the first generation “conventional” 
antipsychotic medication, and later on, the second generation, or “atypical”, have been 
considered as the only traditional treatment in Latin America for persons suffering from 
schizophrenia. For the year 2011, this approach continues as the customary treatment in 
most Latin American countries. Twenty five years ago, rehabilitation and psychosocial 
treatments were nonexistent in this region of the world; however, in the last twenty years 
some changes have occurred at least in three countries: Brazil (2003-2007); Mexico (1982-
2011) and Peru (1998). The most reasonable explanation why psychosocial treatments have 
not been carried out is because of the lack of economic or financial funds. If clinical services 
still face serious deficits: old and huge hospitals, too many patients and a reduced staff, it is 
not difficult to understand why research on behavioural or psychosocial treatments is 
practically nonexistent. With this scenario there is no doubt that the situation in Latin 
America is quite different than first world countries. We have a long way to go. 
5. Conclusion 
Based upon international evidenced-based practices, treatment recommendations and 
practice guidelines for schizophrenia, an area of research that integrated pharmacotherapy 
and psychosocial therapies was implemented for Mexican patients with schizophrenia. 
Valuable contributions from patients, relatives, mental health professionals, as well as 
cultural considerations were taken into account for the design of the interventions. What is 
good to consider was to find out the effectiveness of these therapeutic modalities as 
described in this chapter as a comprehensive care system for people with schizophrenia in 
Mexico. What is new to consider is that these interventions are available for a developing 
Latin American country. However, reality indicates that the great majority of schizophrenia 
patients in Mexico and Latin America do not receive integrated approaches. We recommend 
the implementation of these therapeutic modalities for all schizophrenia patients in Mexico 
and in Latin America, because patients deserve to receive the best quality of service that 
goes beyond the traditional and exclusively approach of pharmacotherapy. Limitations in 
the implementation in clinical settings as well as problems in translating research into 
everyday practice should be considered (Margison, 2003). Although, antipsychotic 
medication can usually help to stabilize symptoms, impairments and disabilities still persist. 
Wouldn’t it be nice if medication could help to restore the individual suffering from 
schizophrenia, to “normal” life, and regain his/her ability to function in society, to make up 
for lost time. However, patients could never learn new skills for their survival in the “real 
world” by taking medication. They need medication as well as psychosocial services. Living 
in the community independently and successfully should be a goal to pursue. The purpose 
is the re-integration of persons with schizophrenia in the community. Future research 
should focus on an independent living-beyond medication- in the community. To reach this 
goal, patients should go through various conditions that include new and resent proposals: 
1) the achievement of “symptomatic remission” (Andreasen et al., 2005), with the use if 
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antipsychotic medication. 2) psychosocial improvements, such as “psychosocial remission”, 
(Barak et al., 2010), with psychosocial approaches, and, 3) the combination of these two 
variables that would led to “recovery” (Leucht & Lasser, 2006; Liberman, et al., 2002; 
Liberman & Kopelowicz, 2005; Liberman, 2008; Torgalsboen & Rund 2010). Understanding 
“functional recovery”as the ultimate goal for an independent living in the community. To 
complete the puzzle, the family must be considered as an important component. Patients 
and relatives can become active participants in the “recovery process” since it has been 
demonstrated that with the use of psychoeducation and family approaches, expressed 
emotion can be reduced, so patients and their carers could live in a less stressful 
psychosocial environment. Enhanced monitoring practices could also help for patients, 
relatives and the treatment team, to be in close contact, as demonstrating “good therapeutic 
alliance” to intervene when necessary, and also verifying that patients are not only “getting 
well”, but also “staying well” in the community (Yeomans et al., 2010). This general picture 
indicates that some patients with schizophrenia are still unable to cope with tasks such as 
having friends, holding a job or living independently. Others have demonstrated that they 
could experience periods of symptomatic relief and enhanced functioning as being “in 
recovery”, considering the notion that recovering from schizophrenia is possible. Recovery 
should be a goal to pursue for the future. 
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1. Introduction 
In 1988 the US Surgeon General’s report stated that tobacco use, in any form, is addicting as 
a result of its nicotine content and defined the processes determining tobacco addiction as 
“similar to those that determine addiction to drugs such as heroin and cocaine” (U.S. Surgeon 
General, 1988). Tobacco smoking has been classified by the WHO International 
Classification of Diseases (ICD-10) under the "Mental and behavioural disorders” (F00-F99 
(http://apps.who.int/classifications/apps/icd/icd10online/). Continuous use of nicotine 
induces adaptive changes in the CNS leading to tolerance, physical or physiological 
dependence, sensitization, craving, reward and relapse. Drug addiction has been defined by 
Koob (2008) as "a chronically relapsing disorder characterized by compulsive drug use and loss of 
control over drug intake". Indeed Koob (2008) proposed that addiction includes three different 
stages, which are: "preoccupation/anticipation, binge/intoxication, and withdrawal/negative affect". 
As a final result chronic use of nicotine produces ‘tolerance’, an occurrence that reduces the 
effect of a drug given dose (Fig. 1.). 
 





Vesterager, L.; Christensen, T.; Olsen, B. B.; Kraup, G.; Forchhammer, H. B.; Melau, M.; 
Gluu, C. & Nordentoft, M. (2011). Cognitive training plus a comprehensive 
psychosocial programme (OPUS) versus the comprehensive psychosocial 
programme alone for patients with first-episode schizophrenia (the NEUROCOM 
trial): A study protocol for a centrally randomized, observer-blinded multicentre 
clinical trial. Bio Med Central, Vol.12, No.35, pp. 1-9, ISSN 1745-6215 
Wahlbeck, K. (1999). Evidence of clozapine’s effectiveness in schizophrenia: a systematic 
review and meta-analysis of randomized trials. The American Journal of Psychiatry, 
Vol. 1 56, pp. 990-999, ISSN 0002-953X 
Wallace, C. J.; Liberman, R. P.; MacKain, S. J.; Blackwell, G. & Eckman, T. E. (1992). 
Effectiveness and replicability of modules for teaching social and instrumental 
skills to the severely mentally ill. American Journal of Psychiatry, Vol. 149, pp. 654-
658, ISSN 0002-953X 
Weiden, P. J. (2006). Switching antipsychotics: an updated review with a focus on 
quetiapine. Journal of Psychopharmacology, vol.20, pp. 104-118, ISSN 0271-0749 
World Health Organization. (2001). World health report mental health: new understanding, new 
hope. World health organization, ISBN 1562013, Geneve 
World Health Organization. (2011). Schizophrenia, In: Mental Health, 06.09.2011, Available 
from http://www.who.int/mental_health/management/schizophrenia/en/  
Xia, J.; Bertil-Merinder, L. & Belgamwar M. R. (2011). Psychoeducation for schizophrenia. 
Schizophrenia Bulletin, Vol. 37, No. 1, pp. 21-22, ISSN 0586-7614 
Yeomans, D.; Taylor, M.; Currie, A.; Whale, R.; Ford, K. & Fear, C. (2010). Resolution and 
remission in schizophrenia: getting well and staying well. Advances in Psychiatric 
Treatment, Vol. 16, pp. 86-95, ISSN 1355-5146 
Zimmer, M.; Godoy, L. A.; Godoy, J. & .Belmonte-de Abreu, P. (2003). Mudanca no 
funcionamiento social e occupational de portadores de esquizofrenia e trastorno de 
humor expostos ao programa de psicoterapia congnitivo-compotamental derivada 
de Roder: um estudi naturalistico de 3 años. Revista Brasileira de Psicoterapia, Vol. 5, 
No. 1, pp. 3-18, ISSN 1516-8530 
Zimmer, M.; Verissimo, A. & Belmonte-de Abreu, P. (2006). Análise qualitativa de variáveis 
relevantes para a aplicacao do programa de terapia psicológica integrada emj 
pacientes com esquizofrenia de tres centros do Sul do Brasil. Revista de Psiquiatria do 
Rio Grande do Sul, Vol. 28, No. 3, pp. 256-264, ISSN 0187-4543 
Zimmer, M.; Verissimo, A.; .Laitano, D.; Ferreira, E. E. & Belmonte-de Abreu, P. (2007). A 
twelve-week randomized controlled study of the cognitive-behavioral integrated 
psychosocial therapy program: posite effect on the social functioning of 
schizophrenic patients. Revista Brasileira de Psiquiatria, Vol. 29, No. 2, pp. 140-147, 
ISSN 1516-4466 
4 
Nicotine Addiction: Role of the Nicotinic 
Acetylcholine Receptors Genetic Variability  
in Knowledge, Prevention and Treatment 
Candida Nastrucci and Patrizia Russo 
Laboratory of Systems Approaches and Non Communicable Diseases,  
IRCCS "San Raffaele Pisana" 
Italy 
1. Introduction 
In 1988 the US Surgeon General’s report stated that tobacco use, in any form, is addicting as 
a result of its nicotine content and defined the processes determining tobacco addiction as 
“similar to those that determine addiction to drugs such as heroin and cocaine” (U.S. Surgeon 
General, 1988). Tobacco smoking has been classified by the WHO International 
Classification of Diseases (ICD-10) under the "Mental and behavioural disorders” (F00-F99 
(http://apps.who.int/classifications/apps/icd/icd10online/). Continuous use of nicotine 
induces adaptive changes in the CNS leading to tolerance, physical or physiological 
dependence, sensitization, craving, reward and relapse. Drug addiction has been defined by 
Koob (2008) as "a chronically relapsing disorder characterized by compulsive drug use and loss of 
control over drug intake". Indeed Koob (2008) proposed that addiction includes three different 
stages, which are: "preoccupation/anticipation, binge/intoxication, and withdrawal/negative affect". 
As a final result chronic use of nicotine produces ‘tolerance’, an occurrence that reduces the 
effect of a drug given dose (Fig. 1.). 
 





Cessation of tobacco use determines a withdrawal syndrome, characterized by agitation, 
irritation, frustration or anger, concentration difficulty, depressed mood, anxiety, 
restlessness, decreased heart rate and increased appetite or weight gain (Benowitz, 2010; 
Perkins, 2002; Shiffman et al., 2004). These symptoms occur after four to twelve hours, peak 
after one week and decrease progressively over time (Perkins, 2002). Nicotine addiction is 
sustained by the individual positive effects experienced during smoking, and by the wish to 
hold off the negative symptoms of nicotine withdrawal. Thus, episodic and repetitive doses 
of nicotine are indispensable to maintain normal levels of functioning. Moreover, stress 
conditions, processes concerning consciousness, evaluation and response to negative, 
threatening or, challenging events or stimuli have been found to exacerbate nicotine 
withdrawal symptoms and increase vulnerability to relapse (Morissette et al., 2007).  
2. Neurochemistry of Nicotinic receptor (nAChR) 
The functional properties of nicotine are related to its interaction with the nicotine receptors 
(nAChR). nAChR are acetylcholine gated ion channels consisting of homo- or hetero-
pentamers subunits arranged symmetrically around a membrane perpendicular axis, 
outlining the ionic hole (Russo et al., 2006; Taly et al., 2009) (Fig. 2.). 
 
Fig. 2. Nicotinic Receptors. nAChR consist of homo- (e.g. or a9, non the left) or hetero-
pentamer (e.g. composed of the various subunits 
) that are arranged symmetrically around an axis perpendicular to the 
membrane, thus delineating the ionic pore. The α subunits are distinguished by the presence 
of adjacent (vicinal) Cysteine residues in loop C, and this originally defined α subunits as 
agonist-binding subunits. The homomeric α7 nAChR is a special case, since having five 
agonist-binding sites per receptor can bind from two to five molecules of agonist. 7-nAChR 
utilizes multiple calcium amplification pathways to efficiently raise the intracellular calcium 
levels by subsequent activation of voltage-gated calcium channels as well as calcium release 
from the endoplasmic reticulum (Russo et al., 2006; Taly et al., 2009).  
The composition and stoichiometry of the pentamer determines receptor pharmacology, 
cations selectivity, desensitization kinetics and spatial distribution. Receptors containing α4 
and β2 subunits are the most abundant in the CNS accounting for the majority of nicotine 
high affinity binding sites (Flores et al., 1992; Schoepfer et al., 1988). It has been shown, by  
Nicotine Addiction: Role of the Nicotinic  
Acetylcholine Receptors Genetic Variability in Knowledge, Prevention and Treatment 
 
71 
pharmacological and ligand-binding experiments, that nAChR containing the β2-subunit 
(β2*nAChR, the asterisk indicates the possibility of other subunits to be incorporated in the 
receptors) bind to nicotine with high affinity (Changeux et al., 1998). -containing nAChR, 
which have been implicated in nicotine self-administration (Picciotto et al., 1998), do not 
influence the onset of nicotine withdrawal symptoms (Salas et al., 2004). Evidence shows 
that acute nicotine self-administration is absent if the * receptors are deleted (Marubio et 
al., 2003; Pons et al., 2008). Activation of  nAChR is sufficient to sustain nicotine-induced 
reward, tolerance and sensitization (Tapper et al., 2004). Since the  and  subunits are 
coexpressed within in the medial habenula (MHb), in the interpeduncular nucleus (IPN) 
and in the peripheral ganglia, it is likely that  and nAChR may be involved in the 
mechanisms of nicotine withdrawal. It has been shown that * nAChR expressed in the 
VTA (ventral tegmental area) are necessary for the effects of systemic nicotine on DA 
(dopamine) neuron activity and DA-dependent behaviours, such as locomotion and 
reinforcement. It was proposed that both  and  receptors are necessary for (at least 
some of) the effects of nicotine on the DA system. In the brain, the homomeric  subtype is 
the most abundant and widespread nAChR (Breese et al., 1997; Quik et al., 2000), being 
involved in the modulation of glutamatergic and cholinergic neurotransmitter release, in the 
synaptic plasticity, in the regulation of neuronal growth, in the differentiation and survival, 
in the regulation of calcium-dependent gene expression and in the mediation of circuit 
excitability (reviewed in Gotti & Clementi, 2004). New data support a model in which the α7 
nAChR, found on glutamate terminals, increases glutamate release contributing to 
presynaptic facilitation and synaptic plasticity and enhancing dopamine release from 
neighbouring boutons (Livingstone et al., 2010). The regulation of the nAChR is linked to 
their intrinsic property of being allosteric receptors. (Changeux & Edelstein, 2005). Thus 
nAChR are susceptible to desensitization and inactivation following, or in some cases 
independent of, channel opening (Giniatullin et al., 2005). Desensitization represents a 
decrease or loss of biological response after prolonged or repetitive stimulation by an 
agonist, such as nicotine, or a neurotransmitter. Indeed, when nicotine is continuously 
applied, nAChR become ‘desensitized’ (i.e. temporarily inactive) (Katz & Thesleff, 1957; 
Quick & Lester, 2002). The sensitisation-desensitization is correlated to the property of 
nAChR to increase their expression (upregulation) when exposed to nicotine (Vallejo et al., 
2005; Gahring et al., 2010). Subtypes containing  and  are not up-regulated by 
chronic nicotine administration (Mao et al., 2008; Marks et al., 1992 ), whereas - or 
containing nAChR (Tapper et al., 2004; Nashmi et al., 2007), containing subunits are up-
regulated following repeated nicotine administration (McCallum et al., 2006). α7 
upregulation occurs at higher nicotine concentrations than are required to increase α4β2 
nAChR (Pauly et al., 1991; Rasmussen & Perry, 2006; Kawai & Berg, 2001). Up-regulation of 
-containing receptors, after nicotine administration, is a process which less clear, since 
studies report either upregulation (Parker et al. 2004), down-regulation (Lai et al., 2005; 
Perry et al., 2007) or no change (Drenan et al., 2008; McCallum et al., 2006).  
3. Mechanism of nicotine addiction 
Although the molecular mechanisms leading to and maintaining NA are not completely 
understood, they involve the regulation of brain monoamines levels and in particular DA 
(Benowitz, 2010; Changeux, 2009). Nicotine stimulates those nAChR placed principally in 
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laterodorsal tegmental nuclei, important neuronal structures of the mesolimbic reward 
pathway (Brunzell et al., 2009; Dani, 2003; Exley & Cragg, 2008; Sharma & Brody, 2009; 
Schiltzet al., 2005). It has been proposed that the change from voluntary drug use to a more 
habitual and compulsive drug use, corresponds to a transition, at the neural level, from 
prefrontal cortical to striatal control, as well a progression from ventral to more dorsal 
domains of the striatum, involving its dopaminergic innervation (Everitt & Robbins, 2005). 
These neural transitions may themselves depend on the neuroplasticity in both cortical and 
striatal structures that is induced by chronic self-administration of drugs. Several nAChR 
subtypes such as: α4α6β2β3, α4β2, α4α5β2, α6β2β3 and α6β2 are expressed on dopamine 
nerve terminals (Grady et al., 2007). Converging indication proposes that the dopaminergic 
system is important in mediating the pleasurable feelings of reward when activated by 
nicotine (Soderpalm et al., 2000; Zoli et al., 2002). It has been hypothesized that exposure to 
nicotine may initially increases the firing of ventral tegmental area GABAergic neurons 
through α7 nAChR activation, followed by 7 nAChR desensitization, that leads the 
disinhibition and firing of DA neurons. This latter event might be also enabled by a more 
prolonged activation of the α7 nAChR expressed on glutamatergic terminals (Wonnacott et 
al., 2005). At the molecular level, several studies have suggested that ERK1/2 activation 
followed by phosphorylation of Cyclic AMP Response Element Binding protein (CREB) at 
Ser133 and the activity of Fos gene are highly involved in many forms of experience 
dependent plasticity, such as long-term potentiation (LTP; Wu et al., 2007). FosB, a long-
lived truncated isoform of the FosB protein, accumulates within the striatum of rats treated 
repeatedly with either cocaine or nicotine, for several weeks and suggesting a sustained 
molecular change initiated by drug experience (Nestler, 2001), although not sufficient to 
account for the perseverance of drug dependence. CREB may play an important role in the 
rewarding and reinforcing effects of many drugs of abuse (Nestler, 2001, 2002), since pCREB 
is required in the NAc to establish nicotine-conditioned place preference (CPP) in mice 
(Brunzell et al., 2009).  
4. Genetic of nicotine addiction 
Meta-analysis of studies on twins showed that both genes and environment are important in 
smoking-related behaviours, with an estimated mean heritability of 0.50 for smoking 
initiation and 0.59 for nicotine dependence (Li et al., 2003). In women, genetic factors have a 
larger role in initiation than in persistence, whereas the opposite is observed in men (Li et 
al., 2003; Madden et al., 1999). Recent genome-wide association studies (GWAS) have shown 
that the CHRNA5-A3-B4 region, on chromosome 15q24-25.1, encoding the  and  
subunits, is strongly associated with nicotine dependence, as well as alcohol and cocaine 
dependence and lung cancer susceptibility (Amos et al., 2008; Amos et al., 2010; Bierut, 2010; 
Caporaso et al., 2009; Saccone et al., 2010; Spitz et al., 2008; Thorgeirsson et al., 2008). One of 
the strongest association within the 15q24-25.1 region is the rs16969968, located in exon 4 of 
CHRNA5, which causes an aminoacid substitution from an aspartic acid (D) to asparagine 
(N) (missense mutation) (D398N). This change reduces the α4β2α5 receptor function 
(Saccone et al. ,2007), as found by in vitro functional studies, which shown that  
receptors, containing the N substitution exhibited a weaker response to nicotine compared 
to the D variant in (Bierut et al., 2008). Other nAChR gene variants associated to ND are 
reported in Table 1. 
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Gene SNP Chromosome number/ position (base pairs) Major/Minor Allele 
CHRNA3 rs1051730 15/76681394 C/T 
CHRNA3 rs11637630 15/76686774 A/G 
CHRNA3 rs3743078 15/76681814 C/G 
CHRNA3 rs578776 15/76675455 C/T 
CHRNA3 rs7177514 15/76694461 C/G 
CHRNA3/B4 rs8023462 15/76701789 C/T 
CHRNA4 rs1044394 20/61452529 C/T 
CHRNA4 rs2236196 20/61448006 A/G 
CHRNA4 rs2273504 20/61458505 A/G 
CHRNA4 rs6122429 15/76701810 C/T 
CHRNA5 rs16969968 15/76669680 G/A 
CHRNA5 rs17486278 15/76654537 A/C 
CHRNA5 rs2036527 15/7663870 C/T 
CHRNA5 rs569207 15/76660174 GA 
CHRNA5 rs637137 15/7661031 T/A 
CHRNA5 rs8034191 15/45468658 G/A 
CHRNA6 rs1072003 8/42729008 C/G 
CHRNA6 rs2304297 8/42725148 C/G 
CHRNA6 rs892413 8/42727356 A/C 
CHRNB2 rs2072658 1/152806850 A/G 
CHRNB2 rs2072660 1/152815345 C/T 
CHRNB2 rs2072661 1/152815504 A/G 
CHRNB3 rs13280604 8/ 42678742 A/G 
CHRNB3 rs4950 8/42671789 C/T 
CHRNB4 rs1948 15/76704500 C/T 
Table 1. Association Results for Significant SNP–Phenotype Associations 'Current Frequent 
Smokers', Reviewed in Russo, 2011. 
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Database of Systematic Reviews 2009 (Hajek et al., 2009) that reassessed different 
randomized or quasi-randomized controlled trials of relapse prevention interventions, 
with a minimum follow up of six months, concluded that: (i) extended treatment with 
Bupropion is unlikely to have a clinically important effect; (ii) studies of extended 
treatment with nicotine replacement are needed and (iii) extended treatment with 
Varenicline may prevent relapse.  
Varenicline [Systematic IUPAC name: 7,8,9,10-tetrahydro- 6,10-methano- 6H-pyrazino 
(2,3-h)(3) benzazepine (trade name Chantix), is an α4β2 nicotinic receptor partial agonist 
and an 7 full agonist. The partial agonist activity induces modest receptor stimulation 
that attenuates the symptoms of nicotine withdrawal and inhibits the surges of dopamine 
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Nicotine Addiction: Role of the Nicotinic  
Acetylcholine Receptors Genetic Variability in Knowledge, Prevention and Treatment 
 
73 
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2005; Foulds, 2006). Consequently, Varenicline suppresses the symptoms of nicotine 
withdrawal and reduces the pharmacologic reward from cigarette smoking (Rollema et 
al., 2007).  
Bupropion [Systematic IUPAC name: (±)-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-
one], initially approved by the FDA as an atypical antidepressant, belongs to the chemical 
class of aminoketones. Although its mechanism of action in smoking cessation is not 
completely understood, Bupropion is an inhibitor of DA and of nor-epinephrine reuptake; 
but it is also a weak antagonist of nicotinic receptors (Cryan et al., 2003; Fryer & Lukas, 
1999;).  
6. Drugs and nAChR gene variants 
Although the association of nAChR variants and ND have been extensively studied, their 
role in drug therapy for smoking cessation is only pioneristic. Conti et al. (2008) have 
identified two polymorphisms within the CHRNB2 (rs2072661 and rs2072660) having 
significant association with the abstinence rates, within a 6-month follow-up study on the 
effects of Bupropion in smoking cessation, in a placebo-controlled trial. Specifically, 
although a difference was found in the relapse rates at EOT (end of treatment), between 
carriers and non-carriers, for individuals who received Bupropion, there was a substantial 
increase in the relapse rates for those individuals carrying the minor allele, after they went 
off treatment. Follow-up analyses on the top SNP (rs2072661) indicated a role in the time to 
relapse within the 6-month follow-up period and an impact on withdrawal symptoms at 
TQD (target quit date). These two SNPs (rs2072661 and rs2072660) may be robust markers 
for identifying smokers most likely to relapse and those who may benefit from Bupropion 
therapy. In addition, these SNPs should be examined within pharmacogenetic studies of 
Varenicline for smoking cessation. There is evidence that smokers with a heterozygous TC 
genotype at SNP rs2236196 in CHRNA4 are more likely to maintain abstinence with nicotine 
nasal spray (Hutchison et al., 2007). Moreover, looking at rs2072661, smokers with the 
CHRNB2 GG genotype, could sustain more days of abstinence during the nicotine versus 
placebo patch week, compared with those with the AG or AA genotypes; regardless of 
patch condition, quitting on the ‘target quit day’ was more likely to occur in those 
individuals with the GG genotype versus AA/AG genotypes. Genetic associations were not 
observed for craving or withdrawal responses to nicotine versus placebo patch (Perkins et 
al., 2009). A recent research studied the association of the CHRNA3 gene (Tyr215Tyr or 
rs1051730) with quitting success in response to controlled short-term nicotine patch use in 
hospitalized individuals (De Ruyck et al., 2010). Point abstinence was considered, and it was 
found that neither this genetic polymorphisms, nor the interaction of genotype versus 
treatment group, were significantly associated with quit rates, at any of the considered time 
points. A recent smoking cessation pharmacogenetics study (King et al., 2012) analyzed 1476 
consenting individuals (524 who take Varenicline; 440 Bupropion; 512 placebo). Among the 
subjects receiving Varenicline, two variants in CHRNB2 (rs3811450 and rs4262952) were 
significantly associated with continuous smoking abstinence. Interestingly Bupropion 
abstinence was associated with several SNPs within CYP2B6, one enzyme important for the 
metabolism of nicotine, including rs8109525. 
Indeed, CYP2B6.8 (the K139E variant) is unable to metabolize Bupropion under normal 
turnover conditions (Zhang et al., 2011). All these data support the evidence that genetic loci 
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contribute to smoking cessation and therapeutic response. On the other hand, the response 
treatment to Varenicline versus Bupropion is associated with different genetic signals, 
implying that in future research clinically useful markers shall guide treatment decisions to 
achieve improved smoking cessation rates and reduction in smoking occurrence.  
7. Conclusions 
Recognition that tobacco use is driven by the “neurobiological diseases” of “nicotine 
dependence” and “nicotine withdrawal”, linked to specific nAChR variants, provides a 
rational basis for the development of drugs and treatment, as well as supporting the 
inclusion of pharmacotherapies for dependence and withdrawal, along with those targeting 
other medical disorders. In fact, the need to prevent public health and economic 
devastation, caused by tobacco use, supports treatment as a high priority in health care. 
Pharmacotherapy for tobacco dependence is also cost effective when compared to many 
widely supported forms of pharmacotherapy for diseases, such as hypertension and 
hypercholesterolemia, as well as preventive periodic screening such as mammography or 
Papanicolaou smears. Moreover, the nAChR SNPs examination is less expensive and less 
invasive that spiral-CT or PET-SCAN examination, as screening in smokers. Taken together, 
these data suggest that genetic susceptibility to nicotine dependence is linked to several 
nAChR subtype genes and variants, in each subunit gene, and that may give independent, 
as well as interactive, contributions to nicotine dependency at molecular level. 
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1. Introduction 
Psychiatric symptoms are very frequent in medical practice, up to 40% of the people that 
have physical problems present anxiety or depressive symptoms associated to physical 
illness. Due to this, psychiatric liaison is an important part of hospital attention and many 
people usually have psychiatric drugs associated to other treatments.  
Psychiatric drugs usually are classified into six great families depending on their principal 
focus of action or their use in the main psychiatric disorders: 
 Antidepressants: these drugs act on depressive illness through the action on various 
neurotransmitter systems: serotonine, noradrenaline and dopamine. The most used of 
these are SSRI (serotonine selective reuptake inhibitors), because of their efficacy and 
good profile of side effects. 
 Antipsychotics: they are used in the control of psychotic symptoms and as major 
tranquilizers. Antipsychotics are classified on first generation and second generation. 
The first of them act upon dopamine receptors and the second ones upon serotonine 
and dopamine receptors to have antipsychotic effects. This second generation 
substances have less side effects and a different profile of action. 
 Anxiolytics: the most widely used are benzodiacepines, which act upon a specific 
GABA receptor. This family of drugs has a very quick effect, but they aren’t 
recommended for a long time use because they can produce dependence and their 
effects are limited. They are also used like anticonvulsivants. 
 Antiepileptics: This group of drugs is used in psychiatry for the maintenance and 
control of bipolar disorders, and they are useful too like antiaggressive drugs. The 
therapeutic drug monitoring is necessary when some of these substances are 
administrated because of their potential toxicity and the pharmacological interactions 
with other treatments. 
 Lithium: it is a salt used for control of manic symptoms and maintenance of bipolar 
disorders. Its action mechanism is unknown, despite its usefulness and generalized 
utilization. It’s necessary to control its plasmatic level into a tight range to avoid toxicity 
and to achieve its function. 
 Other drugs widely used in psychiatric disorders: methadone, anticholinesterases, 
stimulants, alcohol aversives are also important due to their side effects and their 
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First antidepressant drugs were a casual finding and they affect to various 
neurotransmitters systems. Usually these old drugs produce many secondary effects. 
Afterwards, some hypotheses have emerged about the neurotransmission implicated in 
depression (monoamines: serotonin, noradrenalin and dopamine). Drug development 
progresses in parallel to this investigation so more selective drugs appeared as Selective 
Serotonin Reuptake Inhibitors, (from now on SSRIs), ameliorating secondary effects.  
Antidepressant classification depends on the assumption of their action mechanism. 
Following that schema, there are eight different pharmacological mechanisms at least. The 
most of the antidepressants block monoamine reuptake, but others block alpha-2 receptors 
or monoamineoxidase enzyme.  
2.1 Monoamine reuptake inhibitors 
2.1.1 Tricyclic and tetracyclic antidepressants (TCA)  
The tricyclic and tetracyclic branch of antidepressants has a demonstrated and high efficacy, 
only limited by their sedative and anticholinergic effects. They act on a huge number of 
receptors, and are cardiotoxic in case of overdoses, as anticholinergic toxicity and 
convulsions.  
Pharmacological actions: A significant part is absorbed totally after oral administration. 
They have a significant metabolism by first-pass. Maximum plasmatic concentration is 
reached in 2-48 hours but equilibrium appears after 5-7 days. Their long half-life allows 
them to be used once in a day. Clearance of tricyclics is dependent primarily on hepatic 
cytochrome P450 (CYP) oxidative enzymes.  
Effects on organs and special systems: Significant effects on the cardiovascular system 
appear at therapeutic dose: they are classified as anti-arrhythmic type IA, since they 
interrupt the ventricular fibrillation and can increase the collateral blood flow of ischemic 
heart. In overdose they are highly cardiotoxic and cause a decrease in contractility, increased 
irritability myocardial, hypotension and tachycardia. 
2.1.2 Main therapeutic indications 
Depression: treatment of one major depressive episode and prophylaxis of one major 
depressive episode (main directions); depression in Bipolar type I disorder (in resistant 
cases, with many precautions to prevent swinging: associated with anticonvulsivants or 
lithium); one depressive episode with psychotic manifestations almost always requires the 
simultaneous administration of an antipsychotic drug and an antidepressant; Disorder 
mood due to a general medical disease with depressive features 
 Panic disorder.  
 Generalized anxiety disorder. 
 Obsessive-compulsive disorder: clomipramin especially. None of the others seems so 
effective. 
 Others: Alimentary conduct disorder and pain disorder. 
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2.1.3 Precautions and adverse reactions 
 Psychopathological effects: possibility of inducing a manic episode, especially in 
patients with a history of Bipolar disorder. It has been also described that the tricyclic 
antidepressants can exacerbate or precipitate psychotic symptoms in vulnerable 
patients. 
 Anticholinergic effects: They consist of dry mouth, constipation, blurred vision, urinary 
retention, closed angle glaucoma 
 Sedation.  
 Effects on the autonomous nervous system: orthostatic hypotension, profuse sweating, 
palpitations, and increased blood pressure. 
 Effects on the cardiovascular system: tachycardia, QT prolongation, flattening of T 
wave, ST depression, etc. 
 Neurological effects: Delirium (cholinergic effects). Psychomotor stimulation. 
Parkinsonism, dyskinesia, akathisia, and inclusive by dopaminergic blockade: 
neuroleptic malignant syndrome. Finally there is a relatively small risk of induce 
convulsions, so in risky patients is encouraged to use lower doses. 
 Allergic and haematological effects: rash, and much less frequently jaundice, 
agranulocytosis, leukocytosis, leukopenia, and eosinophilia. 
 Other: frequent weight gain, sexual dysfunction, digestive discomfort (nausea, 
vomiting) and much more rarely syndrome of inappropriate secretion of antidiuretic 
hormone. 
 Avoid in pregnancy and lactation. Use with caution in patients with kidney or liver 
disease. Increased risk of cardiac adverse effects if it is associated to electroconvulsive 
therapy. If there is a history of heart disease the TCA administration must start with 
low-dose, gradually increasing while maintaining a surveillance of cardiac functions. 
Their administration must be suspended the prior days to a surgical intervention, due 
to the risk of hypertensive episodes. Prior to starting treatment with any TCA basal 
EKG should be made. Try to avoid in patients with closed glaucoma, if necessary you 
may need to manage at the same time pilocarpine eye drops.  
2.2 Serotonin Selective Reuptake Inhibitors (SSRIS) 
Serotonin is a neurotransmitter especially relevant in neurobiological basis in affective 
disorders, compulsive-obsessive disorder, and aggressive behavior.  
SSRIs block the serotonin reuptake bombs action, augmenting serotonin concentration in 
synapsis and postsynapsis receptors’ occupation. Though this effect appears early during 
treatment, clinical effects delay 3-6 weeks.  
They are metabolized at liver, present a low affinity except for serotonin receptors, are 
enough sure in overdoses, change sleep structure (reduce latency and total amount of REM 
sleep) and might be avoid used with MAOIs, due to the risk of serotoninergic syndrome.  
Therapeutic indications: Depression; Anxiety disorders, including Obsessive-Compulsive 
Disorder; Bulimia nervosa; Psychosomatic disorders 
Precautions and adverse reactions: Sexual dysfunction, digestive discomfort, weight gain, 
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alterations in electrolytes and glucose, allergic and endocrine reactions, galactorrea, and 
abrupt suspension discontinuation syndrome. 
2.3 Noradrenalin selective reuptake inhibitors (reboxetine) 
It selectively inhibits the reuptake of norepinephrine, but it has little effect on the reuptake of 
serotonin or dopamine. It is structurally related to fluoxetine. It has little affinity for muscarinic 
receptors or cholinergic and does not interact with the alfa1, alpha2, adrenergic beta, 
serotonergic, dopaminergic or histaminergic receptors. Therefore, SSRIs and reboxetine have 
some complementarity effects and are used together in the clinic in some resistant depressions. 
Reboxetine has a rapid absorption; food does not affect the speed of it. It is metabolized in 
liver, mainly through the 3A4 isozyme of cytochrome P450 and it is excreted by kidney.  
Medical indications: depressive disorders and social phobia. Adverse reactions: the most 
common are: faltering urination, headache, constipation, nasal congestion, sweating, dizziness, 
dry mouth, decreased libido, insomnia. Hypertension and tachycardia can appear at high doses, 
as well as psychomotor retardation if it is taken with alcohol. The syndrome of inappropriate 
secretion of antidiuretic hormone is exceptional. Precautions: contraindicated in pregnancy and 
breastfeeding. The doses must be reduced in elderly patients and serious renal impairment. 
2.4 Inhibitors of the reuptake of serotonin and norepinephrine 
2.4.1 Venlafaxine 
It is a potent inhibitor of the reuptake of serotonin, at higher doses inhibits the reuptake of 
noradrenaline and slightly inhibits the reuptake of dopamine.  
The absorption is good at digestive level and suffer important hepatic metabolism, by CYP 2D6 
isoenzyme, so some SSRIs isozyme inhibitor drugs may increase plasma levels of venlafaxine, 
giving effects at low doses which are resolved once the inhibitor drug is withdrawn.  
Therapeutic indications: depression, generalized anxiety disorder. Venlafaxine can be 
effective in: OCD, panic disorder, agoraphobia, social phobia, Attention Deficit and 
Hiperactivity Disorder (ADHD) and treatment of chronic pain. The most frequent side 
effects are nausea (less frequent with the retard formulation), drowsiness, dry mouth, 
dizziness, anxiety, constipation, asthenia, sweating, anxiety, anorexia, blurred vision, sexual 
dysfunction. A syndrome of discontinuation can appear if it stopped suddenly (nausea, 
drowsiness and insomnia...), so it should be reduced gradually. At high doses can 
precipitate high blood pressure.  
It should be used cautiously in patients with pre-existing hypertension, administering lower 
doses, avoid its use in pregnancy and lactation and in children has not established safety or 
efficacy. In major liver or kidney function deterioration doses must be reduced. Venlafaxine 
overdosage may be more serious than with SSRIs and similar to tricyclic. It may be 
appropriate to avoid prescribing venlafaxine to patients who have high risk of poisoning. 
2.4.2 Duloxetine 
Like venlafaxine, it inhibits the reuptake of both serotonin and norepinephrine, Duloxetine 
has a minimal affinity for dopamine and histamine receptors.  
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It has significant hepatic metabolism, with many metabolites. It’s a moderate inhibitor of 
CYP 2D6. Its excretion is renal. 
Clinical indications: depression, Treatment of diabetic peripheral neuropathic pain. 
Contraindications: it must never be administered in patients with liver failure and it’s not 
recommended in patients with terminal stage renal disease. Secondary gastrointestinal 
effects are common: nausea, dry mouth and constipation. Diarrhea and vomiting are less 
frequent. Insomnia, dizziness, somnolence and sweating are also common. Sexual 
dysfunction appears less frequently than with SSRIs, particularly in women.  
2.4.3 Inhibitors of the reuptake of norepinephrine and dopamine (bupropion) 
It is usually more effective on symptoms of depression than anxiety and quite useful in 
combination with SSRIs. It has some dopaminergic effects and therefore can induce mild 
psychostimulant effects. The mechanism of action is not known with accuracy. It seems that 
weakly inhibits the reuptake of dopamine, raising levels of it in the nucleus accumbens. This 
increase in dopamine levels in the "area of reward" of the brain may be responsible for the 
use of bupropion in the cessation. Some data indicate that it exerts its antidepressant effects 
increasing the functional efficiency of the noradrenergic systems. Apparently it has no effect 
on the serotonin system, so it is not effective to block panic attacks. 
Pharmacokinetics: Good absorption at digestive tract; extensively metabolized in the liver. 
It seems to inhibit the isozyme CYP 2D6. It is also important to note that drugs that inhibit 
the isozyme will increase levels of bupropion, raising the risk of seizures.  
Indications: depression: because of its stimulating effect, is used in depressive patients with 
fatigue and lack of concentration. The improvement of the sleep at the beginning of the 
treatment is less common than with other antidepressants, but does not alter sleep 
architecture. It is useful for abandonment of tobacco, in combination with conduct 
programs. It has also proposed its use in disorders attention deficit and on substance abuse 
(seems to decrease the craving in cocaine addiction). 
Contraindications: Bulimia and anorexia, history of seizures or epilepsy, alcohol 
consumption, recent discontinuation of benzodiazepines, organic brain disease, cranial 
traumatism or EEG discharges. It isn’t recommended in pregnancy or lactation.  
The most common side effects are high respiratory discomfort, nausea, headache and 
insomnia. There may also be anxiety, agitation and irritability. It’s the antidepressant with 
less inhibition of sexual function and it is more likely to reduce the weight than to increase 
it. The retard formulation is associated with an incidence of seizures of 0.1% at usual doses. 
Exceptionally it could cause psychotic hallucinations, delusions, catatonia symptoms, as 
well as delirium (by enhancing dopamine). It can increase blood pressure in previously 
hypertensive patients. There is no indication of significant effects on the heart, kidney or 
liver function.  
2.5 Blockers of presynaptic autorreceptors: Mirtazapine 
Its unique mechanism of action is blocking the receptors Alpha2 pre and post synaptic, as 
well as the serotonergic 5HT2 and 5HT3 receptors. In contrast to the TCA, mirtazapine has 
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alterations in electrolytes and glucose, allergic and endocrine reactions, galactorrea, and 
abrupt suspension discontinuation syndrome. 
2.3 Noradrenalin selective reuptake inhibitors (reboxetine) 
It selectively inhibits the reuptake of norepinephrine, but it has little effect on the reuptake of 
serotonin or dopamine. It is structurally related to fluoxetine. It has little affinity for muscarinic 
receptors or cholinergic and does not interact with the alfa1, alpha2, adrenergic beta, 
serotonergic, dopaminergic or histaminergic receptors. Therefore, SSRIs and reboxetine have 
some complementarity effects and are used together in the clinic in some resistant depressions. 
Reboxetine has a rapid absorption; food does not affect the speed of it. It is metabolized in 
liver, mainly through the 3A4 isozyme of cytochrome P450 and it is excreted by kidney.  
Medical indications: depressive disorders and social phobia. Adverse reactions: the most 
common are: faltering urination, headache, constipation, nasal congestion, sweating, dizziness, 
dry mouth, decreased libido, insomnia. Hypertension and tachycardia can appear at high doses, 
as well as psychomotor retardation if it is taken with alcohol. The syndrome of inappropriate 
secretion of antidiuretic hormone is exceptional. Precautions: contraindicated in pregnancy and 
breastfeeding. The doses must be reduced in elderly patients and serious renal impairment. 
2.4 Inhibitors of the reuptake of serotonin and norepinephrine 
2.4.1 Venlafaxine 
It is a potent inhibitor of the reuptake of serotonin, at higher doses inhibits the reuptake of 
noradrenaline and slightly inhibits the reuptake of dopamine.  
The absorption is good at digestive level and suffer important hepatic metabolism, by CYP 2D6 
isoenzyme, so some SSRIs isozyme inhibitor drugs may increase plasma levels of venlafaxine, 
giving effects at low doses which are resolved once the inhibitor drug is withdrawn.  
Therapeutic indications: depression, generalized anxiety disorder. Venlafaxine can be 
effective in: OCD, panic disorder, agoraphobia, social phobia, Attention Deficit and 
Hiperactivity Disorder (ADHD) and treatment of chronic pain. The most frequent side 
effects are nausea (less frequent with the retard formulation), drowsiness, dry mouth, 
dizziness, anxiety, constipation, asthenia, sweating, anxiety, anorexia, blurred vision, sexual 
dysfunction. A syndrome of discontinuation can appear if it stopped suddenly (nausea, 
drowsiness and insomnia...), so it should be reduced gradually. At high doses can 
precipitate high blood pressure.  
It should be used cautiously in patients with pre-existing hypertension, administering lower 
doses, avoid its use in pregnancy and lactation and in children has not established safety or 
efficacy. In major liver or kidney function deterioration doses must be reduced. Venlafaxine 
overdosage may be more serious than with SSRIs and similar to tricyclic. It may be 
appropriate to avoid prescribing venlafaxine to patients who have high risk of poisoning. 
2.4.2 Duloxetine 
Like venlafaxine, it inhibits the reuptake of both serotonin and norepinephrine, Duloxetine 
has a minimal affinity for dopamine and histamine receptors.  
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It has significant hepatic metabolism, with many metabolites. It’s a moderate inhibitor of 
CYP 2D6. Its excretion is renal. 
Clinical indications: depression, Treatment of diabetic peripheral neuropathic pain. 
Contraindications: it must never be administered in patients with liver failure and it’s not 
recommended in patients with terminal stage renal disease. Secondary gastrointestinal 
effects are common: nausea, dry mouth and constipation. Diarrhea and vomiting are less 
frequent. Insomnia, dizziness, somnolence and sweating are also common. Sexual 
dysfunction appears less frequently than with SSRIs, particularly in women.  
2.4.3 Inhibitors of the reuptake of norepinephrine and dopamine (bupropion) 
It is usually more effective on symptoms of depression than anxiety and quite useful in 
combination with SSRIs. It has some dopaminergic effects and therefore can induce mild 
psychostimulant effects. The mechanism of action is not known with accuracy. It seems that 
weakly inhibits the reuptake of dopamine, raising levels of it in the nucleus accumbens. This 
increase in dopamine levels in the "area of reward" of the brain may be responsible for the 
use of bupropion in the cessation. Some data indicate that it exerts its antidepressant effects 
increasing the functional efficiency of the noradrenergic systems. Apparently it has no effect 
on the serotonin system, so it is not effective to block panic attacks. 
Pharmacokinetics: Good absorption at digestive tract; extensively metabolized in the liver. 
It seems to inhibit the isozyme CYP 2D6. It is also important to note that drugs that inhibit 
the isozyme will increase levels of bupropion, raising the risk of seizures.  
Indications: depression: because of its stimulating effect, is used in depressive patients with 
fatigue and lack of concentration. The improvement of the sleep at the beginning of the 
treatment is less common than with other antidepressants, but does not alter sleep 
architecture. It is useful for abandonment of tobacco, in combination with conduct 
programs. It has also proposed its use in disorders attention deficit and on substance abuse 
(seems to decrease the craving in cocaine addiction). 
Contraindications: Bulimia and anorexia, history of seizures or epilepsy, alcohol 
consumption, recent discontinuation of benzodiazepines, organic brain disease, cranial 
traumatism or EEG discharges. It isn’t recommended in pregnancy or lactation.  
The most common side effects are high respiratory discomfort, nausea, headache and 
insomnia. There may also be anxiety, agitation and irritability. It’s the antidepressant with 
less inhibition of sexual function and it is more likely to reduce the weight than to increase 
it. The retard formulation is associated with an incidence of seizures of 0.1% at usual doses. 
Exceptionally it could cause psychotic hallucinations, delusions, catatonia symptoms, as 
well as delirium (by enhancing dopamine). It can increase blood pressure in previously 
hypertensive patients. There is no indication of significant effects on the heart, kidney or 
liver function.  
2.5 Blockers of presynaptic autorreceptors: Mirtazapine 
Its unique mechanism of action is blocking the receptors Alpha2 pre and post synaptic, as 
well as the serotonergic 5HT2 and 5HT3 receptors. In contrast to the TCA, mirtazapine has 
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low affinity receptors alfa1 blocking. It has little interaction with receptors for acetylcholine, 
but blocks histamine receptors in a powerful way. 
It is proposed that the antagonism of the presynaptic Alpha2 receptors leads to a significant 
increase in noradrenergic neurotransmission. This augmentation produced by mirtazapine 
increases the release of serotonin, producing the antidepressant effect. 
Pharmacokinetics: rapid and complete absorption in the digestive tract; plasma clearance: 
up to 30% slower if there is impaired liver function, up to 50% slower if there is 
deterioration of kidney function. It has hepatic metabolism, by CYP 1A2, 3A4, 2D6 and 
CYP2C9.  
Side effects: drowsiness (50% of treated patients). Managing at bedtime can be reduced. It 
appears more at low doses. It causes weight gain, increase in appetite, dry mouth, dizziness 
and lower risk of sexual dysfunction than with other antidepressants.   
Precautions: it can increase levels of cholesterol and triglycerides, increase transaminases, 
reduce of the absolute count of neutrophils to 500/mm3 or below (some of the patients had 
symptomatic infections), it is a reversible alteration and is more likely to occur if there are 
other risk factors for neutropenia. In elderly individuals, kidney or liver failure can be 
necessary to use lower doses. 
2.6 Serotoninergic modulators: Trazodone 
Its mechanism of action is the modulation of serotonergic neurotransmission; it is a 
relatively specific inhibitor of the reuptake of serotonin. It does not cause any 
anticholinergic effects. It has Alfa1 adrenergic antagonism and antihistaminergic activity, so 
has more sedative effects than other antidepressants. The sedative effects appear to one hour 
after administration and antidepressant effects at 2-4 weeks. 
Indications: Depression (especially effective in regulating the quality of sleep). Also it has 
been proposed for use in anxiety disorder, disorder panic, obsessive-compulsive disorder, 
insomnia, severe agitation in older people (50 mg/day), post-traumatic stress disorder 
(PTSD) and as coadjuvant in schizophrenia 
Most common side effects: sedation (it is often used at low doses: 50 - 100 mg/day to induce 
sleep or treat insomnia due to SSRI); nausea, postural hypotension, priapism (rare, but 
dangerous).  
Special situations: it has been rarely associated with cardiac arrhythmias and it should be 
used cautiously in patients with cardiac disease. It is contraindicated in pregnancy and 
lactation. It should be used cautiously in patients with kidney or liver disease. 
2.7 Monoamine Oxidase Inhibitors (MAOIs) 
They inhibit the enzyme MAO, who is responsible for the oxidative deamination of 
neurotransmitters such as serotonin, norepinephrine, or dopamine. 
There are two ways for MAO enzyme: MAOa and MAOb. The MAOa metabolizes the 
monoaminergic neurotransmitters more closely associated with depression (norepinephrine 
and serotonin). The MAOb acts upon some aminergic substrates, called protoxins, toxins 
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that can cause neural damage. Therefore the inhibition of the MAOa is associated both 
hypertensive effects and therapeutic effects. Inhibition of the MAOb is associated with the 
prevention of neurodegenerative disorders, such as Parkinson's disease processes. 
The MAO is widely distributed in the body. The blockade of the MAOa in the 
gastrointestinal tract is responsible for the "cheese effect". It consists of a severe hypertensive 
crisis that occurs in patients who are taking MAOIs and ingest food containing tyramine. 
Tyramine is usually metabolized in the digestive tract but the blocking of the MAOa 
allowed their passage into general circulation. So, patients in treatment with IMAOs must 
follow a tyramine-restricted diet. 
They exert their effects primarily in the CNS. They act on the mood, decreased sleep and 
insomnia and daytime sleepiness. They are characterized by a significant reduction of REM 
sleep. The MAOIs are not considered antidepressants in frontline due to restrictions in the 
diet, its pharmacological interactions and its broad side effect profile. 
Medical indications: depression, Panic disorder, PTSD, eating disorders, social phobia and 
pain disorder. 
Side effects: the most frequent: orthostatic hypotension, insomnia, weight gain, dry mouth, 
headache, edema, and sexual dysfunction. Rare: spontaneous hypertensive crisis. Rarely: 
paresthesias, myoclonus, and muscle ache. Confusion or drunkenness (it is necessary to 
reduce doses). They have few liver toxic effects and less cardiac effects than the tryciclic 
antidepressants.  
RIMA (reversible monoamine oxidasa inhibitor: moclobemide) can produce dizziness, 
nausea and insomnia. It has less gastrointestinal effects than SSRIs and no sexual effect.  
Special situations: caution in patients with renal, cardiovascular disease or 
hyperthyroidism. In diabetes they can reduce blood glucose, so physician can be forced to 
change the dose of hypoglycaemic drugs. They have been associated to manic induction in 
individuals in depressive phase of a Bipolar disorder type I and psychotic decompensation 
in patients with schizophrenia. They are contraindicated in pregnancy and lactation. In 
elderly: the MAO activity increases with age, so the dose of MAOIs to elderly people and 
young adults are the same. Phenelzine and isocarboxazid have been associated with 
significant risk of hepatotoxicity. 
Drug interactions: can be serious and even fatal. They can never be administered with 
drugs that increase the concentrations at the synaptic level of biogenic amines: most 
antidepressants. There is risk of trigger a serotonin syndrome. They enhance alcohol and 
barbiturates, and other CNS depressants sedative effects. It is important to make a washing 
period when changing treatment.  
Rich in tyramine foods must be avoided during treatment with a MAOIs: cheeses, cured 
meats, sausages, bananas, avocados, dried figs, smoked fish, chocolate, alcoholic beverages.  
3. Classic and second generation antipsychotics 
3.1 Classic antipsychotics 
Among classis antipsychotics (AP) there is no one that has a clear superiority over the 
others, so choice must be made depending on previous response or side effects profile.  
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low affinity receptors alfa1 blocking. It has little interaction with receptors for acetylcholine, 
but blocks histamine receptors in a powerful way. 
It is proposed that the antagonism of the presynaptic Alpha2 receptors leads to a significant 
increase in noradrenergic neurotransmission. This augmentation produced by mirtazapine 
increases the release of serotonin, producing the antidepressant effect. 
Pharmacokinetics: rapid and complete absorption in the digestive tract; plasma clearance: 
up to 30% slower if there is impaired liver function, up to 50% slower if there is 
deterioration of kidney function. It has hepatic metabolism, by CYP 1A2, 3A4, 2D6 and 
CYP2C9.  
Side effects: drowsiness (50% of treated patients). Managing at bedtime can be reduced. It 
appears more at low doses. It causes weight gain, increase in appetite, dry mouth, dizziness 
and lower risk of sexual dysfunction than with other antidepressants.   
Precautions: it can increase levels of cholesterol and triglycerides, increase transaminases, 
reduce of the absolute count of neutrophils to 500/mm3 or below (some of the patients had 
symptomatic infections), it is a reversible alteration and is more likely to occur if there are 
other risk factors for neutropenia. In elderly individuals, kidney or liver failure can be 
necessary to use lower doses. 
2.6 Serotoninergic modulators: Trazodone 
Its mechanism of action is the modulation of serotonergic neurotransmission; it is a 
relatively specific inhibitor of the reuptake of serotonin. It does not cause any 
anticholinergic effects. It has Alfa1 adrenergic antagonism and antihistaminergic activity, so 
has more sedative effects than other antidepressants. The sedative effects appear to one hour 
after administration and antidepressant effects at 2-4 weeks. 
Indications: Depression (especially effective in regulating the quality of sleep). Also it has 
been proposed for use in anxiety disorder, disorder panic, obsessive-compulsive disorder, 
insomnia, severe agitation in older people (50 mg/day), post-traumatic stress disorder 
(PTSD) and as coadjuvant in schizophrenia 
Most common side effects: sedation (it is often used at low doses: 50 - 100 mg/day to induce 
sleep or treat insomnia due to SSRI); nausea, postural hypotension, priapism (rare, but 
dangerous).  
Special situations: it has been rarely associated with cardiac arrhythmias and it should be 
used cautiously in patients with cardiac disease. It is contraindicated in pregnancy and 
lactation. It should be used cautiously in patients with kidney or liver disease. 
2.7 Monoamine Oxidase Inhibitors (MAOIs) 
They inhibit the enzyme MAO, who is responsible for the oxidative deamination of 
neurotransmitters such as serotonin, norepinephrine, or dopamine. 
There are two ways for MAO enzyme: MAOa and MAOb. The MAOa metabolizes the 
monoaminergic neurotransmitters more closely associated with depression (norepinephrine 
and serotonin). The MAOb acts upon some aminergic substrates, called protoxins, toxins 
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that can cause neural damage. Therefore the inhibition of the MAOa is associated both 
hypertensive effects and therapeutic effects. Inhibition of the MAOb is associated with the 
prevention of neurodegenerative disorders, such as Parkinson's disease processes. 
The MAO is widely distributed in the body. The blockade of the MAOa in the 
gastrointestinal tract is responsible for the "cheese effect". It consists of a severe hypertensive 
crisis that occurs in patients who are taking MAOIs and ingest food containing tyramine. 
Tyramine is usually metabolized in the digestive tract but the blocking of the MAOa 
allowed their passage into general circulation. So, patients in treatment with IMAOs must 
follow a tyramine-restricted diet. 
They exert their effects primarily in the CNS. They act on the mood, decreased sleep and 
insomnia and daytime sleepiness. They are characterized by a significant reduction of REM 
sleep. The MAOIs are not considered antidepressants in frontline due to restrictions in the 
diet, its pharmacological interactions and its broad side effect profile. 
Medical indications: depression, Panic disorder, PTSD, eating disorders, social phobia and 
pain disorder. 
Side effects: the most frequent: orthostatic hypotension, insomnia, weight gain, dry mouth, 
headache, edema, and sexual dysfunction. Rare: spontaneous hypertensive crisis. Rarely: 
paresthesias, myoclonus, and muscle ache. Confusion or drunkenness (it is necessary to 
reduce doses). They have few liver toxic effects and less cardiac effects than the tryciclic 
antidepressants.  
RIMA (reversible monoamine oxidasa inhibitor: moclobemide) can produce dizziness, 
nausea and insomnia. It has less gastrointestinal effects than SSRIs and no sexual effect.  
Special situations: caution in patients with renal, cardiovascular disease or 
hyperthyroidism. In diabetes they can reduce blood glucose, so physician can be forced to 
change the dose of hypoglycaemic drugs. They have been associated to manic induction in 
individuals in depressive phase of a Bipolar disorder type I and psychotic decompensation 
in patients with schizophrenia. They are contraindicated in pregnancy and lactation. In 
elderly: the MAO activity increases with age, so the dose of MAOIs to elderly people and 
young adults are the same. Phenelzine and isocarboxazid have been associated with 
significant risk of hepatotoxicity. 
Drug interactions: can be serious and even fatal. They can never be administered with 
drugs that increase the concentrations at the synaptic level of biogenic amines: most 
antidepressants. There is risk of trigger a serotonin syndrome. They enhance alcohol and 
barbiturates, and other CNS depressants sedative effects. It is important to make a washing 
period when changing treatment.  
Rich in tyramine foods must be avoided during treatment with a MAOIs: cheeses, cured 
meats, sausages, bananas, avocados, dried figs, smoked fish, chocolate, alcoholic beverages.  
3. Classic and second generation antipsychotics 
3.1 Classic antipsychotics 
Among classis antipsychotics (AP) there is no one that has a clear superiority over the 
others, so choice must be made depending on previous response or side effects profile.  
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The AP are well absorbed orally, although their bioavailability is altered with the intake of 
certain foods, coffee, calcium antacids and excessive consumption of nicotine, which can 
reduce the absorption from the intestinal tract. They have great solubility and easily cross 
the blood-brain barrier. 
Classic antipsychotics include: Clorpromacine, levomepromacine, flufenacine, perfenacine, 
trifluoperacine, haloperidol, zuclopentixol, molindone, and pimocide.  
The AP show a great affinity for plasma proteins (85-90%), which involves risk of toxicity 
when other drugs that also bind to proteins are running simultaneously. On the other hand, 
given that they pass easily through the blood-brain barrier, concentrations achieved in CNS 
doubles those that are quantified in the peripheral circulation. They also cross the placental 
barrier, reaching to the fetus during pregnancy. Due to their lipophilic properties, 
antipsychotics are stored in the peripheral fat, so dialysis is ineffective in cases of overdose. 
Traditional antipsychotic drugs are metabolized in the liver via hydroxylation and 
demethylation in cytochrome P450 processes. Some, such as haloperidol, suffer an 
additional glucuronidation and remain active as dopamine antagonists. Major isozymes in 
the metabolism of these drugs are the 2D6 and the 3A4. It is estimated that between 5 and 
10% of individuals in white, and one much higher proportion of black individuals are slow 
track metabolizers of cytochrome P450 2D6, so it is predictable that submit side effects with 
a greater frequency and severity.  
The AP are removed primarily by urine and feces, through bile, but also by the saliva, tears, 
sweat, and breast milk. The elimination half-life varies between 18 and 40 hours. In the 
elderly, who often have impaired kidney function to a greater or lesser extent, physician 
should proportionally reduce the dose. 
3.1.1 Clinical Indications 
The AP have been the most commonly used drugs in the treatment of acute episodes and as 
therapy for schizophrenia maintenance. Its mechanism of action is basically attributed to the 
blockade of receptors D2 between five types of recipient described dopamine. The blocking 
dopamine at mesolimbic track is responsible for the therapeutic effect, with reduction of 
delusions and hallucinations. For its part, the nigroestriada via controls movement, and so 
its blockade produces akathisia and dystonia and parkinsonism. The dopaminergic 
mesocortical via seems involved in the mediation of negative and cognitive symptoms of 
schizophrenia, and last but not least, the tubero-infundibular that controls the secretion of 
prolactin, blocked by antipsychotic medication stimulates production with galactorrhea. 
The usefulness of antipsychotics in the treatment of affective disorders that have psychotic 
symptoms, as well as the acute control Mania and severe bipolar disorder is well known. 
Antipsychotics are used as antiemetics and in the palliative treatment of some movement 
disorders as Huntington and other chorea disorders. Tics that characterised the Tourette's 
syndrome also respond well to dopamine antagonists. 
The more sedative action and lower incidence of extrapyramidal side effects with some AP 
are particularly indicated for the treatment of great psychomotor agitation, especially in 
situations of urgency and in a timely manner. 
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3.1.2 Side effects 
The low-power typical antipsychotics, those that require higher doses to produce 
therapeutic benefits, tend to have more sedative, anticholinergic, and antihypertensive 
effects than the most powerful drugs. At the same time the latter tend to cause more 
extrapyramidal symptoms because of the antagonistic effect of dopamine on the 
dopaminergic nigroestriatal via. 
The anticholinergic effects of less incisive drugs, or incisive at high doses, cause sometimes 
problems in elderly and heavily dependent patients, which may present difficulties in 
concentration, decreased performance, confusion and delirium. These effects are more 
intense in the early stages of treatment and generate some tolerance over time. On the other 
hand, the less powerful drugs have idiosyncratic reactions more often. For example, 
chlorpromazine can cause hypersensitivity to light or greyish skin patches requiring the 
preventive use of sunscreens. 
Extrapiramidalism: Akathisia, a subjective sensation of motor restlessness and associated 
psychological discomfort, is the most common extrapyramidal adverse effect. It can appear 
at any time, being most common at the beginning of the treatment. Akathisia can improve 
decreasing the dose of the antipsychotic or associating with it a β-Blocker such as 
propranolol or a long-life benzodiazepine. 
Acute dystonia is a short, sharp and painful muscle spasm that usually affects the face 
muscles, neck (retrocolis spasm), back (opisthotonos) and the extraocular muscles. This side 
effect usually affects young males who had not received prior treatment with antipsychotic 
medication. Dystonia is much more prevalent, the greater is the power of the drug. 
Symptoms usually improve managing anticholinergic drugs. 
Tardive dyskinesia is a persistent syndrome in patients that keep treatment with 
antipsychotic drugs for prolonged periods. It is characterized by involuntary and repetitive 
abnormal choreoatethosic movements of the head, trunk and extremities. 
Neuroleptic Malignant Syndrome is a very serious idiosyncratic reaction that appears hours 
or days after the initiation or augmentation of treatment with antipsychotic drugs. There are 
elevation of transaminases and lactate dehydrogenase (LDH). This syndrome involves a 
mortality approaching 30% being the most common causes of death, cardiac arrhythmias, 
secondary respiratory failure, aspiration pneumonia and renal failure for rhabdomyolysis. 
Bromocriptine has traditionally been used for mild cases and dantrolene intravenous for 
more serious cases 
Cardiac effects: due to the action of the AP on the adrenergic α1 receptors in the initial 
stages of the treatment may appear hypotension postural and tachycardia that tend to 
improve progressively with the time. The low-power APs may cause arrhythmia with 
widening of the QRS or QTc interval, polymorphous ventricular tachycardia and ventricular 
fibrillation. 
Gastrointestinal side effects: due to the anticholinergic activity it appears dryness of 
mouth, nausea, vomiting and especially constipation that can even evolve towards ileus. 
Endocrine effects of hyperprolactinemia: galactorrhea, menstrual disturbances, delays of 
ovulation and infertility, early reduction of bone density and osteoporosis, erectile 
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The AP are well absorbed orally, although their bioavailability is altered with the intake of 
certain foods, coffee, calcium antacids and excessive consumption of nicotine, which can 
reduce the absorption from the intestinal tract. They have great solubility and easily cross 
the blood-brain barrier. 
Classic antipsychotics include: Clorpromacine, levomepromacine, flufenacine, perfenacine, 
trifluoperacine, haloperidol, zuclopentixol, molindone, and pimocide.  
The AP show a great affinity for plasma proteins (85-90%), which involves risk of toxicity 
when other drugs that also bind to proteins are running simultaneously. On the other hand, 
given that they pass easily through the blood-brain barrier, concentrations achieved in CNS 
doubles those that are quantified in the peripheral circulation. They also cross the placental 
barrier, reaching to the fetus during pregnancy. Due to their lipophilic properties, 
antipsychotics are stored in the peripheral fat, so dialysis is ineffective in cases of overdose. 
Traditional antipsychotic drugs are metabolized in the liver via hydroxylation and 
demethylation in cytochrome P450 processes. Some, such as haloperidol, suffer an 
additional glucuronidation and remain active as dopamine antagonists. Major isozymes in 
the metabolism of these drugs are the 2D6 and the 3A4. It is estimated that between 5 and 
10% of individuals in white, and one much higher proportion of black individuals are slow 
track metabolizers of cytochrome P450 2D6, so it is predictable that submit side effects with 
a greater frequency and severity.  
The AP are removed primarily by urine and feces, through bile, but also by the saliva, tears, 
sweat, and breast milk. The elimination half-life varies between 18 and 40 hours. In the 
elderly, who often have impaired kidney function to a greater or lesser extent, physician 
should proportionally reduce the dose. 
3.1.1 Clinical Indications 
The AP have been the most commonly used drugs in the treatment of acute episodes and as 
therapy for schizophrenia maintenance. Its mechanism of action is basically attributed to the 
blockade of receptors D2 between five types of recipient described dopamine. The blocking 
dopamine at mesolimbic track is responsible for the therapeutic effect, with reduction of 
delusions and hallucinations. For its part, the nigroestriada via controls movement, and so 
its blockade produces akathisia and dystonia and parkinsonism. The dopaminergic 
mesocortical via seems involved in the mediation of negative and cognitive symptoms of 
schizophrenia, and last but not least, the tubero-infundibular that controls the secretion of 
prolactin, blocked by antipsychotic medication stimulates production with galactorrhea. 
The usefulness of antipsychotics in the treatment of affective disorders that have psychotic 
symptoms, as well as the acute control Mania and severe bipolar disorder is well known. 
Antipsychotics are used as antiemetics and in the palliative treatment of some movement 
disorders as Huntington and other chorea disorders. Tics that characterised the Tourette's 
syndrome also respond well to dopamine antagonists. 
The more sedative action and lower incidence of extrapyramidal side effects with some AP 
are particularly indicated for the treatment of great psychomotor agitation, especially in 
situations of urgency and in a timely manner. 
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3.1.2 Side effects 
The low-power typical antipsychotics, those that require higher doses to produce 
therapeutic benefits, tend to have more sedative, anticholinergic, and antihypertensive 
effects than the most powerful drugs. At the same time the latter tend to cause more 
extrapyramidal symptoms because of the antagonistic effect of dopamine on the 
dopaminergic nigroestriatal via. 
The anticholinergic effects of less incisive drugs, or incisive at high doses, cause sometimes 
problems in elderly and heavily dependent patients, which may present difficulties in 
concentration, decreased performance, confusion and delirium. These effects are more 
intense in the early stages of treatment and generate some tolerance over time. On the other 
hand, the less powerful drugs have idiosyncratic reactions more often. For example, 
chlorpromazine can cause hypersensitivity to light or greyish skin patches requiring the 
preventive use of sunscreens. 
Extrapiramidalism: Akathisia, a subjective sensation of motor restlessness and associated 
psychological discomfort, is the most common extrapyramidal adverse effect. It can appear 
at any time, being most common at the beginning of the treatment. Akathisia can improve 
decreasing the dose of the antipsychotic or associating with it a β-Blocker such as 
propranolol or a long-life benzodiazepine. 
Acute dystonia is a short, sharp and painful muscle spasm that usually affects the face 
muscles, neck (retrocolis spasm), back (opisthotonos) and the extraocular muscles. This side 
effect usually affects young males who had not received prior treatment with antipsychotic 
medication. Dystonia is much more prevalent, the greater is the power of the drug. 
Symptoms usually improve managing anticholinergic drugs. 
Tardive dyskinesia is a persistent syndrome in patients that keep treatment with 
antipsychotic drugs for prolonged periods. It is characterized by involuntary and repetitive 
abnormal choreoatethosic movements of the head, trunk and extremities. 
Neuroleptic Malignant Syndrome is a very serious idiosyncratic reaction that appears hours 
or days after the initiation or augmentation of treatment with antipsychotic drugs. There are 
elevation of transaminases and lactate dehydrogenase (LDH). This syndrome involves a 
mortality approaching 30% being the most common causes of death, cardiac arrhythmias, 
secondary respiratory failure, aspiration pneumonia and renal failure for rhabdomyolysis. 
Bromocriptine has traditionally been used for mild cases and dantrolene intravenous for 
more serious cases 
Cardiac effects: due to the action of the AP on the adrenergic α1 receptors in the initial 
stages of the treatment may appear hypotension postural and tachycardia that tend to 
improve progressively with the time. The low-power APs may cause arrhythmia with 
widening of the QRS or QTc interval, polymorphous ventricular tachycardia and ventricular 
fibrillation. 
Gastrointestinal side effects: due to the anticholinergic activity it appears dryness of 
mouth, nausea, vomiting and especially constipation that can even evolve towards ileus. 
Endocrine effects of hyperprolactinemia: galactorrhea, menstrual disturbances, delays of 
ovulation and infertility, early reduction of bone density and osteoporosis, erectile 
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dysfunction and decreased libido. They can precipitate increase in weight and intolerance to 
the carbohydrates and diabetes 
Genitourinary effects: urinary retention and difficulty in starting urination, secondary 
urinary tract infections.  
Hematological effects: leukopenia, (in general, it is temporal and it is not severe), 
thrombocytopenic Purpura, hemolytic anemia and pancytopenia  
3.2 Atypical or Second Generation Antipsychotics (SGA) 
Clozapine produces a total blockade of D2 receptors, so it does not cause extrapyramidal 
symptoms. Properties of clozapine are due to the combination of a low affinity for the D2 
receptors along with strong affinity to serotonergic 5HT2A and 5HT1C, adrenergic and 
cholinergic receptors. Clozapine joins less intensely this receiver, which is displaced by 
endogenous dopamine. This property is present in many SGA, not only clozapine, so these 
drugs cause fewer movement disorders as side effects 
The indication of clozapine is the treatment of schizophrenia in patients who do not respond 
(after at least two months of treatment at appropriate doses) or that they do not tolerate the 
AP, although occasionally prescribed for other purposes such as the treatment of psychosis 
by L-DOPA in Parkinson's disease patients with mania. It can produce leukopenia, so it’s 
important to control it weekly during the first six months of treatment and every fifteen 
days from then. However, it should be noted that this risk is low, less than 1%. Other 
adverse effects are: orthostatic hypotension and tachycardia, increased sedation, and the 
decline of the seizure threshold with the consequent risk of convulsions in 5-10% of cases. 
Some patients develop a symptomatic complex called metabolic syndrome which consists of 
weight gain, increased insulin resistance, increased risk of diabetes type 2, and elevation of 
plasma lipids. Clozapine may increase plasma levels of enzymes such as transaminases GOT 
and GPT (alanino aminotransferase and aspartate aminotransferase), alkaline phosphatase, 
gamma glutamiltranspeptidasa (GGT) and lactate dehydrogenase. 
Risperidone: Its mechanism of action is mediated by its high affinity for D2 receptors, 
5HT2A receptors and the adrenergic α1 and α2 receptors. Unlike haloperidol shows a low 
affinity for muscarinic receptors for which leads to fewer anticholinergic effects. With a 
similar effectiveness or even something greater than haloperidol, involves a greater 
tolerance, although risperidone at high doses can also cause extrapyramidal symptoms. 
It is considered a SGA first line in the treatment of psychoses with particular effectiveness in 
the prevention of recurrences. It has been used in child psychiatry in the treatment of 
aggressive and serious behaviour disorders.  
There is an increase in brain-vascular accidents in connection with the use of risperidone 
and olanzapine in elderly patients with dementia, a complication which advised the 
prescription of this drug with much caution in such patients. 
There is a long-acting form of risperidone that can be used twice a month in injection for 
maintenance treatment.  
Adverse reactions that occur more frequently with therapeutic doses of risperidone are 
sedation, orthostatic hypotension, tachycardia, increase in weight and erectile dysfunction, 
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hyperprolactinemia. At high doses anticholinergic effects such as dry mouth, constipation, 
changes in vision, and urinary retention may appear. 
No significant pharmacological interaction with risperidone has been described what can be 
a great advantage in patients with a lot of pharmacological treatment, particularly in the 
framework of liaison psychiatry.  
Olanzapine: its main indication has been the treatment of schizophrenia, acute episodes of 
mania and maintenance of bipolar affective disorder. Its structure is similar to clozapine and 
its mechanism of action is unknown, although it has a stronger affinity for the receptor 
5HT2A than by the dopamine receptor D2. Olanzapine also acts at various levels, interacting 
with D1 and D2 dopaminergic, 5HT2A serotoninergic, H1 histaminergic, and muscarinic 
receptors.  
Among his include anorexia nervosa, post-traumatic stress disorder and borderline 
personality disorder where, at low doses, it seems to improve objectives such as aggression 
and impulsiveness parameters. 
Olanzapine is metabolized in the liver by oxidation and glucuronidation by cytochrome 
P450 isoenzyme 1A2. In smokers it must be important to adjust the dose, since the 
consumption of cigarettes induce 1A2 isozyme and increases drug elimination. 
The main adverse effect that occurs in patients in treatment with olanzapine is weight gain, 
so, an important risk that must be taken into account in relation to this and other drugs 
which produce significant weight gain is the metabolic syndrome. Other side effects of 
olanzapine are: sedation, elevation of prolactin, leukopenia (without agranulocytosis), and 
decrease the seizure threshold. Olanzapine carries a lower risk of episodes of Parkinsonism, 
dystonia and tardive dyskinesia.  
Quetiapine has clozapine similar profile, with a moderate affinity to D2 receptors and 
moderate-intense to 5HT2 serotoninergic repceptors. It is a partial agonist of 5HT1A 
receptors, which increase dopamine concentrations in mesocortical area, improving 
cognitive and negative schizophrenics symptoms.  
It produces few extrapyramidal symptoms and risk of tardive dyskinesia. These features 
make it the choice for the treatment of disorders of behavior in Parkinson's patients and 
patients treated within the framework of liaison psychiatry. Undesirable side effects are 
sedation and weight gain with alteration of glucose and lipid metabolism. However, it does 
not produce a significant increase in prolactin levels 
Quetiapine is metabolized in the liver by the cytochrome P450 3A4 enzyme, so drugs that 
produce a large inhibition of the isozyme (such as erythromycin) may increase their serum 
levels. Carbamazepine and phenytoin reduce levels of quetiapine as behave as enzyme 
inducers forcing adjust the dose to avoid possible relapse in patients who are 
simultaneously being treated with these drugs. 
Ziprasidone has high antagonism of 5HT2A, 5HT1D, 5HT2C serotoninergic and D2 
dopaminergic receptors. It has a low tendency to cause extrapyramidal effects because their 




dysfunction and decreased libido. They can precipitate increase in weight and intolerance to 
the carbohydrates and diabetes 
Genitourinary effects: urinary retention and difficulty in starting urination, secondary 
urinary tract infections.  
Hematological effects: leukopenia, (in general, it is temporal and it is not severe), 
thrombocytopenic Purpura, hemolytic anemia and pancytopenia  
3.2 Atypical or Second Generation Antipsychotics (SGA) 
Clozapine produces a total blockade of D2 receptors, so it does not cause extrapyramidal 
symptoms. Properties of clozapine are due to the combination of a low affinity for the D2 
receptors along with strong affinity to serotonergic 5HT2A and 5HT1C, adrenergic and 
cholinergic receptors. Clozapine joins less intensely this receiver, which is displaced by 
endogenous dopamine. This property is present in many SGA, not only clozapine, so these 
drugs cause fewer movement disorders as side effects 
The indication of clozapine is the treatment of schizophrenia in patients who do not respond 
(after at least two months of treatment at appropriate doses) or that they do not tolerate the 
AP, although occasionally prescribed for other purposes such as the treatment of psychosis 
by L-DOPA in Parkinson's disease patients with mania. It can produce leukopenia, so it’s 
important to control it weekly during the first six months of treatment and every fifteen 
days from then. However, it should be noted that this risk is low, less than 1%. Other 
adverse effects are: orthostatic hypotension and tachycardia, increased sedation, and the 
decline of the seizure threshold with the consequent risk of convulsions in 5-10% of cases. 
Some patients develop a symptomatic complex called metabolic syndrome which consists of 
weight gain, increased insulin resistance, increased risk of diabetes type 2, and elevation of 
plasma lipids. Clozapine may increase plasma levels of enzymes such as transaminases GOT 
and GPT (alanino aminotransferase and aspartate aminotransferase), alkaline phosphatase, 
gamma glutamiltranspeptidasa (GGT) and lactate dehydrogenase. 
Risperidone: Its mechanism of action is mediated by its high affinity for D2 receptors, 
5HT2A receptors and the adrenergic α1 and α2 receptors. Unlike haloperidol shows a low 
affinity for muscarinic receptors for which leads to fewer anticholinergic effects. With a 
similar effectiveness or even something greater than haloperidol, involves a greater 
tolerance, although risperidone at high doses can also cause extrapyramidal symptoms. 
It is considered a SGA first line in the treatment of psychoses with particular effectiveness in 
the prevention of recurrences. It has been used in child psychiatry in the treatment of 
aggressive and serious behaviour disorders.  
There is an increase in brain-vascular accidents in connection with the use of risperidone 
and olanzapine in elderly patients with dementia, a complication which advised the 
prescription of this drug with much caution in such patients. 
There is a long-acting form of risperidone that can be used twice a month in injection for 
maintenance treatment.  
Adverse reactions that occur more frequently with therapeutic doses of risperidone are 
sedation, orthostatic hypotension, tachycardia, increase in weight and erectile dysfunction, 
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hyperprolactinemia. At high doses anticholinergic effects such as dry mouth, constipation, 
changes in vision, and urinary retention may appear. 
No significant pharmacological interaction with risperidone has been described what can be 
a great advantage in patients with a lot of pharmacological treatment, particularly in the 
framework of liaison psychiatry.  
Olanzapine: its main indication has been the treatment of schizophrenia, acute episodes of 
mania and maintenance of bipolar affective disorder. Its structure is similar to clozapine and 
its mechanism of action is unknown, although it has a stronger affinity for the receptor 
5HT2A than by the dopamine receptor D2. Olanzapine also acts at various levels, interacting 
with D1 and D2 dopaminergic, 5HT2A serotoninergic, H1 histaminergic, and muscarinic 
receptors.  
Among his include anorexia nervosa, post-traumatic stress disorder and borderline 
personality disorder where, at low doses, it seems to improve objectives such as aggression 
and impulsiveness parameters. 
Olanzapine is metabolized in the liver by oxidation and glucuronidation by cytochrome 
P450 isoenzyme 1A2. In smokers it must be important to adjust the dose, since the 
consumption of cigarettes induce 1A2 isozyme and increases drug elimination. 
The main adverse effect that occurs in patients in treatment with olanzapine is weight gain, 
so, an important risk that must be taken into account in relation to this and other drugs 
which produce significant weight gain is the metabolic syndrome. Other side effects of 
olanzapine are: sedation, elevation of prolactin, leukopenia (without agranulocytosis), and 
decrease the seizure threshold. Olanzapine carries a lower risk of episodes of Parkinsonism, 
dystonia and tardive dyskinesia.  
Quetiapine has clozapine similar profile, with a moderate affinity to D2 receptors and 
moderate-intense to 5HT2 serotoninergic repceptors. It is a partial agonist of 5HT1A 
receptors, which increase dopamine concentrations in mesocortical area, improving 
cognitive and negative schizophrenics symptoms.  
It produces few extrapyramidal symptoms and risk of tardive dyskinesia. These features 
make it the choice for the treatment of disorders of behavior in Parkinson's patients and 
patients treated within the framework of liaison psychiatry. Undesirable side effects are 
sedation and weight gain with alteration of glucose and lipid metabolism. However, it does 
not produce a significant increase in prolactin levels 
Quetiapine is metabolized in the liver by the cytochrome P450 3A4 enzyme, so drugs that 
produce a large inhibition of the isozyme (such as erythromycin) may increase their serum 
levels. Carbamazepine and phenytoin reduce levels of quetiapine as behave as enzyme 
inducers forcing adjust the dose to avoid possible relapse in patients who are 
simultaneously being treated with these drugs. 
Ziprasidone has high antagonism of 5HT2A, 5HT1D, 5HT2C serotoninergic and D2 
dopaminergic receptors. It has a low tendency to cause extrapyramidal effects because their 




Ziprasidone is metabolized in the liver by isoenzymes 3A4 of the P450, through a process of 
reduction effect of aldehyde oxidase. Its bioavailability increase when ziprasidone is 
administrated along with food. This compound intensely joins proteins and has not been 
shown to see displaced by other drugs with similar affinity. 
In addition to the indication in the acute treatment and maintenance of schizophrenia, given 
that it exists in injectable presentation, you can use in patients who do not collaborate in the 
taking of oral medication and in emergency situations characterized by agitation or serious 
behavior disorders. 
It is the antipsychotic with a lesser influence upon weight. The most frequent adverse effects 
are drowsiness, insomnia, constipation and nausea. Normally these effects tend to be 
temporary and, in general, ziprasidone is well tolerated. 
Amisulpiride: While it has no affinity for subtypes D1, D4 and D5 presents affinity on the 
D2 and D3 of the dopamine receptor subtypes. Unlike other AP, it has no affinity for 
serotonergic, adrenergic, cholinergic and H1 histaminergic receptors. 
An important feature that distinguishes it from other antipsychotic group is its low liver 
metabolism which must be taken into account within the framework of the psychiatric 
consultations when treating patients with liver failure that you do not need to adjust the 
dose. Their degree of plasma protein binding is low (around 16%). The drug is eliminated 
through the kidneys in 90% during the first 24 hours. In patients with severe kidney disease 
dosages should be reduced. 
Adverse reactions that occur most often are: insomnia, anxiety and even turmoil 
psychomotor, which can appear at the beginning of treatment and declining thereafter. As 
with other antipsychotics the amisulpiride can reduce the seizure threshold, which requires 
a control of treatment in patients with a history of seizures. A reversible increase of plasma 
levels of prolactin can be seen. No drug interactions with this compound have been 
described so far. 
Aripiprazol: This is a partial agonist of dopamine receptor D2, D3 and serotonergic 5HT1A 
and works as a 5HT2A serotonin receptor antagonist. 
In some situations aripiprazole would act as an antagonist and in others as agonist. That 
way there would be a self-regulation of dopamine, so the drug would act as antidopamine 
at the mesolimbic via and as prodopamine at the mesocortical via, without significantly 
affecting the nigroestriada or the tuberoinfundibular paths. 
Its theoretical advantages would be improvement in cognitive aspects and motor effects in 
the long term such as tardive dyskinesia. It is metabolized in the liver by isoenzymes of the 
cytochrome P450 3A4, and 2D6 so that compounds which interact at this level 
(carbamazepine, quinidine, ketoconazole, fluoxetine and paroxetine) could alter the plasma 
concentrations of aripiprazole. It is a well tolerated drug that does not affect significantly the 
weight or the levels of prolactin for patients, or metabolism of glucose and lipids. The most 
frequent side effect is drowsiness. 
Paliperidone: It is an active metabolite of risperidone. It presents a great affinity for 
5HT2A receptors and moderated by the D2 receptors, with a lower lipophilicity than 
risperidone. The pharmacological activity of this compound is similar to other high power 
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SGA. The receptor binding profile is similar to risperidone and ziprasidone, though unlike 
risperidone and other SGA it has a low rate of hepatic metabolism. Its adverse effects are 
similar to the risperidone although they produce a greater increase in the rate of 
hyperprolactinemia. 
4. Lithium and anticonvulsants 
Although there is no agreed definition, stabilizer of the mood would be the drug with the 
potential to be used as monotherapy in acute bipolar disorder (BD) phases and its 
prophylaxis.  
Lithium: Its mechanism of action is not clearly established, although it competes with other 
monovalent cations, such as sodium, altering metabolism and the action of certain 
neurotransmitters such as serotonin and Catecholamines. 
Indications: bipolar and recurrent major depressive disorders. It has a narrow therapeutic 
range (between 0,60 and 1.5 mEq/L). 
Contraindications Leukemia for possible reactivation. 
Side effects: are frequent, could be severe and usually related to doses. Initial symptoms are 
nausea, diarrhea, abdominal pain, dizziness, muscle weakness, fine trembling hands. It can 
precipitate a rhenal Diabetes Insipidus (polyuria and polydipsia), which can lead to 
dehydration and increased toxicity. Hypothyroidism has benn described in prolonged 
treatments, it is recommended to carry out periodic checks on the thyroid function. Other: 
increase in weight, swelling, leukocytosis, hypercalcemia due to hyperparathyroidism, 
hipermagnesemia. 
Interactions: the thiazides may reduce renal excretion of lithium and may increase its 
toxicity. NSAIDs: reduce renal excretion of lithium and increase the risk of toxicity, 
particularly indomethacin. The analgesic of choice if needed would be ASA and 
acetaminophen. Carbamazepine: have described cases of serious neurotoxicity. ACE 
Inhibitors: can decrease renal excretion of lithium in patients of advanced age, renal failure 
or hypovolemia. Selective serotonin reuptake inhibitors: risk of serotonin syndrome. 
Valproate: It facilitates the action of GABA, a neural inhibitor neurotransmitter, and as a 
result decreases neuronal excitability.  
Indications Epilepsy, Infantile febrile convulsions, Bipolar disorder 
It is postulated that there is a good correlation between the pharmacological effect and the 
plasma concentration, with a margin of optimal concentration of 50-150 mg/l. Some patients 
respond to concentrations outside this interval. Valproic acid is hepatotoxic. 
Side effects are relatively frequent and usually transient or dose-related adverse effects. 
Gastrointestinal: nausea and vomiting, polyphagia with weight gain; rarely pancreatitis; 
increase of liver enzymes, hepatitis and hepatic encephalopathy syndrome (Reye in children), 
has described particularly in the first months of treatment. Nervous system: tremor and 
headache (usually the first sign of overdose), drowsiness, ataxia, confusion, dementia. 
Hematological: idiosyncratic depression of the bone marrow with thrombocytopenia, 
leukopenia and agranulocytosis, not related to the dose in nature. Skin: idiosyncratic character. 
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Ziprasidone is metabolized in the liver by isoenzymes 3A4 of the P450, through a process of 
reduction effect of aldehyde oxidase. Its bioavailability increase when ziprasidone is 
administrated along with food. This compound intensely joins proteins and has not been 
shown to see displaced by other drugs with similar affinity. 
In addition to the indication in the acute treatment and maintenance of schizophrenia, given 
that it exists in injectable presentation, you can use in patients who do not collaborate in the 
taking of oral medication and in emergency situations characterized by agitation or serious 
behavior disorders. 
It is the antipsychotic with a lesser influence upon weight. The most frequent adverse effects 
are drowsiness, insomnia, constipation and nausea. Normally these effects tend to be 
temporary and, in general, ziprasidone is well tolerated. 
Amisulpiride: While it has no affinity for subtypes D1, D4 and D5 presents affinity on the 
D2 and D3 of the dopamine receptor subtypes. Unlike other AP, it has no affinity for 
serotonergic, adrenergic, cholinergic and H1 histaminergic receptors. 
An important feature that distinguishes it from other antipsychotic group is its low liver 
metabolism which must be taken into account within the framework of the psychiatric 
consultations when treating patients with liver failure that you do not need to adjust the 
dose. Their degree of plasma protein binding is low (around 16%). The drug is eliminated 
through the kidneys in 90% during the first 24 hours. In patients with severe kidney disease 
dosages should be reduced. 
Adverse reactions that occur most often are: insomnia, anxiety and even turmoil 
psychomotor, which can appear at the beginning of treatment and declining thereafter. As 
with other antipsychotics the amisulpiride can reduce the seizure threshold, which requires 
a control of treatment in patients with a history of seizures. A reversible increase of plasma 
levels of prolactin can be seen. No drug interactions with this compound have been 
described so far. 
Aripiprazol: This is a partial agonist of dopamine receptor D2, D3 and serotonergic 5HT1A 
and works as a 5HT2A serotonin receptor antagonist. 
In some situations aripiprazole would act as an antagonist and in others as agonist. That 
way there would be a self-regulation of dopamine, so the drug would act as antidopamine 
at the mesolimbic via and as prodopamine at the mesocortical via, without significantly 
affecting the nigroestriada or the tuberoinfundibular paths. 
Its theoretical advantages would be improvement in cognitive aspects and motor effects in 
the long term such as tardive dyskinesia. It is metabolized in the liver by isoenzymes of the 
cytochrome P450 3A4, and 2D6 so that compounds which interact at this level 
(carbamazepine, quinidine, ketoconazole, fluoxetine and paroxetine) could alter the plasma 
concentrations of aripiprazole. It is a well tolerated drug that does not affect significantly the 
weight or the levels of prolactin for patients, or metabolism of glucose and lipids. The most 
frequent side effect is drowsiness. 
Paliperidone: It is an active metabolite of risperidone. It presents a great affinity for 
5HT2A receptors and moderated by the D2 receptors, with a lower lipophilicity than 
risperidone. The pharmacological activity of this compound is similar to other high power 
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SGA. The receptor binding profile is similar to risperidone and ziprasidone, though unlike 
risperidone and other SGA it has a low rate of hepatic metabolism. Its adverse effects are 
similar to the risperidone although they produce a greater increase in the rate of 
hyperprolactinemia. 
4. Lithium and anticonvulsants 
Although there is no agreed definition, stabilizer of the mood would be the drug with the 
potential to be used as monotherapy in acute bipolar disorder (BD) phases and its 
prophylaxis.  
Lithium: Its mechanism of action is not clearly established, although it competes with other 
monovalent cations, such as sodium, altering metabolism and the action of certain 
neurotransmitters such as serotonin and Catecholamines. 
Indications: bipolar and recurrent major depressive disorders. It has a narrow therapeutic 
range (between 0,60 and 1.5 mEq/L). 
Contraindications Leukemia for possible reactivation. 
Side effects: are frequent, could be severe and usually related to doses. Initial symptoms are 
nausea, diarrhea, abdominal pain, dizziness, muscle weakness, fine trembling hands. It can 
precipitate a rhenal Diabetes Insipidus (polyuria and polydipsia), which can lead to 
dehydration and increased toxicity. Hypothyroidism has benn described in prolonged 
treatments, it is recommended to carry out periodic checks on the thyroid function. Other: 
increase in weight, swelling, leukocytosis, hypercalcemia due to hyperparathyroidism, 
hipermagnesemia. 
Interactions: the thiazides may reduce renal excretion of lithium and may increase its 
toxicity. NSAIDs: reduce renal excretion of lithium and increase the risk of toxicity, 
particularly indomethacin. The analgesic of choice if needed would be ASA and 
acetaminophen. Carbamazepine: have described cases of serious neurotoxicity. ACE 
Inhibitors: can decrease renal excretion of lithium in patients of advanced age, renal failure 
or hypovolemia. Selective serotonin reuptake inhibitors: risk of serotonin syndrome. 
Valproate: It facilitates the action of GABA, a neural inhibitor neurotransmitter, and as a 
result decreases neuronal excitability.  
Indications Epilepsy, Infantile febrile convulsions, Bipolar disorder 
It is postulated that there is a good correlation between the pharmacological effect and the 
plasma concentration, with a margin of optimal concentration of 50-150 mg/l. Some patients 
respond to concentrations outside this interval. Valproic acid is hepatotoxic. 
Side effects are relatively frequent and usually transient or dose-related adverse effects. 
Gastrointestinal: nausea and vomiting, polyphagia with weight gain; rarely pancreatitis; 
increase of liver enzymes, hepatitis and hepatic encephalopathy syndrome (Reye in children), 
has described particularly in the first months of treatment. Nervous system: tremor and 
headache (usually the first sign of overdose), drowsiness, ataxia, confusion, dementia. 
Hematological: idiosyncratic depression of the bone marrow with thrombocytopenia, 




 Liver function: recommended a special control of high-risk patients, including the 
epilepsy with combination therapy, and evaluate the liver function before treatment 
and for at least every six.  
 Discontinuation of treatment: the sudden suspension of the drug should be avoided 
because of the risk of seizures.  
 Pregnancy: category D of the FDA. Isolated cases of defects of the neural tube in 
newborn infants, especially in women with combination therapy have been described. 
It has been observed that the incidence is higher than with other antiepileptic drugs. It 
is recommended to assess each case carefully, because the risk of the treatment is lower 
than the derivative of precipitate seizures. In any case, it is recommended to take 
supplements of folic acid before conception and during pregnancy to prevent these 
defects. 
 Lactation: it is excreted in breast milk in a proportion that does not seem to pose risk to 
the infant. It is compatible, although some cases of thrombocytopenia associated with 
valproic in an infant has been described. 
Interactions Carbamazepine, phenytoin, and Phenobarbital: the interaction is complex and 
unpredictable. Polytherapy recommends adjusting the dosage on plasma levels and the 
patient's clinical status. Lamotrigine: valproic increases lamotrigine plasma levels by 
inhibiting its metabolism. In addition, severe toxic reactions (rash, tremors) have been 
described. It is recommended halving the dose of lamotrigine. 
Carbamazepine: It inhibits the voltage-dependent sodium channels of the CNS neurons, 
reducing neuronal excitability of the epileptic focus. It also has analgesic and antimaniac 
properties. 
Indications: Epilepsy, Trigeminal neuralgia, Bipolar disorder and potential use in impulsive 
disorder, addiction and personality disorders. 
Hematological, hepatic, renal and cardiac functions and electrolytes should be explored 
before starting treatment. Plasma levels are: optimum plasma concentration 6 - 12 mg/L in 
monotherapy and 4 - 8 mg/L in combination therapy. 
Contraindications: A history of depression of the bone marrow, Atrioventricular 
conduction disturbances, Porphyria due to risk of exacerbation of disease.  
Adverse effects are relatively frequent (up to 50% of patients) and generally related to the 
dose. 
 Nervous system: drowsiness, dizziness, headache, blurred vision and dyplopia, nausea 
and vomiting, confusion and agitation (in older people). 
 Hematological: idiosyncratic character, unrelated with the dose. Leukopenia, 
thrombocytopenia, agranulocytosis, and rare cases of fatal aplastic anemia has been 
occasionally described.  
 Skin: idiosyncratic character. Regard rash, rarely Stevens-Johnson Syndrome.  
 Other: hyponatremia, urinary retention, impotence, proteinuria, glycosuria, peripheral 
neuropathy, paresthesias, tinnitus, alopecia. 
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Precautions  
 Liver failure: increases the risk of toxicity because the drug is eliminated mostly by this 
route. It is recommended to carry out periodic checks on the liver function.  
 Renal insufficiency: increases the risk of toxicity because the active metabolite is 
eliminated through the kidneys. It should adjust the dose according to the functional 
level.  
 Heart failure: can worsen and cause arrhythmia and fluid retention.  
 Blood disorders: increases the risk of aplastic anemia or agranulocytosis. It is 
recommended to carry out periodic checks on hemogram.  
 Alcohol: it should be avoided because it induces hepatic metabolism of the drug and is 
epileptogenic  
 Suspension of the treatment: the sudden suspension should be avoided because there is 
a risk of seizure. 
 Pregnancy: category C of the FDA. Although isolated cases of abnormalities in 
newborns have been described, it is recommended not to suspend the antiepileptic 
treatment unless the risk of seizures is low, because the risk of the treatment is lower 
than the derivate of precipitate seizures.  
 Breastfeeding: it is excreted in breast milk in a proportion that does not seem to pose 
risk to the infant. It is compatible, although at high doses there is risk of liver disease in 
infant.  
 Geriatrics: it is recommended to use lower initial doses, usually half of it and adjust 
according to plasma level. 
Interactions: With Phenytoin, valproic acid the interaction is complex, because both can 
induce the metabolism of the other. Occasionally neurotoxicity can appear with lithium.  
Oxcarbazepine: It is a carbamazepine analog, and its indications are partial seizures with or 
without secondary generalization, bipolar disorder and other potential uses in psychiatry as 
carbamazepine.  
Side effects:  
 Nervous system: frequently, drowsiness, headache, and dizziness. Also nystagmus, 
Vertigo. Occasionally ataxia, agitation, difficulty in concentration.  
 Gastrointestinal: frequently, nausea and vomiting. Occasional constipation, diarrhea, 
and abdominal pain. Occasionally increase in liver transaminases 
 Skin: rash, acne, alopecia.  
 Eye: frequently diplopia, blurred vision.  
 Hyponatremia: it can be severe, especially for elderly, renal failure or treatment with 
diuretics. 
Special situations:  
 Suspension of the treatment: the sudden suspension should be avoided because it can 
cause seizures.  
 Pregnancy: category C of the FDA. Malformations in animals have been described but 
there is no information in humans.  
 Breastfeeding: Oxcarbazepine and its active metabolite are largely excreted in breast 




 Liver function: recommended a special control of high-risk patients, including the 
epilepsy with combination therapy, and evaluate the liver function before treatment 
and for at least every six.  
 Discontinuation of treatment: the sudden suspension of the drug should be avoided 
because of the risk of seizures.  
 Pregnancy: category D of the FDA. Isolated cases of defects of the neural tube in 
newborn infants, especially in women with combination therapy have been described. 
It has been observed that the incidence is higher than with other antiepileptic drugs. It 
is recommended to assess each case carefully, because the risk of the treatment is lower 
than the derivative of precipitate seizures. In any case, it is recommended to take 
supplements of folic acid before conception and during pregnancy to prevent these 
defects. 
 Lactation: it is excreted in breast milk in a proportion that does not seem to pose risk to 
the infant. It is compatible, although some cases of thrombocytopenia associated with 
valproic in an infant has been described. 
Interactions Carbamazepine, phenytoin, and Phenobarbital: the interaction is complex and 
unpredictable. Polytherapy recommends adjusting the dosage on plasma levels and the 
patient's clinical status. Lamotrigine: valproic increases lamotrigine plasma levels by 
inhibiting its metabolism. In addition, severe toxic reactions (rash, tremors) have been 
described. It is recommended halving the dose of lamotrigine. 
Carbamazepine: It inhibits the voltage-dependent sodium channels of the CNS neurons, 
reducing neuronal excitability of the epileptic focus. It also has analgesic and antimaniac 
properties. 
Indications: Epilepsy, Trigeminal neuralgia, Bipolar disorder and potential use in impulsive 
disorder, addiction and personality disorders. 
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dose. 
 Nervous system: drowsiness, dizziness, headache, blurred vision and dyplopia, nausea 
and vomiting, confusion and agitation (in older people). 
 Hematological: idiosyncratic character, unrelated with the dose. Leukopenia, 
thrombocytopenia, agranulocytosis, and rare cases of fatal aplastic anemia has been 
occasionally described.  
 Skin: idiosyncratic character. Regard rash, rarely Stevens-Johnson Syndrome.  
 Other: hyponatremia, urinary retention, impotence, proteinuria, glycosuria, peripheral 
neuropathy, paresthesias, tinnitus, alopecia. 
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Precautions  
 Liver failure: increases the risk of toxicity because the drug is eliminated mostly by this 
route. It is recommended to carry out periodic checks on the liver function.  
 Renal insufficiency: increases the risk of toxicity because the active metabolite is 
eliminated through the kidneys. It should adjust the dose according to the functional 
level.  
 Heart failure: can worsen and cause arrhythmia and fluid retention.  
 Blood disorders: increases the risk of aplastic anemia or agranulocytosis. It is 
recommended to carry out periodic checks on hemogram.  
 Alcohol: it should be avoided because it induces hepatic metabolism of the drug and is 
epileptogenic  
 Suspension of the treatment: the sudden suspension should be avoided because there is 
a risk of seizure. 
 Pregnancy: category C of the FDA. Although isolated cases of abnormalities in 
newborns have been described, it is recommended not to suspend the antiepileptic 
treatment unless the risk of seizures is low, because the risk of the treatment is lower 
than the derivate of precipitate seizures.  
 Breastfeeding: it is excreted in breast milk in a proportion that does not seem to pose 
risk to the infant. It is compatible, although at high doses there is risk of liver disease in 
infant.  
 Geriatrics: it is recommended to use lower initial doses, usually half of it and adjust 
according to plasma level. 
Interactions: With Phenytoin, valproic acid the interaction is complex, because both can 
induce the metabolism of the other. Occasionally neurotoxicity can appear with lithium.  
Oxcarbazepine: It is a carbamazepine analog, and its indications are partial seizures with or 
without secondary generalization, bipolar disorder and other potential uses in psychiatry as 
carbamazepine.  
Side effects:  
 Nervous system: frequently, drowsiness, headache, and dizziness. Also nystagmus, 
Vertigo. Occasionally ataxia, agitation, difficulty in concentration.  
 Gastrointestinal: frequently, nausea and vomiting. Occasional constipation, diarrhea, 
and abdominal pain. Occasionally increase in liver transaminases 
 Skin: rash, acne, alopecia.  
 Eye: frequently diplopia, blurred vision.  
 Hyponatremia: it can be severe, especially for elderly, renal failure or treatment with 
diuretics. 
Special situations:  
 Suspension of the treatment: the sudden suspension should be avoided because it can 
cause seizures.  
 Pregnancy: category C of the FDA. Malformations in animals have been described but 
there is no information in humans.  
 Breastfeeding: Oxcarbazepine and its active metabolite are largely excreted in breast 
milk. Although the effects on the infant are unknown, its use is not recommended.  
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 Renal insufficiency: half of the initial dose is recommended in case of serious failure 
and then adjust the dose more slowly 
Lamotrigine: It reduces the excitability of neuronal inhibitor dependent sodium channels 
and blocks the release of glutamate. Its indications are epilepsy, Lennox-Gastaut syndrome 
and bipolar disorder 
Side effects: They are relatively common, while in most cases these effects are minimized if 
the dose is gradually increased. It can produce headache, dizziness and drowsiness; nausea 
and vomiting, and abdominal pain; dyplopia, nystagmus, arthralgia, sore back, depression 
of the bone marrow (anemia, leukopenia, thrombocytopenia and associated infections) and 
dysmenorrhoea. 
Special situations:  
 Liver failure: increases the risk of toxicity because the drug is eliminated mostly by this 
route. Initial and maintenance doses should be reduced typically in moderate failure to 
50% and 75% in the event of serious failure.  
 Pregnancy: cat.C of the FDA. There has been an increase in the risk of oral fissure.  
 Lactation: excreted in milk, can reach therapeutic concentrations in the infant.  
Gabapentine: It is structurally similar to GABA with antiepileptic and analgesic action. It 
facilitates neural inhibitory action of this neurotransmitter, and consequently decreases the 
epileptic crises responsible of neuronal excitability. It is eliminated by renal excretion with a 
half-life of 5-7 hours, unlike traditional antiepileptic, eliminated by hepatic metabolism. 
Special situations:  
 Renal insufficiency: due to it is removed by this way, it is important to adjust the dose 
to the functional level.  
 Special activities: the onset of drowsiness and dizziness before driving or operate 
dangerous machinery must be controlled.  
 Pregnancy: category C of the FDA.  
 Lactation: it is excreted in breast milk but unknown effects on the infant. Caution is 
advised. 
Topiramate: It inhibits the voltage sodium dependent channels implicated in the spread of 
the epileptic focus, it reduces the excitatory action of glutamate. It is eliminated by renal 
excretion with a half-life of 20-24 hours. 
Indications: Epilepsy in adults and children (monotherapy or combination therapy), 
Lennox-Gastaut syndrome, in combination therapy. Migraine prophylaxis in patients. 
Bulimia with overweight and alcoholism, binge disorder and bipolar disorder 
Side effects: are frequent but generally moderate. They can be minimized by gradually 
increasing the dose and usually resolve spontaneously over treatment or when the dose is 
reduced. Nervous system: 10-30% of patients can suffer from fatigue and sleepiness and 
paresthesias at the beginning of treatment, although they are not usually serious. It also 
produces ataxia, nervousness, confusion, loss of concentration, anxiety, depression, 
cognitive disturbances. Visual: the first month of treatment may be acute nearsightedness, 
diplopia and/or nystagmus, not related to the dose, which can lead to glaucoma. 
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Gastrointestinal: abdominal pain, nausea, anorexia, taste alterations, gingivitis. Other: anorexia 
and weight loss associated with a diuretic effect (very common) and nephrolithiasis. 
Special situations: there is risk of formation of nephrolithiasis in patients with antecedents. 
It is necessary to maintain adequate hydration during the treatment. As it is excreted 
through the kidneys, in renal failure doses must be reduced up to 50%.  
Pregabaline: It is structurally similar to GABA, with antiepileptic, anxiolytic and analgesic 
action. It facilitates neural inhibitory action of this neurotransmitter and consequently 
decreases the epileptic crises. 
Indications: Treatment of adult central and peripheral neuropathic pain. Epilepsy in adults: 
combined treatment of partial seizures with or without secondary generalization. Anxiety 
disorders in adults. 
5. Benzodiacepines 
Benzodiacepines (BZD) are CNS depressors with anxiolytic and hypnotic-sedative 
properties, and antiepileptic and muscle relaxing effects. They are more secure in overdoses 
than barbiturates and other sedative drugs. They have similar action mechanism and side 
effects, and differ in onset time and activity duration, which is relevant in treatment and 
indications.  
Absorption in the gastrointestinal tract is very good, especially on an empty stomach, so that 
the oral via is the choice for these agents. Diazepam and clorazepate are absorbed more 
quickly than the others. Other routes of administration are less recommended and should be 
reserved only for cases of urgency: the intramuscular absorption is erratic and intravenous 
absorption can be dangerous. The BZD are lipophilic agents, so cross the blood-brain barrier 
well, exerting their action at the level of the central nervous system quickly. They also cross 
the placental barrier and are excreted through breast milk. Furthermore, their solubility 
makes that most of them are accumulated, gradually, in body fat resulting in a high volume 
of distribution, which directly influences the duration of the action. 
The biotransformation is at hepatic level through a process of oxidation and conjugation. 
Some BZD (such as the diacepam or cloracepato) have pharmacologically active metabolites 
which, sometimes, even have longer life than the active ingredient.  
In addition, should take into account that in the healthy elderly these processes are altered, 
so you have to choose BZD not metabolized by microsomal liver enzymes and without 
active metabolites as oxazepam or lorazepam. They are eliminated on a majority basis 
through the kidneys (70-90%), after their hepatic metabolism. The rest are eliminated 
through the stool or bile. 
All BZD’s action is at CNS, by their ability to enhance the inhibitory actions of GABA, 
stimulating the GABA-A receptor. It is believed that their anxiolytic action is due to the 
inhibitory action on neurons in the limbic system, including the amygdala, and serotonergic 
and noradrenergic neurons of the CNS. The fact that ethanol, barbiturates, and BZD have 
similar actions on the same receptor explains their drug synergy (and therefore the danger 
of the combined overdose) and its cross tolerance. This last property is used in the 
detoxification of alcoholics with BZD. 
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half-life of 5-7 hours, unlike traditional antiepileptic, eliminated by hepatic metabolism. 
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 Special activities: the onset of drowsiness and dizziness before driving or operate 
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Topiramate: It inhibits the voltage sodium dependent channels implicated in the spread of 
the epileptic focus, it reduces the excitatory action of glutamate. It is eliminated by renal 
excretion with a half-life of 20-24 hours. 
Indications: Epilepsy in adults and children (monotherapy or combination therapy), 
Lennox-Gastaut syndrome, in combination therapy. Migraine prophylaxis in patients. 
Bulimia with overweight and alcoholism, binge disorder and bipolar disorder 
Side effects: are frequent but generally moderate. They can be minimized by gradually 
increasing the dose and usually resolve spontaneously over treatment or when the dose is 
reduced. Nervous system: 10-30% of patients can suffer from fatigue and sleepiness and 
paresthesias at the beginning of treatment, although they are not usually serious. It also 
produces ataxia, nervousness, confusion, loss of concentration, anxiety, depression, 
cognitive disturbances. Visual: the first month of treatment may be acute nearsightedness, 
diplopia and/or nystagmus, not related to the dose, which can lead to glaucoma. 
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Gastrointestinal: abdominal pain, nausea, anorexia, taste alterations, gingivitis. Other: anorexia 
and weight loss associated with a diuretic effect (very common) and nephrolithiasis. 
Special situations: there is risk of formation of nephrolithiasis in patients with antecedents. 
It is necessary to maintain adequate hydration during the treatment. As it is excreted 
through the kidneys, in renal failure doses must be reduced up to 50%.  
Pregabaline: It is structurally similar to GABA, with antiepileptic, anxiolytic and analgesic 
action. It facilitates neural inhibitory action of this neurotransmitter and consequently 
decreases the epileptic crises. 
Indications: Treatment of adult central and peripheral neuropathic pain. Epilepsy in adults: 
combined treatment of partial seizures with or without secondary generalization. Anxiety 
disorders in adults. 
5. Benzodiacepines 
Benzodiacepines (BZD) are CNS depressors with anxiolytic and hypnotic-sedative 
properties, and antiepileptic and muscle relaxing effects. They are more secure in overdoses 
than barbiturates and other sedative drugs. They have similar action mechanism and side 
effects, and differ in onset time and activity duration, which is relevant in treatment and 
indications.  
Absorption in the gastrointestinal tract is very good, especially on an empty stomach, so that 
the oral via is the choice for these agents. Diazepam and clorazepate are absorbed more 
quickly than the others. Other routes of administration are less recommended and should be 
reserved only for cases of urgency: the intramuscular absorption is erratic and intravenous 
absorption can be dangerous. The BZD are lipophilic agents, so cross the blood-brain barrier 
well, exerting their action at the level of the central nervous system quickly. They also cross 
the placental barrier and are excreted through breast milk. Furthermore, their solubility 
makes that most of them are accumulated, gradually, in body fat resulting in a high volume 
of distribution, which directly influences the duration of the action. 
The biotransformation is at hepatic level through a process of oxidation and conjugation. 
Some BZD (such as the diacepam or cloracepato) have pharmacologically active metabolites 
which, sometimes, even have longer life than the active ingredient.  
In addition, should take into account that in the healthy elderly these processes are altered, 
so you have to choose BZD not metabolized by microsomal liver enzymes and without 
active metabolites as oxazepam or lorazepam. They are eliminated on a majority basis 
through the kidneys (70-90%), after their hepatic metabolism. The rest are eliminated 
through the stool or bile. 
All BZD’s action is at CNS, by their ability to enhance the inhibitory actions of GABA, 
stimulating the GABA-A receptor. It is believed that their anxiolytic action is due to the 
inhibitory action on neurons in the limbic system, including the amygdala, and serotonergic 
and noradrenergic neurons of the CNS. The fact that ethanol, barbiturates, and BZD have 
similar actions on the same receptor explains their drug synergy (and therefore the danger 
of the combined overdose) and its cross tolerance. This last property is used in the 
detoxification of alcoholics with BZD. 
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5.1 Other hypnotics/anxiolytics agents 
Zolpidem, zopiclone and zaleplon: Three non-benzodiacepinic preparations that interact 
with a smaller subset of receptor GABA-A (type 1), therefore presenting crossed reactivity 
with these to some extent. It seems that by their more selective binding, they are effective for 
short-term insomnia treatment, but they lack significant muscle relaxing, anti-epileptic and 
anti-anxiety effects. They have lower risk of dependence and abstinence than BZD. 
Buspirone: It is believed that it exerts anxiolytic effect acting as a partial agonist of the 5-
HT1A receptors (of serotonin). Its advantages include the absence of induced physical 
dependence and withdrawal, does not interact with alcohol or other CNS depressants, has 
no sedative effect and amnesiante, does not diminish the psychomotor performance and not 
depressed respiration (being useful in the elderly and patients with respiratory problems). 
Its main drawback is the delay in the onset of the anxiolytic effect (up to 2 weeks) and its 
ineffectiveness in patients previously treated with BZD. 
5.2 Adverse effects and contraindications  
The most frequent adverse effects are: drowsiness, sedation and psychomotor performance. 
Anterograde amnesia is associated with the use of more powerful BZD. Very rarely allergic 
reactions or a paradoxical increase in aggressiveness have been described. They can produce 
respiratory deficiency in patients with chronic obstructive pulmonary disease or sleep 
apnea. They should be administered with caution in patients with substance abuse, liver 
disease, kidney disease, Porphyria, depression from CNS or myasthenia gravis. Despite 
being one of the tools most often used in cases of suicidal ideation, Benzodiazepines alone 
are relatively safe in overdose (especially as compared with other sedatives like 
barbiturates). In addition, the fact of having selective antagonists of the benzodiacepinic 
receptor, such as Flumazenil, limited the dangerousness of these poisonings. The most 
dangerous effects occur when administered concomitantly with other sedatives such as 
alcohol (in these cases can occur excessive sleepiness, disinhibition and respiratory 
depression, as well as severe cognitive deficits).  
Buspirone, zolpidem, zopiclone and zaleplon can produce nausea, dizziness and headaches, and 
except the first, others can also produce drowsiness and certain anterograde amnesia. 
There are few absolute contraindications for BZD: allergic reactions to the drug and angle 
closure glaucoma. Other related are: severe apnea sleep, first trimester of pregnancy, 
respiratory failure and cognitive disorders.  
5.3 Tolerance and dependence 
All BZD may exhibit properties of tolerance and dependence. However, there is to be noted that 
they do not constitute a group of drugs of addictive nature, as with the characteristics of drugs 
of abuse have no place tolerance is defined as the increasingly low intense effects production, 
maintaining the same dose of drugs. The use of BZD at long term can cause a phenomenon of 
tolerance to their pharmacological effects, it is clearer to the hypnotic, sedative effect and 
impaired psychomotor performance (1-2 weeks tolerance). On the other hand, tolerance to the 
anxiolytic effects and mnesic is very unlikely, and when it appears, at very late onset. 
Most antianxiety agents give after their sudden suspension, a series of symptoms of withdrawal 
or "deletion syndrome" which usually correspond to the image in mirror of its therapeutic effects  
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5.4 Clinical indications 
Anxiety, insomnia, depression, alcohol deshabituation. Although Benzodiazepines are 
marketed for other indications (such as fluracepam, temacepam or triazolam for insomnia, 
or diazepam for anxiety) is likely all drugs of this class to share most of their therapeutic 
properties. The indications for which they are adopted reflect many times commercial 
decisions rather than a rational therapeutic. It is best to choose the drug based on differences 
in pharmacokinetic and power. 
5.5 Special situations 
Pregnancy and breastfeeding: BZD cross the placental barrier and GABA is involved in the 
reorganization of the massif of the palate. There are studies in which there has been an 
increase of teratogenia in pregnant women treated with chlordiazepoxide during the first 
quarter and retrospective studies and cases in which noted an increase in risk of cleft palate 
and cleft lip associated with the use of BZD by the mother.  
 Syndrome of the hypotonic newborn: depression of the CNS, with hypotonia, lethargy, 
weak suction and respiratory depression.  
 Neonatal abstinence syndrome: hyperactivity, irritability, and hypertonia. 
BZD are excreted in breast milk. Infants metabolize them slowly, so it is possible the 
accumulation and toxicity, with lethargy, feeding difficulty and weight loss as well as 
withdrawal symptoms in the infant. For this reason, and despite the fact that the 
plasma/milk proportions are low in some BZD is necessary the evaluation of risk-benefit 
from the establishment of breastfeeding. In case of need for treatment BZD in postpartum 
period, as a general rule will be necessary to resort to artificial feeding. 
Elderly: There is the need of a special caution in the treatment with BZD in this population 
due to there is increased sensitivity to the pharmacological action, there are deficiencies in 
the hepatic metabolization (reducing the reactions of phase I: oxidation) and possible 
decreases in renal elimination, increase in the amount of free medication for decrease in 
plasma proteins, increase in the volume of distribution with the possibility of accumulation. 
These cause an increase in side effects in this population: sedation, cognitive alterations and 
decline of the alert. There is an increase in the risk of falls and fractures and an increased 
risk of suffering from delirium, especially in treatments with long half life BZD. It is 
recommended a reduction of 30 to 50% of the doses, and the use of short half life BZD that 
are metabolized in phase II (glucuronidation) as oxazepam and lorazepam. 
Children and adolescents: There are few studies of effectiveness/security in concrete 
disorders, and there is risk of abuse/dependence and paradoxical reactions.  
Liver insuficience: Liver failure affects mainly the metabolic processes involving the 
cytochrome P450. So, there have been significant increases in the half-life of diazepam, 
chlordiazepoxide and its metabolites. Also, the metabolism of alprazolam, clobazam and 
diazepam and midazolam is affected significantly in cirrhosis, it would be advisable to drop 
doses in these BZD. BZD who suffer processes of glucuronidation (lorazepam, oxazepam 
and temazepam) are little affected in liver failure, being at low doses the choice treatment. 
Patients with liver failure are more sensitive to the sedative effects of BZD, and these may 
precipitate hepatic encephalopathy, so they are contraindicated in cases of serious-
preencefalopatic liver failure and hepatic encephalopathy. 
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Anterograde amnesia is associated with the use of more powerful BZD. Very rarely allergic 
reactions or a paradoxical increase in aggressiveness have been described. They can produce 
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marketed for other indications (such as fluracepam, temacepam or triazolam for insomnia, 
or diazepam for anxiety) is likely all drugs of this class to share most of their therapeutic 
properties. The indications for which they are adopted reflect many times commercial 
decisions rather than a rational therapeutic. It is best to choose the drug based on differences 
in pharmacokinetic and power. 
5.5 Special situations 
Pregnancy and breastfeeding: BZD cross the placental barrier and GABA is involved in the 
reorganization of the massif of the palate. There are studies in which there has been an 
increase of teratogenia in pregnant women treated with chlordiazepoxide during the first 
quarter and retrospective studies and cases in which noted an increase in risk of cleft palate 
and cleft lip associated with the use of BZD by the mother.  
 Syndrome of the hypotonic newborn: depression of the CNS, with hypotonia, lethargy, 
weak suction and respiratory depression.  
 Neonatal abstinence syndrome: hyperactivity, irritability, and hypertonia. 
BZD are excreted in breast milk. Infants metabolize them slowly, so it is possible the 
accumulation and toxicity, with lethargy, feeding difficulty and weight loss as well as 
withdrawal symptoms in the infant. For this reason, and despite the fact that the 
plasma/milk proportions are low in some BZD is necessary the evaluation of risk-benefit 
from the establishment of breastfeeding. In case of need for treatment BZD in postpartum 
period, as a general rule will be necessary to resort to artificial feeding. 
Elderly: There is the need of a special caution in the treatment with BZD in this population 
due to there is increased sensitivity to the pharmacological action, there are deficiencies in 
the hepatic metabolization (reducing the reactions of phase I: oxidation) and possible 
decreases in renal elimination, increase in the amount of free medication for decrease in 
plasma proteins, increase in the volume of distribution with the possibility of accumulation. 
These cause an increase in side effects in this population: sedation, cognitive alterations and 
decline of the alert. There is an increase in the risk of falls and fractures and an increased 
risk of suffering from delirium, especially in treatments with long half life BZD. It is 
recommended a reduction of 30 to 50% of the doses, and the use of short half life BZD that 
are metabolized in phase II (glucuronidation) as oxazepam and lorazepam. 
Children and adolescents: There are few studies of effectiveness/security in concrete 
disorders, and there is risk of abuse/dependence and paradoxical reactions.  
Liver insuficience: Liver failure affects mainly the metabolic processes involving the 
cytochrome P450. So, there have been significant increases in the half-life of diazepam, 
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diazepam and midazolam is affected significantly in cirrhosis, it would be advisable to drop 
doses in these BZD. BZD who suffer processes of glucuronidation (lorazepam, oxazepam 
and temazepam) are little affected in liver failure, being at low doses the choice treatment. 
Patients with liver failure are more sensitive to the sedative effects of BZD, and these may 
precipitate hepatic encephalopathy, so they are contraindicated in cases of serious-
preencefalopatic liver failure and hepatic encephalopathy. 
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Renal failure: When treating with BZD patients with renal failure is necessary to take into 
account: the degree of renal failure, the existence of active metabolites, whose clearance may 
be diminished and binding to plasma proteins. To avoid this risk, is preferable to the use of 
BZD without active metabolites in low doses. 
Respiratory failure: The BZDs, due to its CNS depressant effect, can reduce ventilatory 
response to hypoxia, so they must be used with caution in patients with COPD and are 
contraindicated in sleep apnea. 
Porphyria: The hepatic metabolism of BZD may enhance the synthesis of ALAsintetasa, 
giving rise to an increase of Porphyrin with exhacerbación of the disease. 
Dementia and delirium: Action on the CNS of BZD has been linked to cognitive 
impairment and their use in patients with dementia can precipitate delirium, so, as far as 
possible, it’s better to avoid their use, being preferable to the use of antipsychotics in low 
doses. In delirium, except for the secondary to abstinence from alcohol or benzodiazepines, 
it is necessary to avoid the use of BZD, especially those of long half life, as they may 
aggravate the confusional syndrome. 
Interactions: The main pharmacodynamic of BZD interactions occur with central nervous 
system depressant drugs (opioids, barbiturates, anticonvulsants, anesthetics, tricyclic 
antidepressants, central antihistamines, MAOIs, antipsychotic drugs and alcohol). In 
combination with these drugs, there is a strengthening of the depression of the CNS, which 
increased sedation, impaired psychomotor and respiratory depression. 
Pharmacokinetic interactions are those related to the absorption, fixation to plasma proteins, 
metabolism and excretion. BZD requiring metabolization by reactions of phase I are 
influenced by processes of inhibition and metabolic induction, unlike BZD who suffer 
glucoronización are hardly influenced. 
6. Drugs used in opioid addiction: Methadone  
Methadone is an opioid analgesic with an outstanding action on the mu receptor. In cases of 
opioid dependence methadone is useful for treatment of detoxification, maintenance, and 
harm reduction. 
Side effects: The most frequent are nausea, vomiting, constipation, sweating, sedation, 
euphoria, dependency and respiratory depression. In addition, it has a special impact effects 
on sexual function (decreased libido, decrease of serum levels of testosterone in men) and 
endocrine (deficit of production of ACTH and subsequent secondary hyposuprarrenalism 
cases). Other less common but important side effects are: urinary retention, agitation, 
drowsiness, headache, disturbance of sleep, confusion and psychotic symptoms. 
Special situations: Opioid analgesics are generally contraindicated in acute respiratory 
depression, obstructive respiratory processes and patients in treatment with opioid 
antagonists (naltrexone). They are also contraindicated or should be used with great caution 
in alcoholism, seizure disorders, head injuries and processes that have increased intracranial 
pressure. They must not be administered to patients in a coma. In patients with biliary 
disorders it’s usually recommended to avoid the use of opiates. Opioid analgesics should be 
administered with caution or dosage reduced in patients with: hypothyroidism, 
adrenocortical insufficiency, asthma, or decreased respiratory reserve, kidney or liver 
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failure, prostate hyperplasia, hypotension, shock, inflammatory or obstructive intestinal 
disorders and myasthenia gravis. The dose should be reduced in elderly or debilitated 
patients. Methadone can prolong cardiac QT interval, increasing the risk of torsades de 
pointes, which implies risk of sudden death.  
7. Stimulants 
It is a group of drugs that in addition to its use in hyperactivity (ADHD) and attention 
deficit disorder have been used in the treatment of resistant depression, and narcolepsy.  
Amphetamine is a sympathomimetic which facilitates the release of NA and dopamine. It 
has a strong stimulatory effect on the central nervous system (CNS), particularly with 
regard to the cerebral cortex 
Side effects: The most frequent are anxiety, agitation, and decrease in sleep. Sometimes, dry 
mouth, anorexia, colic and other gastrointestinal discomfort. They can also lead to 
headaches, dizziness, tremors, sweating, tachycardia, palpitations and elevation (sometimes 
decrease) of blood pressure. Serious adverse effects such as psychosis, arrhythmias, 
hyperthermia, rhabdomyolysis, and seizures, especially with toxic doses that in some cases 
are not necessarily high are described. There is reasonable evidence that stimulant 
medication, especially at high doses, inhibits growth moderately. There are indications of 
that part of the growth is recovered when the treatment is interrupted.  
Special situations: It is contraindicated in patients with cardiovascular disease, including 
hypertension moderate to severe, and in patients with hyperthyroidism, glaucoma, 
psychosis, or states of agitation. It is more likely abusive consumption in patients with a 
history of alcoholism or drug addiction. Amphetamines can trigger symptoms in patients 
with tics or Gilles de la Tourette syndrome.  
Methylphenidate: Methylphenidate is a stimulant of the central nervous system and an 
indirect sympathomimetic (inhibits the reuptake of norepinephrine and dopamine) with the 
same indications as dexamfetamine. It is indicated in Narcolepsy, ADHD and Treatment-
resistant depression. The most frequent adverse effects are similar to amphetamines.  
Modafinil is a "wakefulness Enhancer compound". It selectively activates the hypothalamus 
areas that regulate the vigilia-sueño cycle, although the exact mechanism of action is not 
known. It is indicated in narcolepsy, excessive daytime sleepiness adults, in ADHD 
improves attention and impulse control. Adverse effects on the CNS may give rise to 
nervousness, excitement, irritability, insomnia and anorexia, which rarely require the 
removal of the treatment. Also it has been associated with gastrointestinal disorders, such as 
nausea and abdominal pain, dry mouth, headache, and cardiovascular effects such as 
hypertension, palpitations and tachycardia. Modafinil is contraindicated in patients with 
hypertension of moderate to severe cardiac arrhythmias, it is not recommended in patients 
with a history of left ventricular hypertrophy or coronary alterations of the EKG, chest pain 
and prolapse of the mitral valve. 
8. Non-stimulant treatment of ADHD 
Atomoxetine is a selective inhibitor of the reuptake of norepinephrine used in the treatment 
of the attention deficit and hyperactivity disorder in adolescents and children from 6 years. 
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Renal failure: When treating with BZD patients with renal failure is necessary to take into 
account: the degree of renal failure, the existence of active metabolites, whose clearance may 
be diminished and binding to plasma proteins. To avoid this risk, is preferable to the use of 
BZD without active metabolites in low doses. 
Respiratory failure: The BZDs, due to its CNS depressant effect, can reduce ventilatory 
response to hypoxia, so they must be used with caution in patients with COPD and are 
contraindicated in sleep apnea. 
Porphyria: The hepatic metabolism of BZD may enhance the synthesis of ALAsintetasa, 
giving rise to an increase of Porphyrin with exhacerbación of the disease. 
Dementia and delirium: Action on the CNS of BZD has been linked to cognitive 
impairment and their use in patients with dementia can precipitate delirium, so, as far as 
possible, it’s better to avoid their use, being preferable to the use of antipsychotics in low 
doses. In delirium, except for the secondary to abstinence from alcohol or benzodiazepines, 
it is necessary to avoid the use of BZD, especially those of long half life, as they may 
aggravate the confusional syndrome. 
Interactions: The main pharmacodynamic of BZD interactions occur with central nervous 
system depressant drugs (opioids, barbiturates, anticonvulsants, anesthetics, tricyclic 
antidepressants, central antihistamines, MAOIs, antipsychotic drugs and alcohol). In 
combination with these drugs, there is a strengthening of the depression of the CNS, which 
increased sedation, impaired psychomotor and respiratory depression. 
Pharmacokinetic interactions are those related to the absorption, fixation to plasma proteins, 
metabolism and excretion. BZD requiring metabolization by reactions of phase I are 
influenced by processes of inhibition and metabolic induction, unlike BZD who suffer 
glucoronización are hardly influenced. 
6. Drugs used in opioid addiction: Methadone  
Methadone is an opioid analgesic with an outstanding action on the mu receptor. In cases of 
opioid dependence methadone is useful for treatment of detoxification, maintenance, and 
harm reduction. 
Side effects: The most frequent are nausea, vomiting, constipation, sweating, sedation, 
euphoria, dependency and respiratory depression. In addition, it has a special impact effects 
on sexual function (decreased libido, decrease of serum levels of testosterone in men) and 
endocrine (deficit of production of ACTH and subsequent secondary hyposuprarrenalism 
cases). Other less common but important side effects are: urinary retention, agitation, 
drowsiness, headache, disturbance of sleep, confusion and psychotic symptoms. 
Special situations: Opioid analgesics are generally contraindicated in acute respiratory 
depression, obstructive respiratory processes and patients in treatment with opioid 
antagonists (naltrexone). They are also contraindicated or should be used with great caution 
in alcoholism, seizure disorders, head injuries and processes that have increased intracranial 
pressure. They must not be administered to patients in a coma. In patients with biliary 
disorders it’s usually recommended to avoid the use of opiates. Opioid analgesics should be 
administered with caution or dosage reduced in patients with: hypothyroidism, 
adrenocortical insufficiency, asthma, or decreased respiratory reserve, kidney or liver 
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failure, prostate hyperplasia, hypotension, shock, inflammatory or obstructive intestinal 
disorders and myasthenia gravis. The dose should be reduced in elderly or debilitated 
patients. Methadone can prolong cardiac QT interval, increasing the risk of torsades de 
pointes, which implies risk of sudden death.  
7. Stimulants 
It is a group of drugs that in addition to its use in hyperactivity (ADHD) and attention 
deficit disorder have been used in the treatment of resistant depression, and narcolepsy.  
Amphetamine is a sympathomimetic which facilitates the release of NA and dopamine. It 
has a strong stimulatory effect on the central nervous system (CNS), particularly with 
regard to the cerebral cortex 
Side effects: The most frequent are anxiety, agitation, and decrease in sleep. Sometimes, dry 
mouth, anorexia, colic and other gastrointestinal discomfort. They can also lead to 
headaches, dizziness, tremors, sweating, tachycardia, palpitations and elevation (sometimes 
decrease) of blood pressure. Serious adverse effects such as psychosis, arrhythmias, 
hyperthermia, rhabdomyolysis, and seizures, especially with toxic doses that in some cases 
are not necessarily high are described. There is reasonable evidence that stimulant 
medication, especially at high doses, inhibits growth moderately. There are indications of 
that part of the growth is recovered when the treatment is interrupted.  
Special situations: It is contraindicated in patients with cardiovascular disease, including 
hypertension moderate to severe, and in patients with hyperthyroidism, glaucoma, 
psychosis, or states of agitation. It is more likely abusive consumption in patients with a 
history of alcoholism or drug addiction. Amphetamines can trigger symptoms in patients 
with tics or Gilles de la Tourette syndrome.  
Methylphenidate: Methylphenidate is a stimulant of the central nervous system and an 
indirect sympathomimetic (inhibits the reuptake of norepinephrine and dopamine) with the 
same indications as dexamfetamine. It is indicated in Narcolepsy, ADHD and Treatment-
resistant depression. The most frequent adverse effects are similar to amphetamines.  
Modafinil is a "wakefulness Enhancer compound". It selectively activates the hypothalamus 
areas that regulate the vigilia-sueño cycle, although the exact mechanism of action is not 
known. It is indicated in narcolepsy, excessive daytime sleepiness adults, in ADHD 
improves attention and impulse control. Adverse effects on the CNS may give rise to 
nervousness, excitement, irritability, insomnia and anorexia, which rarely require the 
removal of the treatment. Also it has been associated with gastrointestinal disorders, such as 
nausea and abdominal pain, dry mouth, headache, and cardiovascular effects such as 
hypertension, palpitations and tachycardia. Modafinil is contraindicated in patients with 
hypertension of moderate to severe cardiac arrhythmias, it is not recommended in patients 
with a history of left ventricular hypertrophy or coronary alterations of the EKG, chest pain 
and prolapse of the mitral valve. 
8. Non-stimulant treatment of ADHD 
Atomoxetine is a selective inhibitor of the reuptake of norepinephrine used in the treatment 
of the attention deficit and hyperactivity disorder in adolescents and children from 6 years. 
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Adverse effects described in patients in treatment with Atomoxetine include dyspepsia and 
other gastrointestinal disorders, anorexia and weight loss, fatigue, disturbances of sleep, 
irritability, and mood swings. Also hypertension, tachycardia, dizziness, cough, sinusitis or 
runny nose, bed wetting or urinary retention, decrease of libido and sexual dysfunction, 
rash, increased sweating and hot flashes. Rarely, hypersensitivity reactions occur. There 
have been some reports of serious hepatotoxicity. Atomoxetine is contraindicated in patients 
with glaucoma. It should be used with caution in patients with hypertension, tachycardia, or 
cerebrovascular or cardiovascular disease. Treatment with Atomoxetine should start with 
caution in patients with a history of seizures. There is a potential risk of seizures with 
Atomoxetine. 
9. Special situations 
9.1 Psychiatric drugs in pregnancy and lactation 
All psychotropic so far studied cross the placenta, most reach the amniotic fluid and almost 
all are eliminated through breast milk. 3-5% of the newborns have genetic malformations; 
65-70% by unknown factors, hereditary factors 12-25%, 10% by environmental factors 
(drugs, infections, diseases...) and 3% by direct exposure to drugs. Most studies suggest that 
the psychotropic drugs are not associated with a significantly increased risk of organic 
disgenesias. Congenital anomalies are not more frequent in a group of regular consumers of 
drugs compared with a control group. Perinatal mortality was similar in both groups (0.8% 
and 0.9%). It is essential to inform the patient of the potential risks of medication, obtain the 
informed consent of the patient, taking into account the ability and desire to tolerate the 
symptoms without drugs. 
Absortion Metabolism 
Decrease in the rate of gastric emptying. 
Reduction of intestinal motility. 
Increase in cardiac output.  
Changes in the activity of various liver enzymes 
Distribution Elimination 
Increase of blood flow in the tissues.  
Increase in plasma volume.  
Increase in the extracellular fluid volume. 
Increase in adipose tissue (nearly all 
psychotropic are highly fat-soluble).  
Changes in the concentration of some plasma 
proteins. 
Increase in the renal blood flow.  
Increased glomerular filtration rate. 
Table 1. Changes in drug metabolism during pregnancy 
The prescription of psychoactive drugs only must be made if the benefit (to mother) is 
greater than the risk (to the fetus). If possible, avoid all drugs (especially during the first 
trimester of pregnancy) and managing the minimum effective dose. It is preferable to use 
drugs already tested with good safety profile, than new drugs, with a theoretical more 
secure profile but not tested. Smaller than 1,500 molecular weight drugs can cross the 
placental barrier and potentially affect the fetus, but few have demonstrated teratogenic 
effects. It is important to provide contraceptive information to women in chronic treatment 
and review the treatment early in the pregnancy. 
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Due to changes in pharmacokinetic and pharmacodynamic factors during pregnancy, often 
different doses are needed (may be higher or lower) than in normal conditions to treat the 
symptoms properly. 
The intensity of fetal exposure to the psychotropic also depends on the placental 
transference: Type I or complete transference: the concentrations are quickly balanced 
between maternal and fetal compartments; Type II or excessive transference: Fetal drug 
concentrations are higher than the maternal ones; Type III or incomplete transference: Fetal 
concentrations are lower than the maternal ones. 
9.2 Elderly 
General elderly people have a health more fragile than other stages of life. They suffer from 
various diseases and receive different treatments, which leads to higher risk of adverse 
reactions. As a result of this overlap pharmacokinetics and pharmacodynamics changes in 
this age group and responses to treatments are different. Variations in therapeutic response 
and side effects and interactions, which are more frequent and more serious, result in more 
yatrogenia and worst compliance. 
Interactions in the elderly, drug interactions are between 3 and 5 times more frequent than 
in other stages of life. The elderly modifies the absorption process. Esophageal motility is 
reduced. The aclorhydria increases with age. Gastric motility and intestinal irrigation are 
reduced. But, in general, all these changes in the absorption are not very relevant from a 
clinical point of view.  
The majority of psychoactive drugs, except lithium, are lipophilic and go preferably to fatty 
tissue, including the brain. With age, albumin decreases and increases the proportion of free 
drug, increases the fat mass generally between 25-40%, it’s reduced lean mass and the 
proportion of body water, especially with relative increase in the extracellular intracellular 
water, which increases the volume of distribution of soluble drugs and decreases of the 
water-soluble. Clinically the relevance is moderate but it can extend drugs half-life. 
Old age significantly modifies the metabolism by loss of hepatic mass, decreased blood 
flow, lower microsomial enzyme activity and tendency to prolong the half-life. From the age 
of 65, hepatic perfusion is reduced in about one-third. 
With age, glomerular filtration and hepatic metabolism are reduced which leads to increase 
drug concentration and, consequently, increasing the therapeutic and toxic effect. It can be 
compensated reducing the dose or spacing this. Drugs with long half life tend to accumulate.  
Elders suffer almost always several concomitant pathologies so they receive the respective 
treatments. The majority of clinical trials have been developed in younger people. Receiving 
different products makes pharmacokinetic and pharmacodynamics interactions more 
frequent. It is common that an older is receives at least 6-8 drugs a day, each with its 
corresponding mechanism of action, side effects that join or therapeutic effects to be 
antagonized. In addition, it’s not exceptional self-medication through acquaintances or 
relatives, with increased risk. 
The frequency of adverse reactions is doubled in the elderly with respect to those that occur 
among adults and its severity is much greater. The greater is the number of drugs receives, 
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Adverse effects described in patients in treatment with Atomoxetine include dyspepsia and 
other gastrointestinal disorders, anorexia and weight loss, fatigue, disturbances of sleep, 
irritability, and mood swings. Also hypertension, tachycardia, dizziness, cough, sinusitis or 
runny nose, bed wetting or urinary retention, decrease of libido and sexual dysfunction, 
rash, increased sweating and hot flashes. Rarely, hypersensitivity reactions occur. There 
have been some reports of serious hepatotoxicity. Atomoxetine is contraindicated in patients 
with glaucoma. It should be used with caution in patients with hypertension, tachycardia, or 
cerebrovascular or cardiovascular disease. Treatment with Atomoxetine should start with 
caution in patients with a history of seizures. There is a potential risk of seizures with 
Atomoxetine. 
9. Special situations 
9.1 Psychiatric drugs in pregnancy and lactation 
All psychotropic so far studied cross the placenta, most reach the amniotic fluid and almost 
all are eliminated through breast milk. 3-5% of the newborns have genetic malformations; 
65-70% by unknown factors, hereditary factors 12-25%, 10% by environmental factors 
(drugs, infections, diseases...) and 3% by direct exposure to drugs. Most studies suggest that 
the psychotropic drugs are not associated with a significantly increased risk of organic 
disgenesias. Congenital anomalies are not more frequent in a group of regular consumers of 
drugs compared with a control group. Perinatal mortality was similar in both groups (0.8% 
and 0.9%). It is essential to inform the patient of the potential risks of medication, obtain the 
informed consent of the patient, taking into account the ability and desire to tolerate the 
symptoms without drugs. 
Absortion Metabolism 
Decrease in the rate of gastric emptying. 
Reduction of intestinal motility. 
Increase in cardiac output.  
Changes in the activity of various liver enzymes 
Distribution Elimination 
Increase of blood flow in the tissues.  
Increase in plasma volume.  
Increase in the extracellular fluid volume. 
Increase in adipose tissue (nearly all 
psychotropic are highly fat-soluble).  
Changes in the concentration of some plasma 
proteins. 
Increase in the renal blood flow.  
Increased glomerular filtration rate. 
Table 1. Changes in drug metabolism during pregnancy 
The prescription of psychoactive drugs only must be made if the benefit (to mother) is 
greater than the risk (to the fetus). If possible, avoid all drugs (especially during the first 
trimester of pregnancy) and managing the minimum effective dose. It is preferable to use 
drugs already tested with good safety profile, than new drugs, with a theoretical more 
secure profile but not tested. Smaller than 1,500 molecular weight drugs can cross the 
placental barrier and potentially affect the fetus, but few have demonstrated teratogenic 
effects. It is important to provide contraceptive information to women in chronic treatment 
and review the treatment early in the pregnancy. 
 
Psychiatric Drugs in Medical Practice 103 
Due to changes in pharmacokinetic and pharmacodynamic factors during pregnancy, often 
different doses are needed (may be higher or lower) than in normal conditions to treat the 
symptoms properly. 
The intensity of fetal exposure to the psychotropic also depends on the placental 
transference: Type I or complete transference: the concentrations are quickly balanced 
between maternal and fetal compartments; Type II or excessive transference: Fetal drug 
concentrations are higher than the maternal ones; Type III or incomplete transference: Fetal 
concentrations are lower than the maternal ones. 
9.2 Elderly 
General elderly people have a health more fragile than other stages of life. They suffer from 
various diseases and receive different treatments, which leads to higher risk of adverse 
reactions. As a result of this overlap pharmacokinetics and pharmacodynamics changes in 
this age group and responses to treatments are different. Variations in therapeutic response 
and side effects and interactions, which are more frequent and more serious, result in more 
yatrogenia and worst compliance. 
Interactions in the elderly, drug interactions are between 3 and 5 times more frequent than 
in other stages of life. The elderly modifies the absorption process. Esophageal motility is 
reduced. The aclorhydria increases with age. Gastric motility and intestinal irrigation are 
reduced. But, in general, all these changes in the absorption are not very relevant from a 
clinical point of view.  
The majority of psychoactive drugs, except lithium, are lipophilic and go preferably to fatty 
tissue, including the brain. With age, albumin decreases and increases the proportion of free 
drug, increases the fat mass generally between 25-40%, it’s reduced lean mass and the 
proportion of body water, especially with relative increase in the extracellular intracellular 
water, which increases the volume of distribution of soluble drugs and decreases of the 
water-soluble. Clinically the relevance is moderate but it can extend drugs half-life. 
Old age significantly modifies the metabolism by loss of hepatic mass, decreased blood 
flow, lower microsomial enzyme activity and tendency to prolong the half-life. From the age 
of 65, hepatic perfusion is reduced in about one-third. 
With age, glomerular filtration and hepatic metabolism are reduced which leads to increase 
drug concentration and, consequently, increasing the therapeutic and toxic effect. It can be 
compensated reducing the dose or spacing this. Drugs with long half life tend to accumulate.  
Elders suffer almost always several concomitant pathologies so they receive the respective 
treatments. The majority of clinical trials have been developed in younger people. Receiving 
different products makes pharmacokinetic and pharmacodynamics interactions more 
frequent. It is common that an older is receives at least 6-8 drugs a day, each with its 
corresponding mechanism of action, side effects that join or therapeutic effects to be 
antagonized. In addition, it’s not exceptional self-medication through acquaintances or 
relatives, with increased risk. 
The frequency of adverse reactions is doubled in the elderly with respect to those that occur 
among adults and its severity is much greater. The greater is the number of drugs receives, 
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higher is the risk. In elderly the most frequent adverse reactions are acute confusional states, 
psychomotor agitation, instability and falls, extrapyramidal symptoms, constipation or 
incontinence, anticholinergic symptoms, orthostatic hypotension or impaired heart function. 
If these factors are not taken into account, the yatrogenia among the old can be high and 
with unpredictable consequences. 
9.3 Psychopharmacology in children and adolescents 
The decision to use a pharmacological treatment in a child or adolescent with psychiatric 
disease should be based on a clear clinical need. Prepubescent children often metabolize 
drugs rapidly and tolerate doses of drugs per unit weight slightly higher than the adult. 
After puberty, metabolism seems to young adults. In general if a drug is safe in adults, it 
will be also in children. The period of maximum drug vulnerability is in the intrauterine 
stage. The majority of psychoactive drugs have not been approved by the FDA for use in 
children and adolescents, mainly because there are no studies to support it. 
1. Psychiatric diagnosis must be made before the prescription of psychotropic drugs.  
2. Define clearly target symptoms and the goals of treatment for the use of psychotropics 
3. The doctor should carefully consider the possible side effects, including those which are 
rare but potentially serious, and assess the overall benefits from the risk of 
pharmacological treatment except in cases of urgency. 
4. Informed consent must be obtained before starting medication psychotropic  
5. Monotherapy wherever possible  
6. Doses must be, in general, low and when it’s necessary to increase, do it carefully.  
7. The frequency of doctor-patient follow-up should be appropriate according to the 
severity of the pathology and must comply with to control the response. 
8. In the treatment of depression, it’s important to assess the possibility of that emerge 
suicidal tendencies during the treatment, especially at the beginning.  
9. If who carries out the prescription is not a child psychiatrist, the patient must be sent for 
consultation specializing in child and adolescent mental health. 
10. Before adding other psychotropic medications, it should be evaluated the proper 
adherence to treatment, the accuracy of the diagnosis, the emergence of comorbid 
disorders, and the influence of psychosocial stressors.  
11. If a drug is being used for a symptom not associated to a diagnosis of psychotic disorder in 
DSM IV, and this symptom has been in remission for six months, it should be considered 
seriously to initiate the reduction and subsequent suspension of the drug. If you decide to 
continue with treatment, the need of it should be evaluated at least every six months. 
12. The clinician must clearly document the care provided in the medical record, including 
medical history, mental status evaluation, physical findings (when appropriate), the 
diagnostic impressions, a proper follow-up of laboratory tests to rule out use of 
substances and the potential known risks, response to medication, presence or absence 
of side effects, treatment plan and prescripted medications. 
10. Hepatic failure 
With the notable exception of the lithium the liver is the responsible for the clearance of the 
majority of psychoactive drugs, as they are generally lipophilic and therefore need to be 
transformed into water-soluble compounds so that they can be filtered and eliminated by the 
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kidney. This transformation takes place largely in the liver, but also occurs to a lesser extent in 
other tissues. The inactivation is carried out by the large number of enzymes available in 
hepatocytes, which are responsible for reducing the size of the molecules or to add 
components to turn them into more hydrosoluble, with the final result of an easier elimination. 
Due to the anatomical arrangement of the blood circulation of the gastrointestinal tract, 
absorbed drugs cross the liver before entering the general circulatory system. On some 
occasions, originated substance is an active metabolite, although the level of activity can vary 
widely. This effect called "first step" at times is very significant. This phenomenon also helps 
explain why parenteral medications are often more powerful than the oral equivalent. For 
example, antipsychotic drug intramuscular administration has approximately twice the 
power of those administered by mouth, although this varies widely from patient to patient. 
The greater the degree of liver failure, greater degree of alteration of metabolism, and 
therefore, higher risk of toxicity from drugs. As a result, it is convenient to use possible smaller 
start dose, gradually setting it up to a maximum dose as low as possible. Patients are going to 
suffer more readily predictable or frequent adverse effects. Liver function tests do not 
necessarily correlate well with the deterioration of the metabolism, although they can serve as 
a reasonable approximation. It is important to be very careful with drugs with a high first pass 
metabolism, which in case of liver disease will be a minor inactivation during transport from 
the intestine to the circulatory system and therefore will be far higher plasma levels. As a 
general rule, avoid drugs that have marked effects like constipation and sedation in patients 
with severe liver disease. Monitor - wherever possible - the plasma levels of the drugs used 
11. Renal failure and psychoactive drugs 
If the drug is dialyzable, such as lithium, it will experience a sharp decline in its blood levels 
after dialysis, so post-dialytic of such drugs levels should be obtained to determine what 
amount is provided after the process. Certain drugs that are metabolized / eliminated by 
the kidney will accumulate, with the risk of toxicity, despite not using high doses of these, 
so that such drugs should be avoided or give at lower doses. 
In general, the doses to be used will be two-thirds of the usual doses of the drug, except 
drugs with primarily renal elimination, in which will have to evaluate the clearance of 
creatinine (ClCr) as an indicator of renal function and the dose to use of the drug. Plasma 
levels of the drug in question must be controlled, at least once a month, and immediately 
after the initial dose of medication must provide wherever possible.  
In renal failure protein binding is lower than in healthy individuals, so usually there is a 
greater amount of free drug in plasma, with higher therapeutic and side effects. The higher 
protein binding, the lesser dialyzable is the drug, what it’s important to prescribe lower 
doses. In general, the most of the psychotropic substances aren’t dialyzable, except lithium, 
gabapentine, pregabaline and others.  
12. Cardiopathy and arterial hypertension 
Antidepressant in cardiac illness must be used in therapeutical efficient doses, not lower 
doses, because metabolism is not affected if there is no hepatic afectation. Tryciclic 
antidepressants have severe cardiac side effects, so they have to be avoided if there is not a 
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higher is the risk. In elderly the most frequent adverse reactions are acute confusional states, 
psychomotor agitation, instability and falls, extrapyramidal symptoms, constipation or 
incontinence, anticholinergic symptoms, orthostatic hypotension or impaired heart function. 
If these factors are not taken into account, the yatrogenia among the old can be high and 
with unpredictable consequences. 
9.3 Psychopharmacology in children and adolescents 
The decision to use a pharmacological treatment in a child or adolescent with psychiatric 
disease should be based on a clear clinical need. Prepubescent children often metabolize 
drugs rapidly and tolerate doses of drugs per unit weight slightly higher than the adult. 
After puberty, metabolism seems to young adults. In general if a drug is safe in adults, it 
will be also in children. The period of maximum drug vulnerability is in the intrauterine 
stage. The majority of psychoactive drugs have not been approved by the FDA for use in 
children and adolescents, mainly because there are no studies to support it. 
1. Psychiatric diagnosis must be made before the prescription of psychotropic drugs.  
2. Define clearly target symptoms and the goals of treatment for the use of psychotropics 
3. The doctor should carefully consider the possible side effects, including those which are 
rare but potentially serious, and assess the overall benefits from the risk of 
pharmacological treatment except in cases of urgency. 
4. Informed consent must be obtained before starting medication psychotropic  
5. Monotherapy wherever possible  
6. Doses must be, in general, low and when it’s necessary to increase, do it carefully.  
7. The frequency of doctor-patient follow-up should be appropriate according to the 
severity of the pathology and must comply with to control the response. 
8. In the treatment of depression, it’s important to assess the possibility of that emerge 
suicidal tendencies during the treatment, especially at the beginning.  
9. If who carries out the prescription is not a child psychiatrist, the patient must be sent for 
consultation specializing in child and adolescent mental health. 
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kidney. This transformation takes place largely in the liver, but also occurs to a lesser extent in 
other tissues. The inactivation is carried out by the large number of enzymes available in 
hepatocytes, which are responsible for reducing the size of the molecules or to add 
components to turn them into more hydrosoluble, with the final result of an easier elimination. 
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11. Renal failure and psychoactive drugs 
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12. Cardiopathy and arterial hypertension 
Antidepressant in cardiac illness must be used in therapeutical efficient doses, not lower 
doses, because metabolism is not affected if there is no hepatic afectation. Tryciclic 
antidepressants have severe cardiac side effects, so they have to be avoided if there is not a 
 
Pharmacotherapy 106 
clear indication, monitoring EKG frequently. Venlafaxine can increase arterial tension in 
high doses. SSRIs, bupropion and mirtazapine are secure in cardiac patients. Stimulants 
have to be avoided due to cardiac effects.  
Lithium can produce sinodal nodus dysfunction and can be altered if there are rapid 
alterations of electrolite equilibrium. Carbamacepine has quinidin-like effects.  
Antipsychotic drugs can prolong QT interval and produce orthostatic hypotension, and new 
substances can induce diabetes mellitus type II and weight gain.  
13. Pneumology 
Main pharmacologic interactions in patients with respiratory illness are those that appear 
between rifampicine and theophiline, and psychotropic drugs.  
Benzodiacepines produce relaxation on respiratory vias and reduce the air pass, so they are 
contraindicated in sleep obstructive apnea and in chronic restrictive pulmonary illness. 
Zolpidem is the hipnotic drug with less effect on respiration.  
There are some drugs used in pneumologic illness that have been related to psychiatric 
syndromes, as corticoides, diuretics, beta-blockers or central action antihypertensives. 
14. Obesity and diabetes 
When treating a patient suffering from morbid obesity, diabetes or organic pathology 
which could be descomensated with weight gain, the drug must have little effect on 
weight. It is recommended to use SSRIs or noradrenergic with little effect on weight and 
watch for possible hipoglucemias that could need adjusting antidiabetic drug. Avoid 
MAOIs and heterociclic antidepressants. Clozapine and olanzapine promove weight gain 
and can precipitate diabetes. Risperidone and quetiapine produce lower weight gain and 
ocasionally diabetes. Aripripazol and ziprasidone don’t alter weight and don’t produce 
metabolic syndrome. When a patient with overweight, obesity, prediabetes, diabetes or 
diabets risk factors is receiving any psychoactive drug, it’s important to monitorize 
laboratory analysis, arterial tension, and weight, at least basal, every three months the first 
year and then yearly. 
15. Oncology 
In the treatment of patients suffering from cancer or in a final stage of the illness, the 
pharmacological prescription has to be accurate to physical state secondary not only to 
symptomatology related to cancer but to treatment too. In general, it’s better to use drugs 
without active metabolites, without hepatic metabolism, well know drugs, without 
anticholinergic side effects (due to adition to cancer treatment ones) and with a good side 
effects profile. Though these considerations, psychiatric symptoms must be treated when 
appear in association to opioid analgesia if there is pain. In many cases the treatment with 
stimulants and antidepressants if there is depression is more efficacy than antidepressants 
alone, with a low risk of dependence. Zolpidem and zopiclone can produce metallic taste, so 
they must be avoid in cancer patients.  
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16. AIDS 
There is risk of a poor tolerance, especially with high potence antipsychotics in the final 
stages of AIDS, due to extrapiramidal effects. Risperidone seems to have low interactions 
profile with drugs used for the infection. Agranulocytosis risk can be increased in treatment 
with clozapine. To treat depression it is recommended the use of citalopram, escitalopram 
and sertralina due to the lower risk of interactions (especially with ritonavir), though a 
serotoninergic síndrome can appear. There are sparse and poor evidence of interactions with 
other antidepressants. Oxazepam, lorazepam and temazepam are anxiolytic choice 
treatment, due to their short half life, their metabolism and low profile or interactions. 
Lithium provokes frequently side effects. When using anticonvulsivants as mood stabilizers, 
it’s important to monitorize liver function. Stimulants can be used with a good profile of 
secureness and tolerance in patients with cognitive deterioration and depression.  
Many drugs used in HIV infection treatment precipitate psychiatric symptoms (depression, 
anxiety, and insomnia). It is frequent the use of illegal drugs that interfere with treatment 
and can produce symptoms too.  
17. Delirium 
Treatment of delirium may complicate evolution of it, so it’s important to select drugs with 
little sedative and anticholinergic effect, if possible one only drug, starting at low doses and 
during a short time, maintaining non-pharmacological measures (soft light, orientation, 
treatment of basal physical state…). The treatment is based in the use of antipsychotics, 
except in alcohol abstinence, where benzodiacepines must be used. Haloperidol is the choice 
drug, though there is little evidence about the usefulness of atypical antipsychotics. 
Benzodiacepines must be avoided because can cause a paradoxical effect with an increase of 
agitation. 
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1. Introduction  
The steroidal and non-steroidal anti-inflammatory drugs are known to be among the most 
commercialized drugs worldwide, however several discussions have been raised about its 
side effects, caused especially in the chronic use. In this context, the discovery of new 
prototypes with improved anti-inflammatory activity and therapeutic safety is one of the 
targets in the area of research, development and innovation of the pharmaceutical industry. 
The intensive search for new anti-inflammatory therapeutic options with effective therapies 
and fewer adverse effects resulted in the development of non-steroidal anti-inflammatory 
drugs (NSAIDs) with selective inhibition of cyclooxygenase-2 (coxibs). This new generation 
of drugs came to market due to their greater efficiency and minor capacity to damage gastric 
and renal sites compared to non-selective NSAIDs. This advantage would be 
pharmacodynamically explained by its ability to selectively inactivate the inducible 
cyclooxygenase-2 (COX-2), the enzyme that induces prostaglandin synthesis at the 
inflammation site, preserving the constitutive cyclooxygenase-1 (COX-1) responsible for 
physiological protection carried by prostaglandins in those sites. Despite the therapeutic 
efficiency, some of the developed coxibs has been removed from the market by causing 
significant cardiovascular effects.  
Thus, efforts are still underway to discover new anti-inflammatory chemical entities. Several 
studies have been conducted with synthetic agonists (thiazolidinodiones) of a biological 
anti-inflammatory target discovered in the nineties, the peroxisome proliferator activated 
receptor γ (PPARγ). The research of drugs with anti-inflammatory activity carried out by 
different mechanisms of action from the conventional ones is extremely important in an 
attempt to expand the therapeutic options for patients who have restrictions on the use of 
the available anti-inflammatory drugs. 
1.1 History 
The hability to treat fever and inflammation dates back to 2500 years ago (400 B.C.) to a time 
when the Greek physician Hippocrates prescribed an extract from willow bark and leaves 
(Rao & Knaus, 2008). Later, in 1860, with the discovery of the active ingredient of willow 
bark salicin in Europe, the Kolbe company in Germany started mass producing salicylic 
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acid. Acetysalicylic acid (Aspirin®), the more palatable form of salicylic acid was introduced 
into the market by Bayer in 1899 (Vane, 2000). 
In the 1930s and 1940s, numerous developed studies allowed the recognition of the effects of 
adrenocortical hormones on electrolyte balance (mineralocorticoids effects) and 
carbohydrate metabolism (glucocorticoids effects). In 1946, cortisol was synthesized, and in 
1948, first used by Hench in patients with rheumatoid arthritis. In the 1950s, changes in the 
structure of cortisol resulted in new drugs such as prednisone and prednisolone. Later, the 
side effects related to the use of these therapies have been recognized, adding limitations to 
the therapeutic use of glucocorticosteroids.  
In 1946 was brought to the market phenylbutazone, the first drug other than Aspirin® of the 
category of what are now known as the NSAIDs, followed by indomethacin in the 1960’s (by 
Merck & Co). In the 1950-1960’s Ibuprofen was developed by Boots (UK), and it was the first 
NSAID (other than Aspirin®) to be approved for non-prescription use in the UK (1963), then 
USA (1964), and later in many other countries worldwide. Just after the advent of Ibuprofen, 
in the seventies John Vane discovered the mechanism of action of Aspirin® and other 
NSAIDs: the inhibition of cyclooxygenase (COX) enzyme (Vane, 1971). After that, a large 
number of pharmaceutical companies undertook the discovery and development of many 
other NSAIDs. 
In the early 90’s there was reported the presence of an inducible isoform of the COX 
enzyme, later identified as COX-2 (Kujubu & Herschman, 1992). This discovery led to the 
hipothesis that the non-inflammatory prostaglandins were produced by the constitutive 
COX-1 and pro-inflammatory prostaglandins by the non-constitutive COX-2 (Meade et al., 
1993). The conventional anti-inflammatory drugs were known to inhibit both isoforms of the 
enzyme. The COX-1 inhibition would explain the gastrointestinal adverse effects caused by 
the NSAIDs. In an attempt to research new therapeutic agents with fewer adverse effects, 
the pharmaceutical companies focused their efforts on the design of selective COX-2 
inhibitors. In 1999, G.D. Searle and Pfizer (now Pfizer Inc) launched the first selective COX-2 
inhibitor, celecoxib (Celebrex®) (Rao & Knaus, 2008). This was followed by the launch of 
Merck’s rofecoxib (Vioxx®) and other coxibs (Prasit, 1999).  
The research and development of new therapies to treat inflammation, pain and arthritis is 
still a constant in the pharmaceutical industry. Between 1999 and 2010, at least 12 arthritis 
and inflammation related new chemical and biological entities were released, 5 of them anti-
inflammatory agents. However, rofecoxib (Vioxx®) and valdecoxib (Bextra®) were still 
withdrawn from the market due to the high cardiovascular risk related to its use (United 
States Food and Drug Administration [FDA], 2011). 
1.2 Anti-Inflammatory use and market 
The anti-inflammatory class of drugs is among the most widely prescribed groups of 
medicines in clinical practice worldwide. The global market for treatment of pain in 2009 
amounted to US$ 50 billion, of which 27 billion in the seven largest economies (USA, Japan, 
France, Germany, Italy, Spain and UK). Of these US$ 27 billion, NSAIDs constitute 28% 
NSAIDs and selective COX-2 inhibitors 7% (Melnikova, 2010). Other data that brings the 
high use of anti-inflammatory drugs reveal that 40 thousand tons of acetyl-salicylic acid are 
ingested every year around the world (Menezes et al., 2009), besides the large number of 
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NSAIDs available for purchase in the market, many of them obtained without prescription. 
This fact can explain the high cash income derived from the NSAIDs prescription. 
Recently, a study carried out in six European countries showed an increase in the use of 
anti-inflammatory drugs during the 2002-2007 period. It is important to emphasize that 
during this period the use of conventional NSAIDs increased by 2.07%, while the stronger 
COX-2 inhibitors use increased by 325% (Inotai et al., 2010). 
The numbers regarding the use of corticosteroids as anti-inflammatory therapy in the U.S. 
shows that each year approximately 67 million prescriptions are written, despite their 
multiple side effects. In 2007, the combined annual sales for corticosteroids totaled about 
US$ 7.4 billion, not including generics (Hollis-Eden Pharmaceuticals, 2007). 
Associated with these high values regarding anti-inflammatory therapies, there are other 
ones related to its adverse effects. Some studies developed at the US showed that, for each 
dollar spent on NSAIDs, from U$0.66 to U$1.25 may be spent due to gastrointestinal adverse 
effects. Aditionally, almost 1/3 of the medical costs in arthritis patients may be related with 
gastrointestinal effects (Laine et al., 2010). 
1.3 Physiopathology 
Acute inflammation may be triggered by a variety of stimuli and is characterized by the 
rapid host response to the sites of infection or tissue injury, with the delivery of leukocytes 
and plasma proteins, such as antibodies, to the referred site. Chronic inflammation may 
develop following acute inflammation and may last for weeks or months, and in some 
instances for years.  
During both acute and chronic inflammatory processes, a number of soluble factors are 
involved in leukocyte recruitment through increased expression of cellular adhesion 
molecules and chemoattraction. Through this mechanism, many soluble mediators regulate 
the activation of resident cells, such as endothelial cells, fibroblasts, tissue macrophages and 
mast cells, as well as newly recruited inflammatory cells such as monocytes, lymphocytes, 
neutrophils and eosinophils. Some of these mediators result in the systemic inflammatory 
responses, as fever, hypotension, the synthesis of acute phase proteins, leukocytosis and 
cachexia (Feghali & Wright, 1997). 
Some transcription factors play a significant role in the inflammatory process. In this 
context, an important one is Nuclear Factor-kappa B (NF-κB), which controls the 
transcription of DNA (Gilmore, 2006). Activation of the NF-κB transcription family, by 
nuclear translocation of cytoplasmic complexes, plays a central role in inflammation 
through its ability to induce transcription of proinflammatory genes and consequently 
mediators like cytokines and chemokines, matrix metalloproteinases (MMPs), COX-2, and 
inducible nitric oxide (iNOS) (Baldwin, 1996). NF-κB activation also increases expression of 
the adhesion molecules E-selectin, vascular cell adhesion molecule 1 (VCAM-1), and 
intercellular adhesion molecule 1 (ICAM-1), while inhibition reduces leukocyte adhesion 
and transmigration (Chen et al., 1995). The activity of NF-kB is tightly regulated by 
interaction with inhibitory IkB proteins (Gilmore, 2006). 
The mediators that act in the inflammatory process can be divided in cell-derived and 
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NSAIDs available for purchase in the market, many of them obtained without prescription. 
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 Cell-derived: Histamin, Serotonin, Prostaglandins, Leukotrienes, Platelet-activating 
factor, Reactive oxygen species, Nitric oxide, Cytokines (tumor necrosis factor – TNF, 
interleukin-1 – IL-1), Chemokines; 
 Plasma-protein derived: Complement products (C3a, C4a, C5a), Kinins, Proteases 
activated during coagulation. 
Among the mediators of inflammation many are derived from the arachidonic acid. The 

































Fig. 1. The arachidonic acid cascade leads to a number of mediators of inflammation. As 
indicated in red, many steps of this cascade are potential anti-inflammatory targets, such as 
enzymes and eicosanoids receptors. In this chapter, will be discussed the NSAIDs and 
glucocorticosteroids. PAF, platelet-activating factor; PG, prostaglandin; 12-HETE, 12-
hydroxyeicosatetraenoate; 5-HPETE, 5-hydroperoxyeicosatetraenoate; TXA2, thromboxane 
A2; LT, leukotriene.  
The classic anti-inflammatory therapies are based on the inhibition of the cyclooxygenase 
enzymes (NSAIDs) and cyclooxygenase 2 expression (glucocorticosteroids), thus preventing 
the prostanoids to be generated and on the phospholipase A2 enzyme expression inhibition 
(glucocorticosteroids), inhibiting the whole arachidonic acid cascade. Moreover, 
corticosteroids induce key anti-inflammatory genes and selectively repress specific 
inflammatory genes that encode a number of other mediators of inflammation, consequently 
inhibiting the inflammatory response. The anti-inflammatory response of these medicines can 
be explained by the reduction of the inflammatory response of such mediators, once its 
generation is decreased by the action of the medicines. Many side effects experienced by these 
drugs users can be explained by the absent physiological role of these mediators (Table 1).  
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promotes TH2 cell 
differentiation. PGD2 
also can activate 
mature TH2 cells and 
eosinophils via its 
DP2 receptor. 
Inflammation: Increases local blood 
flow, vascular permeability, and 
leukocyte infiltration 
Pain: Reduces the threshold to 
stimulation of nociceptors, causing 
peripheral sensitization 
Fever: PGE2 can cross the blood-brain 
barrier and acts on EP3 and perhaps 
EP1 receptors on thermosensitive 
neurons. This triggers the 
hypothalamus to elevate body 
temperature by promoting an increase 







Table 1. The diverse activities of prostaglandins are reflected by their involvement in both 
normal homeostasis (blue) and pathophysiology (red). Many of the NSAIDs side effects can 
be explained by the absent physiological role of prostanoids (renal, cardiovascular, 
gastrointestinal) due to the COX inhibition (Goodman et al., 2010). 
Among the soluble factors that mediate inflammation, a group of secreted polypeptides 
known as cytokines play essential roles in orchestrating the process. They can be divided 
into two groups: those involved in acute inflammation and those responsible for chronic 
inflammation (See Figure 2 and Table 2). 
The most important cytokines involved in inflammatory reactions are listed. In this context, 
TNF-α and IL-1 are important in developing the acute and sustaining the chronic 
inflammatory process (O’Neill, 2008). Working in concert with each other and various 
cytokines and growth factors (such as IL-6, IL-8 and granulocyte-macrophage colony-
stimulating factor [GM-CSF]), they induce gene expression and protein synthesis (including 
expression of COX-2, adhesion molecules, and acute-phase proteins) in a range of cells to 
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CHRONIC INFLAMMATION  
Fig. 2. Cytokines involved in acute and chronic inflammatory responses. IL, interleukin; 
TNF, tumor necrosis factor; GM-CSF, Granulocyte-colony stimulating factor; TGF, 
Transforming growth factor; IFN, interferon. 
Principal 
cytokines Principal sources Principal actions in inflammation 
TNF Mast Cells, Macrophages, T lymphocytes 
Stimulates expression of endothelial 
adhesion molecules and secretion of other 
cytokines; systemic effects 
IL-1 Macrophages, endothelial cells Similar to TNF; greater role in fever 
IL-6 Macrophages, other cells Systemic effects 
IL-12 Dendritic cells, macrophages Increased production of IFN-γ 
IL-17 T-Lymphocytes Recruitment of neutrophils and monocytes 
Chemokines 
Macrophages, endothelial cells, T 
lymphocytes, mast cells, other cell 
types 
Recruitment of leukocytes to sites of 
inflammation; migration of cells to normal 
tissues 
IFN-γ T lymphocytes, NK cells Activation of macrophages (increased ability to kill microbes and tumor cells) 
Table 2. Principal cytokines in inflammation (Robbins et al., 2010). NK, natural killer. 
The extravasion of leukocytes is controlled by the expression of cell surface adhesion 
molecules on both the circulating cells and on the vascular endothelium. The TNF-α 
signaling pathway, mediated by NF-κB, is responsible for the expression of adhesion 
molecules such as VCAM-1 and ICAM-1 in the endothelium (Collins et al., 1995). TNF-α 
was previously shown to induce ICAM-1 expression (Fingar et al., 1997). These adhesion 
molecules allow the attachment of leukocytes to the endothelium and may permit their 
subsequent transmigration into peripheral tissue. At the same time, microvascular 
permeability is increased (Frank & Lisanti, 2008). 
2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
The NSAIDs are a heterogeneous group of molecules that share certain therapeutic actions 
and side effects. The first drug belonging this class, Aspirin®, was introduced to the market 
in 1899. After that, several other anti-inflammatory drugs were introduced over the years, 
until the discovery of selective inhibitors of COX-2, called coxibs. Both traditional NSAIDs 
and the recent coxibs are effective anti-inflammatory agents and analgesics. However, in 
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recent years it has been questioned the safety associated with the use of these drugs in 
clinical practice, due to the range of side effects caused due to consumption of these drugs, 
many times inappropriately. 
2.1 Mechanism of action 
The anti-inflammatory action of NSAIDs can be explained by the effect of inhibiting the 
enzyme COX, which is responsible for the synthesis of prostaglandins, mediators with a 
great ability to induce inflammation (Tanaka et al., 2009). COX has two isoforms: COX-1 and 
COX-2. The first is constitutively expressed in a wide variety of cells, promoting 
physiological functions, such as gastric mucosal protection, control of renal blood flow, 
hemostasis, autoimmune responses, lungs, central nervous system, cardiovascular system 
and reproductive functions (Grosser et al., 2006). 
On the other hand, COX-2 is an inductive enzyme, which is expressed significantly due to 
various stimuli such as cytokines, endotoxins and growth factors. COX-2 originates 
inducing prostaglandins, which contribute to the development of the four cardinal signs of 
inflammation: pain, heat, redness and swelling (Fitzgerald, 2004), thus being considered as 
the main target for the anti-inflammatory action. In this context, the recently developed 
coxibs act through selective inhibition of COX-2. However, although inductive, this COX 
isoform is also expressed in normal vascular endothelial cells, synthesizing prostacyclin, an 
important substance in maintaining the prothrombotic/antithrombotic blood balance 
(Antman et al., 2007), which can trigger severe cardio-vascular problems. 
2.2 Therapeutic uses 
The effects of inhibiting the COX enzyme explain the clinical uses of the NSAIDs (including 
selective COX-2 inhibitors), mainly as antipyretics, analgesics and anti-inflammatory agents. 
 Inflammation: As anti-inflammatory agents, are used to treat muscle injuries, 
tendinitis, bursitis and in relieving postoperative pain, in addition to its indication for 
chronic rheumatic diseases such as rheumatoid arthritis, osteoarthritis, gouty arthritis 
and ankylosing spondylitis (Pountos et al., 2011). In the latter cases, NSAIDs are often 
associated with disease modifying anti-rheumatic drugs (DMARDs), so that in addition 
to reducing pain and discomfort of the patient, also promote the regression of the 
disease.  
 Pain: Its use as analgesic is indicated for relieving mild to moderate pain. They are 
particularly effective when inflammation has caused peripheral and/or central 
sensitization of pain perception. Thus, postoperative pain or pain arising from 
inflammation, such as arthritic pain, is controlled well by NSAIDs, whereas pain arising 
from the hollow viscera usually is not relieved (Goodman et al., 2010). 
 Fever: NSAIDs are thought to be antipyretic largely through inhibition of prostaglandin 
production in the hypothalamus. They can reduce fever in most situations, but not the 
circadian variation in temperature or the rise in response to exercise or increased 
ambient temperature. McAdam et al. (1999), in a comparative study of the impact of 
non-selective NSAIDs and selective COX-2 inhibitors, suggested that COX-2 is the main 
source of PGs that mediate the rise in temperature caused by bacterial 
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 Cardioprotection: The suppression of platelet TxA2 formation promotes the 
cardioprotective effect of aspirin. It is used as an antiplatelet drug, in the management 
of the myocardial infarction and in angina, reducing the risk of serious vascular events 
in high-risk patients (e.g., those with previous myocardial infarction) by 20-25%. Low-
dose (<100 mg/day) aspirin, is as effective as higher doses (e.g., 325 mg/day) but is 
associated with a lower risk for gastrointestinal adverse events (Goodman et al., 2010). 
 Cancer Chemoprevention: Studies of patients with familial adenomatous polyposis and 
Gardner’s syndrome (Waddell et al., 1983, 1989) introduced the idea that NSAIDs may 
inhibit cancer progression. Cha & Raymond (2007) found that in colorectal cancers the 
same occurs because COX-2 is selectively upregulated, which was subsequently found to 
be elevated in other epithelial tumors including breast, stomach, pancreas, bladder, lung 
and prostate cancers. Since the NSAID action is inhibition of the enzymatic activities of 
COX-1 and COX-2, it was hypothesized that the beneficial effect of NSAIDs was due, in 
part, to inhibition of COX-2 in the tumor microenvironment. Additionally, recent clinical 
trials clearly demonstrate that celecoxib is very effective in reducing polyp recurrence in 
patients who have undergone a polypectomy (Arber et al.; Bertagnolli et al., 2006). This 
drug is particularly effective in reducing recurrence of very large polyps, which are more 
likely to progress into cancer. Recently, a new group of NSAIDs have been explored for 
their effectiveness in several diseases, such as cardiovascular, rheumatological and lung 
diseases, Alzheimer's disease, and cancer: the Nitric oxide-donating nonsteroidal 
antiinflammatory drugs (NO-NSAIDs). These drugs consist of a traditional NSAID to 
which a NO releasing moiety is covalently attached, and may have an important role in 
colon cancer prevention and/or treatment (Yeh et al., 2004).  
 Alzheimer's Disease: Observational studies have suggested that NSAID use, in 
particular ibuprofen, is associated with lower risk of developing Alzheimer's disease. 
The same was not observed when a randomized, controlled clinical trial comparing 
celecoxib, naproxen, and placebo (ADAPT Research Group, 2008) was performed, 
where the researchers did not find a significant reduction in Alzheimer's dementia with 
the use of NSAIDs. 
 Other Clinical Uses: In patients with systemic mastocytosis, PGD2, released from mast 
cells in large amounts, has been found to be the major mediator of severe episodes of 
flushing, vasodilation, and hypotension. The addition of aspirin or ketoprofen has 
provided relief (Worobec, 2000). Large doses of niacin (nicotinic acid), effectively used to 
lower serum cholesterol levels, reduce low-density lipoprotein, and raise high-density 
lipoprotein, can induce intense facial flushing. This flushing is mediated largely by release 
of PGD2 from the skin, which can be inhibited by treatment with aspirin (Jungnickel et al., 
1997). Bartter syndrome includes a series of rare disorders characterized by hypokalemic, 
hypochloremic metabolic alkalosis with normal blood pressure and hyperplasia of the 
juxtaglomerular apparatus. Renal COX-2 is induced, and biosynthesis of PGE2 is 
increased. Treatment with indomethacin, combined with potassium repletion and 
spironolactone, is associated with improvement in the biochemical derangements and 
symptoms. Selective COX-2 inhibitors also have been used (Guay-Woodford, 1998). 
2.3 Side effects 
The use of NSAIDs has been associated with a high number of side effects. Thus, the 
prescription of these drugs should be made through a previous study of the individual patient, 
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taking into account the required dosage and the use of other drugs, in order to understand the 
patient risk-benefit relation. The most prominent side effects are described below: 
 Gastrointestinal effects: Several prostanoids, especially prostacyclin and PGE 2, are 
crucial to protect the gastric mucosa from the corrosive effects of stomach acid, as well 
as to maintain the naturally healthy condition of the gastric mucosa (Antman, 2007). 
Therefore, the consequences of inhibition of COX-1 may lead to the triggering of 
various side effects ranging from nausea to bleeding ulcers, which can lead the user to 
death (Pountus et al., 2011). The use of high doses or the prolonged consumption of 
NSAIDs, along with its administration with corticosteroids and/or anticoagulant drugs, 
smoking and/or alcohol, increases the probability of experiencing these effects. 
However, some in vitro studies reported that there is a relationship between the besides 
the NSAIDs and COX adversities stomach: Some drugs shown to have direct cytotoxic 
action on cells of the gastric mucosa, may also be the reason of such effects (Siew & 
Francis, 2010).  
 Cardiovascular effects and the coxibs: Some prostaglandins and other substances 
produced by COX regulates complex interactions between platelets and the blood 
vessel walls. In this context, prostacyclin, a substance produced by COX-2, antagonizes 
the action of platelet aggregation by interacting with its receptor IP. However, platelets 
contain only one isoform of COX, able to convert a large quantity of arachidonic acid to 
a potent aggregating agent, thromboxane A2 (TXA2). Therefore, with the 
administration of selective COX-2 drugs (coxibs), an imbalance can occur in the 
production of prostacyclin and TXA2, reflecting in a prothrombotic/antithrombotic 
blood imbalance and a consequent increase in risk of thrombotic events (Topol, 2004; 
Antman et al., 2005). In this context, the studies of Grahamm and coworkers (2005) 
showed an increase of 1.49 times in the risk of acute myocardial infarction patients for 
consuming rofecoxib at a dose of 25mg/day (maximum dose chronic allowed) in a 
three years period. Additionally, the author noticed an increase of 3.58 times in this risk 
with the consumption of doses greater than 25mg/day of celecoxib. A number of other 
studies reported a significant increase in the risk of developing acute myocardial 
infarction associated with the use of such medicines (Bresalier et al., 2005). Given these 
results, the Food and Drug Administration (FDA) has formalized the limited use of 
these drugs. Two of them (rofecoxib and valdecoxib) were still withdrawn from the 
market (United States Food and Drug Administration [FDA], 2011).  
 Erectile dysfunction: Inhibition of prostaglandin synthesis and TXA2 by NSAIDs may 
interfere with the physiological process of penile erection through nitric oxide, which is 
an essential physiological signal for penile erection (Shiri et al., 2006). According to the 
study of Shiri and coworkers, 2006, Erectile dysfunction is related to the used therapy, 
regardless the incident disease. The author of the study showed that the onset of the 
erectile dysfunction in patients with arthritis treated with NSAIDs was lower than 
expected in the use of the drug in the absence of a disease, indicating a negative 
function between the use of NSAIDs in arthritis and the risk of developing the disorder. 
In addition, the study concluded that it is a reversible process, with enhanced sexual 
performance when the drug is discontinued. 
 Nephrotoxicity: Inhibition of COX-1 results in declining levels of renal vasodilatory 
prostaglandins, which among other effects, maintains renal blood flow and glomerular 
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and acting as angiotensin II and norepinephrine antagonists. Aditionally, they cause an 
increase in organ perfusion and reduction in the release of noradrenaline. In this context, 
the inhibition of such mechanisms tends to decrease the total renal perfusion and 
redistribute blood flow to the cortex, especially when there is stimulation of the renin-
angiotensin-aldosterone system and/or stimulation of the sympathetic nervous system. 
Such processes may result in acute renal vasoconstriction, medullar ischemia, and under 
certain conditions, acute renal failure. Therefore, the use of NSAIDs may result in varying 
degrees of renal dysfunction, ranging from the reversible commitment of glomerular 
filtration rate to irreversible renal damage (Winkelmayer et al. 2008; Pountos, 2011). 
2.4 Contra-indications 
The contraindications for NSAIDs are quite understandable and are closely related to its 
adverse effects. The FDA proposes the contraindications for hypertensive patients, patients 
with chronic renal, cardiovascular and gastroesophageal diseases (Keenan et al., 2011). 
Additionally, there is not a clear dividing line for the clinical use of NSAIDs and their 
toxicology, where it is necessary the cautious interpretation of clinical risk factors. Such 
factors may increase the likelihood of developing these side effects, and are described in 
Table 3 (Holdgate & Pollock, 2004; Berenbaum, 2004). 
Risk factors related to the consumption of NSAIDs 
Patient Older than 65 years, consumption of alcohol and/or smoke. 
Clinical History Gastrointestinal (GI) events or ulcers, prior induction of GI events by NSAIDs consumption, comorbid conditions, poor functional status. 
Drug Chronic use, high doses, concomitant use with other NSAIDs. 
Table 3. Risk factors related to the use of NSAIDs (Pountos et al., 2011).  
Several studies include pregnant and lactating women in the clinical contraindicated profile, 
which culminated in a warning issued by the Adverse Drug Reactions Advisory Committee 
(ADRAC) in 1991. It emphasized the congestive heart failure and poor prognosis risks 
related to the use of NSAIDs during pregnancy (Hofstadler et al., 1996), reporting cases of 
premature closure or constriction of the ductus arteriosus in women with diclofenac, 
indomethacin and mefenamic acid treatment due to low back pain, premature labor and 
polyhydramnios, respectively. 
2.5 Drug interactions 
Some studies report that the administration of traditional NSAIDs concomitantly with 
Aspirin® may antagonize its antiplatelet action, compromising its cardioprotective function 
(Kurth et al., 2003). Additionally, the combination of NSAIDs and coxibs with low-dose 
Aspirin® significantly increases the likelihood of gastroinestinais adverse events compared 
with the isolated use of any NSAID (Gladding et al., 2008). 
The combined therapy of these drugs with angiotensin-converting enzyme (ACE) inhibitors 
can cause renal failure (Seeling et al., 1990), commonly seen in elderly patients. The same 
results from the attenuation of the effectiveness of ACE inhibitors due to the blocked 
production of vasodilator and natriuretic prostaglandins by NSAIDs. The drug interaction 
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also occurs with thiazide diuretics, which can cause impaired renal function and electrolyte 
imbalance (Secoli, 2010). 
Although they are often used to treat rheumatoid arthritis and cancer, the concomitant use 
of NSAIDs and methotrexate leads to drug interaction, increasing the blood concentration 
and time of excretion of methotrexate. According to Maeda et al., 2008, there is a 
competition for the renal transporter, the main route of elimination of methotrexate.  
NSAIDs also present interactions with alcohol. Studies have demonstrated that this 
interaction causes the prolongation of the bleeding mediated by Aspirin® when 
administered concomitantly. This mechanism is not yet well understood, but some in vitro 
studies show that this relationship arises from the increase in the inhibiting power of 
prostacyclin on platelet aggregation (Jakubowski et al., 1988). 
2.6 Main categories of NSAIDs 
 Salicylates: Aspirin® is the pioneer of this class of anti-inflammatory drugs. It is often 
used for prophylaxis of cardiovascular events at a dosage of 40 to 80 mg/day. 
Additionally, it has analgesic action and antipyretic in the dosage of 325 to 650mg every 
4 to 6 hours. At a dosage of 1g every 4 to 6 hours is indicated for the treatment of 
rheumatic fever. The dosage for children is changed, being 10mg/kg every 4 to 6 hours. 
Diflunisal® (difluorophenyl) has about 4 to 5 times more analgesic and anti-
inflammatory power than Aspirin®. However, its antipyretic effect is reduced. The 
administration of diflunisal is performed at doses of 250 to 500mg every 8 to 12 hours. It 
presents fewer side effects on platelets and the gastrointestinal tract. Its excretion can be 
achieved through breast milk, being contraindicated for pregnant women. 
 Para-aminophenol derivatives: Acetaminophen or Paracetamol has effective analgesic 
and antipyretic activity, but its anti-inflammatory activity is insufficient. It is used at a 
dosage of 10 to 15 mg/kg every 4 hours, not exceeding the maximum of 5 doses every 
24 hours. High doses of acetaminophen cause the production of toxic metabolites and 
hepatic necrosis. 
 Acetic acid derivatives: Indomethacin is 10 to 40 times more potent than salicylic acid. 
Its peak blood concentration is reached 1-2 hours after administration. It is used at a 
dosage of 25 mg 2-3 times/day or 75 to 100 mg/night. Its side effects affect 30 to 50% of 
users, characterized by frontal headache, neutropenia and thrombocytopenia. About 
20% of patients discontinue the therapy. Fenamates have similar effectiveness 
compared to acetylsalicylic acid, but isolated cases of hemolytic anemia have been 
reported. Its side effects can reach about 25% of users. Tolmetin, a heteroaryl acetate 
derivative, also has similar effectiveness compared to Aspirin®. It is used at a dose of 
400 to 600mg, three times a day, and 20mg/kg/day for children, in 3 to 4 fractionated 
doses. The absorption of Tolmetin is delayed and decreased in the presence of food. The 
interruption of therapy occurs in 5-10% of patients. Diclofenac, a phenylacetate 
derivative, is administered in doses of 50mg three times daily or 75mg, 2 times a day. It 
is more potent than Aspirin®, but 20% of patients develop side effects, 2% discontinue 
the use and 15% develop elevation of liver enzymes. 
 Propionic acid derivates: In general, they are better tolerated than Aspirin®, with 
equivalent to or higher power than the same. Ibuprofen is widely used in clinical 
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the use and 15% develop elevation of liver enzymes. 
 Propionic acid derivates: In general, they are better tolerated than Aspirin®, with 
equivalent to or higher power than the same. Ibuprofen is widely used in clinical 





discontinue treatment due to adverse effects. It is administered at a dose of 200 to 
400mg every 4 to 6 hours for analgesia, whereas for anti-inflammatory the dosage is 
300mg every 6-8h or 400 to 800mg three to four times a day. The dosage for anti-
inflammatory for children decreases to 5 to 10mg/kg every 6h, with the maximum dose 
of 40 mg/kg/day. In children, anti-inflammatory action is achieved with dosages of 20 
to 40 mg/kg/day in 3 to 4 fractionated doses. Naproxen has a long half-life of 14 hours, 
and can provide cardioprotection in some patients. It is used in the maximum daily 
dose of 1000 mg being 250 mg 4 times daily or 500 mg two times a day. For children, 
anti-inflammatory dosage is reduced to 5mg/kg, two times a day. In elderly patients, 
the drug has lower protein binding and delayed excretion, increasing the likelihood of 
toxicity in these patients. In the case of fenoprofen, the dosage is 200mg 4-6 times a day. 
About 15% of users experience side effects, but few discontinue use. Drugs with high 
half-life, as oxaprozin (40 to 60h) allows administration once daily. However, it is 
indicated for fever or acute analgesia because the onset of action is slow. Oxaprozin is 
used in dosage from 600 to 1800 mg/day. 
 Enolic acid derivates: This class is constituted by piroxicam, meloxicam and 
nabumetone. Both meloxicam and nabumetone have relative selectivity for COX-2. 
Piroxicam has equivalent power to Aspirin® and is better tolerated. However, it can 
inhibit the activation of neutrophils and the activity of collagenase and proteoglycanase. 
This drug is administered in daily doses of 20mg. About 20% of users develop side 
effects, while 5% discontinue the treatment. Nabumetone has fewer side effects than 
many NSAIDs. Its administration is performed at doses of 500 to 1000mg, 1 to 2 times a 
day. Meloxicam dosage is 7.5 to 15 mg/day (Goodman et al., 2010). 
3. Glucocorticosteroids (GCs) 
Glucocorticosteroids (GCs) (glucocorticoids; also known as corticosteroids or steroids) are 
steroid hormones derived from cholesterol metabolism. Their basic molecular structure is 
the cyclopentanoperhydrophenanthrene, derived from cholesterol.  
The natural GC representative is the cortisol or hydrocortisone. They are effective anti-
inflammatory and immunosuppressive agents, produced naturally in the adrenal gland 
after stimulation of the hypothalamic-pituitary-adrenal (HPA) (Fernandes et al., 2008; 
Barnes & Adcock, 2009). Since the availability of cortisone in the late 1950s, several synthetic 
GC agonists have been developed, such as prednisone, dexamethasone and betamethasone 
(Löwenberg et al., 2008). The synthetic GCs are obtained from folic acid (taken from cattle) 
or some plants of the families Liliaceae and Dioscoreaceae (Timóteo & Dos Santos, 2008). For 
decades, they have been among the most commonly prescribed classes of 
immunomodulatory and anti-inflammatory drugs, being widely used as treatment of choice 
for several autoimmune and inflammatory diseases, including asthma, rheumatoid arthritis, 
inflammatory bowel disease and polymyalgia rheumatica. However, serious side effects, 
such as osteoporosis, skin atrophy, cushingoid appearance, diabetes and glaucoma, 
frequently accompany GC therapy, which place limitations on the use of higher dosages and 
long-term use of GCs (Flammer & Rogatsky, 2008; Löwenberg et al., 2008). Moreover, 
nowadays, various side effects of glucocorticoids are well-known and physicians often 
anticipate on these side effects (De Nijs, 2008). 
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3.1 Molecular actions of glucocorticosteroids 
GCs act through many molecular mechanisms. One of them occurs through traditional 
glucocorticoid receptor mediated pathways to directly regulate gene expression. In this 
mechanism, the CGs freely diffuses across the cell membrane and act by binding to and 
activating specific cytosolic glucocorticoid receptors (GR). In its inactive state, the GR exists 
as a cytosolic protein bound to two heat shock protein 90 chaperonin molecules. The 
binding to the GC ligand results in a conformational change that allows dissociation of the 
GR from the protein complex, and a quick translocation into the cell nucleus where they can 
modulate gene transcription either by stimulation or inhibition (De Paiva & Pflugfelder, 
2008; Barnes & Adcock, 2009). The glucocorticoid-receptor complex can either induce key 
anti-inflammatory genes that encode anti-inflammatory molecules (e.g. lipocortin-1, IL-10, 
IL-1Rα6, TGF-β and inhibitory IkB proteins) following direct association with glucocorticoid 
response elements (GREs) in the promoter regions of these genes, or selectively repress 
specific inflammatory genes that encode cytokines (e.g. IL-1, IL-6, IL-8, TNF-α), chemokines, 
adhesion molecules (e.g. adhesion molecules E-selectin, ICAM-1, VCAM-1), inflammation-
associated enzymes (e.g. phospholipase A2, COX-2, iNOS), lipid mediators of inflammation 
(e.g. prostaglandins) and receptors by protein-to-protein interaction with transcription 
factors such as the nuclear factor (NF)-кB and activator protein 1 (AP-1), which interact with 
transcriptional coactivator molecules to activate gene transcription (Derendorf & Meltzer, 
2008; Fernandes et al., 2008). Multiple mechanisms are involved in GC-mediated anti-
inflammatory activity in addition to direct GR/NF-кB interaction, such as GC-induced up-
regulation of IкB and glucocorticoid-induced leucine zipper (GILZ), two proteins able to 
bind and inhibit NF-кB activation (Cuzzocrea et al., 2008). 
Furthermore, it has been reported that peroxisome proliferator activated receptor-α (PPAR-
α) can contribute to the anti-inflammatory activity of GCs. PPAR-α is an intracellular 
transcription factor activated by fatty acids that plays a role in inflammation. Previous 
studies indicate that PPAR-α expression is induced by GCs and can mediate some of the GC 
effects, such as modulation of insulin sensitivity and resistance, and can contribute to GC-
induced hyperglycemia and blood pressure increase. Moreover, it has been reported that 
PPAR-α activation can result in inhibition of NF-кB activation and inflammatory gene 
expression (Cuzzocrea et al., 2008).  
3.2 Therapeutic uses 
 Skin diseases: Several skin diseases are typically treated with systemic or topical GCs. 
The main indications are psoriasis, contact dermatitis, atopic dermatitis, exfoliative 
erythroderma, pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, 
cicatricial pemphigoid, gestational herpes, acquired epidermolysis bullosa, linear IgA 
bullous dermatosis, Stevens Johnson syndrome, toxic epidermal necrolysis, erythema 
multiforme minor, lupus erythematosus, dermatomyositis, vasculitis, pyoderma 
gangrenosum, sweet's syndrome, behcet's disease, lichen planus, sarcoidosis and 
chronic urticaria (Pereira et al., 2007; Akama et al., 2009). In pediatric dermatology, 
long-term systemic steroids may be used for the treatment of erythroderma due to 
atopic eczema, pustular psoriasis, childhood pemphigus, chronic bullous dermatosis of 
childhood, systemic lupus erythematosus, pyoderma gangrenosum or complicated 
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3.1 Molecular actions of glucocorticosteroids 
GCs act through many molecular mechanisms. One of them occurs through traditional 
glucocorticoid receptor mediated pathways to directly regulate gene expression. In this 
mechanism, the CGs freely diffuses across the cell membrane and act by binding to and 
activating specific cytosolic glucocorticoid receptors (GR). In its inactive state, the GR exists 
as a cytosolic protein bound to two heat shock protein 90 chaperonin molecules. The 
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GR from the protein complex, and a quick translocation into the cell nucleus where they can 
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long-term systemic steroids may be used for the treatment of erythroderma due to 
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 Respiratory tract diseases: Intranasal GCs are effective treatments for allergic rhinitis, 
rhinosinusitis, and nasal polyposis. They are the most common treatment for patients 
with nasal polyposis and have been designated as the treatment of choice for allergic 
rhinitis (Derendorf & Meltzer, 2008; Zele et al., 2010). The systemic GCs are effective in 
treating allergic rhinitis, but the high risk of serious toxicity with long-term 
administration has hindered their usefulness. The first successful use of GC as a 
pressurized aerosol with no apparent evidence of systemic toxicity was the 
beclomethasone in 1972. In the following years, corticosteroid molecules have been 
refined to create more potent agents with lower bioavailability and enhanced safety 
profiles. Nowadays, various compounds are approved for the management of allergic 
rhinitis in the United States: triamcinolone acetonide, flunisolide, budesonide, 
beclomethasone dipropionate, ciclesonide, fluticasone propionate, mometasone furoate, 
fluticasone furoate (Derendorf & Meltzer, 2008; Zele et al., 2010). Likewise, GCs are the 
most effective and widely used anti-inflammatory drugs for the treatment of asthma 
(Maneechotesuwan et al., 2010; Hagan et al., 2011). The introduction of GCs, in the form 
of cortisone, for the treatment of asthma more than 60 years ago resulted in pronounced 
clinical effects. Today, inhaled GCs are considered to be the most effective anti-
inflammatory treatment, safe in appropriate doses when given to asthmatic children 
and adults who need regular therapy to control symptoms or prevent exacerbations 
owing to reduced systemic absorption and risk of systemic side-effects (Rottier & 
Duiverman, 2009). Moreover, about 40-50% of patients with chronic obstructive 
pulmonary disease are being treated with inhaled GCs (Löwenberg et al., 2008).  
 Rheumatologic diseases: Long-term therapy with GCs is often necessary to control the 
symptoms of rheumatoid arthritis and other rheumatic conditions (Neeck et al., 2002; 
Paul-Clark et al., 2002). It has been reported that up to 60% of patients with rheumatoid 
arthritis are treated more or less continuously with GCs (Löwenberg et al., 2008). 
Polymyalgia rheumatica is also a common indication for long-term glucocorticoid 
therapy and has a favorable prognosis. However there is considerable heterogeneity in 
patients’ clinical course and response to this therapy. In addition, the patients are 
usually maintained on the lowest possible dose to control disease symptoms and to 
minimize GCs complications (Salvarani et al., 2002; Kremers et al., 2007). 
 Gastrointestinal inflammatory diseases: Glucocorticoids are an effective treatment for 
inflammatory bowel disease such as ulcerative colitis and Crohn's disease (Löwenberg 
et al., 2008). Crohn's disease is a chronic inflammatory disorder of the bowel whose 
cause is unknown. During the acute phase of the disease, glucocorticoids such as 
prednisolone and prednisone are commonly used (Thomsem et al., 1998). In ulcerative 
colitis prednisolone was found to induce remission of symptoms concomitantly with 
reduction of endoscopically viewed colonic inflammation (Olaison et al., 1990). 
However, failure to respond, acutely or chronically, to GC therapy is a common 
indication for surgery in inflammatory bowel disease, with as many as 20% of patients 
with ulcerative colitis and approximately 50% of patients with Crohn’s disease 
requiring surgery in their lifetime as a result of poor response to medical therapy 
(Farrell & Kelleher, 2003). 
 Other therapeutic uses: GCs have been successfully used in the management of 
patients with renal diseases, allergic reactions, thrombocytopenia, corneal epithelial 
disease in dry eye and Graves' ophthalmopathy (De Paiva & Pflugfelder, 2008). In 
addition, these agents play an important role in the treatment of immune disorders, 
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including reducing the immune response in autoimmune diseases and organ 
transplantation (Grbović; Radenković, 2005). In short term, high dose suppressive GC 
therapy is also indicated in the treatment of medical emergencies such as necrotising 
vasculitis, status asthmaticus and anaphylactic shock (Swartz; Dluhy, 1978).  
3.3 Side effects and contraindications 
The physiologic effects of GCs are numerous and widespread. They influence electrolyte 
and water balance, carbohydrate metabolism, protein metabolism, lipid metabolism, 
cardiovascular system, skeletal muscle, central nervous system (CNS), formed elements of 
blood and affect other organs and tissues in a wide variety of ways (Chaney, 2002). The 
effect on fluid and electrolytes is due to their mineralocorticoid effect. It causes salt and 
water retention leading to edema, weight gain and hypertension. The potassium loss 
leading to hypokalemia can cause severe weakness (Deshmukh, 2007). Hyperglycemia is a 
known complication of GC therapy caused mainly by increased hepatic capacity for 
gluconeogenesis and reduced sensitivity to insulin. This increase in blood sugar levels can 
be a negative prognostic factor for ill patients (Davenport et al., 2010). Furthermore, GCs 
also increase lipid levels because of increased lipid production in liver and due to lipolysis 
from adipose tissue; and cause redistribution of carbohydrate, fat and protein reserves. This 
along with the increase in appetite can lead to the Cushingoid habitus (moon facies, buffalo 
hump and central obesity) (Deshmukh, 2007).  
Due to these effects in the body, GC therapy is frequently hampered by severe side effects, 
especially when used in high doses for prolonged durations. The adverse effects of 
corticosteroids seen during short-term therapy include increased appetite, weight gain, fluid 
retention, gastritis, headache, mood swings, increase in blood sugar, hypertension and 
glaucoma. Adverse effects seen when therapy is given for longer duration include suppressed 
immunity, increased susceptibility to infections, increased cholesterol levels, weight gain, 
osteoporosis, deposition of body fat, thinning of skin, cataracts, stunting and 
hypothalamopituitary axis suppression (Löwenberg et al., 2008). Bone loss is one of the most 
important side effects of GC use. It starts promptly after initiation and mainly takes place in 
the first six months of treatment. Several studies and reports show a decrease in bone mineral 
density and an increased risk of fractures during GC use. The main effect of GC on bone is 
inhibition of osteoblast function, leading to a decrease in bone formation (De Nijs, 2008). 
These side effects are responsible for several contraindications and limit the use of higher 
dosages and long-term use of GCs (Niedner, 2001; Löwenberg et al., 2008) The most 
important contraindications for the therapy of systemic GCs are uncontrolled hypertension, 
glaucoma, uncontrolled diabetes mellitus, osteoporosis, acute viral infections, bacterial 
infections, systemic fungal infections, parasitic diseases and psychiatric history (Niedner, 
2001). Thus, the clinician must carefully consider in each case the presence of 
contraindications and the gains that can reasonably be expected from GC therapy versus the 
inevitable undesirable side effects of prolonged therapy (Niedner, 2001). The risk of 
glucocorticoid-induced osteoporosis can be reduced, for example, by general measurements 
like prescribing GCs in a low dose and for a short period of time. Furthermore, calcium and 
plain vitamin D3 supplementation and pharmacological intervention with bisphosphonates 
are considered as important support for prevention and treatment of glucocorticoid-induced 
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3.4 Glucocorticosteroid resistance in inflammatory diseases 
GCs resistance or insensitivity is a major barrier to the treatment of several common 
inflammatory diseases, including chronic obstructive pulmonary disease and acute 
respiratory distress syndrome; it is also an issue for some patients with asthma, rheumatoid 
arthritis, and inflammatory bowel disease. The resistance to the anti-inflammatory effects of 
GCs can be induced by several mechanisms that may differ between patients. These 
mechanisms include reduced GR expression, altered affinity of the ligand for GR, reduced 
ability of the GR to bind to DNA, increased expression of inflammatory transcription factors 
(eg, NF-кB, AP-1), raised macrophage migration inhibitory factor, and increased P-
glycoprotein-mediated drug efflux. Patients with GC resistance can be treated with 
alternative broad-spectrum anti-inflammatory treatments, such as calcineurin inhibitors and 
other immunomodulators, or novel anti-inflammatory treatments, such as inhibitors of 
phosphodiesterase 4 or NF-кB (Barnes & Adcock, 2009). 
3.5 Main glucocorticoid drugs 
Several synthetic GC agonists have been developed since the availability of cortisone in the 
late 1950s (Löwenberg et al., 2008). The pharmacologic differences among various GCs 
derivatives result from structural alterations of the basic steroid nucleus and its side groups 
(Cevc & Blume, 2004). The main representatives of this class drugs and their peculiarities are 
described below. 
 Hydrocortisone: A steroid hormone secreted by the adrenal cortex, is a short-acting GC 
(biological half-life of 8–12 hours) available in drug forms as unchanged hormone either 
different salts thereof (acetate, cypionate, sodium phosphate, butyrate, valerate, and 
sodium succinate). The hydrocortisone is used orally, in combination with 
fludrocortisone, for replacement therapy in adrenal insufficiency (Deshmukh, 2007). 
The effect of this agent on the milk is not known (Damiani et al., 2001). Hydrocortisone 
sodium succinate, the water-soluble derivative, is administered parenterally for a 
quicker effect in emergencies (Deshmukh, 2007); 
 Prednisone: An intermediate-acting GC (biological half-life of 12–36 hours), is four to 
five times more potent than hydrocortisone (Zoorob; Cender, 2000). This GC is a 
prodrug, converted in normal circumstances in the body to prednisolone. It’s widely 
used orally in the acute and long-term management of various disorders and for anti-
inflammatory and immunosuppressant effects (Deshmukh, 2007). The use of 
prednisone can be done in nursing mothers (Damiani et al., 2001); 
 Methylprednisolone: An intermediate-acting GC, is four to five times more potent than 
hydrocortisone as well as prednisone (Zoorob; Cender, 2000). It has less 
mineralocorticoid activity than prednisone/prednisolone while having a similar 
duration of action and may be preferred when mineralocorticoid effect is particularly 
undesirable. An alternate day regimen should be considered during long-term therapy 
(Deshmukh, 2007). The use of methylprednisolone can be done in nursing mothers, 
only in low dose (less than 8 mg/day) and the child should be breastfed after 4 hours of 
taking the GC (Damiani et al., 2001);  
 Triamcinolone: An intermediate-acting GC, five times more potent than hydrocortisone 
can be done in nursing mothers (Damiani et al., 2001); 
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 Dexamethasone: Is a long-acting GC (biological half-life of 36–72 hours) highly potent, 
available as oral, parenteral, topical (spray), and ophthalmic dosage forms (Cevc; 
Blume, 2004). Its potency is about 25 times greater than the short-acting products 
(Zoorob; Cender, 2000). This GC has minimal mineralocorticoid activity and is used 
most often in the management of acute disorders because prolonged treatment is 
associated with severe suppression of the HPA axis. Furthermore it's not suitable for 
alternate day regimens where the aim is to maintain the responsiveness of the HPA axis 
(Deshmukh, 2007); 
 Betamethasone: Similar to dexamethasone, is unsuitable for long-term alternate-day 
therapy due to its long duration of action (Deshmukh, 2007). 
The therapeutic dosing regimen of these agents is very wide and depends on the indication 
for treatment. The basis for the use of different dosages in different clinical conditions is 
essentially empirical. Thus, the appropriate dose for a specific therapeutic effect should be 
determined by trial and error as well as should be reassessed periodically, particularly when 
complications arise during a therapy (Buttgereit et al., 2002) 
3.6 Drug Interactions 
GCs are known substrates and inducers of cytochrome P450 3A (CYP3A), enzymes which 
constitute the major phase one drug-metabolizing enzyme family in humans (Anglicheau et 
al., 2003). Thus, drugs that inhibit CYP 3A4, such as erythromycin, clarithromycin, 
ketoconazole, itraconazole, act to reduce serum levels of GC, consequently increasing the 
incidence and severity of side effects of GCs. On the other hand, drugs that induce CYP 3A4, 
such as barbiturates, phenytoin, rifampin, act to reduce serum levels, consequently 
decreasing the activity of several systemic GCs (Pereira et al., 2007).  
These agents are also known substrates and inducers of P-glycoprotein (P-gp), product of 
the multidrugresistance gene responsible for the transmembrane efflux of many drugs. P-gp 
reduces the intracellular concentration of various xenobiotics. The high dose steroid therapy 
was recently shown to lower tacrolimus blood levels in the rat, as a result of the induction of 
P-gp and CYP3A in the intestine and liver (Anglicheau et al., 2003). 
Other drug interactions, which involve other mechanisms, are described below (Table 4): 
Drug Mechanism of drug interaction Consequence 
Estrogens ↑ half-life and ↓ clearance of GCs ↑ action of GCs 
Antacids ↓ absorption of GCs ↓ action of GCs 
Cholestyramine ↓ absorption of GCs ↓ action of GCs 
Ephedrine ↓ half-life and increased clearance of GCs, particularly of dexamethasone ↓ action of GCs 
Cyclosporine Inhibition of metabolism of cyclosporine by prednisolone ↑ action of cyclosporine 
Isoniazid ↓ level serum of isoniazid by GCs ↓ action of isoniazid 
Salicylates ↑ clearance of salicylates by GCs ↓ action of salicylates 
Digitalics GC-induced hypokalemia may ↑ serum concentration of digitalics 
↑ action of 
digitalics 
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available as oral, parenteral, topical (spray), and ophthalmic dosage forms (Cevc; 
Blume, 2004). Its potency is about 25 times greater than the short-acting products 
(Zoorob; Cender, 2000). This GC has minimal mineralocorticoid activity and is used 
most often in the management of acute disorders because prolonged treatment is 
associated with severe suppression of the HPA axis. Furthermore it's not suitable for 
alternate day regimens where the aim is to maintain the responsiveness of the HPA axis 
(Deshmukh, 2007); 
 Betamethasone: Similar to dexamethasone, is unsuitable for long-term alternate-day 
therapy due to its long duration of action (Deshmukh, 2007). 
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determined by trial and error as well as should be reassessed periodically, particularly when 
complications arise during a therapy (Buttgereit et al., 2002) 
3.6 Drug Interactions 
GCs are known substrates and inducers of cytochrome P450 3A (CYP3A), enzymes which 
constitute the major phase one drug-metabolizing enzyme family in humans (Anglicheau et 
al., 2003). Thus, drugs that inhibit CYP 3A4, such as erythromycin, clarithromycin, 
ketoconazole, itraconazole, act to reduce serum levels of GC, consequently increasing the 
incidence and severity of side effects of GCs. On the other hand, drugs that induce CYP 3A4, 
such as barbiturates, phenytoin, rifampin, act to reduce serum levels, consequently 
decreasing the activity of several systemic GCs (Pereira et al., 2007).  
These agents are also known substrates and inducers of P-glycoprotein (P-gp), product of 
the multidrugresistance gene responsible for the transmembrane efflux of many drugs. P-gp 
reduces the intracellular concentration of various xenobiotics. The high dose steroid therapy 
was recently shown to lower tacrolimus blood levels in the rat, as a result of the induction of 
P-gp and CYP3A in the intestine and liver (Anglicheau et al., 2003). 
Other drug interactions, which involve other mechanisms, are described below (Table 4): 
Drug Mechanism of drug interaction Consequence 
Estrogens ↑ half-life and ↓ clearance of GCs ↑ action of GCs 
Antacids ↓ absorption of GCs ↓ action of GCs 
Cholestyramine ↓ absorption of GCs ↓ action of GCs 
Ephedrine ↓ half-life and increased clearance of GCs, particularly of dexamethasone ↓ action of GCs 
Cyclosporine Inhibition of metabolism of cyclosporine by prednisolone ↑ action of cyclosporine 
Isoniazid ↓ level serum of isoniazid by GCs ↓ action of isoniazid 
Salicylates ↑ clearance of salicylates by GCs ↓ action of salicylates 
Digitalics GC-induced hypokalemia may ↑ serum concentration of digitalics 
↑ action of 
digitalics 





4. New anti-inflammatory agents 
Nowadays, the increasing research developments in the fields of chemistry, pharmacology 
and molecular modeling, among others, share a common purpose: the pursuit and design of 
new agents and therapeutic targets. In this context, one area has raised interest in the field of 
therapeutic innovation: the treatment of inflammatory diseases. 
Although its high therapeutic power, the anti-inflammatory therapies on the market have a 
high incidence of side effects resulting from its use (especially chronic), making unfavorable 
the risk/benefit ratio of these medications in many patients. Given this context, it becomes 
necessary to introduce new therapeutic options with more effective, specific and with fewer 
adverse effects actives. Currently, several targets and agents are being tested for their anti-
inflammatory activity, such as: 
 Components of signal transduction (e.g. NF-ĸB and mitogen-activated protein kinase 
such as p38 kinase and c-Jun N-terminal kinases - JNKs): Some of small molecules that 
inhibit p38 kinase are in the final stages of clinical trials (Kulkarni et al., 2006);  
 Dual inhibitiors of COX-2 and 5-lipoxygenase (5-LOX): Various structural families of 
dual inhibitors have been designed and several compounds are currently undergoing 
pre-clinical or clinical development. By preventing the biosynthesis of both prostanoids 
and LTs, they are potent anti-inflammatory agents (Charlier & Michaux, 2003);  
 Proinflammatory cytokines: Given their central role in the regulation of inflammatory 
responses, cytokines are clearly appealing targets for therapeutic intervention. 
Emphasis has been placed on cytokines that are produced early in the inflammatory 
cascade such as TNF-α and IL-6. Therapeutics neutralizing these cytokines or their 
receptors are already on the market or in late-phase development (Kopf et al., 2010). 
Recently, a new biological target for anti-inflammatory therapy has been identified: the 
peroxisome proliferator-activated receptors (PPAR). PPARs are ligand-activated transcription 
factors belonging to the nuclear receptor superfamily. This superfamily includes steroidal 
transcription factors, non-steroidal receptors, PPARs and liver X receptor (LXR). 
Three major subtypes of the receptor have been identified: PPAR-α, PPAR-β and PPAR-γ. 
Originally, the PPAR activity was thought to be limited to lipid metabolism and glucose 
homeostasis, being the PPAR-γ agonists (known as thiazolidinediones) commonly 
prescribed for the treatment of diabetes. Later studies showed that PPAR activation 
regulates other biological functions such as cell proliferation, differentiation and apoptosis 
(Moraes et al, 2006).  
Several studies have showed that PPAR-α and PPAR-γ inhibit the expression of 
inflammatory genes. All available data indicate that the activation of PPAR-α and PPAR-γ 
modulates oxidative stress-sensitive pathways, NF-ĸB, AP-1, and signal transducers and 
activators of transcription (STAT). These findings strongly indicate the potential as 
therapeutic target sites of PPAR-α and PPAR-γ in controlling the inflammatory process and 
age-related inflammatory diseases. In support of evidence on the role of PPAR-α in the 
suppression of NF-B activity, PPAR-α agonists are shown to decrease production of pro-
inflammatory mediators such as IL-6, IL-12, IL-1a, iNOS, and COX-2, which are associated 
with the decrease in NF-B activation. 
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Apart from its role as a transcription factor, PPAR-γ also acts as a trans-repressor of 
macrophage inflammatory genes. Ligand-independent activation of PPAR-/ can suppress 
bowel disease by down regulation of inflammatory signaling (Chung et al., 2008). 
During inflammatory responses, PPARs can be activated by eicosanoids. Ligands for PPAR-
γ include leukotriene B4, 8(S)-hydroxyecosatetraenoic acid (HETE), 15-deoxy-D-12,14-
prostaglandin J2, 15-HETE and 13-hydroxyoctadecadienoic acid. Nuclear receptors can 
regulate macrophage gene expression in response to changes in cellular lipids and 
arachidonic acid metabolites that occur during inflammatory responses (Rizzo & Fiorucci, 
2006). 
PPAR-γ protein was identified in the antigen presenting cells, monocytes and macrophages 
and synthetic PPAR-γ agonists including pioglitazone, troglitazone and rosiglitazone were 
shown to suppress production of inflammatory cytokines by these cells (Jiang et al., 1998; 
Ricote et al., 1998). Subsequently, PPAR-γ was identified in dendritic cells. The same 
thiazolidinedione compounds were demonstrated to decrease dendritic cell secretion of IL-
12, a potent TH1-type inflammatory cytokine (Martin, 2010). 
In this context, PPAR-γ agonists have been investigated for their anti-inflammatory effects. 
Beneficial effects of the PPAR-γ activator, rosiglitazone, were reported in two recent clinical 
trials for the treatment of Ulcerative Colitis (Lewis et al., 2008; Liang & Ouyang, 2008). 
Animal models of inflammation are now being used to explore the utility of PPAR-γ 
agonists in other inflammatory diseases. 
5. Conclusion 
The steroidal and non-steroidal anti-inflammatory drugs provide efficient therapies for the 
treatment of inflammatory diseases. However, several adverse effects related to acute and 
especially cronic use of such drugs limit its use in some patients. Thus, the clinician should 
take into account the risks and benefits of treatment for the patient before starting the 
therapy. 
Recent searches for new targets and anti-inflammatory agents aim to attend the demand for 
new secure and equally efficient therapies for the treatment of inflammation. In this context, 
PPAR- agonists appear as candidates for anti-inflammatory drugs. 
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1. Introduction 
Respiratory allergy (allergic rhino conjunctivitis and allergic asthma), is community 
encountered medical condition that cause substantial morbidity and mortality worldwide 
[1]. Asthma is still remains a concerning and coasty epidemic that is largely unexplained [2]. 
In Iraq, both allergic rhinitis and asthma cause poor performance at work and school and 
diminished quality of life [3]. Suspected allergen(s) avoidance is the first-line treatment for 
these conditions. However, in many cases, exposure to a particular allergen cannot be 
completely avoided [4]. Pharmacotherapy, whether that reversing inflammation or 
controlling the effect of released mediators are not always fully effective or well tolerated 
[4]. Allergen immunotherapy is widely accepted as an efficacious treatment in allergic 
rhinitis and asthma [5-9]. Well characterized dust mite extracts have shown significant 
benefit by reducing symptoms, medication requirements and sensitivity to dust mite 
allergens [10]. Recent studies of specific immunotherapy using standardized extracts also 
showed improvement in symptoms, medication and bronchial hyperresponsiveness [10-13]. 
However, Adkinson et al [14] were unable to show any significant improvement in 
symptoms, medication use, peak flow rate, BHR or rate of asthma remission following 
multiple allergens SIT in asthmatic children. 
More recent studies in children and adults show additional positive outcomes of SIT which are 
decreased tendency for additional environmental sensitization [15], as well as a decreased 
incidence of asthma in treated allergic rhinitis patients [16]. Although the documented 
effectiveness of SIT in the treatment of allergic rhinitis and allergic asthma, the real life efficacy 
and use of this treatment option is severely limited by perceived low patient compliance [17, 
18], adverse local and systemic side effects [19, 20] and significant delay in effect after the 
initiation of therapy, all of which may lead to relatively low adherence rate [8]. 
Although there is much and convincing evidence for SIT effectiveness and efficacy from 
international studies only single study has prospectively investigated the real-life efficacy 
in Iraqi patients [21]. This prospective study of patients undergoing SIT in an office 
setting to produce practical data of efficacy of house dust mite extracts for allergic 
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Objectives: To  
1. Determine the therapeutic efficacy of house dust mite immunotherapy in Iraqi patients 
with allergic rhinitis and asthma. 
2. Clarify whether specific immunotherapy of therapeutic benefits in patient with asthma 
and allergic rhinitis.  
2. Patients and methods 
2.1 Patients 
From January 2000 to December 2008, we selected 822 patients with allergic rhinitis and asthma 
to receive subcutaneous specific immunotherapy according to European Academy of Allergy 
and Clinical Immunology (EAACI) guidelines [22] in a double blind placebo controlled clinical 
trial. Subjects were recruited from asthma clinic in the city of Tikrit, Iraq, only subjects who 
fulfilled the GINA guidelines for mild to moderate asthma and/or allergic rhinitis [23] and had 
positive skin prick-test to Dermatophagoides pteronyssinus and/or D. farines were included. 
Subjects excluded if their PEER of <80% of predicted value recorded on 3 occasions during the 
2 week prior to randomization, with positive SPT to animals and pets at home; asthma 
exacerbation during the last month prior to first visit, forced expiratory volume at 1 second 
(FEV1) of <60% predicted during the screening visits, had any serious chronic underlying 
illness. Patients were evaluated by medical history, clinical examination and skin prick test 
with common allergen. All data were collected prospectively, including information on 
exposure, social factors, additional diagnosis and medication usage, family history of allergic 
diseases, exposure to house pets, active or passive smoking, measures of treatment efficacy, 
and patients’ satisfaction as well as local and systemic reactions to the SIT shots. The protocol 
was approved by Tikrit University College of Medicine Ethical Committee and informed 
written consent taken from each patient. After patient selection, they were randomized to SIT 
and/or placebo and pharmacotherapy. The two groups were comparable at baseline (Table-1). 
 
Variable Immunotherapy Placebo P value 
Patients no. 411 411 NS 
Female/Male 198/213 194/217 NS 
Defaulted 73(18%) 94(23%) NS 
Patients for analysis 338(82%) 317(77%) NS 
Age range 6-65 6-65 NS 
Age mean 32±15 31±18 NS 
Clinical history 
AR 52(15%) 54(17%) NS 
Asthma 115(34%) 107(34%) NS 
AR+ Asthma 171(51%) 156(49%) NS 
Use of medication 
Antihistamine 270(80%) 269(85%) NS 
Glucocorticoids 135(39%) 127(40%) NS 
Β2-mimetics 166(49%) 149(47%) NS 
Mast cell stabilizer 101(30%) 111(35%) NS 
Table 1. Patient characteristics. 
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2.2 Asthma and allergic rhinitis diagnosis 
The diagnosis of asthma and classification was performed by specialist physicians based on 
the National Heart Blood and Lung Institute / World Health Organization (NHLBI/WHO) 
workshop on the Global Strategy for Asthma [24]. Allergic rhinitis diagnosis was performed 
according to previously reported guidelines [25].  
2.3 Lung function test 
Computerized Spirometer (Autosphiror, Discom-14, Chest Corporation, and Japan) was 
used for measurement of FEV1 predicted percent of the patients at their enrollment in the 
study and when indicated according to studies design. 
2.4 Skin prick test 
The skin prick tests were performed for all patients and control and evaluated in accordance 
with European Academy of Allergy and Clinical Immunology subcommittee on allergy 
standardization and skin tests using standards allergen panel (Stallergen, France). The panel 
for skin test include: dust mite ( Dermatophagoides farina, Dermatophagoides 
peteronyssinus), Aleternaria, Cadosprium, Penicillum mixture, Aspergillus mixture, Grasses 
mixture, Feather mixture, Dog hair, Horse hair, Cat fur, Fagacae, Oleaceae, Betulaceae, 
Plantain, Bermuda grass, Chenopodium and Mugworth. All tests were performed in the 
outpatient Asthma and Allergy Centre, Mosul by a physician using a commercial allergen 
extracts (Stallergen, France) and a lancet skin prick test device. A wheal diameter of 3 mm or 
more in excess of the negative control was considered as positive test result.  
2.5 Allergen extracts for SCIT 
Therapeutic vaccines containing allergen extracts were purchased from Stallergen, France. 
Both aqueous and glycenerated extracts were used to achieve a concentrate of 1:100 w/v of 
the mixed extract. In standardized extracts the stock formulation was prepared by tenfold 
dilution. Separate vial was used for allergen extract to reduce proteolysis degradation. All 
extracts were stored at 8 0C . Therapeutic vaccine varied with each individual patient based 
on specific allergen identified during testing. Moist patients received a variety of 
aeroallergen combination.  
2.6 SCIT protocol 
The treatment protocol is of two stage, the attack and maintenance stages. The attack treatment 
with gradual increase in dose and concentration of vaccine content were carried weekly for a 
period of 20 weeks. The vaccine is injected by deep subcutaneous route in the posterior aspect 
of upper arm. The maintenance treatment dose given in a constant dose every 15 days and 
then every 4 or 6 weeks interval. The interval between two maintenance injections must not 
exceed 6 weeks. Local reaction size was measured 20 minutes after each injection. Observed 
large local reactions (more than 20 mm wheal size) mandated a repeat of the same dose on the 
next visit, while systemic allergic reactions (skin, respiratory, cardiovascular, and / or 
gastrointestinal) required a two fold reduction in vaccine concentration. Maintenance dose 
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2.7 Immunotherapy schedule 
Immunotherapy was given in term of conventional schedule. Conventional Immunotherapy 
build- up was typically given as injection per week until the maintenance dose was reached 
and it was given once monthly. Allergen vaccines were administered subcutaneously 
according to EAACI guidelines [26] after the patients had given their informed consent. 
3. Evaluation of treatment efficacy 
3.1 Symptom score 
A 10 cm visual analogue scales from 0=absent to 10=sever symptoms, for each symptom: 
rhinorrhoea, nasal congestion, nasal itching, ocular itching, sneezing, asthma symptoms 
(chest tightness, shortness of breath, cough) and wheezing as recommended by the ARIA 
review [27]. A change of 2 or more points on this scale is considered a clinically significant 
change with consequent significant change in the patient quality of life. 
3.2 Medication score 
Medication usage was recorded by patients on a VAS from 0=no medication to 10=repeated 
daily use of nasal corticosteroids, antihistamine oral medication, eye drops, inhaler 
corticosteroids, systemic corticosteroids, and beta agonists. 
Patients graded their symptoms retrospectively at each visit. The use of rescue medication 
was recorded on the diary card in addition to regular medications. 
3.3 Determination of serum eosinophil cationic protein 
Serum ECP was determined by ELISA kit (MBL MESCACUP ECP TEST) from Medical and 
Biological Laboratories Co. LTD, Japan. Serum ECP determined by ELISA kit (MBL 
MESCACUP ECP TEST) from Medical and Biological Laboratories Co, LTD, Japan. This 
ELISA detects s human ECP with a minimum detection limit of 0.125 ng/ml. The test 
performed according to the instruction of manufacturer. Briefly, In the wells coated with 
antihuman ECP monoclonal antibody, 100 ul of diluted serum samples ( 1:5 sample 
diluents) or standards were added and incubated for 60 minutes at room temperature (20 - 
25 0C ). After washing for 4 times, a 100ul of peroxidase conjugated antihuman ECP 
polyclonal antibody is added into the wells and incubated for 60 minutes at room 
temperature. After another 4 times washing, a 100 ul of peroxidase substrate reagent is 
added to each well and the plate incubated for 10 minutes at room temperature. The add 100 
ul of stop solution (0.5 mol/l H2SO4) and read the absorbance at 450 nm using a microplate 
reader. The concentration of ECP is calibrated from a standard curve based on reference 
standards. 
3.4 Statistical analysis and data collection 
The results of the study are reported as ratios and/or percentage of the entire cohort. Paired 
sample t-test was used for the comparison of symptoms and medication scores. Chi square 
test was used for comparison of the SPF and pulmonary function test in both groups, using 
SPSS computer package. P values of < 0.05 were considered significant.  
 




A total of 822 patients were randomized into two treatment groups (411 for each). Of them 
167 subject defaulted during the trial (73 subjects, 18% in the SIT group; 94 subjects, 23% in 
placebo group). In most cases this was due to logistical barriers, work schedule, travel 
distance to the clinic and patients and some doctors wrong opinion regarding SIT. Thus 655 
subjects were eligible for analysis (338 subjects, 82% in the SIT group; 317 subjects, 77% in 
the placebo group), with age range of 6-65 years (Mean 32±15 for SIT group and 31±18 for 
the placebo group), completed at least 3 years of treatment. There was no significant 
difference in the frequency of AR, Asthma and AR with asthma between immunotherapy 
and placebo groups. 
4.1 Asthma group 
A negative PFT was demonstrated in 87% of asthmatic patients receiving SIT and in 91% of 
patients in placebo group (P=0.0001). In addition PFT improvement was demonstrated in 
67% in SIT group and in 19% of placebo group (P=0.0001). Symptom score reduced from 
7.56±1.84 to 3.30±1.74 in SIT group (P=0.0001), while it was reduced from 7.63±1.66 to 
7.11±2.65 in placebo group (P=0.08). Medication score significantly declined from 5.38±1.12 
to 2.20±0.90 in SIT group. While in placebo it was reduced from 5.30±1.41 to 4.94±1.31 in the 
placebo group (P=0.05). Combined symptom and medication score significantly (P=0.0000) 
declined from 6.64±1.48 to 2.73±0.97 in SIT group. In placebo group the reduction was not 
significant (P=0.99). Serum ECP reduced significantly (P=0.000) in both SIT (29.3±7.21 to 
15.3±4.11) and placebo (27.1±6.14 to 17.2±3.27). Table -2. 
Variables Immunotherapy Placebo P value 
No of patients 115 107  
SPT negative 87% 9.1% 0.0001 
PFT improvement  67% 19% 0.0001 
Symptom score 
Pre- treatment  7.56(0.84) 7.63(0.66) 0.49 
Post-treatment  3.30(0.74) 5.56(0.65) 0.0001 
P value 0.0001 0.0004  
Medication score 
Pre-treatment  5.38(1.12) 5.30(1.01) 0.94 
Post-treatment  2.20(0.90) 3.84(1.11) 0.001 
P value 0.0003 0.002  
Combined symptom and medication score 
Pre-treatment  6.64(1.48) 6.47(1.47) 0.39 
Post –treatment 2.73(0.97) 4.70(1.25) 0.0001 
P value 0.0001 0.0001  
ECP 
Pre –treatment 29.3(7.21) 27.1(6.14) 0.01 
Post –treatment 15.3(4.11) 17.2(3.27) 0.0002 
P value 0.0001 0.0001  
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Variables Immunotherapy Placebo P value 
No of patients 115 107  
SPT negative 87% 9.1% 0.0001 
PFT improvement  67% 19% 0.0001 
Symptom score 
Pre- treatment  7.56(0.84) 7.63(0.66) 0.49 
Post-treatment  3.30(0.74) 5.56(0.65) 0.0001 
P value 0.0001 0.0004  
Medication score 
Pre-treatment  5.38(1.12) 5.30(1.01) 0.94 
Post-treatment  2.20(0.90) 3.84(1.11) 0.001 
P value 0.0003 0.002  
Combined symptom and medication score 
Pre-treatment  6.64(1.48) 6.47(1.47) 0.39 
Post –treatment 2.73(0.97) 4.70(1.25) 0.0001 
P value 0.0001 0.0001  
ECP 
Pre –treatment 29.3(7.21) 27.1(6.14) 0.01 
Post –treatment 15.3(4.11) 17.2(3.27) 0.0002 
P value 0.0001 0.0001  





4.2 Allergic rhinitis group 
After 3 years of intervention, negative SPT demonstrated in 81% of patients receiving SIT 
and in 19% of placebo group (P=0.000). Symptom score reduced significantly (P=0.0001) 
from 6.61±1.62 to 2.71±0.74 in SIT group. The reduction of symptom score in placebo group 
was not significant (6.67±1.37 to 6.00±1.16, P=0.99). Furthermore, medication score declined 
significantly (P=0.0001) from 5.35±1.85 to 2.21±1.87 in SIT group, while the reduction was 
not significant (P=0.98) in placebo group. 
In addition, combined medication and symptom score was significantly reduced (P=0.0001) 
from 6.12±1.7 to 2.52±1.78 in SIT group, while the reduction in placebo group was not 
significant. Serum ECP reduced significantly in both SIT (19.3±7.01 to 14.2±5.10, P=0.0001) 
and placebo group (20.1±5.30 to 17.3±6.31, P=0.014) Table -3. 
Variables Immunotherapy Placebo P value 
No of patients 52 54  
SPT negative 81% 19% 0.0001 
Symptom score 
Pre-treatment  6.61(1.62) 6.67(1.37) 0.76 
Post -treatment 2.71(0.74) 5.64(1.16) 0.0001 
P value 0.0001 0.0001  
Medication score 
Pre –treatment 5.35(1.85) 5.3(2.27) 0.85 
Post –treatment 2.21(0.87) 4.10(2.44) 0.0001 
P value 0.0001 0.009  
Combined symptom and medication score 
Pre-treatment  6.12(1.7) 6.16(1.75) 0.86 
Post -treatment 2.52(0.78) 5.10(1.80) 0.0001 
P value 0.0001 0.002  
ECP 
Pre-treatment 19.3(7.01) 20.1(5.30) 0.37 
Post -treatment 14.2(5.10) 17.3(6.31) 0.0001 
P value 0.0001 0.014  
Table 3. Response to SCIT in patients with allergic rhinitis. 
4.3 Patients with both allergic rhinitis and asthma 
PFT improvement was demonstrated in 65% of SIT group while it was 25% in placebo group 
(P=0.0001). In addition, negative SPT was demonstrated in 78% of patients receiving SIT, 
while the corresponding value was 23% in placebo group (P=0.0001). 
Symptom score declined significantly (P=0.0001) from 7.56±1.87 to 3.42±1.55 in SIT group, 
while the reduction in placebo group was not significant (P=0.052). 
Medication score reduced significantly (P=0.0001) from 5.22±2.72 to 2.72±1.53 in SIT, but the 
reduction in placebo group was not significant (5.30±1.99 to 4.99±1.86, P=0.10). 
Combined symptom and medication score reduced significantly (P=0.0001) from 6.72±1.51 
to 3.18±1.63 in SIT, while the reduction in placebo group was not significant (6.32±2.72 to 
6.32±1.99, P=0.31). 
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Serum ECP reduced significantly (P=0.0001) in both SIT (34.2±13.2 to 16.3±6.72) and placebo 
group (31.1±11.7 to 19.2±5.4) Table -4. 
Variables Immunotherapy Placebo P value 
No of patients 171 156  
SPT negative 78% 23% 0.0001 
PFT improvement  65% 25% 0.0001 
Symptom score 
Pre –treatment 7.56(0.87) 7.35(0.84) 0.06 
Post – treatment 3.43(0.55) 5.69(0.87) 0.0001 
P value 0.0001 0.0001  
Medication score 
Pre –treatment 5.22(0.89) 5.30(0.79) 0.48 
Post –treatment 2.72(0.53) 4.26(0.86) 0.0001 
P value 0.0001 0.0001  
Combined symptom and medication score 
Pre-treatment  6.72(1.51) 6.62(1.29) 0.59 
Post -treatment 3.18(0.63) 5.19(1.10) 0.0001 
P value 0.0001 0.0001  
ECP 
Pre –treatment 34.2(13.20) 31.1(11.7) 0.34 
Post -treatment 16.3(6.72) 19.2(5.4) 0.0005 
P value 0.0001 0.0001  
Table 4. Response to SCIT in patients with asthma and allergic rhinitis. 
4.4 All patients 
We combined the data of the three groups together. There was a significant decline 
(P<0.0001) in symptom score from baseline value to that of after 3 years intervention in the 
SIT (P=0.0001, 7.29±1.2 to 3.18±1.54), but not in the placebo treated subjects (7.23±2.89 to 
6.93±1.85, P=0.12). Medication score significantly (P=0.0001) declined in SIT (5.38±1.05 to 
2.42±1.66), and placebo (5.31±2.38 to 4.82±2.14, P=0.03). 
The SIT resulted in significant (P=0.0001) decline in combined symptom and medication 
score (6.61±1.46 to 2.91±1.68). In addition, placebo group demonstrated a significant 
reduction (P=0.03) in combined medication and symptom score (6.27±2.37 to 
5.88±2.2).Serum ECP reduced significantly (P=0.0001) in both SIT (30.2±7.9 to 15.6±2.32) and 
placebo (27.9±6.37 to 18.2±5.8) groups. Table -5. 
Variables Immunotherapy Placebo P value 
No of patients 338 317  
SPT negative 82%(5) 17%(7) 0.0001 
PFT improvement  66(2) 22(4) 0.0001 
Symptom score 
Pre –treatment 7.29(1.20) 7.23(0.99) 0.48 
Post –treatment 3.18(0.54) 5.63(0.85) 0.0001 
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Serum ECP reduced significantly (P=0.0001) in both SIT (34.2±13.2 to 16.3±6.72) and placebo 
group (31.1±11.7 to 19.2±5.4) Table -4. 
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(P<0.0001) in symptom score from baseline value to that of after 3 years intervention in the 
SIT (P=0.0001, 7.29±1.2 to 3.18±1.54), but not in the placebo treated subjects (7.23±2.89 to 
6.93±1.85, P=0.12). Medication score significantly (P=0.0001) declined in SIT (5.38±1.05 to 
2.42±1.66), and placebo (5.31±2.38 to 4.82±2.14, P=0.03). 
The SIT resulted in significant (P=0.0001) decline in combined symptom and medication 
score (6.61±1.46 to 2.91±1.68). In addition, placebo group demonstrated a significant 
reduction (P=0.03) in combined medication and symptom score (6.27±2.37 to 
5.88±2.2).Serum ECP reduced significantly (P=0.0001) in both SIT (30.2±7.9 to 15.6±2.32) and 
placebo (27.9±6.37 to 18.2±5.8) groups. Table -5. 
Variables Immunotherapy Placebo P value 
No of patients 338 317  
SPT negative 82%(5) 17%(7) 0.0001 
PFT improvement  66(2) 22(4) 0.0001 
Symptom score 
Pre –treatment 7.29(1.20) 7.23(0.99) 0.48 
Post –treatment 3.18(0.54) 5.63(0.85) 0.0001 





Variables Immunotherapy Placebo P value 
Medication score 
Pre –treatment 5.38(1.05) 5.31(1.08) 0.62 
Post treatment 2.42(0.66) 4.10(1.15) 0.0001 
P value 0.0001 0.0001  
Combined symptom and medication score 
Pre –treatment 6.61(1.46) 6.54(1.37) 0.71 
Post –treatment 2.91(0.68) 5.10(1.20) 0.0001 
P value 0.0001 0.0001  
ECP 
Pre –treatment 30.2(7.9) 27.9(6.37) 0.01 
Post -treatment 15.6(2.32) 18.2(5.8) 0.0001 
P value 0.0001 0.0001  
Table 5. Response to SCIT in all patients. 
4.5 Percentage and amount of score changes  
The SIT resulted in significantly (P=0.0001) greater subjective rating of improvement than 
placebo treatment in all four parameters (symptom score, medication score, combined 
symptom and medication score, and serum ECP). Whether the analysis performed for each 
disease condition alone (allergic rhinitis, asthma, both allergic rhinitis and asthma) or 
combined in one group (all patients). 
The results are summarized in Table -6. 
Variables Immunotherapy Placebo P value 
No of patients 338 317  
SPT negative 277 54 0.0001 
PFT improvement 223 70 0.0001 
Asthma group 
Symptom score 4.17(55.2%) 2.07(27%) 0.0001 
Medication score 3.18(59.1%) 1.46(27.5%) 0.0001 
Both scores 3.73(56.2%) 1.77(27.4%) 0.0001 
ECP 15.3(52.2%) 9.9(36.5%) 0.0001 
Allergic rhinitis group 
Symptom score 3.91(59.2%) 1.03(15.4%) 0.0001 
Medication score 3.14(59%) 1.20(22.6%) 0.0001 
Both scores 3.60(59%) 1.06(17.2%) 0.0001 
ECP 5.10(26.4%) 2.80(14%) 0.0001 
Allergic rhinitis and Asthma group 
Symptom score 4.13(55%) 1.66(22.5%) 0.0001 
Medication score 2.50(48%) 1.04(20%) 0.0001 
Both scores 3.54(53%) 1.43(22%) 0.0001 
ECP 17.90(52.3%) 11.90(38.3%) 0.0001 
All patients 
Symptom score 4.11(56.4%) 1.60(22.1%) 0.0001 
 
House Dust Mite Immunotherapy in Iraqi Patients with Allergic Rhinitis and Asthma 
 
149 
Variables Immunotherapy Placebo P value 
Medication score 2.96(55%) 1.21(23%) 0.0001 
Both scores 3.7(56%) 1.44(22%) 0.0001 
ECP 14.60(48.3%) 9.70(35%) 0.0001 
Table 6. Reduction in clinical scores following SIT in patients with asthma and allergic 
rhinitis. 
5. Discussion 
Despite numerous studies, the role of IT in the management of asthma remains controversial 
[28, 29], and interpretation of published reports varies considerably, presumably because of 
personal bias [30]. The variability in response to SIT in allergic diseases as reported in the 
literature may be due to uncontrolled factors that differ for people receiving the same 
therapy [30]. These factors are environmental control measures, degree of allergen exposure, 
type of allergen exposure, presence of allergenic sensitivities not incorporated into the 
treatment; non-allergenic triggers of asthma such as infection or exposure chemical 
sensitizer, genetic influence and source of vaccine used in IT. Furthermore, the outcome of 
the treatment trial influenced by allergen specificity used in the treatment as well as the 
dose and treatment schedule employed in the course. 
This is the first clinical trial that evaluated the effectiveness of SIT in Iraq, and includes a 
large treatment group, in which the outcome measured using objective criteria. 
The current study shows conclusively that house dust mite SIT results in significant 
improvement in allergic rhinitis and asthma, symptoms and reduction in rescue medication 
requirement. The results of this study differ from that of less successful studies [14, 31] with 
a population more heterogeneous in their allergen sensitivities. In our study we used a 
single allergen for treatment, as the house dust mite, Dermatophagoides, was by far the 
most important allergen in our study population. However, this study finding was in 
agreement to that reported by others [10, 32-36]. 
Immunotherapy has been established as efficacious treatment for allergic rhinitis by 
seasonal pollens, dust mite, and animal allergens, some studies show controversial findings 
[30]. A recent review [37] concluded that immunotherapy is highly effective in the treatment 
of allergic rhinitis. Several reported studies have shown that immunotherapy is effective for 
the treatment of AR, both in adults and children [14, 38, 39]. 
This study indicated that HDM immunotherapy significantly reduced symptom score, 
medication score and serum ECP level. Furthermore, in patients with both AR and asthma, 
HDM IT significantly reduced the symptom score, medication score and serum ECP mean 
level. However, the response was superior in group of patients with AR alone as compared 
to group of patients with AR and asthma. This finding is consistent with that reported by 
others [33].  
Avoidance and medication provide suboptimal control of AR in up to 40% of some patient 
populations [40]. However, this study demonstrated that HDM IT induced a 59% reduction 
in combined symptom & medication score in patients with allergic rhinitis, while the 
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requirement. The results of this study differ from that of less successful studies [14, 31] with 
a population more heterogeneous in their allergen sensitivities. In our study we used a 
single allergen for treatment, as the house dust mite, Dermatophagoides, was by far the 
most important allergen in our study population. However, this study finding was in 
agreement to that reported by others [10, 32-36]. 
Immunotherapy has been established as efficacious treatment for allergic rhinitis by 
seasonal pollens, dust mite, and animal allergens, some studies show controversial findings 
[30]. A recent review [37] concluded that immunotherapy is highly effective in the treatment 
of allergic rhinitis. Several reported studies have shown that immunotherapy is effective for 
the treatment of AR, both in adults and children [14, 38, 39]. 
This study indicated that HDM immunotherapy significantly reduced symptom score, 
medication score and serum ECP level. Furthermore, in patients with both AR and asthma, 
HDM IT significantly reduced the symptom score, medication score and serum ECP mean 
level. However, the response was superior in group of patients with AR alone as compared 
to group of patients with AR and asthma. This finding is consistent with that reported by 
others [33].  
Avoidance and medication provide suboptimal control of AR in up to 40% of some patient 
populations [40]. However, this study demonstrated that HDM IT induced a 59% reduction 
in combined symptom & medication score in patients with allergic rhinitis, while the 





indicated efficacy of SIT in AR in adults and children [9, 41-45]. There are clinical and 
immunological evidence that supports the long term efficacy of SIT [46]. 
In our study we don’t use BHR to a direct stimulus such as methacholine or histamine since it 
has poor correlations with indices of airway inflammation such as sputum eosinophils [47-49]. 
Thus we used serum ECP because it is a better marker of airway inflammation in asthma as in 
correlates with sputum eosinophils [49] and PFT following IT and medication [50]. Serum ECP 
level decreased after 2 years of immunotherapy in perennial allergic rhinitis [51] and asthma 
[50]. However, the rise in serum ECP after allergen challenge was significantly attenuated after 
just 1 year of immunotherapy in asthmatic patients [52]. Our study indicated a significant 
decrease in serum ECP in both SIT and placebo treated subject. However, the reduction was 
significantly higher in SIT group as compared to placebo group for patients with AR, Asthma, 
and AR with Asthma and when the data of patients pooled together. In placebo treated group 
decline in serum ECP may be due to treatment with inhaled corticosteroids. 
When the data of three disease groups pooled together, the symptom score, medication 
score, combined score and serum ECP significantly reduced in SIT as compared to placebo 
treatment group. Furthermore, SPT negative results and PFT improvement were 
significantly higher in SIT compared to placebo group. 
In this study SIT induces a significant reduction in all parameters used in the study whether 
the patients were with AR, asthma or both combined together. SIT shows overall percent 
reduction of 54%, while it was 17.5% in placebo group. 
Based on the finding of this and other studies, single allergen SIT is likely to be beneficial to 
patients with AR, asthmatic and with both, sensitized to a dominant allergen. However, 
there are other drugs such as inhaled long acting B2-agonist and anileukotriens agents that 
might be better at symptom control and lung function improvement, SIT has some unique 
benefits [10]. 
Haugaard et al [53], reported that SIT reduce airway sensitivity to allergens, which may lead 
subsequently to reduction in frequency of exacerbation and severity of asthma triggered by 
allergen exposure. In addition, the effect of SIT may persist for at least 5-6 years after the 
end of treatment [53]. Furthermore, SIT reduces the conversion of AR to asthma [51] and 
prevents the development of new sensitization [44].  
Different studies show controversial outcome for SIT. Failure to respond to SIT may be due 
to: inadequate dose of allergen, missing allergens not identified during the allergy 
evaluation, inadequate environmental control, and exposure to non allergenic triggers. 
Systemic adverse reactions were developed in 62 (15.1%) individuals from the 411 subjects 
included in the study. None of the developed systemic reactions had life threatening 
reactions. House dust mite was with a predictive value for development of systemic adverse 
reactions (OR=2.3, p=0.0001) [54]. However, this study indicated that HDM specific 
immunotherapy was with good tolerance 
6. Conclusion 
HDM immunotherapy for 3 years significantly reduced symptom and medication use in AR, 
asthma and patients with both conditions, and prevent the consequent development of 
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asthma in patients with AR. This was associated with a greater subjective improvement in 
asthma control. 
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indicated efficacy of SIT in AR in adults and children [9, 41-45]. There are clinical and 
immunological evidence that supports the long term efficacy of SIT [46]. 
In our study we don’t use BHR to a direct stimulus such as methacholine or histamine since it 
has poor correlations with indices of airway inflammation such as sputum eosinophils [47-49]. 
Thus we used serum ECP because it is a better marker of airway inflammation in asthma as in 
correlates with sputum eosinophils [49] and PFT following IT and medication [50]. Serum ECP 
level decreased after 2 years of immunotherapy in perennial allergic rhinitis [51] and asthma 
[50]. However, the rise in serum ECP after allergen challenge was significantly attenuated after 
just 1 year of immunotherapy in asthmatic patients [52]. Our study indicated a significant 
decrease in serum ECP in both SIT and placebo treated subject. However, the reduction was 
significantly higher in SIT group as compared to placebo group for patients with AR, Asthma, 
and AR with Asthma and when the data of patients pooled together. In placebo treated group 
decline in serum ECP may be due to treatment with inhaled corticosteroids. 
When the data of three disease groups pooled together, the symptom score, medication 
score, combined score and serum ECP significantly reduced in SIT as compared to placebo 
treatment group. Furthermore, SPT negative results and PFT improvement were 
significantly higher in SIT compared to placebo group. 
In this study SIT induces a significant reduction in all parameters used in the study whether 
the patients were with AR, asthma or both combined together. SIT shows overall percent 
reduction of 54%, while it was 17.5% in placebo group. 
Based on the finding of this and other studies, single allergen SIT is likely to be beneficial to 
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might be better at symptom control and lung function improvement, SIT has some unique 
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Haugaard et al [53], reported that SIT reduce airway sensitivity to allergens, which may lead 
subsequently to reduction in frequency of exacerbation and severity of asthma triggered by 
allergen exposure. In addition, the effect of SIT may persist for at least 5-6 years after the 
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Different studies show controversial outcome for SIT. Failure to respond to SIT may be due 
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Systemic adverse reactions were developed in 62 (15.1%) individuals from the 411 subjects 
included in the study. None of the developed systemic reactions had life threatening 
reactions. House dust mite was with a predictive value for development of systemic adverse 
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6. Conclusion 
HDM immunotherapy for 3 years significantly reduced symptom and medication use in AR, 
asthma and patients with both conditions, and prevent the consequent development of 
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asthma in patients with AR. This was associated with a greater subjective improvement in 
asthma control. 
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1. Introduction 
Hypertension is a major risk factor in the development of cardiovascular disease, with 
myocardial infarction, stroke and renal failure being one of the most important health 
problems worldwide due to its high prevalence and deleterious impact on the population in 
terms of excessive morbidity and mortality. Currently, hypertension is estimated to affect 
approximately 30% of the US and European population and 1 thousand million people 
worldwide and, as the population ages, this number is expected to increase even further 
(Wolf-Maier et al., 2003; Kearney et al., 2005; Yoon et al., 2010). Moreover, despite advances 
in treatment of the condition, hypertension control rates continue to be suboptimal in both 
the US and Europe as only about one third have their blood pressure (BP) reduced to the 
recommended levels by the 7th Joint National Committee (JNC-7) to under 140/90 mm Hg 
for uncomplicated hypertension, and less than 130/80 mmHg for those with diabetes 
mellitus or renal disease (Chobanian et al., 2003). 
Hypertension is a controllable disease and effective pharmacological therapies have been 
available for nearly 50 years. Socio-economic conditions, medication non-adherence, 
inadequate prevention strategies and resistant hypertension have all been implicated as 
barriers to adequate BP control. The major pharmacological strategies currently used for 
hypertension management include volume control with diuretics, suppression of central 
and peripheral sympathetic nervous system activity with beta-blockers and alfa-blockers, 
vasodilation with ion channel manipulation and blockade of renin-angiotensin-aldosterone 
system (RAAS). Since monotherapy controls the BP of less than 50% of treated hypertensive 
patients (Materson et al., 1993; Cushman et al., 2002), combination therapy with two or more 
antihypertensive medications with complementary mechanisms is often required to achieve 
BP control to recommended levels (Chobanian et al., 2003; Mancia et al., 2007). At present, 
the most widely used antihypertensive combinations involve hydrochlorothiazide (HCTZ) 
and drugs that block the RAAS, such as angiotensin-converting enzyme (ACE) inhibitors 
and angiotensin II type-1 receptor blockers (ARBs). 
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Recently a new blocker of the RAAS, aliskiren, has been developed and approved by the US 
Food and Drug Administration (FDA, on 5th March 2007) and by the European Medicines 
Agency (EMEA, on 22nd August 2007) for the treatment of essential hypertension. Aliskiren 
is an oral direct renin inhibitor, the rate-limiting enzyme in the production of the end 
product of the RAAS cascade, angiotensin II (Ang II), a potent vasoactive peptide. Aliskiren 
is a long-acting antihypertensive (half-life ≈ 40 hours) and has been shown in several clinical 
trials to be effective in lowering BP, safe and well tolerated in daily doses of 150 and 300 mg 
(approved once-daily doses) (Musini et al., 2009). In a recent systematic review and meta-
analysis of six double-blind randomized clinical trials to quantify the systolic and diastolic 
BP (SBP and DBP) lowering efficacy of aliskiren in the treatment of adults with essential 
hypertension, the obtained weighted mean differences with 95% CI (confidence interval) 
were: aliskiren 150 mg, -5.5 (-6.5, -4.4)/-3.0 (-3.7, -2.3) mm Hg; aliskiren 300 mg, -8.7 (-9.7, -
7.6)/-5.0 (-5.6, -4.3) mm Hg (Musini et al., 2009). 
Several clinical trials revealed that aliskiren/HCTZ combination therapy reduced SBP and 
DBP from baseline to a significantly greater extent than placebo, aliskiren monotherapy and 
HCTZ monotherapy (Chrysant 2008; Baldwin and Plosker 2009). Aliskiren/HCTZ also 
produced significant additional SBP and DBP reductions in patients inadequately 
responsive to 4 weeks’ prior treatment with aliskiren or HCTZ alone (Baldwin and Plosker 
2009). Single-pill combinations (SPCs) of aliskiren/HCTZ (150/12.5 mg, 150/25 mg, 
300/12.5 mg, 300/25 mg) have recently been approved by the US FDA (18th January 2008) 
and by EMEA (16th January 2009) for the treatment of adults with essential hypertension 
whose BP is not adequately controlled with aliskiren or HCTZ alone, and as a substitution 
treatment in patients with hypertension adequately treated by the two individual drugs 
concomitantly at the equivalent fixed dosage. In this chapter, we briefly reviewed the 
pharmacodynamic and pharmacokinetic profile of aliskiren and assessed the 
antihypertensive efficacy and tolerability of the aliskiren/HCTZ combination therapy in 
reducing SBP and DBP in patients with mild to moderate hypertension by using a 
systematic review of the literature and a meta-analytical approach to combine data from 
different clinical trials. 
2. Aliskiren: Pharmacodynamic and pharmacokinetic properties 
A schematic of the RAAS is depicted in Figure 1. Renin is an aspartic protease produced by 
the juxtaglomerular cells in the kidney. This enzyme catalyses the cleavage of 
angiotensinogen, the only know substrate of renin, to the decapeptide angiotensin I (Ang I). 
This is the rate-limiting step of RAAS activation. In the presence of ACE, Ang I is converted 
into the octapeptide hormone Ang II, a potent vasoconstrictor that mediates its activity 
through the type-1 angiotensin II (AT1) receptor. Binding of Ang II to AT1 receptor 
increases BP, and promotes aldosterone secretion from adrenal cortex, sodium reabsorption 
in renal proximal tubules, and catecholamine release from pre-synaptic nerve endings and 
adrenal medulla (Kim and Iwao 2000). Pathological activation of RAAS can result in high BP 
with consequent end-organ damage. 
Several drugs can inhibit the RAAS cascade but redundant biochemical pathways limit the 
potential beneficial effects of these drugs. 
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Fig. 1. The renin-angiotensin-aldosterone system (Staessen et al., 2006). Black arrows show 
stimulation and red arrows show inhibition. Dotted lines show alternative pathways mainly 
documented in experimental studies. Βeta-blockers, renin inhibitors, inhibitors of 
angiotensin-converting enzyme (ACE) and angiotensin II type-1 receptor blockers (ARB) 
reduce the activity of the renin-angiotensin system (RAS). Abbreviations: AT-R, angiotensin 
receptor; EP, endopeptidases; EC, endothelial cells. From reference Staessen et al., with 
permission from Elsevier. 
ACE inhibitors block the conversion of Ang I to Ang II but non-ACE pathways of Ang II 
generation such as a chymase and presumably other enzymes pathways present in end 
organs including heart, kidney and blood vessels get activated under conditions of ACE 
inhibition (Urata et al., 1996; Hollenberg et al., 1998). The existence of alternative pathways 
for Ang II generation that are unaffected by ACE inhibitors raises questions about whether 
ACE is the optimal target for RAAS suppression. Furthermore, ACE inhibitors are not 
specific for RAAS and can prevent ACE-induced inactivation of bradykinin and substance P 
that are thought to be responsible for ACE-inhibitor related side effects as cough and 
angioedema. ARBs exert their effect by blocking AT1 receptors activation by Ang II. This 
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II receptors (AT2 and AT4 receptors). Physiological role of these receptors are not clear but 
may be important for endothelial function (Wantanabe et al 2005). Over stimulation of AT2 
receptors can generate deleterious agents such as oxygen free radicals, pro-inflammatory 
cytokines and pro-fibrotic mediators and may promote left ventricular hypertrophy 
(Williams 2001; Azizi et al 2006). On the other hand, beneficial effects such as inhibition of 
renin synthesis and Ang II formation are also reported following AT2 receptor activation 
(Siragy et al 2005). Both ACE inhibitors and ARBs stimulate renal renin production by 
interrupting the normal feedback suppression of renin secretion from the kidneys. The 
reactive rise in circulating active renin leads to greater generation of Ang II via pathways 
dependent or independent of ACE. 
2.1 Pharmacodynamic properties of aliskiren 
Recently, a new blocker of RAAS, aliskiren, has been developed and approved for the 
treatment of hypertension. Aliskiren is a direct inhibitor of renin, the enzyme that catalyses 
the conversion of angiotensinogen to Ang I. This is the rate limiting step in the production 
of the end product of RAAS cascade, which makes renin inhibition an attractive option for 
effective RAAS blockade. Renin is measured as plasma renin concentration (PRC) and 
plasma renin activity (PRA). PRC measures the actual amount of renin in plasma regardless 
of its enzymatic activity and is expressed as either μU/mL or pg/mL. PRA denotes the 
enzymatic activity of renin and is measured as the rate of Ang I production after adding 
serum to angiotensinogen and is expressed as ng/ml/hour. Like ACE inhibitors and ARBs, 
aliskiren can reactively lead to an increase in PRC. However, unlike these other inhibitors of 
the RAAS, the effects of renin are suppressed with aliskiren, resulting in a reduction in PRA. 
Aliskiren is a small molecular weight, orally active, non-peptide direct renin inhibitor with 
very high affinity and specificity for human and primate renin (Wood et al., 2003). It is  
significantly less active against renin from dogs, rats, rabbits, pigs and cats, which made the 
process of conducting preclinical experimental studies a challenging one (Wood et al., 2003). 
As a result, these preclinical studies have been performed in marmosets (primates) and 
double-transgenic rats that express the human renin and human angiotensinogen genes 
(Pilz et al., 2005; Wood et al., 2005). 
Aliskiren is a potent inhibitor of renin with an IC50 (concentration inhibiting 50% of activity) 
of 0.6 nmol/L. Aliskiren oral doses of 3 and 10 mg/kg completely suppressed PRA for 24 
hours in mildly sodium depleted marmosets (Wood et al., 2005; Vaidyanathan et al., 2006; 
O'Brien et al., 2007; Vaidyanathan et al., 2007a; Vaidyanathan et al., 2007b). It decreased 
PRA, Ang I and Ang II levels in normotensive volunteers in a dose dependent manner but 
caused a 10-fold increase in PRC (Nussberger et al., 2002). A decrease in plasma and urine 
aldosterone levels were also noted with daily aliskiren doses of 80 mg and above 
(Nussberger et al., 2002). 
Effects of various medications on RAAS pathway are shown in Table 1. With the exception 
of beta-blockers, all other agents blocking RAAS and diuretics including HCTZ increase 
PRC. Aliskiren and ACE inhibitors achieve this by decreasing Ang II levels and ARBs by 
blocking inhibitory effects of Ang II on AT1 receptors on juxtaglomerular cells. Diuretics 
increase PRC by inducing volume depletion. The extent of PRC elevation is more marked 
when aliskiren is combined with HCTZ. PRA is increased by ACE inhibitors, ARBs and 
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HCTZ while aliskiren use alone and in combination with HCTZ is associated with a 
decrease in PRA. Other agents that can decrease PRA include beta-blockers and central alfa-
2 receptor agonists. 
Antihypertensive 
medications 
Enzymes Substrates End-products 
PRC PRA Angiotensinogen Ang I Ang II Ang1-7 Aldosterone 
Beta-blockers ↓ ↓ − ↓ ↓ ↓ ↓ 
ACE inhibitors ↑ ↑ ↓ ↑ ↓ ↑ ↓ 
ARBs ↑ ↑ ↓ ↑ ↑ ↑ ↓ 
Aliskiren ↑↑ ↓↓ - ↓ ↓ ↓ ↓ 
HCTZ ↑ ↑ ↓ ↑ ↑ ↑ ↑ 
Aliskiren/HCTZ 
combination 
↑↑↑ ↓ − − − − − 
Abbreviations: ACE, angiotensin-converting enzyme; Ang I, angiotensin I; Ang II, angiotensin II; Ang 
1–7, angiotensin 1–7; ARBs, angiotensin II type-1 receptor blockers; HCTZ, hydrochlorothiazide; PRA, 
plasma renin activity; PRC, plasma renin concentration; ↑, increased; ↓, decreased; −, unchanged or 
unknown. Adapted from (Sureshkumar 2008). 
Table 1. Antihypertensive medication effects on RAAS pathway 
2.2 Pharmacokinetic properties of aliskiren 
The pharmacokinetic properties of aliskiren have been studied in animals, healthy human 
subjects, patients with compromised liver and kidney function, and subjects with mild 
hypertension (Waldmeier et al., 2007). Aliskiren has a poor bioavailability (2-6%), but this is 
compensated by its high solubility and the already mentioned high inhibitory effect (IC50 = 
0.6 nM) from in vitro inhibition of human renin (Wood et al., 2005; Azizi et al., 2006). 
After oral administration, peak plasma concentrations (Cmax) of aliskiren are reached 
within 1–3 hours (Vaidyanathan et al., 2006; Zhao et al., 2006). When taken with a high-fat 
meal, the mean area under the plasma concentration–time curve (AUC) and Cmax of 
aliskiren are decreased by 71% and 85%, respectively (Novartis_Europharm_Limited 2007. 
Available at http://www.ema.europa.eu/docs/pt_PT/document_library/EPAR_-
_Product_Information/human/000780/WC500047010.pdf. Accessed on 27th August 2011). 
Steady state is achieved after approximately 7 days with once daily dosing (Nussberger et 
al., 2002). Aliskiren is not extensively bound (49.5%) to plasma proteins (Novartis 
Europharm Limited, 2007). The volume of distribution at steady state is 135 L (Novartis 
Europharm Limited, 2007). 
Aliskiren undergoes minimal hepatic metabolism. In vitro studies indicate that aliskiren is a 
substrate of the cytochrome P450 (CYP) 3A4 isoenzyme; however, it is neither an inhibitor 
nor an inducer of CYP isoenzymes (Vaidyanathan et al., 2006). Aliskiren is primarily 
eliminated by the hepatobiliary route as unmetabolized drug. Less than 1% of an orally 
administered dose is excreted in the urine as unchanged drug (Waldmeier et al., 2007). After 
oral administration of a single 300-mg dose of aliskiren to healthy volunteers, the mean ± SD 
clearance corrected for bioavailability [i.e., clearance/drug bioavailability (Cl/F)] was 234 ± 
137 L/hour (Zhao et al., 2006). The terminal half-life of aliskiren ranges from 24–40 hours 
(Nussberger et al., 2002; Azizi et al., 2004; Zhao et al., 2006). This half-life, which is longer 
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concentrations of aliskiren have been shown to accumulate by about 2-fold at steady state 
compared with administration of a single dose (Vaidyanathan et al., 2006). 
3. Aim of the review 
The aim of this review was to assess the antihypertensive efficacy and tolerability of the 
aliskiren/HCTZ combination therapy (as a combination of the individual components or as 
SPCs) in reducing SBP and DBP in patients with mild to moderate hypertension by using 
systematic analysis of the literature and meta-analytical approach to combine data from 
different randomized, double-blind, clinical trials. 
4. Methodology for selection of clinical trials and data analysis 
A literature search to identify clinical trials using aliskiren in combination with HCTZ for 
the treatment of hypertension was conducted on July 2011 to obtain all published study 
reports that met our inclusion criteria. 
4.1 Inclusion and exclusion criteria 
We included all articles in the literature written in any of the major languages. To be 
included in our review studies were required to be randomized, double-blind, clinical trials 
using aliskiren in combination with HCTZ (as a combination of the individual components 
or as SPCs) for the treatment of hypertension. Additionally, studies were included if they 
evaluated the antihypertensive efficacy [outcome measure) of aliskiren/HCTZ in patients 
with mild or moderate essential hypertension (SBP 140-179 mm Hg and/or DBP 90-109 mm 
Hg, as defined in current international guidelines (Mancia et al., 2007)] and patient age ≥ 18 
years. Articles were automatically excluded if their results were not reported or had been 
presented in forms such as abstracts, letters, or commentaries. 
4.2 Literature search strategy 
We searched the following electronic databases: International Pharmaceutical Abstracts, 
MEDLINE, The Cochrane Library and ISI Web of Knowledge. Each database was 
independently searched by 2 reviewers for articles published from 2000 to and including 
June 30, 2011, using the search terms aliskiren, aliskiren/hydrochlorothiazide, aliskiren-
hydrochlorothiazide, aliskiren in combination with hydrochlorothiazide, renin inhibitor. The 
reviewers selected articles based on the predefined inclusion/exclusion criteria and results 
were matched. A consensus method was applied to judge any article selection divergences. 
The rationale for decisions was discussed until reviewers agreed on the final decision. A 
third author was called to resolve any remaining discrepancies concerning article eligibility. 
Selected articles’ references and reviews of the subject were hand searched for additional 
studies that were not obtained through our initial electronic search. 
4.3 Data extraction 
The following information was gathered for each clinical trial: author names, year of 
publication, study design and duration, setting, characteristics of the patients enrolled, sizes 
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of the treatment groups, daily treatment regimens and primary endpoint. Outcomes 
extracted from articles included mean and variation of SBP and DBP at baseline and final 
assessments for each group, responder rate (DBP < 90 mm Hg or ≥10 mm Hg reduction 
from baseline) and BP control rate (SBP < 140 mm Hg and DBP < 90 mm Hg). Changes from 
baseline in PRA and PRC with aliskiren/HCTZ and with either component alone were also 
extracted whenever reported, as well as adverse events recorded during the trials. During 
the data extraction phase, we wrote to corresponding authors of studies to request missing 
data and clarify study details. 
4.4 Quality assessment 
The quality of selected articles was assessed by the same principles used in article selection 
and data extraction (i.e., 2 independent reviewers), and was based on the Jadad et al. 
method to measure the risk of bias (Jadad et al., 1996). Their 3-item quality assessment 
checklist evaluates the following methodological parameters: controlled trial, random 
allocation of treatments, double-blind follow-up, dropout rate, intention-to-treat (ITT) 
analysis and absence of other biases. Quality scores were presented as proportions of the 
total possible score (i.e., 5) of the quality assessment scale (where 100% represents the 
maximum quality). The scores were categorized according to the following criteria: weak 
(<60%), fair (60%), good (80%), or very good (100%). 
4.5 Analysis method 
For trials meeting the criteria for inclusion in the analysis, the efficacy of treatment was 
evaluated via measurements of SBP and DBP at the start of the trial (baseline) and after 8 
weeks of therapy. The meta-analytical approach therefore compared the efficacy of each 
aliskiren/HCTZ dose combination in reducing SBP and DBP over this period of time. The 
analysis method used was based on calculation of the mean BP reduction for a set of 
aliskiren/HCTZ dose combinations evaluated, by weighting the combined data for the trial 
size using the following formula: (BP reduction [trial 1] • number of patients [trial 1] +…+ BP 
reduction [trial n] • number of patients [trial n])/total number of patients (trial 1 +…+ trial n). 
5. Results 
A completed QUOROM flow chart (Moher et al., 1999) of the literature search strategy 
applied and results found is depicted in Figure 2. Initially, 52 potentially relevant RCTs 
were identified that appeared to meet the inclusion criteria and were screened for retrieval 
based on their titles and abstracts. Thirty-six of those articles were excluded for not 
evaluating aliskiren in combination with hydrochlorothiazide. The remaining 16 articles 
were retrieved for full-text review. Eleven of those articles were excluded for the following 
reasons: two had data that were not extractable (Andersen et al., 2008; Andersen et al., 2009), 
three presented excluded study designs (O'Brien et al., 2007; Chrysant et al., 2008; Littlejohn 
et al., 2009), one enrolled patients with severe hypertension (Strasser et al., 2007), four 
appeared only in the abstract form (Sica et al., 2006; Gradman et al., 2007; Prescott et al., 
2007; Calhoun et al., 2008) and one was indexed in MEDLINE in duplicate (Nickenig et al., 
2008). Therefore, after exclusion criteria were applied, a total of 5 studies involving a total of 
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extracted from articles included mean and variation of SBP and DBP at baseline and final 
assessments for each group, responder rate (DBP < 90 mm Hg or ≥10 mm Hg reduction 
from baseline) and BP control rate (SBP < 140 mm Hg and DBP < 90 mm Hg). Changes from 
baseline in PRA and PRC with aliskiren/HCTZ and with either component alone were also 
extracted whenever reported, as well as adverse events recorded during the trials. During 
the data extraction phase, we wrote to corresponding authors of studies to request missing 
data and clarify study details. 
4.4 Quality assessment 
The quality of selected articles was assessed by the same principles used in article selection 
and data extraction (i.e., 2 independent reviewers), and was based on the Jadad et al. 
method to measure the risk of bias (Jadad et al., 1996). Their 3-item quality assessment 
checklist evaluates the following methodological parameters: controlled trial, random 
allocation of treatments, double-blind follow-up, dropout rate, intention-to-treat (ITT) 
analysis and absence of other biases. Quality scores were presented as proportions of the 
total possible score (i.e., 5) of the quality assessment scale (where 100% represents the 
maximum quality). The scores were categorized according to the following criteria: weak 
(<60%), fair (60%), good (80%), or very good (100%). 
4.5 Analysis method 
For trials meeting the criteria for inclusion in the analysis, the efficacy of treatment was 
evaluated via measurements of SBP and DBP at the start of the trial (baseline) and after 8 
weeks of therapy. The meta-analytical approach therefore compared the efficacy of each 
aliskiren/HCTZ dose combination in reducing SBP and DBP over this period of time. The 
analysis method used was based on calculation of the mean BP reduction for a set of 
aliskiren/HCTZ dose combinations evaluated, by weighting the combined data for the trial 
size using the following formula: (BP reduction [trial 1] • number of patients [trial 1] +…+ BP 
reduction [trial n] • number of patients [trial n])/total number of patients (trial 1 +…+ trial n). 
5. Results 
A completed QUOROM flow chart (Moher et al., 1999) of the literature search strategy 
applied and results found is depicted in Figure 2. Initially, 52 potentially relevant RCTs 
were identified that appeared to meet the inclusion criteria and were screened for retrieval 
based on their titles and abstracts. Thirty-six of those articles were excluded for not 
evaluating aliskiren in combination with hydrochlorothiazide. The remaining 16 articles 
were retrieved for full-text review. Eleven of those articles were excluded for the following 
reasons: two had data that were not extractable (Andersen et al., 2008; Andersen et al., 2009), 
three presented excluded study designs (O'Brien et al., 2007; Chrysant et al., 2008; Littlejohn 
et al., 2009), one enrolled patients with severe hypertension (Strasser et al., 2007), four 
appeared only in the abstract form (Sica et al., 2006; Gradman et al., 2007; Prescott et al., 
2007; Calhoun et al., 2008) and one was indexed in MEDLINE in duplicate (Nickenig et al., 
2008). Therefore, after exclusion criteria were applied, a total of 5 studies involving a total of 






Fig. 2. Quorom flow chart of literature search strategy applied and results. Five double-blind 
randomized controlled trials met the inclusion criteria, using aliskiren in combination with 
HCTZ for the treatment of hypertension. 
Table 2 presents the overall characteristics of the evaluated studies. The average sample size 
was 1102 ± 947 (mean ± SD), with a median of 722 and range from 489–2776 patients. All 
included studies were randomized, double-blind, multicenter clinical trials, proceeded by a 
single-blind, placebo (Villamil et al., 2007) / active comparator (Jordan et al., 2007; Nickenig 
et al., 2008; Blumenstein et al., 2009; Geiger et al., 2009), run-in period of 2-4 weeks. 
Moreover, all five studies specified the change from baseline (start of double-blind 
treatment) in mean sitting DBP (msDBP) at 8 weeks as the primary endpoint. 
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Fig. 2. Quorom flow chart of literature search strategy applied and results. Five double-blind 
randomized controlled trials met the inclusion criteria, using aliskiren in combination with 
HCTZ for the treatment of hypertension. 
Table 2 presents the overall characteristics of the evaluated studies. The average sample size 
was 1102 ± 947 (mean ± SD), with a median of 722 and range from 489–2776 patients. All 
included studies were randomized, double-blind, multicenter clinical trials, proceeded by a 
single-blind, placebo (Villamil et al., 2007) / active comparator (Jordan et al., 2007; Nickenig 
et al., 2008; Blumenstein et al., 2009; Geiger et al., 2009), run-in period of 2-4 weeks. 
Moreover, all five studies specified the change from baseline (start of double-blind 
treatment) in mean sitting DBP (msDBP) at 8 weeks as the primary endpoint. 
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aIn each published clinical trial, patient baseline and demographic characteristics were comparable for 
all treatment groups. 
bThe percentage of the total possible score (i.e., 5) of the quality assessment scale applied (100% 
represents the maximum quality). 
cMethod to generate the sequence of randomization and method of double blind were not described; 
additionally, some information on outcome variability was not provided. 
dMethod to generate the sequence of randomization and method of double blind were not described. 
Abbreviations: BP, blood pressure; HCTZ, hydrochlorothiazide; HT, hypertension; msDBP, mean sitting 
diastolic blood pressure; pts, patients; wk, week. 
Table 2. Published clinical trials of aliskiren/HCTZ for treatment of mild to moderate 
hypertension 
Secondary efficacy measures included the change in mean sitting SBP (msSBP) (Jordan et al., 
2007; Villamil et al., 2007; Nickenig et al., 2008; Blumenstein et al., 2009; Geiger et al., 2009), 
the proportion of patients with successful response to treatment (defined as msDBP < 90 
mmHg and/or a ≥ 10 mmHg reduction from baseline) (Jordan et al., 2007; Villamil et al., 
2007) and the proportion of patients attaining BP control (defined as msDBP < 90 mmHg 
and msSBP < 140 mm Hg) (Jordan et al., 2007; Villamil et al., 2007; Nickenig et al., 2008; 
Blumenstein et al., 2009; Geiger et al., 2009). Two trials used the SPC (Jordan et al., 2007; 
Villamil et al., 2007), and three combined the individual components (Nickenig et al., 2008; 
Blumenstein et al., 2009; Geiger et al., 2009), with aliskiren and HCTZ administered orally as 
single daily doses in all studies. One trial enrolled obese hypertensive patients only (obesity 
defined as body mass index of ≥ 30 kg/m2) (Jordan et al., 2007), although in the remaining 
four trials subgroups of patients with obesity were also present. In the five included clinical 
trials patient demographics and baseline characteristics were similar across treatment 
groups. Brief details of the characteristics of each individual trial and treatment group, 
including mean patient ages, sex ratios, body mass index / obesity and baseline SBP and 
DBP are provided in Table 3. 
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Values are mean ±SD unless otherwise stated. 
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; F, female; HCTZ, 
hydrochlorothiazide; M, male; NR, not reported; Pts, patients; SBP, systolic blood pressure. 
Table 3. Main patient baseline and demographic characteristics by treatment group of the 
included clinical trials (randomized population) 
The average quality score of study reporting was 84% ± 22% (range 60–100%), which could 
be categorized as very good. One study failed to report all information on data variability 
(Villamil et al., 2007), which prevented the use of an approximation for standard error of the 
mean (SEM) or confidence interval (CI) estimation, when calculating some weighted 
average reductions in SBP and DBP. We contacted the corresponding author of this study by 
email to request missing data on SEM as well as on BP control rate at endpoint for each 
aliskiren/HCTZ, aliskiren and HCTZ daily doses tested, but no response was provided. 
Table 4 details results from clinical trials on the efficacy of aliskiren/HCTZ in reducing BP. 
In the only placebo-controlled study (and also the largest of the RCTs), aliskiren/HCTZ 
combination reduced SBP and DBP from baseline to a significantly (p ≤ 0.0001) greater 
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Blumenstein et al., 2009; Geiger et al., 2009), with aliskiren and HCTZ administered orally as 
single daily doses in all studies. One trial enrolled obese hypertensive patients only (obesity 
defined as body mass index of ≥ 30 kg/m2) (Jordan et al., 2007), although in the remaining 
four trials subgroups of patients with obesity were also present. In the five included clinical 
trials patient demographics and baseline characteristics were similar across treatment 
groups. Brief details of the characteristics of each individual trial and treatment group, 
including mean patient ages, sex ratios, body mass index / obesity and baseline SBP and 
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Values are mean ±SD unless otherwise stated. 
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; F, female; HCTZ, 
hydrochlorothiazide; M, male; NR, not reported; Pts, patients; SBP, systolic blood pressure. 
Table 3. Main patient baseline and demographic characteristics by treatment group of the 
included clinical trials (randomized population) 
The average quality score of study reporting was 84% ± 22% (range 60–100%), which could 
be categorized as very good. One study failed to report all information on data variability 
(Villamil et al., 2007), which prevented the use of an approximation for standard error of the 
mean (SEM) or confidence interval (CI) estimation, when calculating some weighted 
average reductions in SBP and DBP. We contacted the corresponding author of this study by 
email to request missing data on SEM as well as on BP control rate at endpoint for each 
aliskiren/HCTZ, aliskiren and HCTZ daily doses tested, but no response was provided. 
Table 4 details results from clinical trials on the efficacy of aliskiren/HCTZ in reducing BP. 
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Changes in blood pressure are presented as the least-squares mean changes (with ± SEM, whenever 
provided by the authors). 
aP < 0.05, bP < 0.001, cP ≤ 0.0001 vs placebo; dP < 0.05 vs each component monotherapy; eP < 0.0001 vs 
HCTZ 25 mg; fP < 0.05 vs HCTZ 25 mg; gP = 0.0005 vs HCTZ 25 mg; hP > 0.05 vs aliskiren/HCTZ 
300/25 mg; iP = 0.052 vs aliskiren/HCTZ 300/25 mg; jP < 0.001 vs aliskiren 300 mg; kP = 0.002 vs 
aliskiren 300 mg; lP < 0.001 vs HCTZ 25 mg; mP = 0.009 vs aliskiren/HCTZ 150/25 mg; nP < 0.001 vs 
aliskiren/HCTZ 150/25 mg; oP = 0.033 vs aliskiren/HCTZ 150/25 mg; pP < 0.001 vs aliskiren/HCTZ 
300/25 mg; qP < 0.01 vs valsartan/HCTZ 320/25 mg; rP < 0.001 vs valsartan/HCTZ 320/25 mg. 
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; ITT, 
intention-to-treat analysis; NR, not reported; SBP, systolic blood pressure. 
Table 4. Clinical trial data on the efficacy of aliskiren/HCTZ in reducing blood pressure 
Furthermore, aliskiren/HCTZ combination (at all but the 75/12.5 mg and 150/6.25 mg 
dosages, both of which are not commercially available) decreased SBP and DBP from 
baseline to a significantly (p < 0.05) greater extent than the component monotherapies 
(Villamil et al., 2007). In the other selected RCTs, all of which with an active comparator and 
a non-responder study design (Jordan et al., 2007; Nickenig et al., 2008; Blumenstein et al., 
2009; Geiger et al., 2009), aliskiren/HCTZ combination was an effective treatment option, 
producing significantly additional reductions in SBP and DBP in patients with mild to 
moderate hypertension inadequately responsive to 4 weeks’ prior treatment with aliskiren 
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(Nickenig et al., 2008) or HCTZ (Jordan et al., 2007; Blumenstein et al., 2009; Geiger et al., 
2009) alone. In the five included RCTs, BP control rates were also significantly higher with 
all aliskiren/HCTZ combinations commercially available than with placebo, aliskiren alone 
and HCTZ alone. One of the included studies did not report the BP response rate (Geiger et 
al., 2009), in the remaining four studies, BP response rates were also significantly higher 
with all aliskiren/HCTZ combinations commercially available than with placebo; however, 
only the three higher dosages of aliskiren/HCTZ combinations yielded significantly higher 
BP response rates than the component monotherapies (Jordan et al., 2007; Villamil et al., 
2007; Nickenig et al., 2008; Blumenstein et al., 2009). 
Two studies also compared the efficacy of aliskiren/HCTZ 300/25 mg combination in 
reducing and controlling BP with other treatment combinations (amlodipine/HCTZ 10/25 
mg, irbesartan/HCTZ 300/25 mg, valsartan/HCTZ 320/25 mg and 
aliskiren/valsartan/HCTZ 300/320/25 mg) (Jordan et al., 2007; Geiger et al., 2009). Only the 
last combination yielded significantly greater decreases in SBP and DBP and higher BP 
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150/12.5 mg 1 184 -17.6 -11.9 [37.4, 59.5]
a 
Aliskiren/HCTZ 
150/25 mg 2 429 -15.8 -10.3 [43.8, 53.5]
a 
Aliskiren/HCTZ 
300/12.5 mg 2 472 -15.9 -11.8 [50.1, 58.5]
a 
Aliskiren/HCTZ 
300/25 mg 5 966 -16.9±0.4 -11.6±0.3 [51.9, 55.9]
a 
Changes in blood pressure are presented as the weighted least-squares mean changes ± SEM (not all 
variability information was provided in the trial of Villamil (2007), preventing the use of an 
approximation for SEM or confidence intervals estimation for the first three aliskiren/HCTZ dose 
combinations). 
aThe range presented is due to the trial of Villamil (2007), which presented the range of BP control rate 
for aliskiren/HCTZ combination, without specify the values for each dose combination. 
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; SBP, 
systolic blood pressure. 
Table 5. Weighted average reductions from baseline of SBP and DBP and BP control rate for 
each aliskiren/HCTZ combination commercially available 
The Q statistic for heterogeneity of effects was not significant, both for SBP (χ2 = 1.14, p = 
0.89) and for DBP (χ2 = 0.62, p = 0.96); therefore we considered the study results to be 
combinable and a fixed-effects model was used in the analysis. Table 5 presents the 
weighted mean reductions from baseline of SBP and DBP and BP control rate for each 
aliskiren/HCTZ combination commercially available. It should be noted that four RCTs 
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Changes in blood pressure are presented as the least-squares mean changes (with ± SEM, whenever 
provided by the authors). 
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Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; ITT, 
intention-to-treat analysis; NR, not reported; SBP, systolic blood pressure. 
Table 4. Clinical trial data on the efficacy of aliskiren/HCTZ in reducing blood pressure 
Furthermore, aliskiren/HCTZ combination (at all but the 75/12.5 mg and 150/6.25 mg 
dosages, both of which are not commercially available) decreased SBP and DBP from 
baseline to a significantly (p < 0.05) greater extent than the component monotherapies 
(Villamil et al., 2007). In the other selected RCTs, all of which with an active comparator and 
a non-responder study design (Jordan et al., 2007; Nickenig et al., 2008; Blumenstein et al., 
2009; Geiger et al., 2009), aliskiren/HCTZ combination was an effective treatment option, 
producing significantly additional reductions in SBP and DBP in patients with mild to 
moderate hypertension inadequately responsive to 4 weeks’ prior treatment with aliskiren 
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(Nickenig et al., 2008) or HCTZ (Jordan et al., 2007; Blumenstein et al., 2009; Geiger et al., 
2009) alone. In the five included RCTs, BP control rates were also significantly higher with 
all aliskiren/HCTZ combinations commercially available than with placebo, aliskiren alone 
and HCTZ alone. One of the included studies did not report the BP response rate (Geiger et 
al., 2009), in the remaining four studies, BP response rates were also significantly higher 
with all aliskiren/HCTZ combinations commercially available than with placebo; however, 
only the three higher dosages of aliskiren/HCTZ combinations yielded significantly higher 
BP response rates than the component monotherapies (Jordan et al., 2007; Villamil et al., 
2007; Nickenig et al., 2008; Blumenstein et al., 2009). 
Two studies also compared the efficacy of aliskiren/HCTZ 300/25 mg combination in 
reducing and controlling BP with other treatment combinations (amlodipine/HCTZ 10/25 
mg, irbesartan/HCTZ 300/25 mg, valsartan/HCTZ 320/25 mg and 
aliskiren/valsartan/HCTZ 300/320/25 mg) (Jordan et al., 2007; Geiger et al., 2009). Only the 
last combination yielded significantly greater decreases in SBP and DBP and higher BP 
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150/12.5 mg 1 184 -17.6 -11.9 [37.4, 59.5]
a 
Aliskiren/HCTZ 
150/25 mg 2 429 -15.8 -10.3 [43.8, 53.5]
a 
Aliskiren/HCTZ 
300/12.5 mg 2 472 -15.9 -11.8 [50.1, 58.5]
a 
Aliskiren/HCTZ 
300/25 mg 5 966 -16.9±0.4 -11.6±0.3 [51.9, 55.9]
a 
Changes in blood pressure are presented as the weighted least-squares mean changes ± SEM (not all 
variability information was provided in the trial of Villamil (2007), preventing the use of an 
approximation for SEM or confidence intervals estimation for the first three aliskiren/HCTZ dose 
combinations). 
aThe range presented is due to the trial of Villamil (2007), which presented the range of BP control rate 
for aliskiren/HCTZ combination, without specify the values for each dose combination. 
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; SBP, 
systolic blood pressure. 
Table 5. Weighted average reductions from baseline of SBP and DBP and BP control rate for 
each aliskiren/HCTZ combination commercially available 
The Q statistic for heterogeneity of effects was not significant, both for SBP (χ2 = 1.14, p = 
0.89) and for DBP (χ2 = 0.62, p = 0.96); therefore we considered the study results to be 
combinable and a fixed-effects model was used in the analysis. Table 5 presents the 
weighted mean reductions from baseline of SBP and DBP and BP control rate for each 
aliskiren/HCTZ combination commercially available. It should be noted that four RCTs 





differed in these studies (Jordan et al., 2007; Nickenig et al., 2008; Blumenstein et al., 2009; 
Geiger et al., 2009). In these circumstances, appraisal of the change from baseline in SBP and 
DBP achieved by each aliskiren/HCTZ combination allows some appreciation of their 
antihypertensive efficacy since all data are derived from studies of similar design. 
Nevertheless, the higher BP reductions reported in the Villamil (2007) trial (Villamil et al., 
2007) with aliskiren/HCTZ (a fact also observed with aliskiren and HCTZ monotherapies) 
must be observed with some caution, as they clearly diverged upward from the results 
obtained by other authors and yielded an unexpected higher effect of the lowest dose of 
aliskiren/HCTZ commercially available (150/12.5 mg). 
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The overall incidence of treatment-related 
adverse events (AEs) was slightly higher in 
the HCTZ (9.3-11.0%) and combination 
groups (8.7-16.6%) compared with placebo 
(8.8%) and aliskiren (6.5-9.8%) groups. 
However, this could not be attributed to any 
particular AE or class of AE. Hypokalaemia 
(serum potassium <3.5 mmol/L) occurred 
with the highest frequency in HCTZ 12.5 
and 25mg groups (3.9 and 5.2%, 
respectively). When these doses of HCTZ 
were administered in combination with 
aliskiren, the frequency of hypokalaemia 
decreased to 0.7–2.0% for the combination 
groups with HCTZ 12.5mg and to 2.2–3.4% 




















Amlodipine/HCTZ group had the highest 
rate of AEs (45.2%) because of a higher 
incidence of peripheral edema. Incidence of 
AEs in the other treatment groups was: 
39.3% - aliskiren/HCTZ; 38.5% – HCTZ; 
36.1% - Irbesartan/HCTZ. The proportion of 
patients experiencing nasopharyngitis, 
dizziness and hyperkalaemia were slightly 
higher in aliskiren/HCTZ group (8.2%, 3.3% 















Aliskiren/HCTZ SPC treatment showed 
similar tolerability to aliskiren monotherapy. 
Headache, hypercholesterolemia and 
nasopharyngitis occurred in ≥2% of patients 
in any treatment group. The proportion of 
patients with hypokalaemia was lower in the 
aliskiren/HCTZ 300/12.5 mg group (0.4%) 
and aliskiren 300 mg monotherapy group 
(0.4%) than in the aliskiren/HCTZ 300/25 
mg group (2.5%). 
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Aliskiren/HCTZ SPC treatment showed 
similar tolerability to HCTZ alone and a 
numerically lower incidence of 
hypokalaemia (aliskiren/HCTZ, 1.3-2.2%; 
HCTZ alone, 3.4%). AEs reported in ≥2% of 
patients in any treatment group were 





















Aliskiren/HCTZ SPC treatment showed 
similar tolerability to HCT alone and a 
numerically lower incidence of 
hypokalaemia (aliskiren/HCTZ, 5.0%; 
HCTZ alone, 9.3%), nasopharyngitis 
(aliskiren/HCTZ, 3.0%; HCTZ alone, 6.6%) 
and headache (aliskiren/HCTZ, 2.4%; HCTZ 
alone, 5.3%). 
aJordan (2007); bVillamil (2007); cGeiger (2009); dP > 0.05 vs baseline; eP > 0.05 vs placebo; fP < 0.05 vs 
pretreatment; gP > 0.75 vs baseline; hP < 0.001 vs baseline; iP ≥ 0.05 vs baseline; jP < 0.05 vs baseline. 
Abbreviations: AE, adverse event; HCTZ, hydrochlorothiazide; ITT, intention-to-treat analysis; NR, not 
reported; PRA, plasma renin activity; PRC, plasma renin concentration; Pts, patients; SPC, single-pill 
combination. 
Table 6. Changes from baseline in PRA and PRC with aliskiren and HCTZ monotherapy and 
combination therapy 
Some authors also studied changes from pre-treatment (Jordan et al., 2007) (start of single-
blind treatment) or baseline (Villamil et al., 2007; Geiger et al., 2009) (start of double-blind 
treatment) in PRA and PRC with aliskiren and HCTZ monotherapy and combination 
therapy (Table 6). Aliskiren 75, 150 and 300 mg/day decreased (the geometric) PRA from 
baseline by 54.2%, 65.1% and 57.6%, respectively (Villamil et al., 2007). Conversely, HCTZ 
monotherapy significantly increased PRA at 12.5 and 25 mg/day dosages (Jordan et al., 
2007; Villamil et al., 2007). When combined, aliskiren/HCTZ significantly reduced PRA 
from pretreatment (by 45%) (Jordan et al., 2007) and baseline (by 40.5-62.3%) (Villamil et al., 
2007; Geiger et al., 2009), whereas combined treatment with amlodipine/HCTZ, 
irbesartan/HCTZ and valsartan/HCTZ significantly increased PRA (Jordan et al., 2007; 
Geiger et al., 2009). Aliskiren elevated PRC from baseline in a dose-dependent manner, with 
increases of 164%, 192% and 348% at dosages of 75, 150 and 300 mg/day, respectively 
(Villamil et al., 2007). HCTZ 25 mg/day increased PRC by 108%, whereas lower dosages did 
not cause alterations in PCR that significantly differed from placebo. All aliskiren/HCTZ 
combinations significantly increased PCR (Villamil et al., 2007; Geiger et al., 2009), the 
magnitude of increases was related to the dosages of both components, with the most 
marked increase (1211% from baseline) occurring in the aliskiren/HCTZ 300/25 mg group 
(Villamil et al., 2007). Furthermore, increases in PRC in several combination groups were 
considerably greater than the sum of the increases seen with each component (Villamil et al., 
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DBP achieved by each aliskiren/HCTZ combination allows some appreciation of their 
antihypertensive efficacy since all data are derived from studies of similar design. 
Nevertheless, the higher BP reductions reported in the Villamil (2007) trial (Villamil et al., 
2007) with aliskiren/HCTZ (a fact also observed with aliskiren and HCTZ monotherapies) 
must be observed with some caution, as they clearly diverged upward from the results 
obtained by other authors and yielded an unexpected higher effect of the lowest dose of 
aliskiren/HCTZ commercially available (150/12.5 mg). 
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Aliskiren/HCTZ SPC treatment showed 
similar tolerability to aliskiren monotherapy. 
Headache, hypercholesterolemia and 
nasopharyngitis occurred in ≥2% of patients 
in any treatment group. The proportion of 
patients with hypokalaemia was lower in the 
aliskiren/HCTZ 300/12.5 mg group (0.4%) 
and aliskiren 300 mg monotherapy group 
(0.4%) than in the aliskiren/HCTZ 300/25 
mg group (2.5%). 
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Aliskiren/HCTZ SPC treatment showed 
similar tolerability to HCT alone and a 
numerically lower incidence of 
hypokalaemia (aliskiren/HCTZ, 5.0%; 
HCTZ alone, 9.3%), nasopharyngitis 
(aliskiren/HCTZ, 3.0%; HCTZ alone, 6.6%) 
and headache (aliskiren/HCTZ, 2.4%; HCTZ 
alone, 5.3%). 
aJordan (2007); bVillamil (2007); cGeiger (2009); dP > 0.05 vs baseline; eP > 0.05 vs placebo; fP < 0.05 vs 
pretreatment; gP > 0.75 vs baseline; hP < 0.001 vs baseline; iP ≥ 0.05 vs baseline; jP < 0.05 vs baseline. 
Abbreviations: AE, adverse event; HCTZ, hydrochlorothiazide; ITT, intention-to-treat analysis; NR, not 
reported; PRA, plasma renin activity; PRC, plasma renin concentration; Pts, patients; SPC, single-pill 
combination. 
Table 6. Changes from baseline in PRA and PRC with aliskiren and HCTZ monotherapy and 
combination therapy 
Some authors also studied changes from pre-treatment (Jordan et al., 2007) (start of single-
blind treatment) or baseline (Villamil et al., 2007; Geiger et al., 2009) (start of double-blind 
treatment) in PRA and PRC with aliskiren and HCTZ monotherapy and combination 
therapy (Table 6). Aliskiren 75, 150 and 300 mg/day decreased (the geometric) PRA from 
baseline by 54.2%, 65.1% and 57.6%, respectively (Villamil et al., 2007). Conversely, HCTZ 
monotherapy significantly increased PRA at 12.5 and 25 mg/day dosages (Jordan et al., 
2007; Villamil et al., 2007). When combined, aliskiren/HCTZ significantly reduced PRA 
from pretreatment (by 45%) (Jordan et al., 2007) and baseline (by 40.5-62.3%) (Villamil et al., 
2007; Geiger et al., 2009), whereas combined treatment with amlodipine/HCTZ, 
irbesartan/HCTZ and valsartan/HCTZ significantly increased PRA (Jordan et al., 2007; 
Geiger et al., 2009). Aliskiren elevated PRC from baseline in a dose-dependent manner, with 
increases of 164%, 192% and 348% at dosages of 75, 150 and 300 mg/day, respectively 
(Villamil et al., 2007). HCTZ 25 mg/day increased PRC by 108%, whereas lower dosages did 
not cause alterations in PCR that significantly differed from placebo. All aliskiren/HCTZ 
combinations significantly increased PCR (Villamil et al., 2007; Geiger et al., 2009), the 
magnitude of increases was related to the dosages of both components, with the most 
marked increase (1211% from baseline) occurring in the aliskiren/HCTZ 300/25 mg group 
(Villamil et al., 2007). Furthermore, increases in PRC in several combination groups were 
considerably greater than the sum of the increases seen with each component (Villamil et al., 





the 4-week single-blind HCTZ period (Geiger et al., 2009). Therefore, the effect of HCTZ on 
PRA and PRC might have been stabilized with this initial therapy and no further changes 
after the 8-week additional HCTZ treatment was observed (Geiger et al., 2009). 
Table 6 also describes the most common adverse events reported in the clinical trials. 
Aliskiren/HCTZ, as a SPC or as a combination of the individual components concurrently 
administered, was generally well tolerated in the five clinical trials reviewed. The majority 
of adverse events were mild and transient in nature, with the most commonly reported 
events including nasopharyngitis (Jordan et al., 2007; Villamil et al., 2007; Nickenig et al., 
2008; Blumenstein et al., 2009; Geiger et al., 2009), headache (Jordan et al., 2007; Villamil et 
al., 2007; Nickenig et al., 2008; Blumenstein et al., 2009; Geiger et al., 2009), dizziness (Jordan 
et al., 2007; Blumenstein et al., 2009), back pain (Blumenstein et al., 2009), vertigo 
(Blumenstein et al., 2009) and hypercholesterolemia (Nickenig et al., 2008). 
The proportion of patients experiencing hypokalaemia (defined as serum potassium levels 
<3.5 mmol/L) were numerically lower with aliskiren/HCTZ than with HCTZ alone 
(Villamil et al., 2007; Blumenstein et al., 2009; Geiger et al., 2009). The proportion of patients 
with hypokalaemia was also lower in the aliskiren/HCTZ 300/12.5 mg group (0.4%) and 
aliskiren 300 mg monotherapy group (0.4%) than in the aliskiren/HCTZ 300/25 mg group 
(2.5%) (Nickenig et al., 2008). In obese hypertensive patients, hypokalaemia occurred in 4.9% 
patients of the aliskiren/HCTZ group versus 2.5%, 10.3% and 4.1% of patients treated with 
irbesartan/HCTZ, amlodipine/HCTZ or HCTZ alone, respectively (Jordan et al., 2007). 
6. Discussion 
SPCs of aliskiren/HCTZ has recently been introduced in European Union for the second-
line treatment of adults with essential hypertension whose BP is not adequately controlled 
with either drug alone, or as a substitution treatment in patients with hypertension 
adequately treated by the two individual drugs concomitantly at the equivalent fixed 
dosage. To our knowledge, this study represents the first published meta-analytical 
approach to the efficacy of aliskiren/HCTZ in reducing BP in patients with mild to 
moderate hypertension. Although other reviews dealing with the same topic are available in 
the literature, no study has provided a synthesis of data from clinical trials. 
The five studies included in this systematic review are short-term (8-12 weeks) randomized, 
double-blind, clinical trials with a similar design and comparable primary endpoints and 
secondary efficacy measures. All studies compared the change in SBP and DBP from baseline 
(start of double-blind treatment) to week 8 endpoint in each aliskiren/HCTZ combination 
group with that in placebo and/or aliskiren monotherapy and/or HCTZ monotherapy group. 
Patient demographics and baseline characteristics were also similar across treatment groups in 
all included studies, except that one study included obese patients only (Jordan et al., 2007). 
The average quality of the articles was considered to be very good. 
In this study we chose to present the results by way of weighted average sums of BP 
reductions over 8 weeks, a period consistent with current clinical recommendations for 
assessing the clinical efficacy and tolerability of antihypertensive drugs following their 
initiation (Chobanian et al., 2003; Mancia et al., 2007). The weighted means method, which 
has been used in other meta-analyses (Conlin et al., 2000; Baguet et al., 2005; Baguet et al., 
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2007), takes into account the different sizes of trials and provides results that are easy to 
interpret clinically. 
In all clinical trials selected for analysis, commercially available aliskiren/HCTZ 
combinations (150/12.5 mg, 150/25 mg, 300/12.5 mg and 300/25 mg) provided clinically 
significant additional SBP and DBP reductions and improved BP control rates over aliskiren 
or HCTZ monotherapy, which demonstrates that aliskiren/HCTZ SPCs are a effective 
treatment option for patients with mild to moderate hypertension who do not achieve BP 
control with aliskiren 300 mg or HCTZ 25 mg alone. A meta-analysis of 354 randomized 
clinical trials involving more than 40,000 treated patients with hypertension revealed that 
the additional reduction in BP achieved with antihypertensive combination therapy versus 
monotherapy provide a reduced risk of stroke and ischemic heart events (Law et al., 2003). 
In another meta-analysis, examining individual data from one million adults in 61 
prospective studies, it was found that, at ages 40-69 years, each increase of 20 mm Hg usual 
SBP (or, approximately equivalently, 10 mm Hg usual DBP) is associated with more than a 
twofold difference in the stroke death rate, and with twofold differences in the death rates 
from ischaemic heart disease and from other vascular causes (Lewington et al., 2002). Thus, 
the additional mean BP reductions of up to 8.0/4.8 mmHg (versus HCTZ 25 mg) or 6.0/3.1 
mmHg (versus aliskiren 300 mg) provided by aliskiren/HCTZ 300/25 mg in the present 
analysis might be expected to reduce the risk of cardiovascular mortality. However, long-
term and large-scale studies analysing the effects of aliskiren/HCTZ combination therapy 
on clinical outcomes are required to confirm this hypothesis. 
The capacity of aliskiren to enhance the antihypertensive efficacy of HCTZ reflects its 
complementary mode of action, targeting the RAAS at its point of activation and thus 
suppressing PRA. HCTZ monotherapy increased PRA, as a result of stimulated renin release 
in response to reduced intravascular volume. The addition of aliskiren counteracted this 
effect, resulting in a significant (p < 0.05) overall decrease in PRA compared with HCTZ 
monotherapy (Jordan et al., 2007; Villamil et al., 2007; Geiger et al., 2009). Furthermore, 
aliskiren effectively inhibited the renin enzyme, despite marked elevation in PRC, to 
produce an overall reduction in PRA from baseline. This contrasts to agents that block the 
RAAS at other points, such as ACE inhibitors and ARBs, which induce increases in PRA in 
parallel with PRC (Nussberger et al., 2002; Jordan et al., 2007; Geiger et al., 2009). 
Aliskiren/HCTZ was generally well tolerated in the clinical trials reviewed and not 
associated with a notably higher incidence of adverse events than treatment with either 
component alone. These results are consistent with a long-term open-label study in 1955 
hypertensive patients showing that aliskiren/HCTZ free combinations were well tolerated 
over up to 12 months of treatment (Sica et al., 2006; Gradman et al., ) 2007). In three included 
trials, when aliskiren and HCTZ was administered in combination, aliskiren opposed the 
adverse hypokalaemic effects of HCTZ (Villamil et al., 2007; Blumenstein et al., 2009; Geiger 
et al., 2009). The safety profile of an aliskiren/valsartan/HCTZ combination was also 
investigated in one clinical trial and was similar to the 2-drug combinations 
(aliskiren/HCTZ or valsartan/HCTZ), with a greater BP-lowering effect in patients not 
adequately responding to HCTZ monotherapy (Geiger et al., 2009). 
Most patients with hypertension will require combination treatment with two or more 
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hypertensive patients showing that aliskiren/HCTZ free combinations were well tolerated 
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adequately responding to HCTZ monotherapy (Geiger et al., 2009). 
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(Chobanian et al., 2003; Mancia et al., 2007). A meta-analysis of adherence studies showed 
that the use of SPC regimens reduced the rate of non-compliance by 24–26% compared with 
respective free combinations (Bangalore et al., 2007). Aliskiren/HCTZ SPCs therefore offers 
the convenience of a single-tablet once daily treatment regimen, which may improve 
treatment compliance and subsequent BP control. 
The limitations of this study should be noted. Firstly, the intervention effect size as reported 
above (Tables 2 and 3) could be an overestimate due to publication bias since the manufacturer 
(Novartis Pharmaceuticals Corporation) sponsored four (Jordan et al., 2007; Nickenig et al., 
2008; Blumenstein et al., 2009; Geiger et al., 2009) of the included published studies and one 
author of the remaining study (Villamil et al., 2007) is employee of Novartis Pharmaceuticals 
Corporation. It is possible that less optimistic studies have not been published and therefore 
not included in our analysis. Secondly, because the BP lowering efficacy estimate is limited to 
8 weeks, we cannot extrapolate our results to the longer term benefits of the treatments on 
cardiovascular morbidity and mortality. However, in this regard, the 2007 European Society of 
Hypertension (ESH)/European Society of Cardiology (ESC) guidelines are pertinent, which 
state that the size of BP reduction is more important than the class used for cardiovascular 
event reduction (Mancia et al., 2007). Thirdly, an overall of 87% patients included in the RCTs 
analysed were Caucasian, which greatly limits the extraction of conclusions for hypertensive 
patients of other races/ethnicities. Actually, blacks are known to have a less responsive renin-
angiotensin-aldosterone system (He et al., 2001) and ACE inhibitors and angiotensin receptor 
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1. Introduction 
In ulcers’ healing the organic contaminations causes a problem that are not scrupulously 
removed by patients or medical personnel, particularly, where approximately 90 % patients 
suffering from the disease have been cured in an open system care. Secondly, up to the latest 
days there was no appropriate medicine effectively supporting wound’s cleaning. Necrotic 
organic substances remaining in the wound do activate a holder’s immunological system 
and promote bacteria, fungi, and virus increments, in which environment reactive oxygen 
species are created. These very aggressive substances destroy healthy tissues and favour 
accumulating significantly extensive amount of granulocytes which, in turn, affect micro-
obstructions and micro-clots in the wound’s edge area. The mentioned circumstances 
suspend the healing or even preclude this process. Another issue is, that majority of patients 
do not rinse up the whole wound surface while the edges only or they do not change 
bandages sufficiently often. A commonly used salt to rinse the wound is a physiological salt 
or Ringer’s liquid. However, these are the liquids which do not contain a conservation 
mean. Therefore, outstaying usually in an open way for many days, or more often in a room 
temperature, the solutions can be secondarily contaminated. What is more, patients often 
use a tap water which is also bacterially contaminated. Having in mind a nature of the 
wound’s protein components, which are strongly associated with a substratum via fibrins, it 
is not indifferent what the wound is rinse up with (1,2,3,4).  
In the study, the Authors present a new tactics against lasting wounds. It relies on 
supplementing the TIME procedure by the Lav acronym which means lavage (washing, 
cleaning) in the first instance, before wound treatment. Moreover, an effectiveness of wound 
cleaning from the organic elements including bacteria using a physiological salt (NaCl) and 
Prontosan (polyhexanide+betaine) has been reported (5,6).  
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2. Material and method 
In the study have been enrolled 60 patients (19 males and 41 females, 47-83 of age with 58.5 
average). Retired persons (52 patients) were predominant in the group, widowers (43), alone 
(39) and inhabitants of a >100 thou. population city (38). All the patients have been suffering 
from thrombosis for 2-15 years. In the color duplex Doppler’s test in all the patients signs of 
post thrombotic syndrome with damage of venous valves on different levels of the 
extremity has been diagnosed. A valve damage in femoral vein was predominant in 49 
patients (formerly treated but unsuccessfully).  
 Male  Female Total  
Gender  19 41 60 
Retired  14 38 52 
Widower 9 34 43 
Alone 7 32 39 
Citizen of > 100 thou. 
population city 12 26 38 
Kind of profession 
a/ physical worker, 
farmer 

















Age 56 +/- 14 63 +/- 14  
Median 55 62  
Range (20-87) (24-88)  
BMI 27,3 +/- 5,3 28,7 +/- 5,1  
Median 25 27  
Range (16,2-38,2) (15,7-39,1)  
Table 1. The patient demographics 
In the study 30 patients were taken into account with 44 ulcers’ histories (158 visit records). 
From the preliminary set of 60 patients, those were excluded who appeared once or who did 
not restrict the regimes of the treatment procedure. After decoding the bottles’ containments 
and appropriate patients’ assigning to the groups, it was established that 17 patients were 
treated by Prontosan, whereas 13 by the 0.9% NaCl solution, respectively.  
Drop out patients are presented in table 2. 
 Prontosan group 0.9% NaCl group Total  
Adverse events 3 2 5 
Major protocol violation 2 4 6 
Patient wished to leave study 3 5 8 
Patient not compliant 4 3 7 
Significant concomitant illness 1 3 4 
Treatment failure 0 0 0 
Total 13 17 30 
Table 2.  
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2.1 Study design 
This study was an open, multicenter, prospective, randomized, double blind, parallel group 
study on efficacy of Prontosan solution in treatment of venous leg ulcers. 
The study was performed in 3 centers and was included a total number of 60 patients. After 
dropped out 30 patients because of different reasons remaining patients were as follow : 17 
patients for Prontosan and 13 for 0.9% NaCl subgroup. Treated venous leg ulcers were 
classified according to ABI /Ankle-Brachial Index/. The venous leg ulcers were recognized 
when ABI was higher than or equal to 0,9 and no lymphatic disorders revealed. 
All study participants had been treated during 12 weeks or until complete healing is 
achieved (whichever occurs first). 
2.2 Study population 
The study population consists of individuals above 18 years of age, in which venous leg ulcers 
have been identified of the size limited by the size of applied wound dressing and ABI ≥ 0.9.  
Exclusion criteria were as follows: 
a. hypersensitivity to any of Prontosan® components or to any of wound dressing 
components,  
b. active osteomyelitis in the area of the treated ulcer,  
c. active rheumatoidal or collagen disease of blood vessels treated with corticosteroids, 
d. neoplastic disease 
e. serum proteins < 4 g/dl 
f. anemia: < 10g haemoglobin per dl 
g. exclusion of phlebotropic, vasorelaxing and reological medicines for the study period  
h. diabetic foot 
i. lack of compliance of the patient 
j. intolerance to compression therapy 
2.3 Route of administration 
External application. 
2.4 Dosage regimen 
Either Prontosan® or saline solution (depending on the study group) had been applied at 
every change of the wound dressing. Frequency of dressing change: every day. 
3. Application 
1. first, Prontosan/saline solution was used for cleansing of the wound bed; this will be 
done using sterile gauze & sterile gauze compress soaked in the solution an used to 
cover the wound for 15 min, then removed from the wound bed 
2. next, the polyurethane wound dressing was activated with given solution and used to 
cover the wound 
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Prontosan or 0.9% NaCl solution were used to soak and gently remove the wound dressing 
at the time of each dressing change procedure.  
For each patient 10 bottles 350 ml of Prontosan or 0.9% NaCl saline solution were available 
and used as necessary according to applied randomization scheme.  
3.1 Efficacy criteria 
Primary efficacy criteria:  
1. incidence of infection during treatment period 
2. rate of healing of the ulcer in cm2/week 
Secondary efficacy criteria: 
1. complete healing of the ulcer – ulcer is defined as completely healed if there is stable 
wound epithelialization 
2. improved state of the ulcer – ulcer is defined as improved if there is decrease in its 
surface of at least 25% in comparison to the initial findings 
3. lack of improvement of the ulcer – defined as the ulcer that do not belong to any of the 
above listed categories 
Tertiary efficacy criteria: 
1. incidence of pain during dressing change, comfort for the patient – subjective pain scale 
used during the course of study - before, during and after each dressing change (CIVIQ 
questionnaire) 
2. incidence of side effects 
3. change of clinical symptoms of the ulcer (granulation, epithelialization; computer-aided 
analysis of digital pictures of the wound). 
3.2 Methods of evaluation of the efficacy of treatment include: 
- planimetry of the ulcer, software-aided surface evaluation,  
- assessment of clinical status of the ulcer (computer-aided analysis of pictures of wound 
surface) 
- assessment of changes in microbial load in the ulcer in first, second & last visit of the 
study  
- photographic documentation of the treatment (done in a standardized way to allow for 
further computer-aided analysis) 
- laboratory tests: full blood count, total proteins 
3.3 Safety evaluation  
Assessment of differences between measured general health parameters (as listed under 
laboratory tests) as well as incidence of adverse reactions before and after therapeutical 
process. 
Following the study qualification during the initial visit (D-0), for bacteria culture 
inoculation, swabs from the wounds were taken and bottles with unknown liquid together 
with the treatment prescription among the patients were distributed. During the control 
visits before bandaging a digital photographical documentation of healing was conducted.  
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The treatment procedure consisted with: 
Every day applying wet gauze with the liquid from the bottle. The dressing was on the 
wound during fifteen minutes than polyurethan wound dressing ( Allevyn ) was put on. 
Such dressing was covered by two knee stockings. First was a thrombo profilactic and the 
second one was Sigvaris 503 class compression. Day by day patient change the dressings 
according to above mentioned method. To make easier for the patients each one get diary 
with detail prescription how to use getting materials for the treatment.  
The visits’ D-13 and D-31, D-58 consisted with: check the wound healing process, make a 
digital photography, take the culture from the wound bed, put the new dressing on, take 
used bottles off and give new bottles with the medicament. 
The last visit was D-85. During this visit physician estimated the healing process, advers 
events and ask patients about their satisfaction with the treatment. 
4. Statistical analysis 
In the statistical analysis, hierarchical (multi-level) modelling has been performed that 
allows variance in outcome variable (wound surface) to be analysed at multiple hierarchical 
levels (i.e. time of treatment, treatment groups and their interaction) [Raudenbush S., Bryk 
A. (2001). Hierarchical Linear Models: Applications and Data Analysis Methods (2nd ed.). 
Sage Publications, Thousand Oaks CA]. A mixed effects’ model has been applied in the 
study.  
A statistical difference between means of the speed of ulcers’ healing in Prontosan and NaCl 
patients has been estimated with the use of Welch’s t-test that is an adaptation of Student’s 
t-test intended for use with two samples having possibly unequal variance [Welch B. (1947). 
The generalization of “student's” problem when several different population variances are 
involved. Biometrika 34: 28-35] for details.  
A so-called k-means algorithm which classifies a given data set (speed of ulcers’ healing) 
through a certain number of clusters (two time bands) [MacQueen J. (1967). Some Methods 
for classification and Analysis of Multivariate Observations. Proceedings of 5-th Berkeley 
Symposium on Mathematical Statistics and Probability. Berkeley, University of California 
Press 1:281-297].  
A statistical difference in infection numbers between the selected Prontosan and NaCl 
patients’ visits has been estimated through the Mann-Whitney U-test [Mann H., Whitney D. 
(1947). On a test of whether one of two random variables is stochastically larger than the 
other. Annals of Mathematical Statistics 18: 50-60], which is a non-parametric test and 
assesses whether two independent samples of observations (infection numbers in treatment 
groups) come from the same distribution.  
The statistical computation has been conducted in R platform [The R Foundation for 
Statistical Computing (2008). R version 2.8.1 (2008-12-22)].  
The planimetrical estimation of ulcers was carried out based on digital pictures of wounds 
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In the group of patients underwent study were 11 smokers but only two smokers belongs to 
the group of assessed patients, one in group of Prontosan and one in 0.9% NaCl group. 
The ulcer location was predominantly in ankle region (49 ), above ankle ( 11). Status of the 
wound before and following treatment are presented in table 3. 










necrosis 7 6 0 1 
Fibrinogen coating 17 13 0 2 
Infection  9 6 2 5 
Visible tendoms 5 3 2 2 
Fistulas 0 0 0 0 
Granulation faze   17 9 
Epithelialization faze 0 0 17 3 
Table 3. 
Total healing rate in the estimated groups is presented in table 4 
 Prontosan n = 17 0.9% NaCl n = 13 
Total healing of ulcer within 
90 days 16 6 
85% of ulcer healing 1 3 
50% of ulcer healing 0 3 
30% of ulcer healing 0 1 
Lack of improvement of the 
ulcer  0 0 
Table 4. 
All blood and urine tests were in of normal range before and following study procedure. 
Only in three patients of Prontosan group appeared adverse events listed in table 5. 
 Prontosan n = 17 0.9% NaCl n = 13 
Serious adverse events 0 0 
Not serious adverse events   
Headache  0 1 
Excitation/sleepless 0 0 
Stabbing pain of the heart 0 0 
Nausea  0 0 
Itching  2 3 
Eruption of the skin 1 3 
Oedema foots and legs 0 2 
Table 5. 
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In the study 30 patients (17 Prontosan and 13 0.9% NaCl) were taken into account with 44 
ulceration episodes (mean age = 71.9 +/- 10.7). All together in 2008 and 2009, 158 visits were 
documented in the form below:  
Episode  Treatment  Time since 1st visit [days]  Time between visits [days]  Surface [mm^2]  
1  Prontosan  0  0  3006,7  
1  Prontosan  42  42  2057  
1  Prontosan  75  33  1240,9  
1  Prontosan  151  76  183,6  
1  Prontosan  186  35  33,4  
1  Prontosan  224  38  64,2  
2  NaCl  0  0  110,6  
2  NaCl  14  14  178,6  
2  NaCl  17  3  176  
2  NaCl  57  40  45,9  
2  NaCl  71  14  30,1  
3  NaCl  0  0  286,2  
3  NaCl  17  17  198,5  
3  NaCl  33  16  133,3  
4  NaCl  0  0  476,2  
4  NaCl  14  14  510  
4  NaCl  70  56  467  
4  NaCl  91  21  419,8  
*****  *******  *****************  *****************  **********  
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The regression estimates of the assumed hierarchical model are reported in Table 6. 
Parameter  Value  Std. Error  p-value  
intercept  1012,796  178,385  <0,0001  
time  -4,053  1,168  0,0007  
groupProntosan  -86,154  194,633  0,6589  
time:groupProntosan  -5,004  1,479  0,0010  
Table 6. Hierarchical Modelling Analysis 
 A statistically significant reduction of the surface of ulcers in Prontosan and in NaCl 
patiens was observed approximately 4 mm2 per day (time); 
Prontosan patients represented a larger reduction of the wound surface during 
treatment compared to NaCl patients (86 mm2 in average) , however, the difference was 
not statistically significant (groupProntosan); 
 A statistically significant difference in healing effect in time between the treatment 
groups was observed and for each therapy increment of one day, the reduction of 5 
mm2 was larger approximately in Prontosan patients compared to NaCl group 
(time:groupProntosan). 
The graphical model of the reduction of ulcers in treatment groups is presented in Figure 3.  
The average ulcer surface area vs 
time between treatment and control 
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The regression model estimates indicate that a particular 1000 mm2 ulcer wound should be 
approximately healed after 110.4 days of Prontosan therapy whereas 246.8 days with the 
NaCl treatment.  
The estimates of the statistical difference between means of the speed of ulcers’ healing in 
Prontosan and in NaCl patients are presented below 
Treatment Mean Std. Dev. p-value 
Prontosan 13,320 14,763 0,01465 
NaCl 5,641 18,124  
Table 7. Ulcers’ Healing Speed t-test (mm2) 
The t-test estimates provide evidence of the over twice as high ulcer reduction in Prontosan 
treatment patients compared to NaCl group. The average healing in Prontosan patients 
exceeded 13 mm2 per day whereas in NaCl patients it was much below 6 mm2 daily. The 
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Fig. 4. Time-Speed Clusters of Ulcers' Healing in: Prontosan Patients 
 
Fig. 5. Time-Speed Clusters of Ulcers' Healing in: NaCl patients 
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Treatment  Means   
 Cluster 1  Cluster 2  p-value  
Prontosan  14,770  5,164  0,00931  
NaCl  5,730  5,347  0,9152  
Table 8. The t-test analysis for the time-speed clusters in Prontosan and NaCl patients are 
given 
The outcomes testify that there is a significant difference in means of healing speed in 
Prontosan patients between the estimated clusters. The obtained time band can be 
established around the 100 days since the beginning of Prontosan treatment and the average 
speed of ulcer healing reaches nearly 15 mm2 per day up to this time border. After this time 
the speed decreases significantly to 5 mm2/day. The healing speed in NaCl patients does 
not vary with time and in both clusters it is slightly above 5 mm2 per day of treatment. 
Treatment No. of Obs. Rank Sum U statistic Z statistic p-level 
Prontosan 27 509,5 131,5 -3,9054 9,43E-05 
NaCl 26 921,5    
Table 9. The U-test results for the infection numbers between the selected Prontosan and 
NaCl patients’ visits are reported U-Test Infection Numbers Analysis 
The results provide evidence of significantly lower infection numbers in Prontosan patients’ 
ulcers in comparison to the NaCl group (nearly twice as low).  
6. Discussion 
In the study 30 patients were taken into account with 44 ulcers’ histories (158 visit records). 
From the preliminary set of 60 patients, those were excluded who appeared once or who did 
not restrict the regimes of the treatment procedure. After decoding the bottles’ containments 
and appropriate patients’ assigning to the groups, it was established that 17 patients were 
treated by Prontosan, whereas 13 by the NaCl solution, respectively.  
The obtained outcomes provide evidence nearly three times as a higher healing speed in 
those patients who were treated by Prontosan in comparison to the NaCl group. The 
cleaning from bacteria tribes was as twice as higher, respectively. In both the analyses the 
results were statistically significant.  
The importance of lavasepsis for the treatment of chronic wounds results from a 
fundamental, commonly understood and accepted standard, which for wound management 
field translates as follows: “first wound hygiene, then wound tratment (7).” This principle 
goes hand in hand with the generally accepted rule of limiting the use of drugs to an 
essential minimum and giving prophylaxis priority in medicine. What is then the real 
impact of lavasepsis on the individual elements of the TIME framework? 
The effect of lavasepsis on Tissue management is many-sided. It softens and separates 
necroses from healthy tissue, which facilitates their identification and elimination. 
Furthermore, lavasepsis removes crust, scabs and exudate residues, as well as fibrin 
coatings from the wound surface (8, 9). Finally, everyday wound lavasepsis secures effective 
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debridement, but it can considerably help in assessment of the wound and in effective 
employment of the required procedure.  
In the area of Inflammation and infection control, it is worth emphasising the significance of the 
aforementioned cleansing properties, namely the removal of wound coatings and biofilm 
from the wound surface. The use of antiseptics and antibiotics for a wound that is either 
contaminated or coated with a biofilm is inadequate. It can cause the therapy to be 
ineffective and increases the likelihood of the development of drug-resistance (12, 14). 
Wound cleansing or hygiene lowers the microbial load and significantly lowers the risk of 
complications, including infections. The microcirculation, oxygen and nutrient availability, 
as well as the effectiveness of patient’s immune system are improving. Lavasepsis cannot 
replace antisepsis, but secures optimal conditions for the use of local and systemic anti-
infectives. In this way, it minimizes and streamlines their application.  
Maintaining an adequate Moisture balance of the wound is an important element of the 
therapeutic process. Everyday wound lavasepsis helps to remove excessive exudate (also by 
reinforcing the habit of wound cleansing). It facilitates wound moistening in the case of dry 
wounds and raises the effectiveness of wound dressings. Lavasepsis is not meant to replace 
modern wound dressings, which are essential for maintaining a moist wound environment 
and absorbing excessive exudate. It can, however, prepare the wound bed in a way that 
ensures optimal therapeutic effect of their application. 
Epithelial/edge advancement is an element of the TIME framework, for which lavasepsis is 
important because of the fact that the removal of wound coatings facilitates the 
reestablishment of cellular proliferation and angiogenesis. Lavasepsis also removes 
potential physical barriers to epithelial growth across the wound bed. Finally, optimal 
wound bed preparation is a prerequisite for effective use of advanced therapies, such as skin 
transplants and cellular growth factors (11).  
Lavasepsis thus has a significant influence on all elements of the TIME framework, being a 
process of preparing the wound bed per se. Thanks to this, it allows one to achieve optimal 
results from any therapeutic procedures applied at specific stages of wound treatment. 
The above outcomes point to the conclusion that a lack of effective wound cleaning from 
organic elements laying on the wound bed as well as from the remained bacteria (protected by 
the bacterial biofilm which is difficult to remove using physiological salts) result in significant 
elongation of the healing time. Prontosan dissolves and removes contaminations from the 
wound bed, destroys the bacterial biofilm and accelerates the healing of ulcers. Despite of a 
slightly higher price, the use of Prontosan may importantly reduce sufferance in patients 
likewise both the costs carried out by their own and the governmental subsidies, taking the 
time of the medical treatment in mind. Further economical simulation are required to estimate 
such the profits. Our results were confirmed by other investigators (12). 
Lavasepsis is a new term created to describe and delineate a group of products that, 
according to the authors, brings in a new, desired quality to local treatment of chronic 
wounds (13). This new quality arises directly from the evolution of the WBP paradigm and 
TIME framework set earlier by EWMA experts (14). The TIME framework and EWMA 
recommendations are a good milestone not only for clinical practice, but also for 
manufacturers who are trying to adopt their product offering to the needs of contemporary 
medicine. The LAV-TIME concept presented in this paper, extends and supplements the 
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TIME framework with the new and important element of lavasepsis (15,16,17,18). Although 
at present there are few products on the market that can be described as “lavaseptics”, the 
rapid development of this group of products is to be expected, and their availability on the 
medical market will grow. This would certainly be of benefit to the medical world, and most 
of all to the patients (19,20). 
7. Conclusion 
1. A statistically significant difference in healing effect in time between the treatment 
groups was observed and for each therapy increment of one day, the reduction of 5 
mm2 was larger approximately in Prontosan patients compared to NaCl group. 
2. The results provide evidence of significantly lower infection numbers in Prontosan 
patients’ ulcers in comparison to the NaCl group. 
3. Prontosan appeared as a very good tolerated product for patients without any serious 
adverse effects. Only three out of seventeen patients have a temporary local problems 
with Itching ( two patients ) and eruption of the skin ( one patient ). 
4. 16 patients out of 17 in the Prontosan group were totally healed within 90 days of 
treatment and only 6 out of 13 were totally healed in NaCl group at the same time. 
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